<SEC-DOCUMENT>0001493152-22-014266.txt : 20220518
<SEC-HEADER>0001493152-22-014266.hdr.sgml : 20220518
<ACCEPTANCE-DATETIME>20220518061257
ACCESSION NUMBER:		0001493152-22-014266
CONFORMED SUBMISSION TYPE:	424B4
PUBLIC DOCUMENT COUNT:		12
FILED AS OF DATE:		20220518
DATE AS OF CHANGE:		20220518

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OKYO Pharma Ltd
		CENTRAL INDEX KEY:			0001849296
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		424B4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-263326
		FILM NUMBER:		22936975

	BUSINESS ADDRESS:	
		STREET 1:		55 PARK LANE
		CITY:			LONDON
		STATE:			X0
		ZIP:			W1K 1NA
		BUSINESS PHONE:		44 (0) 207 495 2379

	MAIL ADDRESS:	
		STREET 1:		55 PARK LANE
		CITY:			LONDON
		STATE:			X0
		ZIP:			W1K 1NA
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B4
<SEQUENCE>1
<FILENAME>form-424b4.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filed
pursuant to Rule 424(b)(4)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
Statement No. 333- 263326</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0"><B>625,000</B><B> American Depositary Shares</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0"><B>Representing 40,625,000 Ordinary Shares</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="form424b4_001.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 18pt"><B>OKYO Pharma Limited</B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">We</FONT><FONT STYLE="font-size: 8pt">&nbsp;
</FONT><FONT STYLE="font-size: 10pt">are offering 625,000 American Depositary Shares, or ADSs, of OKYO Pharma Limited. Each ADS
represents <FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-variant: normal; font-weight: normal">65
</FONT>ordinary shares. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prior to this offering, there has been no public
market for our ADSs. Our ADSs have been approved for trading on the Nasdaq Capital Market or Nasdaq, under the symbol &ldquo;OKYO.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The initial public offering price is $4.00 per
ADS. Our ordinary shares are admitted to listing on the standard segment of Official List of the United Kingdom Financial Conduct
Authority, or FCA, and to trading on the main market for listed securities, or Main Market, of London Stock Exchange plc, or London Stock
Exchange, under the symbol &ldquo;OKYO.&rdquo; On May 12, 2022, the last reported sale price of our ordinary shares was &pound;0.0613
per share (equivalent to $4.92 per ADS based on an exchange rate of &pound;1.00 to $1.2344). For a discussion of the factors considered
in determining the initial public offering price of our ADSs, see &ldquo;Underwriting&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Investing in our ADSs involves a high degree
of risk. See &ldquo;Risk Factors&rdquo; beginning on page 9 of this prospectus for a discussion of information that you should
consider before investing in our ADSs.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Neither the SEC, nor any state securities commission
has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary
is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are an &ldquo;emerging growth company,&rdquo;
or EGC, as defined under applicable Securities and Exchange Commission, or SEC, rules and, as such, have elected to comply with certain
reduced public company reporting requirements for this and future filings. Two of our directors purchased 50,000 ADSs in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Per ADS</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; font-size: 10pt; text-align: left">Initial public offering price</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 14%; font-size: 10pt; text-align: right">4.00</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 14%; font-size: 10pt; text-align: right">2,500,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Underwriting discounts and commissions (1)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.28</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">175,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Proceeds, before expenses, to us</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">3.72</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">2,325,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Underwriting discounts and commissions do not include a non-accountable
    expense allowance equal to 1.0% of the public offering price (excluding proceeds received from exercise of the underwriters&rsquo;
    over-allotment option) payable to the representative of the underwriters in the offering. See &ldquo;Underwriting.&rdquo; </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have granted the representative of the underwriters
an over-allotment option to purchase up to an additional 93,750 ADSs from us at the IPO price, less the underwriting discounts
and commissions, within 45 days from the date of this prospectus to cover over-allotments, if any. If the representative of the underwriters
exercises their over-allotment option in full, the total underwriting discounts and commissions payable will be $201,250, and
the total proceeds to us, before expenses, will be $2,673,750.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The underwriters expect to deliver our ADSs to purchasers
in this offering on or about May 19, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>ThinkEquity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">The date of this prospectus
is May 16, 2022</P>




<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="form424b4_012.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; width: 48px; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#cr_001">About
    This Prospectus</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#cr_002">Presentation
    of Financial Information</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#cr_003">Prospectus
    Summary</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#cr_005">Risk
    Factors</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#cr_006">Cautionary
    Statement Regarding Forward-Looking Statements</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#cr_007">Market
    and Industry Data</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#cr_008">Trademarks,
    Service Marks and Tradenames</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#cr_009">Exchange
    Rate Information</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#cr_010">Price
    Range of Our Ordinary Shares</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#us_001">Use
    of Proceeds</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#cr_011">Dividend
    Policy</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#cr_012">Capitalization</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#us_002">Dilution</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#cr_013">Selected
    Consolidated Financial Data</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#cr_014">Management&rsquo;s
    Discussion and Analysis of Financial Condition and Results of Operations</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#cr_015">Business</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#cr_016">Management</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#an_001">Certain
    Relationships and Related Party Transactions</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">81</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_001">Principal
    Shareholders</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">83</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_002">Description
    of Share Capital and Memorandum and Articles of Incorporation</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">84</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#lp_001">Description
    of the American Depositary Shares</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">106</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#an_003">Ordinary
    Shares and ADSs Eligible For Future Sale</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">117</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#an_004">Certain
    U.S. and Guernsey Tax Considerations</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">118</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#us_003">Underwriting</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">123</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#an_006">Expenses
    of This Offering</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">129</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#an_007">Legal
    Matters</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">130</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#an_008">Experts</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">130</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#an_009">Service
    of Process and Enforcement of Liabilities</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">130</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#an_010">Where
    You Can Find Additional Information</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">130</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#an_011">Index
    to Consolidated Financial Statements</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
are responsible for the information contained in this prospectus and any free-writing prospectus we prepare or authorize. We have
not authorized anyone to provide you with different information, and we take no responsibility for any
other information others may give you. We are not making an offer to sell our ADSs in any
jurisdiction where the offer or sale is not permitted. For the avoidance of doubt, we are not, making an offer to sell our ordinary shares in any jurisdiction. You should not assume that the information contained in this
prospectus is accurate as of any date other than the date on the front cover of this prospectus, regardless of the time of delivery
of this prospectus or the sale of any ADSs.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
investors outside the United States, we have not done anything that would permit this offering or possession or distribution of
this prospectus in any jurisdiction, other than the United States, where action for that purpose is required. Persons outside the United
States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, this offering
and the distribution of this prospectus outside the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a non-cellular company limited by shares incorporated under the Companies (Guernsey) Law 2008, or the Guernsey Companies Law,
and a majority of our outstanding securities are owned by non-U.S. residents. Under the rules of the SEC, we are currently eligible
for treatment as a &ldquo;foreign private issuer,&rdquo; or FPI. As an FPI, we will not be required to file periodic reports and financial
statements with the SEC as frequently or as promptly as domestic registrants whose securities are registered under the Securities Exchange
Act of 1934, or Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="cr_001"></A>About
This Prospectus</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise indicated or the context otherwise requires, all references in this registration statement to the terms &ldquo;OKYO,&rdquo;
&ldquo;OKYO Pharma Limited,&rdquo; &ldquo;the company,&rdquo; &ldquo;we,&rdquo; &ldquo;us&rdquo; and &ldquo;our&rdquo; refer to OKYO
Pharma Limited and our wholly owned subsidiary OKYO Pharma US Inc..</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Solely
for convenience, the trademarks, service marks and trade names in this registration statement may be referred to without the &reg; and
&trade; symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest
extent under applicable law, their rights thereto. This registration statement contains additional trademarks, service marks and trade
names of others, which are the property of their respective owners. We do not intend to use or display other companies&rsquo; trademarks,
service marks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
this registration statement, unless otherwise stated, all references to &ldquo;U.S. dollars&rdquo; or &ldquo;US$&rdquo; or &ldquo;$&rdquo;
or &ldquo;cents&rdquo; are to the currency of the United States of America, and all references to &ldquo;Pounds Sterling&rdquo; or &ldquo;&pound;&rdquo;
or &ldquo;pence&rdquo; are to the currency of the United Kingdom.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
this registration statement, any reference to any provision of any legislation shall include any amendment, modification, re-enactment
or extension thereof. Words importing the singular shall include the plural and vice versa, and words importing the masculine gender
shall include the feminine or neutral gender.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="cr_002"></A>Presentation
of Financial Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">This prospectus includes our
audited consolidated financial statements as of and for the years ended March 31, 2021 and March 31, 2020 which are prepared in
accordance with International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board, or IASB.
None of our financial statements were prepared in accordance with generally accepted accounting principles in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Our financial information is
presented in U.S. dollars. For the convenience of the reader, in this prospectus, unless otherwise indicated, translations from Pounds
Sterling into U.S. dollars were made at the rate of &pound;1.00 to $1.2344 which was the noon buying rate of the Federal Reserve
Bank of New York on May 6, 2022. Such U.S. dollar amounts are not necessarily indicative of the amounts of U.S. dollars that could
actually have been purchased upon exchange of Pounds Sterling at the dates indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We have made rounding adjustments
to some of the figures included in this prospectus. Accordingly, numerical figures shown as totals in some tables may not be an arithmetic
aggregation of the figures that preceded them.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="cr_003"></A>PROSPECTUS
SUMMARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>This
summary highlights information contained elsewhere in this prospectus and does not contain all of the information that you should consider
in making your investment decision. Before investing in our ADSs or ordinary shares, you should carefully read this entire prospectus,
including our consolidated financial statements and the related notes and the information set forth under the sections titled &ldquo;Risk
Factors,&rdquo; &ldquo;Special Note Regarding Forward-Looking Statements,&rdquo; and &ldquo;Management&rsquo;s Discussion and Analysis
of Financial Condition and Results of Operations,&rdquo; in each case included elsewhere in this prospectus. Unless the context otherwise
requires, we use the terms &ldquo;OKYO,&rdquo; &ldquo;Company,&rdquo; &ldquo;our,&rdquo; &ldquo;us,&rdquo; and &ldquo;we&rdquo; in this
prospectus to refer to OKYO Pharma Limited and, where appropriate, our consolidated subsidiary, OKYO Pharma US, Inc..</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We are a preclinical biopharmaceutical
company developing next-generation therapeutics to improve the lives of patients suffering from inflammatory eye diseases and ocular
pain. Our research program is focused on a novel G Protein-Coupled Receptor, or GPCR, which we believe plays a key role in the pathology
of these inflammatory eye diseases of high unmet medical need. Our therapeutic approach is focused on targeting inflammatory and pain
modulation pathways that drive these conditions. We are presently developing OK-101, our lead preclinical product candidate, for
the treatment of dry-eye disease. We also plan to evaluate its potential in benefiting patients with ocular neuropathic pain,
uveitis and allergic conjunctivitis. We have also been evaluating OK-201, a bovine adrenal medulla, or BAM, lipidated-peptide
preclinical analogue candidate that is currently in developmental stage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">On February 21, 2018, we announced
that we successfully obtained (via assignment from Panetta Partners Ltd., a related party) a license from On Target Therapeutics
LLC, or OTT, to patents owned or controlled by OTT and a sub-license from OTT to certain patents licensed by OTT from Tufts Medical Center
Inc., or TMC, to support our ophthalmic disease drug programs. These licenses gave us the right to exploit the intellectual property,
or IP estate which is directed to compositions-of-matter and methodologies for treating ocular inflammation, DED, with chemerin or lipid-linked
chemerin analogues. We also have a license from TMC to a separate IP estate for treating symptoms of ocular neuropathic pain and uveitis
associated pain. On August 6, 2019, we signed a collaborative agreement with TMC on a research program focused on ocular neuropathic
pain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">On January 7, 2021, we announced
the appointment of Mr. Gabriele Cerrone as Non-Executive Chairman and Director, and Gary S. Jacob, Ph.D. as Chief Executive Officer
and Director. The addition of these two individuals was a significant step for us, highlighting a careful realignment of the strategic
focus of our research and development program, with the aim of facilitating advancement of both of our preclinical programs. We believe
this realignment will allow us to file investigational new drug, or IND, applications on our drug candidates with the U.S. Food and Drug
Administration, or FDA, in the shortest time possible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>OK-101 </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">OK-101, our lead preclinical
product candidate, is focused on keratoconjunctivitis sicca, commonly referred to as dry eye disease, or DED, which is a multifactorial
disease caused by an underlying inflammation resulting in the lack of lubrication and moisture in the surface of the eye. DED is one
of the most common ophthalmic conditions encountered in clinical practice. Symptoms of DED include constant discomfort and irritation
accompanied by inflammation of the ocular surface, visual impairment and potential damage to the ocular surface. There are presently
approximately 20 million people suffering from DED in the U.S. alone (Farrand et al. AJO 2017; 182:90), with the disease affecting approximately up to
34% of the population aged 50+ (Dana et al. AJO 2019; 202:47), and with women representing approximately two-thirds of those affected
(Matossian et al. J Womens Health (Larchmt) 2019; 28:502&ndash;514). Prevalence of DED is anticipated to increase substantially in the
next 10-20 years due to aging populations in the U.S., Europe, Japan and China and use of contact lenses in the younger population. We
believe this increase in prevalence of dry eye syndrome represents a major expanding economic burden to public healthcare. According
to Market Research Report, Dry Eye Syndrome, December 2020, the global DED market in 2019 was approximately $5.22 billion, with the market
size expected to reach $6.54 billion by 2027. In addition, DED causes approximately $3.8 billion annually in healthcare costs and represents
a major economic burden to public healthcare, accounting for more than $50 billion to the U.S. economy annually.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">At present, there are essentially
three major prescription drugs used to treat DED: 1) Restasis (cyclosporine), 2) Xiidra (lifitegrast), and 3) Tyrvaya (Varenicline).
However, DED continues to be a major unmet medical need due to the large number of patients not well served by the treatments available
to them through the medical community. The development of new drugs to treat DED has been particularly challenging due to the heterogeneous
nature of the patient population suffering from DED, and due to the difficulties in demonstrating an improvement in both signs and symptoms
of the disease in well-controlled clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The evidence from over 40 years
of scientific literature, however, suggests inflammation as the most common underlying cause of DED. An increase in the levels of inflammatory
cytokines in both conjunctiva and tears is known to cause the chronic inflammation associated with DED. Consequently, development of new
therapeutic agents that target inflammatory pathways is crucial in improving symptoms in DED patients. OK-101 is focused on an anti-inflammatory
pathway for treating dry eye.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The chemerin receptor (CMKLR1
or ChemR23) is a chemokine like GCPR expressed on select populations of cells including inflammatory mediators as well as epithelial
and endothelial cells. Activation of CMKLR1 by chemerin has been shown to resolve the inflammation in animal models of asthma.
We have been pioneering the development of OK-101, a lipidated-chemerin analogue, which is an agonist of CMKLR1, in treating DED
and other ocular inflammatory conditions. OK-101 was first identified in a program developed by OTT using membrane-tethered ligand
technology.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">To expand our understanding
of the structure-activity relationships of the lipidated-chemerin analogues, such as OK-101. as agonists of the chemerin receptor, we
synthesized a small library of analogues of OK-101. We screened these analogues in a cell-line based receptor binding assay to characterize
the agonist potency of these lipidated-chemerin analogues. This work has also been coupled to an evaluation of a subset of these analogues&rsquo;
potential in treating DED by using a variety of preclinical studies and dry eye animal model studies. After evaluating a number of our
analogues in a mouse model of acute DED by looking at their ability to reduce corneal permeability, a measure of dry-eye effectiveness,
as well as the analogues&rsquo; impact on immune response, we determined that OK-101 was in fact the most potent analogue in reducing
corneal permeability and down-regulating immune response. In addition, in a separate set of animal model experiments, OK-101 was shown
to exhibit potent ocular pain-reducing activity in a mouse model of corneal neuropathic pain. Following these studies, we evaluated
the ocular tolerance of OK-101 <I>via</I> repeated ocular instillation in rabbits followed by clinical ophthalmic observations. Rabbit
ocular tolerance tests on OK-101 showed no adverse signs such as inflammation, chemosis or hyperemia and no signs of local irritation.
With potential anti-inflammatory and analgesic characteristics, we are developing OK-101 for the treatment of DED.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Based on the results from the
DED animal model and ocular tolerance studies, we are moving forward with plans to file an IND in the third or fourth quarter of 2022
on OK-101 to treat DED to enable us to begin clinical trials soon thereafter. During the second quarter of 2021 we successfully manufactured
a 25-gram batch of OK-101 drug substance needed for initiating the IND-enabling studies that were begun during the summer of 2021. To
support this work, we signed an agreement on April 13, 2021 with Ora, Inc., or Ora, a major clinical research organization, or
CRO, specializing in ophthalmic drug development who are providing us the following services:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preparation
    of the OK-101 pre-IND briefing document</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Support
    in requesting and preparing for the OK-101 pre-IND meeting with FDA</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Support
    for regulatory publishing and submission of IND in electronic common technical document, or eCTD, format</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Providing
    quality oversight for development of topical formulation for OK-101</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Providing
    quality oversight for development and qualification of a drug stability analysis method for OK-101 along with conducting stability
    studies to establish formulated drug product is stable for at least 90 days</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Support
    for completing animal toxicology studies in two animal species</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We are committed to
a major effort to finish all IND enabling activities, and we plan to file an IND on OK-101 to treat DED in the
third or fourth quarter of 2022. These activities include:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completing
    topical</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> formulation of the OK-101 drug product
    and initial stability studies</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finalizing
    the bioanalytical</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> method development to support
    the OK-101 clinical program</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completing
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">batch manufacture of current good manufacturing
    practices, or cGMP, OK-101 for clinical trials</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completing
    toxicokinetic</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> method development</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completing
    toxicology</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> studies in rabbits and dogs</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completing
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">stability studies of formulated OK-101</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">We announced on December 6,
2021, based on consultations with Ora, that we are planning to commence the first human study with OK-101 in the fourth quarter of 2022,
and because the drug is designed to be administered topically, we plan to skip the standard Phase 1 studies typically expected
with orally delivered or injectable drug candidates in non-life-threatening conditions. This first trial is planned to be a Phase
2 efficacy clinical trial in DED patients and is anticipated to be conducted in approximately 200 to 250 DED patients. The study is being
designed in conjunction with, and will be managed and monitored by Ora, well known for its leadership of ophthalmic clinical trial activities.
The Phase 2 trial is expected to be completed in 6-8 months from enrollment of the first patient.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">On February 15, 2022, we announced
the successful completion of the pre-IND meeting facilitated by Ora with the FDA regarding development plans for OK-101 to treat DED.
Both nonclinical and clinical development milestones were covered in the pre-IND meeting, with the FDA agreeing that our first
human trial would be a Phase 2 safety and efficacy trial in DED patients. The FDA also provided guidance on the planned
protocol for this trial in DED patients, concurring with our decision to designate co-primary efficacy endpoints covering
both a sign and a symptom of DED in the clinical protocol of the trial. The decision to designate efficacy endpoints as primary endpoints
in this trial is highly significant as should this trial meet its prespecified primary endpoints, this result could accelerate the timeline
to a new drug application, or NDA, filing with the FDA. We are presently on track with our pre-IND work on OK-101 and are planning to
file the IND to treat DED in the third or fourth quarter of 2022, followed by the planned commencement of a Phase 2 trial in DED patients
in the fourth quarter of 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>OKYO Pipeline</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="form424b4_014.jpg" ALT="" STYLE="height: 287px; width: 540px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><B>Additional Applicable Disease Indications for OK-101</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">A second related ophthalmic disease
indication that is the target of our chemerin-based technology is uveitis. Uveitis is the third leading cause of blindness worldwide.
The most common type of uveitis is an inflammation of the iris called iritis (anterior uveitis). Uveitis can damage vital eye tissue,
leading to permanent vision loss. Uveitis is currently treated with corticosteroid eyedrops and injections that reduce inflammation, however,
the long-term use of corticosteroids causes risk of cataract and glaucoma, requiring close monitoring for their potential side effects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We believe that OK-101, in addition
to its potential to treat DED, should also be evaluated to treat allergic conjunctivitis and uveitis. Correspondingly, once we have an
IND on OK-101 in place and are clinically evaluating OK-101 to treat DED, we also plan to explore the drug candidate&rsquo;s potential
to suppress the inflammation associated with allergic conjunctivitis and uveitis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">On January 19, 2021, we announced
that we submitted a patent application to the United States Patent and Trademark Office covering the use of chemerin and chemerin analogues
to treat the cytokine release syndrome associated with COVID-19 infections and other conditions such as acute respiratory distress syndrome,
or ARDS. On January 15, 2021, we signed a research and material transfer agreement with the University of Alabama at Birmingham to
evaluate the potential of chemerin analogs, including OK-101, to minimize the inflammation triggered by SARS-CoV-2 in a model
of lung inflammation. <I>Ex vivo</I> lung tissue will be experimentally induced to produce inflammation, and during the course of inflammation
in the absence and presence, respectively, of a chemerin analogue, a panel of cytokines including TNF&alpha;, IL-6, IL-1&beta; will be
measured. Currently, experiments are underway at the University of Alabama, but we have not reported yet on the results of this
study. Assuming the results are encouraging, our plan is to advance this program as a potential prophylaxis to treat COVID-19 infections,
and to treat other conditions such as ARDS. We plan this work to be under the direction of Dr. Napoleone Ferrara, a member of
our Scientific Advisory Board.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><B><I>OK-201</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">MAS-Related G Protein-Coupled
Receptors, or MRGPRs, mainly expressed in the sensory neurons, are involved in the perception of pain, thus making them a promising analgesic
target. Activation of MRGPR by Bovine Adrenal Medulla, or BAM, peptide inhibits pain perception by modulating Ca2+ influx. OK-201, a BAM
peptide analogue, licensed from TMC on May 1, 2018, is a potent agonist of human MRGPR and a promising candidate for the treatment of
neuropathic and inflammatory pain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">On August 6, 2019,
we signed a collaborative agreement with TMC and Pedram Hamrah, MD, Professor of Ophthalmology at Tufts University School of Medicine,
Boston, MA as Principal Investigator to evaluate OK-201 and other proprietary lead compounds to suppress corneal neuropathic pain
using a mouse ocular pain model recently developed in Dr. Hamrah&rsquo;s laboratory. Our goal was to further develop this lipidated
peptide, as well as explore additional analogues, for their potential use in treating ocular pain, and for potentially treating long-term
chronic pain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.25in">On April 28, 2021, we
announced positive results of OK-201, a non-opioid analgesic drug candidate delivered topically in Dr. Hamrah&rsquo;s mouse
neuropathic corneal pain model, as a potential drug to treat acute and chronic ocular pain. Importantly, OK-201 demonstrated a
reduced corneal pain response equivalent to that of gabapentin, a commonly used oral drug for neuropathic pain. These observations
demonstrated preclinical &lsquo;proof-of-concept&rsquo; for the topical administration of OK-201 as a potential non-opioid analgesic
for ocular pain. Current treatments for corneal pain are limited to short term non-steroidal anti-inflammatory drugs, or NSAIDs,
steroids, and oral gabapentin and opioids in severe cases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Although the results with
OK-201 were encouraging, due to subsequent success obtained with OK-101 (see section on OK-101) in follow-on animal model studies utilizing
the same mouse neuropathic corneal pain model as for OK-201, we have decided to maintain this drug candidate at the exploratory level
while we focus our primary energy on the OK-101 program to treat DED, based on OK-101&rsquo;s combination of anti-inflammatory and ocular
pain-reducing activities in animal models of these conditions.</P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>Summary of</B><B> Risks Affecting Our Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Our business is subject to a number of risks of which you should be aware
before making an investment decision. You should carefully consider all of the information set forth in this prospectus and, in particular,
should evaluate the specific factors set forth in the section titled &ldquo;Risk Factors&rdquo; before deciding whether to invest in our
ADSs. These important risks include, but are not limited to, the following:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#9679;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">We
    have only recently committed to our new business and our product candidates are in the early stages of development and it may be
    some years until we generate revenue, if at all.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#9679;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Our
    product candidates have not been evaluated in clinical trials and results in the clinic may not be reproduced in human trials.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#9679;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">There
    is a high degree of failure for product candidates as they progress through clinical trials and clinical trial data may be interpreted
    in varying ways which may delay, limit or prevent future regulatory approvals.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#9679;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">The
    development of pharmaceutical products carries significant risk of failure in early and late stage development programs.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: normal 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#9679;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">We
    anticipate that we will continue to incur significant losses for the foreseeable future.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#9679;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">We
    will need to spend extensively on further research activities and there can be no guarantee that we will have access to sufficient
    funds to fully realize our research and development plan or to commercialize any products derived from research activities.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#9679;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Even
    if we successfully develop a product which shows efficacy in human subjects there remain high barriers to commercial success.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#9679;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">We
    face significant competition from pharmaceutical companies. We have competitors internationally, including major multinational pharmaceutical
    companies, universities and research institutions. In respect of OK-101 as an indication for the treatment of DED, there are a number
    of established companies engaged in the development and marketing of preparations addressing the DED market. In addition, there are
    a wide range of products addressing the DED market currently approved and marketed by a number of large and small pharmaceutical
    companies.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#9679;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">The
    expiration of certain intellectual property rights or an inability to obtain, maintain or enforce adequate intellectual property
    rights for products that are marketed or in development may result in additional competition from other third-party products. Third
    parties may have blocking intellectual property rights which could prevent the sale of products by us or require that compensation
    be paid to such third parties.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#9679;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Our
    product candidates could infringe patents and other intellectual property rights of third parties.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#9679;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">COVID-19
    has adversely affected our business, and any new pandemic, epidemic or outbreak of an infectious disease may further adversely affect
    our business.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#9679;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">The
    relationship of the UK with the EU could impact our ability to operate efficiently in certain jurisdictions or in certain markets.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#9679;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Even
    if we complete the necessary clinical trials, we cannot predict when, or if, we will obtain regulatory approval to commercialize
    our product candidates and the approval may be for a more narrow indication than we seek.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#9679;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">If
    our competitors are able to obtain orphan drug exclusivity for products that constitute the same drug and treat the same indications
    as our product candidates, we may not be able to have competing products approved by applicable regulatory authorities for a significant
    period of time. In addition, even if we obtain orphan drug exclusivity for any of our products, such exclusivity may not protect
    us from competition.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#9679;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Even
    if we obtain regulatory approval for a product candidate, our product candidates will remain subject to regulatory oversight.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#9679;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Even
    if we obtain and maintain approval for our product candidates in a major pharmaceutical market such as the United States, we may
    never obtain approval for our product candidates in other major markets.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#9679;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">We
    may seek a conditional marketing authorization in the United Kingdom and EU for some or all of our current product candidates,
    but we may not be able to obtain or maintain such designation.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#9679;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Healthcare
    legislative reform measures may have a negative impact on our business and results of operations.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#9679;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">We
    are subject to governmental regulation and other legal obligations related to privacy, data protection and data security. Our actual
    or perceived failure to comply with such obligations could harm our business.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#9679;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">We
    do not know whether an active, liquid and orderly trading market will develop for our ADSs or what the market price of our ADSs will
    be. As a result, it may be difficult for ADS holders to sell their ADSs.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#9679;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">If
    you purchase ADSs in this offering, you will suffer immediate dilution of your investment.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#9679;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Holders
    of our ADSs may experience substantial dilution upon the exercise of outstanding options and warrants.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#9679;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Holders
    of our ADSs have fewer rights than our shareholders and must act through the depositary to exercise their rights.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#9679;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">The
    rights of our shareholders may differ from the rights typically offered to shareholders of a U.S. corporation.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#9679;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">If
    we are a passive foreign investment company, there could be adverse U.S. federal income tax consequences to U.S. holders.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were originally incorporated in the British Virgin Islands as a British Virgin Islands Business Company on July 4, 2007 under the BVI
Business Companies Act 2004 with company number 1415559 under the name Jellon Enterprises, Inc.. Our legal and commercial name
was changed to Minor Metals &amp; Mining, Inc. on October 24, 2007, to Emerging Metals Limited on November 28, 2007, to West African
Minerals Corporation on December 9, 2011, and to OKYO Pharma Corporation on January 10, 2018. On March 9, 2018, shareholders approved
the cancellation of our AIM listing and migration to Guernsey. On July 3, 2018, following the approval of the Guernsey Companies Registry,
we were registered under the Guernsey Companies Law under the name OKYO Pharma Limited, as a Guernsey company with limited liability,
an indefinite life and company number 65220. We are domiciled in Guernsey. On July 17, 2018, our Ordinary Shares were admitted
to listing on the standard segment of the Official List of the FCA and admitted to trading on the Main Market of
the London Stock Exchange. We are subject to the Takeover Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
registered office is located at Martello Court, Admiral Park, St. Peter Port, Guernsey GY1 3HB and our telephone number is +44 (0) 20
7495 2379. Our website address is www.okyopharma.com. The reference to our website is an inactive textual reference only and the information
contained in, or that can be accessed through, our website is not a part of this registration statement. Our agent for service of process
in the United States is OKYO Pharma US, Inc..</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;OKYO,&rdquo;
the OKYO logo and other trademarks or service marks of OKYO Pharma Limited appearing in this prospectus are the property of OKYO or our
subsidiary. This prospectus contains additional trade names, trademarks and service marks of others, which are the property of their
respective owners. Solely for convenience, trademarks and trade names referred to in this prospectus may appear without the &reg; or
<SUP>TM</SUP> symbols.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Implications
of Being an Emerging Growth Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an EGC as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. As such, we may take advantage of certain
exemptions from various reporting requirements that are applicable to other publicly traded entities that are not EGCs. These exemptions
include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    option to present only two years of audited financial statements and related discussion in the section titled &ldquo;Management&rsquo;s
    Discussion and Analysis of Financial Condition and Results of Operations&rdquo; in this prospectus;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
    being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, or Sarbanes-Oxley
    Act;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
    being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory
    audit firm rotation or a supplement to the auditor&rsquo;s report providing additional information about the audit and the financial
    statements (i.e., an auditor discussion and analysis);</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
    being required to submit certain executive compensation matters to stockholder advisory votes, such as &ldquo;say-on-pay,&rdquo;
    &ldquo;say-on-frequency,&rdquo; and &ldquo;say-on-golden parachutes;&rdquo; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
    being required to disclose certain executive compensation related items such as the correlation between executive compensation and
    performance and comparisons of the chief executive officer&rsquo;s compensation to median employee compensation.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
107 of the JOBS Act also provides that an EGC can take advantage of the extended transition period provided in Section 13(a) of the Exchange
Act, for complying with new or revised accounting standards. As a result, an EGC can delay the adoption of certain accounting standards
until those standards would otherwise apply to private companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will remain an EGC until the earliest of: (1) the last day of the first fiscal year in which our annual gross revenues exceed $1.07 billion;
(2) the last day of 2023; (3) the date that we become a &ldquo;large accelerated filer&rdquo; as defined in Rule 12b-2 under the Exchange
Act, which would occur on the last day of any fiscal year that the aggregate worldwide market value of our common equity held by non-affiliates
exceeds $700 million as of the last business day of our most recently completed second fiscal quarter; or (4) the date on which
we have issued more than $1.0 billion in non-convertible debt securities during any three-year period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Implications
of Being a Foreign Private Issuer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the completion of this offering, we will report under the Exchange Act as a non-U.S. company with FPI status. Even after we no longer
qualify as an EGC, as long as we qualify as an FPI under the Exchange Act we will be exempt from certain provisions of the Exchange Act
that are applicable to U.S. domestic public companies, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered
    under the Exchange Act;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading activities and liability
    for insiders who profit from trades made in a short period of time; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    rules under the Exchange Act requiring the filing with the SEC of quarterly reports on Form 10-Q containing unaudited financial and
    other specific information, and current reports on Form 8-K upon the occurrence of specified significant events.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FPIs
are also exempt from certain more stringent executive compensation disclosure rules. Thus, even if we no longer qualify as an EGC, but
remain an FPI, we will continue to be exempt from the more stringent compensation disclosures required of companies that are neither
an EGC nor an FPI.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>The
Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; text-align: justify"><FONT STYLE="font-size: 10pt">ADSs offered by us</FONT></TD>
    <TD STYLE="width: 2%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 58%; text-align: justify"><FONT STYLE="font-size: 10pt">625,000</FONT><FONT STYLE="font-size: 10pt"> ADSs.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Ordinary shares to be outstanding after this offering (1)</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">1,415,040,468</FONT><FONT STYLE="font-size: 10pt"> ordinary
    shares (or 1,421,134,218 ordinary shares if the underwriters exercise in full their over-allotment option to purchase 93,750
    ADSs)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Over-allotment option</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">93,750</FONT><FONT STYLE="font-size: 10pt"> ADSs.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">ADSs</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Each ADS represents 65 ordinary shares of no par value. The depositary will hold the ordinary shares underlying your ADSs and you will have rights as provided in the deposit agreement among us, the depositary, and holders and beneficial owners of ADSs from time to time. To better understand the terms of our ADSs, see &ldquo;Description of the American Depositary Shares.&rdquo; We also encourage you to read the deposit agreement, the form of which is filed as an exhibit to the registration statement of which this prospectus forms a part.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Depositary</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">JPMorgan Chase Bank, N.A..</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Use of proceeds</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We estimate that the net proceeds from our sale
    of ADSs in this offering will be approximately $1.8 million (or approximately $2.2 million if the underwriters exercise their over-allotment
    option in full), at an IPO price of $4.00 per ADS, after deducting the underwriting discounts and commissions and estimated
    offering expenses payable by us.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">We intend to use the
    net proceeds we receive from this offering to advance OK-101 to the filing of an IND, to fund the</FONT><FONT STYLE="font-size: 8pt">&nbsp;</FONT><FONT STYLE="font-size: 10pt">start
    of the first Phase 2 clinical trial of OK-101 and for working capital and other general corporate purposes.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">See &ldquo;Use of Proceeds&rdquo; for additional information.</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Risk factors</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">See &ldquo;Risk Factors&rdquo; and the other information included in this prospectus for a discussion of factors you should carefully consider before deciding to invest in our ADSs.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"> Nasdaq Capital Market symbol</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;OKYO&rdquo;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">(1) The number of ordinary shares
to be outstanding after this offering is based on 1,374,415,468 ordinary shares outstanding as of May 12, 2022, and excludes:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">72,400,000
    ordinary shares issuable upon the exercise of share options at exercise prices of between $0.056 and $0.191 per ordinary
    share of which 14,437,500 ordinary shares are currently exercisable and 57,962,500 are exercisable between July 6, 2022 and January
    31, 2032; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36,659,090 ordinary shares
    that currently may be issued upon the exercise of warrants to purchase ordinary shares at exercise prices of between $0.034
    and $0.17 per ordinary share.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 36px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;otherwise indicated,
    this prospectus reflects and assumes the following:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no exercise of outstanding
    share options or warrants after May 12, 2022; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    exercise of the underwriters&rsquo; over-allotment option.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Summary
Consolidated Financial Data</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables set forth our summary consolidated financial data for the periods indicated. We have derived the consolidated statement
of operations data for the years ended March 31, 20201, 2020 and 2019 and the consolidated balance sheet data as of March 31,
2021 from our audited consolidated financial statements included elsewhere in this prospectus. The unaudited consolidated statement
of operations data for the six months ended September 30, 2020 and 2019 and the unaudited consolidated balance sheet data as at September
30, 2020 have been derived from our unaudited consolidated financial statements for the periods included elsewhere in this prospectus.
Our historical results are not necessarily indicative of the results that should be expected for any future period. You should read the
following summary consolidated financial data together with the audited consolidated financial statements included elsewhere in this
prospectus and the sections titled &ldquo;Exchange Rate Information&rdquo; and &ldquo;Management&rsquo;s Discussion and Analysis of Financial
Condition and Results of Operations.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain our books and records in Pounds Sterling, and we prepare our financial statements in accordance with IFRS as issued by the IASB.
We report our financial results in U.S. dollars.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consolidated
Statement of Operations Data:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Six
    Months Ended<BR> September 30,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Years Ended <BR> March 31,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2021<BR>
    (unaudited)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2020<BR>
    (unaudited)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Revenue</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating expenses:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left; padding-left: 10pt">Research and development</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">(479,700</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">(37,622</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">(173,821</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">(518,098</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">General and administrative</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,254,393</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(517,825</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,192,385</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,016,548</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Total operating expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,734,092</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(555,447</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,366,207</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,534,646</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Loss from operations</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,734,092</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(555,447</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,366,207</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,534,646</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Other income (expense), net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,021</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(69,608</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(12,294</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(85,701</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Tax provision</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">188,761</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(87</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">24,994</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">76,289</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Net loss attributable to ordinary shareholders</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,546,353</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(625,142</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,353,507</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,544,059</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Other comprehensive loss:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Foreign currency translation adjustment</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">37,845</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12,479</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">346,365</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">86,654</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Total comprehensive loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,508,508</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(612,663</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,007,142</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,457,405</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Basic and diluted net loss per ordinary share</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(0.00</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(0.00</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(0.01</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(0.00</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consolidated
Balance Sheet Data:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Six Months Ended</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>September 30, 2021</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Actual</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As Adjusted (1)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: left">Cash and cash equivalents</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">5,184,149</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">7,007,849</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Working capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4,919,488</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6,743,188</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,624,610</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7,448,310</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total shareholders&rsquo; equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4,958,282</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6,781,982</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(1)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">As
                                            adjusted to give effect to the sale by us of 625,000 ADSs (representing 40,625,000
                                            ordinary shares) at an initial public offering price of $4.00 per ADS in this
                                            offering, after deducting the estimated underwriting discounts and commissions and estimated
                                            offering expenses payable by us in connection with this offering.</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="cr_005"></A>RISK
FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>You
should carefully consider the risks described below, together with all of the other information in this registration statement. The risks
and uncertainties below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we believe
to be immaterial may also adversely affect our business. If any of the following risks occur, our business, financial condition and results
of operations could be seriously harmed and potential future investors in our ADSs could lose all or part of their investment. Further,
if we fail to meet the expectations of the public market in any given period, the potential market price of our ADSs could decline. We
operate in a highly competitive environment that involves significant risks and uncertainties, some of which are outside of our control.
If any of these risks actually occurs, our business and financial condition could suffer and the potential market price of our ADSs could
decline. </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Relating to Our Business </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have only recently committed to our new business and our product candidates are in the early stages of development and it may be some
years until we generate revenue, if at all.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product candidates, OK-101 and OK-201, are both very early in the development stage and even the lead product candidate, OK-101,
is still in the pre-clinical stage. Through our scientific collaborators, we have only recently completed initial pre-clinical studies
with respect to OK-101 and OK-201 and our ability to generate product revenue, which is not expected to occur for several years, if ever,
will depend heavily on the successful development of the product candidates, many stages of clinical trials, regulatory approval and
eventual commercialization. We have only recently committed to our new business operating as a life sciences and biotechnology business.
We currently generate no revenue from sales of any product and may never be able to develop or commercialize a marketable product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
product candidates have not been evaluated in clinical trials and results in the clinic may not be reproduced in human trials.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
early stages of our business strategy carry significant risks associated with product candidates which have not been evaluated in human
clinical trials. Not only may encouraging results seen in pre-clinical trials not be indicative of results in later clinical trials but
given that the product candidates have only been evaluated in mouse models to date, unexpected or adverse effects may be seen once the
product candidates enter the human clinical trials stage which in turn may create significant hurdles to further development or lead
to the abandonment of further development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>There
is a high degree of failure for product candidates as they progress through clinical trials and clinical trial data may be interpreted
in varying ways which may delay, limit or prevent future regulatory approvals.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
companies in the life sciences and biotechnology sector have made significant initial progress only to suffer significant setbacks in
later stage clinical trials and there is a high failure rate for product candidates as they proceed through clinical trials. Data obtained
from pre-clinical and clinical activities is subject to varying interpretations which may delay, limit or prevent applications for regulatory
approvals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
development of pharmaceutical products carries significant risk of failure in early and late stage development programs.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development of pharmaceutical products is inherently uncertain, even in late-stage product development programs. There is a high failure
rate in the development of pharmaceutical products and there is a substantial risk of adverse, undesirable, unintended or inconclusive
results from testing or pre-clinical or clinical trials, which may substantially delay, or halt entirely, or make uneconomic, any further
development of our products and may prevent or limit the commercial use of such products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the pre-clinical development of OK-101 and initial studies in animal models have been encouraging, the scope of these studies is limited,
and significant risks exist that OK-101 may never progress to a commercially viable product. Laboratory studies in animal models
carry the risk that similar results may not be seen or reproduced in future tests and trials, and there can be no guarantee that a successful
test in a mouse or other animal model will be capable of being reproduced in a human clinical trial. Small scale trials and the results
thereof, can be misleading as to efficacy, safety and other findings, as the outcome may be influenced by laboratory or demographic factors
and not due to the chemistry or biological effect of the drug candidate being evaluated. Larger scale trials often fail to produce the
same positive results seen in small scale trials for a variety of reasons and clinical trials in humans frequently fail to reproduce
efficacy seen in animal trials in the laboratory. Failure can often result after significant sums have been expended on research and
often where initial trial results (both in animals and in humans) have shown very encouraging results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
initially intends to conduct laboratory and pre-clinical trials to establish safety and efficacy of our products. Due to the inherent
risks involved in developing pharmaceutical products, there is a risk that some or all of our products will not ultimately be successfully
developed or launched. In addition, the planned clinical trials may fail to show the desired safety and efficacy. This may be the case
even if the FDA approves an IND application as positive data in animal studies may not be reflected or reproduced in human trials.
Successful completion of one stage of development of a pharmaceutical product does not ensure that subsequent stages of development will
be successful. Our inability to market any of our products currently under development would adversely affect our business and financial
condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently primarily dependent for our short to medium-term success on a single early-stage product, OK-101, which is a research product
that has shown pre-clinical potential but has not yet been tested on humans and has not obtained the necessary approvals required to
conduct Phase I clinical trials in humans.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
commercial development of OK-101 is highly dependent on a number of factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.45pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    successful conduct of human trials in the initial indications of DED;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">receipt
    of marketing approvals for OK-101 in the United States and other jurisdictions where separate approval is required and where we subsequently
    choose to market OK-101;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">launching
    commercial sales of OK-101, if and when approved;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">acceptance
    of OK-101 by patients, the medical community and third-party payers;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OK-101
    competing effectively with existing therapies and in particular with established products addressing the same clinical needs;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OK-101
    influencing the treatment guidelines in relevant territories; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">further
    clinical trials to provide additional data to support commercialization of OK-101 and to permit wider label claims.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of these milestones are not met, our business, financial condition, prospects and results of operations could be materially adversely
affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Financial Position and Need for Capital.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
will need to raise substantial additional capital to develop and commercialize our product candidates and our failure to obtain funding
when needed may force us to delay, reduce or eliminate our product development programs or collaboration efforts.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">As of September 30, 2021,
our cash and cash equivalents balance was approximately $5.2 million and our working capital was approximately $4.9 million.
Due to our recurring losses from operations and the expectation that we will continue to incur losses in the future, we will be required
to raise additional capital to complete the development and commercialization of our current product candidates. We have historically
relied upon private and public sales of our equity, as well as debt financings to fund our operations. In order to raise additional capital,
we may seek to sell additional equity and/or debt securities or obtain a credit facility or other loan, which we may not be able to do
on favorable terms, or at all. Our ability to obtain additional financing will be subject to a number of factors, including market conditions,
our operating performance and investor sentiment. If we are unable to raise additional capital when required or on acceptable terms,
we may have to significantly delay, scale back or discontinue the development and/or commercialization of our product candidate, restrict
our operations or obtain funds by entering into agreements on unfavorable terms. Failure to obtain additional capital at acceptable terms
would result in a material and adverse impact on our operations.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern, which
may hinder our ability to obtain future financing.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mazars
LLP, our independent registered public accounting firm for the fiscal year ended March 31, 2021, has included an explanatory paragraph
in their opinion that accompanies our audited consolidated financial statements as of and for the year ended March 31, 2021, indicating
that liquidity position post December 2022 raises substantial doubt about our ability to continue as a going concern. If we are unable
to improve our liquidity position by December 2022, we may not be able to continue as a going concern. The accompanying consolidated
financial statements do not include any adjustments that might result if we are unable to continue as a going concern and, therefore,
be required to realize our assets and discharge our liabilities other than in the normal course of business which could cause investors
to suffer the loss of all or a substantial portion of their investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
anticipate that we will continue to incur significant losses for the foreseeable future.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amount of our future net losses will depend, in part, on the rate of our future expenditures, including further research and development
activity. The amount of net losses will also depend on our success in developing and commercializing OK-101 and other products that generate
significant revenue. Any failure by us to become and remain profitable could depress the value of the ADSs and could impair our ability
to expand our business, maintain our research and development efforts, diversify our product offerings or continue our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
will need to spend extensively on further research activities and there can be no guarantee that we will have access to sufficient funds
to fully realize our research and development plan or to commercialize any products derived from research activities.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to incur further significant expenses in connection with our ongoing research and development activities in relation to our products,
including for funding clinical studies, registration, manufacturing, marketing, sales and distribution. In order to finance fully our
strategy, we may require more capital than is available from our existing cash balances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Access
to adequate additional financing, whether through debt financing, an equity capital raise or a suitable partnering transaction may not
be available to us on acceptable terms, or at all. Further, while the potential economic impact brought by, and the duration of the COVID-19
pandemic is difficult to assess or predict, the impact of the COVID-19 pandemic on the global financial markets may reduce our ability
to access capital, which could negatively impact our short-term and long-term liquidity. If we are unable to raise capital, we could
be forced to delay, reduce or eliminate our research and development programs or commercialization efforts. Any additional equity fundraising
may be dilutive for our shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these events could have a material adverse effect on our business financial condition, prospects and results of operation and may
lead us to delay, reduce or abandon research and development programs or commercialization of some of our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Commercialization of Our Product Candidates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even
if we successfully develop a product which shows efficacy in human subjects there remain high barriers to commercial success</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we were to receive regulatory approval for OK-101 or any other products, we may be unable to commercialize them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are a number of factors that may inhibit our efforts to commercialize OK-101 or any other products on our own, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    inability to recruit, train and retain adequate numbers of effective sales and marketing personnel;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    inability of sales personnel to obtain access to or persuade adequate numbers of potential practitioners to prescribe any future
    products;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unforeseen
    costs and expenses associated with creating an independent sales and marketing organization;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    of marketing and promotion above those anticipated by us; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    inability to secure a suitable level of pricing and/or reimbursement approval from the relevant regulatory authorities in the countries
    we are targeting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we may only seek to enter into arrangements with third parties to perform sales and marketing services in non-core territories, any such
arrangements could result in our product revenues (or the profitability of such product revenues) being lower than if we were to market
and sell the products itself. In addition, we may not be successful in entering into arrangements with third parties to sell and market
our products or may be unable to do so on terms that are favorable to us. Acceptable third parties may fail to devote the necessary resources
and attention to sell and market our products effectively. If we do not establish sales and marketing capabilities successfully, either
on our own or in collaboration with third parties, we will not be successful in commercializing our products, which in turn would have
a material adverse effect on our business, prospects, financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have also invested and will continue to invest resources into the development of other products, such as OK-201. Even where these products
are successfully developed and marketing approval is secured from relevant regulatory authorities, these products might not achieve commercial
success. Factors which could limit commercial success of a product include but are not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">limited
    market acceptance or a lack of recognition of the unmet medical need for the product amongst prescribers;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">new
    competitor products entering the market;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number and relative efficacy, safety or cost of competitive products;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    inability to supply a sufficient amount of the product to meet market demand;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">insufficient
    funding being available to market the product adequately;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    inability to enforce intellectual property rights, or the existence of third-party intellectual property rights;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">safety
    concerns arising pre- or post-launch resulting in negative publicity or product withdrawal or narrowing of the product label and
    the group of persons who may receive the product;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">labelling
    being restricted/narrowed in the future and in the future by regulatory agencies; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusals
    by government or other healthcare payors to fund the purchase of the products by healthcare providers at a commercially viable level
    (or at all) or otherwise to restrict the availability of approved products on other grounds.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of the foregoing were to occur, it could materially and adversely affect our business, financial condition, prospects and results
of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
face significant competition from pharmaceutical companies. We have competitors internationally, including major multinational pharmaceutical
companies, universities and research institutions. In respect of OK-101 as an indication for the treatment of DED, there are a number
of established companies engaged in the development and marketing of preparations addressing the DED market. In addition, there are a
wide range of products addressing the DED market currently approved and marketed by a number of large and small pharmaceutical companies</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of our competitors have substantially greater financial, technical and other resources, such as larger research and development teams,
proven marketing and manufacturing organizations and well-established sales forces. Our competitors may succeed in developing, acquiring
or licensing drug products that are more effective or less costly than products which we are currently developing or which it may develop.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Established
pharmaceutical companies may invest heavily to accelerate the discovery and development of products that could make our products less
competitive. In addition, any new product that competes with an approved product must demonstrate compelling advantages in efficacy,
convenience, tolerability or safety in order to overcome price competition and to be commercially successful. Accordingly, our competitors
may succeed in obtaining patent protection, receiving approval from the FDA, the European Medicines Agency, or EMA, or that of another
relevant regulatory authority or discovering, developing and commercializing pharmaceutical products before we do, which would have a
material adverse effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
availability and price of our competitors&rsquo; products could limit the demand, and the price we are able to charge, for any of our
products, if approved for sale. We will not achieve our business plan if acceptance is inhibited by price competition or the reluctance
of physicians to switch from existing drug products to our products, or if physicians switch to other new drug products or choose to
reserve our products for use in limited circumstances. Competition from lower-cost generic pharmaceuticals may also result in significant
reductions in sales volumes or prices for our products, which could materially adversely affect our business, prospects, financial condition
and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are dependent on third party supply, development and manufacturing and clinical service relationships and on single manufacturing sites
for certain products. Our business strategy utilizes the expertise and resources of third parties in a number of areas, including the
conduct of clinical trials, other product development, manufacture and the protection of our intellectual property rights in various
geographical locations. This strategy creates risks for us by placing critical aspects of our business in the hands of third parties
whom we may not be able to manage or control adequately and who may not always act in our best interests.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
we are dependent upon third parties for the development or manufacture of certain products, our ability to procure our development or
manufacture in a manner which complies with regulatory requirements may be constrained, and our ability to develop and deliver such material
on a timely and competitive basis may be materially adversely affected, which may impact revenues.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
requirements for pharmaceutical products tend to make the substitution of suppliers and contractors costly and time-consuming. Alternative
suppliers may not be able to manufacture products effectively or obtain the necessary manufacturing licenses from relevant regulatory
authorities. The unavailability of adequate commercial quantities, the inability to develop alternative sources, a reduction or interruption
in supply of contracted services, or a significant increase in the price of materials and services, could have a material adverse effect
on our ability to manufacture and market our products or to fulfill orders from our distributors or licensees, which in turn would have
a material adverse impact on our cash flows.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Insurance
coverage and reimbursement may be limited, unavailable or may be reduced over time in certain market segments for our products.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Government
authorities and third-party payers, such as private health insurers, decide which pharmaceutical products they will cover and the amount
of reimbursement. Reimbursement may depend upon a number of factors, including the payer&rsquo;s determination that use of a product
is:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    covered benefit under the payor&rsquo;s health plan;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">safe,
    effective and medically necessary;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">appropriate
    for the specific patient;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">cost-effective;
    and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">neither
    experimental nor investigational.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
coverage and reimbursement approval for a product from a government or other third- party payer is a time-consuming and costly process
that could require us to provide supporting scientific, clinical and cost-effectiveness data for the use of our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement, or to demonstrate commercial
value compared to existing established treatments. Even if we are able to furnish the requested data, there is no guarantee that a third-party
payor will cover a product. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory
levels, we may be unable to achieve or sustain profitability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may, in the future, seek approval to market our products in the EU, the US and in selected other jurisdictions. In the EU, the pricing
of prescription pharmaceuticals is subject to national governmental control and pricing negotiations with governmental authorities can,
in some circumstances, take several years after obtaining marketing approval for a product. In addition, market acceptance and sales
of our products will depend significantly on the availability of adequate coverage and reimbursement from third-party payers and may
be affected by existing and future healthcare reform measures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
continuing efforts of governments, insurance companies, managed care organizations and other payers of healthcare services to contain
or reduce costs of healthcare and/or impose price controls may materially adversely affect our ability to set prices for our products,
generate revenues and achieve or maintain profitability. Any reduction in government reimbursement programs may result in a similar reduction
in payments from private payers, which may materially adversely affect our business, prospects, financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Intellectual Property </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
expiration of certain intellectual property rights or an inability to obtain, maintain or enforce adequate intellectual property rights
for products that are marketed or in development may result in additional competition from other third-party products. Third parties
may have blocking intellectual property rights which could prevent the sale of products by us or require that compensation be paid to
such third parties</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
extent of our success will, to a significant degree, depend on our ability to establish, maintain, defend and enforce adequate intellectual
property rights and to operate without infringing the proprietary or intellectual property rights of third parties. We have been granted,
or have in-licensed rights under, a number of key patent families for OK-101 (or other proprietary rights), and patent applications are
pending in the U.S., the EU, and certain other jurisdictions. We may develop or acquire further technology or products that are not patentable
or otherwise protectable. The strength of patents in the pharmaceutical field involves complex legal and scientific questions and can
be uncertain. Patents or other rights might not be granted under any pending or future applications filed or in-licensed by us and any
claims allowed might not be sufficiently broad to protect our technologies and products from competition. Competitors may also successfully
design around key patents held by us, thereby avoiding a claim of infringement. There is a risk that not all relevant prior art has been
identified with respect to any particular patent or patent application and the existence of such prior art may invalidate any patents
granted (or result in a patent application not proceeding to grant). Patents or other registerable rights might also be revoked for other
reasons after grant. Third parties may challenge the validity, enforceability or scope of any granted patents. Our defense of our proprietary
rights could involve substantial costs (even if successful) and could result in declarations of invalidity or significantly narrow the
scope of those rights, limiting their value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competitors
may have filed applications or been granted patents, or obtained additional patents and proprietary rights, which relate to and could
be infringed by our products. An adverse outcome with respect to third party rights such as claims of infringement of patents or third-party
proprietary rights by us could subject us to significant liabilities or require us to obtain a license for the continued use of the affected
rights, which may not be available on acceptable terms or at all, or require us to cease commercialization and development efforts, or
the sale of the relevant products, in whole or in part in the relevant jurisdictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
could be subject to claims for compensation by third parties claiming an ownership interest in the intellectual property rights relating
to a commercially successful product. This may include claims from employee inventors in territories which permit such claims even where
we own the intellectual property rights in question. Any such failure to defend our proprietary intellectual property could have a material
adverse effect on our business, prospects, financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may not be able to obtain, maintain, defend or enforce the intellectual property rights covering our products</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have had certain patents licensed to us in jurisdictions we consider to be important to our business. However, we cannot predict:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    degree and range of protection any patents will afford against competitors and competing technologies, including whether third parties
    will find ways to invalidate or otherwise circumvent the patents by developing a competitive product that falls outside its scope;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if,
    or when any patents will be granted;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">that
    granted patents will not be contested, invalidated or found unenforceable;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    or not others will obtain patents claiming aspects similar to those covered by the Company&rsquo;s patents and patent applications;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    we will need to initiate litigation or administrative proceedings, or whether such litigation or proceedings will be initiated by
    third parties against us, which may be costly and time consuming; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    third parties will claim that our technology infringes upon their rights.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we believe that we have novel composition of matter on the OK-101 peptide and novel methods of its use in treating DED, we cannot be
sure that these patent applications will issue as patents. Each patent office has different patentability requirements, but we believe
that the license patent applications contain patentable subject matter. The process for issuance of a patent involves  correspondence
with each local patent office in the jurisdictions in which the patent application is filed. That process, patent prosecution, involves
a discussion of any relevant prior art and typically a discussion of the scope of the claims. The patent prosecution process can take
several years depending on the jurisdiction and is not in the control of the patent owner, but in the control of the local patent office.
We cannot be sure the outcome of the patent prosecution will be successful and result in issued patents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent
protection is of importance to us in maintaining our competitive position in our planned product lines and a failure to obtain or retain
adequate protection could have a material adverse effect on our business, prospects, financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may not be able to prevent disclosure of our trade secrets, know-how or other proprietary information.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on trade secret protection to protect our interests in proprietary know-how and in processes for which patents are difficult to
obtain or enforce. If we are unable to protect our trade secrets adequately the value of our technology and products could be significantly
diminished. Furthermore, our employees, consultants, contract personnel or third-party partners, either accidentally or through willful
misconduct, may cause serious damage to our programs and/or our strategy by disclosing confidential information to third parties. It
is also possible that confidential information could be obtained by third parties as a result of breaches of our physical or electronic
security systems. Any disclosure of confidential data into the public domain or to third parties could allow third parties to access
confidential information and use it in competition with us. In addition, others may independently discover the confidential information.
Any action to enforce our rights against any misappropriation or unauthorized use and/or disclosure of confidential information is likely
to be time-consuming and expensive, and may ultimately be unsuccessful, or may result in a remedy that is not commercially valuable.
Any such loss of confidential information or failure to enforce our rights in relation to such confidential information, or unsatisfactory
outcome of any related litigation could have a material adverse effect on our business, prospects, financial condition or results of
operation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
product candidates could infringe patents and other intellectual property rights of third parties.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success depends upon our ability, and the ability of any third party with which we may partner to develop, manufacture, market
and sell our products and use our patent- protected technologies without infringing the patents of third parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
products may infringe or may be alleged to infringe existing patents or patents that may be granted in the future which may result in
costly litigation and could result in our having to pay substantial damages or limit our ability to commercialize our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
some patent applications in Europe, the U.S. and many foreign jurisdictions may be maintained in secrecy until the patents are issued,
patent applications in such jurisdictions are typically not published until 18 months after filing, and publications in the scientific
literature often lag behind actual discoveries. Accordingly, we cannot be certain that others have not filed patents that may cover our
technologies, our products or the use of our products. Additionally, pending patent applications which have been published can, subject
to certain limitations, be later amended in a manner that could cover our technologies, our products or the use of our products. As a
result, we may become party to, or threatened with, future adversarial proceedings or litigation regarding patents with respect to our
products and technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are sued for patent infringement, we would need to demonstrate that our products or methods either do not infringe the patent claims
of the relevant patent or that the patent claims are invalid, and we may not be able to do this. If we are found to infringe a third
party&rsquo;s patent, we could be required to obtain a license from such third party to continue developing and marketing our products
and technology or we may elect to enter into such a license in order to settle litigation or in order to resolve disputes prior to litigation.
However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we are able to obtain
a license, it could be non- exclusive, thereby giving our competitors access to the same technologies that are licensed to us and could
require us to make substantial royalty payments. We could also be forced, including by court order, to cease commercializing the infringing
technology or products. A finding of infringement could prevent us from commercializing our products or force us to cease some of our
business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade
secrets of third parties could have a similarly negative impact on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
such claims are likely to be expensive to defend, and some of our competitors may be able to sustain the costs of complex patent litigation
more effectively than us can because they have substantially greater resources. Moreover, even if we are successful in defending any
infringement proceedings, we may incur substantial costs and divert management&rsquo;s time and attention in doing so, which could materially
adversely affect our business, prospects, results of operations or financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Risks
relating to managing growth, employee matters and other risks relating to our business</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Growth
may place significant demands on our management and resources. We expect to experience growth in the number of our employees and the
scope of our operations in connection with the continued development and, in due course, the potential commercialization of our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
potential growth will place a significant strain on our management and operations, and we may have difficulty managing this future potential
growth.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are highly dependent on our current executive officers and their services are critical to the successful implementation of our product
development and regulatory strategies. While suitable contracts of employment are in place including six to 12 months&rsquo; notice periods
for all executive officers, they may give notice to terminate their employment with us at any time. The loss of the services of any of
our executive officers and our inability to find suitable replacements could harm our business, prospects, financial condition, results
of operations and ability to achieve the successful development or commercialization of our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Challenges
in identifying and retaining key personnel could impair our ability to conduct and grow our operations effectively. Our ability to compete
in the highly competitive pharmaceutical industry depends upon our ability to attract and retain highly qualified management and sales
teams. We are intending to recruit our own commercial team and expand our existing central infrastructure team. Many of the other pharmaceutical
companies and academic institutions that we compete against for qualified personnel have greater financial and other resources, different
risk profiles and a longer history in the industry than we do. We might not be able to attract or retain these key persons on conditions
that are economically acceptable. Our inability to attract and retain these key persons could have a material adverse effect on our business,
prospects, financial conditions and results of operation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>COVID-19
has adversely affected our business, and any new pandemic, epidemic or outbreak of an infectious disease may further adversely affect
our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2019, a novel strain of coronavirus, COVID-19, spread globally, substantially impacting the global economy and our operations,
including interrupting preclinical and clinical trial activities and disrupting our supply chain. The spread of an infectious disease,
including COVID-19, may also result in the inability of our suppliers to source or deliver components or raw materials necessary for
our clinical supply on a timely basis or at all. In addition, hospitals may reduce staffing and reduce or postpone certain treatments
in response to the spread of an infectious disease. Such events may result in a period of business disruption, and in reduced operations,
or doctors and medical providers may be unwilling to participate in our clinical trials, any of which could materially affect our business,
financial condition and results of operations. The extent to which COVID-19 impacts our business will depend on future developments,
which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of the coronavirus
and the actions to contain the coronavirus or treat its impact, among others. A significant pandemic as with COVID-19, or any other infectious
disease, could result in a widespread health crisis that could adversely affect the economies and financial markets worldwide, resulting
in an economic downturn that could impact our business, financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may become subject to product liability claims.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
face an inherent risk of product liability and associated adverse publicity as a result of the clinical testing of our products and sales
of our products once marketing approval is received from relevant regulatory authorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Criminal
or civil proceedings might be filed against us any by study subjects, patients, relevant regulatory authorities, pharmaceutical companies,
and any other third party using or marketing our products. Any such product liability claims may include allegations of defects in manufacturing
or design, negligence, strict liability, a breach of warranties and a failure to warn of dangers inherent in the product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit
commercialization of our products, if approved. Even if we successfully defend ourselves against such product liability claims it could
require significant financial and management resources. Regardless of the merits or eventual outcome, product liability claims may result
in:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">decreased
    demand for our products due to negative public perception;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">injury
    to our reputation;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal
    of clinical study participants or difficulties in recruiting new study participants;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">initiation
    of investigations by regulators;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    to defend or settle the related litigation;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">diversion
    of management&rsquo;s time and our resources;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">substantial
    monetary awards to patients, study participants or subjects;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    recalls, withdrawals or labelling, marketing or promotional restrictions;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss
    of revenues from product sales; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    inability to commercialize any of our products, if approved.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we will maintain levels of insurance customary for our sector to cover our current and future business operations, any claim that may
be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance
or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions, and we may be subject
to a product liability claim for which we have no coverage. In such cases, we would have to pay any amounts awarded by a court or negotiated
in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain,
sufficient capital to pay such amounts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we or our partners, licensees and subcontractors were unable to obtain and maintain appropriate insurance coverage at an acceptable cost,
or to protect ourselves in any way against actions for damages, this would seriously affect the marketing of our products and, more generally,
be detrimental to our business, prospects, results of operations or financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
employees, contractors, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance
with regulatory standards.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exposed to the risk of employees, independent contractors, principal investigators, consultants, commercial partners or vendors engaging
in fraud or other misconduct. Misconduct could include intentional failures to comply with FDA or EMA regulations or those of other relevant
regulatory authorities, to provide accurate information to the FDA, EMA or other relevant regulatory authorities, or to comply with manufacturing
standards we have established.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
particular, sales, marketing and business arrangements in the life sciences and biotechnology sector are subject to extensive laws and
regulations intended to prevent fraud, misconduct, bribery and other abusive practices. These laws and regulations may restrict or prohibit
a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee
misconduct could also involve the improper use of information obtained in the course of clinical studies, which could result in regulatory
sanctions and serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions
we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting
us from governmental or relevant regulatory authority investigations or other actions or lawsuits stemming from a failure to be in compliance
with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourself or asserting
our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions,
and our reputation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be vulnerable to disruptions of information technology systems or breaches of data security. We are dependent on information technology
systems and infrastructure to operate our business. In the ordinary course of our business, we collect, store and transmit confidential
information, including intellectual property, proprietary business information and personal information. It is important that we do so
in a secure manner to maintain confidentiality and integrity of such confidential information. Any failure to do so could adversely affect
our business, prospects, results of operation or financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
relationship of the UK with the EU could impact our ability to operate efficiently in certain jurisdictions or in certain markets.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The UK formally exited the EU
on January 31, 2020, which is commonly known as Brexit. Under the terms of its departure, the UK entered a transition period
during which it continued to follow all EU rules until December 31, 2020, or the Transition Period. On December 30, 2020,
the UK and EU signed the Trade and Cooperation Agreement, which includes an agreement on free trade between the two parties.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is considerable uncertainty resulting from a lack of precedent and the complexity of the UK and EU&rsquo;s intertwined legal regimes
as to how Brexit (following the Transition Period) will impact the medical devices industry in Europe. Since a significant proportion
of the regulatory framework in the UK applicable to our business and product candidates is derived from EU directives and regulations,
Brexit could materially impact the regulatory regime with respect to the development, manufacture, importation, approval and commercialization
of our product candidates in the UK or the EU. The impact will largely depend on the model and means by which the UK&rsquo;s relationship
with the EU is governed post-Brexit and the extent to which the UK chooses to diverge from the EU regulatory framework. For example,
following the Transition Period, the UK will no longer be covered by the centralized procedures for obtaining EU-wide marketing authorizations
and our product candidates will therefore require a separate marketing authorization for such products to be marketed in the UK. It is
also unclear as to whether the relevant authorities in the EU and the UK are adequately prepared for the additional administrative burden
caused by Brexit. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, would
prevent us from, or delay commercialization of, product candidates in the UK and/or the EEA and restrict our ability to generate revenue
and achieve and sustain profitability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in the UK for its product candidates,
which could significantly and materially harm our business. There is a degree of uncertainty regarding the overall impact that Brexit
will have on process to obtain regulatory approval in the UK for product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
the UK&rsquo;s withdrawal from the EU has resulted in the relocation of the EMA from the UK to the Netherlands. This relocation has caused,
and may continue to cause, disruption in the administrative and medical scientific links between the EMA and the UK Medicines and
Healthcare Products Regulatory Agency, including delays in granting clinical trial authorization or marketing authorization, disruption
of importation and export of medical devices, active substance and other components of new drug formulations, and disruption of the supply
chain for clinical trial product and final authorized formulations. The cumulative effects of the disruption to the regulatory framework
may add considerably to the development lead time to marketing authorization and commercialization of product candidates in the EU and/or
the UK. Brexit may also result in a reduction of funding to the EMA once the UK no longer makes financial contributions to EU institutions,
such as the EMA. If funding to the EMA is so reduced, it could create delays in the EMA issuing regulatory approvals for our product
candidates and, accordingly, have a material adverse effect on our business, financial condition, results of operations or prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Government Regulation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even
if we complete the necessary clinical trials, we cannot predict when, or if, we will obtain regulatory approval to commercialize our
product candidates and whether the approval may be for a narrower indication than we seek.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot commercialize a product candidate until the appropriate regulatory authorities have reviewed and approved the product candidate.
The FDA must review and approve any new pharmaceutical product before it can be marketed and sold in the United States. The FDA regulatory
review and approval process, which includes evaluation of preclinical studies and clinical trials of a product candidate and proposed
labeling, as well as the evaluation of the manufacturing process and manufacturers&rsquo; facilities, all of which is lengthy, expensive
and uncertain. To obtain approval, we must, among other things, demonstrate with substantial evidence from well-controlled clinical trials
that the product candidate is both safe and effective for each indication where approval is sought. Even if our product candidates meet
the FDA&rsquo;s safety and effectiveness endpoints in clinical trials, the FDA may not complete their review processes in a timely manner,
or we may not be able to obtain regulatory approval. The FDA has substantial discretion in the review and approval process and may refuse
to file our application for substantive review or may determine after review of our data that our application is insufficient to allow
approval of our product candidates. The FDA may require that we conduct additional preclinical studies, clinical trials or manufacturing
validation studies and submit that data before it will reconsider our application. Additional delays may result if an FDA Advisory Committee
or other regulatory authority recommends non-approval or restrictions on approval. In addition, we may experience delays or rejections
based upon additional government regulation from future legislation or administrative action, or changes in regulatory authority policy
during the period of product development, clinical trials and the review process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA, EMA or other regulatory authorities also may approve a product candidate for more limited indications than requested or may impose
significant limitations in the form of narrow indications, warnings or a risk evaluation and mitigation strategy, or REMS. These regulatory
authorities may require precautions or contraindications with respect to conditions of use or may grant approval subject to the performance
of costly post-marketing clinical trials. In addition, the FDA, EMA or other regulatory authorities may not approve the labeling claims
that are necessary or desirable for the successful commercialization of our product candidates. Any of the foregoing scenarios could
harm the commercial prospects for our product candidates and negatively impact our business, financial condition, results of operations
and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Delays
in obtaining regulatory approval of our manufacturing process and facility or disruptions in our manufacturing process may delay or disrupt
our product development and commercialization efforts.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently operate manufacturing facilities for clinical or commercial production of our product candidates. Before we can begin
to commercially manufacture our product candidates, whether in a third-party facility or in our own facility, if and when established,
we must obtain regulatory approval from the FDA for our manufacturing process and facility. A manufacturing authorization must also be
obtained from the appropriate European Union regulatory authorities and from other foreign regulatory authorities, as applicable. In
order to obtain approval, we will need to ensure that all of our processes, methods and equipment are compliant with cGMP, and perform
extensive audits of vendors, contract laboratories and suppliers. If any of our vendors, contract laboratories or suppliers are found
to be non-compliant with cGMP, we may experience delays or disruptions in manufacturing while we work with these third parties to remedy
the violation or while we work to identify suitable replacement vendors. The cGMP requirements govern quality control of the manufacturing
process and documentation policies and procedures. In complying with cGMP, we will be obligated to expend time, money and effort in production,
record keeping and quality control to assure that the product meets applicable specifications and other requirements. If we fail to comply
with these requirements, we would be subject to possible regulatory action and may not be permitted to sell any product candidate that
we may develop.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we or our third-party manufacturers fail to comply with applicable cGMP regulations, the FDA, EMA and other regulatory authorities can
impose regulatory sanctions including, among other things, refusal to approve a pending application for a new product candidate or suspension
or revocation of a pre-existing approval. Such an occurrence may cause our business, financial condition, results of operations and prospects
to be harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
if the supply of our products from our third-party manufacturers to us is interrupted for any reason, including due to regulatory requirements
or actions (including recalls), adverse financial developments at or affecting the supplier, failure by the supplier to comply with cGMP
requirements, contamination, business interruptions or labor shortages or disputes, there could be a significant disruption in commercial
supply of our products. We do not currently have a backup manufacturer of our product candidate supply for clinical trials or commercial
sale. An alternative manufacturer would need to be qualified through a supplement to its regulatory filing, which could result in further
delays. The regulatory authorities also may require additional clinical trials if a new manufacturer is relied upon for commercial production.
Switching manufacturers may involve substantial costs and could result in a delay in our desired clinical and commercial timelines.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
our competitors are able to obtain orphan drug exclusivity for products that constitute the same drug and treat the same indications
as our product candidates, we may not be able to have competing products approved by applicable regulatory authorities for a significant
period of time. In addition, even if we obtain orphan drug exclusivity for any of our products, such exclusivity may not protect us from
competition.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
authorities in some jurisdictions, including the United States and the European Union, may designate products for relatively small patient
populations as orphan drugs. Under the Orphan Drug Act of 1983, the FDA may designate a product candidate as an orphan drug if it is
intended to treat a rare disease or condition, which is generally defined as having a patient population of fewer than 200,000 individuals
in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that
the cost of developing the drug will be recovered from sales in the United States. In the United States, orphan drug designation entitles
a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers.
In the European Union, the EMA&rsquo;s Committee for Orphan Medicinal Products grants orphan drug designation to promote the development
of products that are intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition
affecting not more than five in 10,000 persons in the European Union. Additionally, orphan drug designation is granted for products intended
for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition and when, without
incentives, it is unlikely that sales of the drug in the European Union would be sufficient to justify the necessary investment in developing
the drug or biologic product. In Europe, orphan drug designation entitles a party to a number of incentives, such as protocol assistance
and scientific advice specifically for designated orphan medicines, and potential fee reductions depending on the status of the sponsor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
designation as an orphan product does not guarantee that any regulatory agency will accelerate regulatory review of, or ultimately approve,
that product candidate, nor does it limit the ability of any regulatory agency to grant orphan drug designation to product candidates
of other companies that treat the same indications as our product candidates prior to our product candidates receiving exclusive marketing
approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generally,
if a product candidate with an orphan drug designation receives the first marketing approval for the indication for which it has such
designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA or the EMA from approving another
marketing application for a product that constitutes the same drug treating the same indication for that marketing exclusivity period,
except in limited circumstances. If another sponsor receives such approval before we do (regardless of our orphan drug designation),
we will be precluded from receiving marketing approval for our product for the applicable exclusivity period. The applicable period is
seven years in the United States and 10 years in the European Union. The exclusivity period in the European Union can be reduced
to six years if a product no longer meets the criteria for orphan drug designation or if the product is sufficiently profitable so that
market exclusivity is no longer justified. Orphan drug exclusivity may be revoked if any regulatory agency determines that the request
for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs
of patients with the rare disease or condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we obtain orphan drug exclusivity for a product candidate, that exclusivity may not effectively protect the product candidate from
competition because different drugs can be approved for the same condition. In the United States, even after an orphan drug is approved,
the FDA may subsequently approve another drug for the same condition if the FDA concludes that the latter drug is not the same drug or
is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. In the European
Union, marketing authorization may be granted to a similar medicinal product for the same orphan indication if:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    second applicant can establish in its application that its medicinal product, although similar to the orphan medicinal product already
    authorized, is safer, more effective or otherwise clinically superior;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    holder of the marketing authorization for the original orphan medicinal product consents to a second orphan medicinal product application;
    or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    holder of the marketing authorization for the original orphan medicinal product cannot supply sufficient quantities of orphan medicinal
    product.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even
if we obtain regulatory approval for a product candidate, our product candidates will remain subject to regulatory oversight.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we obtain regulatory approval for our product candidates, they will be subject to ongoing regulatory requirements for manufacturing,
labeling, packaging, storage, advertising, promotion, sampling, record-keeping and submission of safety and other post-market information.
Any regulatory approvals that we receive for our product candidates may also be subject to limitations on the approved indicated uses
for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing
testing, including Phase 4 clinical trials, and surveillance to monitor the quality, safety and clinical effectiveness of the product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of our product candidates are classified as biologics in the United States, and therefore, can only be sold if we obtain a biologics
license application, or BLA, from the FDA. The holder of an approved BLA also must submit new or supplemental applications and obtain
FDA approval for certain changes to the approved product, product labeling or manufacturing process. In addition, the holder of a BLA
approval must comply with the FDA&rsquo;s advertising and promotion requirements, such as those related to the prohibition on promoting
products for uses or in patient populations that are not described in the product&rsquo;s approved labeling (known as &ldquo;off-label
use&rdquo;). Advertising and promotional materials must comply with FDA rules and are subject to FDA review, in addition to other potentially
applicable federal and state laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, product manufacturers and their facilities are subject to payment of user fees and continual review and periodic inspections
by the FDA and other regulatory authorities for compliance with cGMP requirements and adherence to commitments made in the BLA or foreign
marketing application. If we, or a regulatory authority, discover previously unknown problems with a product, such as adverse events
of unanticipated severity or frequency, or problems with the facility where the product is manufactured or if a regulatory authority
disagrees with the promotion, marketing or labeling of that product (in addition to our being obligated as holder of a BLA to monitor
and report adverse events and any failure of a product to meet the BLA specifications), a regulatory authority may impose restrictions
relative to that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or
suspension of manufacturing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail to comply with applicable regulatory requirements following approval of our product candidates, a regulatory or enforcement authority
may:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 14.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue
    a warning letter asserting that we are in violation of the law;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
    an injunction or impose administrative, civil or criminal penalties or monetary fines;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend
    or withdraw regulatory approval;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend
    any ongoing clinical trials;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refuse
    to approve a pending BLA or comparable foreign marketing application (or any supplements thereto) submitted by us or our strategic
    partners;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrict
    the marketing or manufacturing of the product;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">seize
    or detain the product or otherwise require the withdrawal of the product from the market;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refuse
    to permit the import or export of the product; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refuse
    to allow us to enter into supply contracts, including government contracts.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
government investigation of alleged violations of law could require us to expend significant time and resources in response and could
generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our product
candidates and adversely affect our business, financial condition, results of operations and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the FDA&rsquo;s policies, and those of the EMA and other regulatory authorities, may change and additional government regulations
may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature
or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad.
If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not
able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain
profitability, which would negatively impact our business, financial condition, results of operations and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even
if we obtain and maintain approval for our product candidates in a major pharmaceutical market such as the United States, we may never
obtain approval for our product candidates in other major markets.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to market any products in a country or territory, we must establish and comply with numerous and varying regulatory requirements
of such countries or territories regarding safety and effectiveness. Clinical trials conducted in one country may not be accepted by
regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained
in any other country. Approval procedures vary among countries and can involve additional product testing and validation and additional
administrative review periods. Seeking regulatory approvals in all major markets could result in significant delays, difficulties and
costs for us and may require additional preclinical studies or clinical trials, which would be costly and time consuming. Regulatory
requirements can vary widely from country to country and could delay or prevent the introduction of our product candidates in those countries.
For example, in many jurisdictions outside of the United States, a product candidate must be approved for reimbursement before it can
be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products would also be subject to
approval. Satisfying these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays.
In addition, our failure to obtain regulatory approval in any country may delay or have negative effects on the process for regulatory
approval in other countries. We currently do not have any product candidates approved for sale in any jurisdiction, whether in the United
States, Europe or any other international markets, and we do not have experience in obtaining regulatory approval in international markets.
If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, our target market
will be reduced and our ability to realize the full market potential of our product candidates will be compromised.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may seek a conditional marketing authorization in Europe for some or all of our current product candidates, but we may not be able to
obtain or maintain such designation.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of its marketing authorization process, the EMA may grant marketing authorizations for certain categories of medicinal products
on the basis of less complete data than is normally required, when doing so may meet unmet medical needs of patients and serve the interest
of public health. In such cases, it is possible for the Committee for Medicinal Products for Human Use, or CHMP, to recommend the granting
of a marketing authorization, subject to certain specific obligations to be reviewed annually, which is referred to as a conditional
marketing authorization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
may apply to medicinal products for human use that fall under the jurisdiction of the EMA, including those that aim at the treatment,
the prevention, or the medical diagnosis of seriously debilitating or life-threatening diseases and those designated as orphan medicinal
products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
conditional marketing authorization may be granted when the CHMP finds that, although comprehensive clinical data referring to the safety
and therapeutic utility of the medicinal product have not been supplied, all the following requirements are met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    risk-benefit balance of the medicinal product is positive;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it
    is likely that the applicant will be in a position to provide the comprehensive clinical data;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unmet
    medical needs will be fulfilled; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    benefit to public health of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent
    in the fact that additional data is still required.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
granting of a conditional marketing authorization is restricted to situations in which only the clinical part of the application is not
yet fully complete. Incomplete preclinical or quality data may only be accepted if duly justified and only in the case of a product intended
to be used in emergency situations in response to public health threats. Conditional marketing authorizations are valid for one year,
on a renewable basis. The holder will be required to complete ongoing trials or to conduct new trials with a view to confirming that
the benefit-risk balance is positive. In addition, specific obligations may be imposed in relation to the collection of pharmacovigilance
data.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granting
a conditional marketing authorization allows medicines to reach patients with unmet medical needs earlier than might otherwise be the
case and will ensure that additional data on a product is generated, submitted, assessed and acted upon.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Healthcare
legislative reform measures may have a negative impact on our business and results of operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and
proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or
regulate post-approval activities and affect our ability to profitably sell any product candidates for which we obtain marketing approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or the MMA, changed the way Medicare covers
and pays for pharmaceutical products. The MMA expanded Medicare coverage for outpatient drug purchases by adding a new Medicare Part
D program and introduced a new reimbursement methodology based on average sales prices for Medicare Part B physician-administered drugs.
In addition, the MMA authorized Medicare Part D prescription drug plans to limit the number of drugs that will be covered in any therapeutic
class in their formularies. The MMA&rsquo;s cost reduction initiatives and other provisions could decrease the coverage and price that
we receive for any approved products. While the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow
Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement
that results from the MMA may result in a similar reduction in payments from private payors. Similar regulations or reimbursement policies
may be enacted in international markets, which could similarly impact our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2010, the PPACA (as amended by the Health Care and Education Reconciliation Act of 2010) was passed, which substantially changes
the way healthcare is financed by both the government and private insurers, and significantly impacts the U.S. pharmaceutical industry.
The PPACA, among other things: (i) addresses a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate
Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; (ii) increases the minimum Medicaid rebates
owed by manufacturers under the Medicaid Drug Rebate Program and extends the rebate program to individuals enrolled in Medicaid managed
care organizations; (iii) establishes annual fees and taxes on manufacturers of certain branded prescription drugs; (iv) expands the
availability of lower pricing under the 340B drug pricing program by adding new entities to the program; and (v) establishes a new Medicare
Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices of
applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&rsquo;s outpatient
drugs to be covered under Medicare Part D. Additionally, in the United States, the Biologics Price Competition and Innovation Act of
2009 created an abbreviated approval pathway for biologic products that are demonstrated to be biosimilar or &ldquo;interchangeable&rdquo;
with an FDA-approved biologic product. This new pathway could allow competitors to reference data from biologic products already approved
after 12 years from the time of approval. This could expose us to potential competition by lower-cost biosimilars even if we commercialize
a product candidate faster than our competitors. Moreover, the creation of this abbreviated approval pathway does not preclude or delay
a third party from pursuing approval of a competitive product candidate via the traditional approval pathway based on their own clinical
trial data.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
changes that may affect our business include those changes governing enrollment in federal healthcare programs, reimbursement changes,
rules regarding prescription drug benefits under the health insurance exchanges and fraud and abuse and enforcement. Continued implementation
of the PPACA and the passage of additional laws and regulations may result in the expansion of new programs such as Medicare payment
for performance initiatives, and may impact existing government healthcare programs, such as by improving the physician quality reporting
system and feedback program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
each state that does not choose to expand its Medicaid program, there likely will be fewer insured patients overall, which could impact
the sales, business and financial condition of manufacturers of branded prescription drugs. Where patients receive insurance coverage
under any of the new options made available through the PPACA, manufacturers may be required to pay Medicaid rebates on that resulting
drug utilization. The U.S. federal government also has announced delays in the implementation of key provisions of the PPACA. The implications
of these delays for our and our potential partners&rsquo; business and financial condition, if any, are not yet clear.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, there have been judicial and congressional challenges to certain aspects of the PPACA, and we expect the current administration
and Congress will likely continue to seek legislative and regulatory changes, including repeal and replacement of certain provisions
of the PPACA. In January 2017, President Trump signed an Executive Order directing federal agencies with authorities and responsibilities
under the PPACA to waive, defer, grant exemptions from, or delay the implementation of any provision of the PPACA that would impose a
fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical
devices. More recently, the U.S. House of Representatives passed legislation known as the American Health Care Act of 2017, and Senate
Republicans have released a draft bill known as the Better Care Reconciliation Act of 2017, each of which would repeal certain aspects
of the PPACA if ultimately enacted. The prospects for enactment of these legislative initiatives remain uncertain. Further, Congress
also could consider other legislation to replace elements of the PPACA. We cannot know how efforts to repeal and replace the PPACA or
any future healthcare reform legislation will impact our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that the PPACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage
criteria and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from
Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment
measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Department of Health and Human Services Office of Inspector General issued final regulations on November 30, 2020 to eliminate safe harbor
protection under the anti-kickback statute for drug price reductions that pharmaceutical manufacturers pay to Medicare and Medicaid plan
sponsors and their pharmacy benefit managers. The proposal reflects a clear intent to substantially alter many of the current drug discount
and services compensation practices among pharmaceutical manufacturers and Medicare and Medicaid managed care organizations and their
pharmacy benefit managers. The proposal also reflects a skepticism that current drug discount and compensation practices among manufacturers
and pharmacy benefit managers are sufficiently transparent to health plans to ensure that all appropriate cost reductions and value is
passed through to health plans and reflected in lower health plans costs and lower premiums for beneficiaries. The Biden Administration
has delayed the effective date of this rule until January 1, 2023, and a lawsuit initiated by the Pharmaceutical Care Management Administration
has challenged this final rule. If the regulation becomes effective it could result in lower prices for pharmaceutical products in general.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Centers for Medicare and Medicaid Services issued an interim final rule on November 20, 2020 that would tie prices for certain drugs
under Medicare Part B to the lowest price for those drugs available in certain countries that are members of the Organization for Economic
Co-operation and Development. This &ldquo;most favored nation&rdquo; drug pricing rule is also the subject of lawsuits, and a federal
court has placed an injunction on the implementation of the rule. This rule, if finalized, could also result in lower prices for pharmaceutical
products in general.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Biden Administration will have the opportunity to address these regulations as well as drug pricing, health care access, and other health
care reform issues. Any further legislative or administrative action to reduce reimbursement or health benefits to beneficiaries under
the Medicare or Medicaid program could affect the payment we could collect from sale of any product in the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts
that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product
candidates or additional pricing pressures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are subject to stringent and changing privacy laws, regulations and standards as well as contractual obligations related to data privacy
and security. Our actual or perceived failure to comply with such obligations could harm our reputation, subject us to significant fines
and liability, or otherwise adversely affect our business</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>or
prospects.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to data privacy and protection laws, regulations, policies and contractual obligations that apply to the collection, transmission,
storage, processing and use of personal information or personal data, which among other things, impose certain requirements relating
to the privacy, security and transmission of personal information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
legislative and regulatory landscape for privacy and data protection continues to evolve in jurisdictions worldwide, and there has been
an increasing focus on privacy and data protection issues with the potential to affect our business. Failure to comply with laws, regulations
and other obligations governing personal information could result in enforcement actions against us, including fines, imprisonment of
company officials and public censure, processing penalties, claims for damages by affected individuals, damage to our reputation and
loss of goodwill, any of which could have a material adverse effect on our business, financial condition, results of operations or prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
regulatory framework for the collection, use, retention, safeguarding, disclosure, sharing, transfer and other processing of personal
information worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future. Globally, virtually every jurisdiction
in which we operate has established its own data security and privacy frameworks with which we must comply. For example, the collection,
use, disclosure, transfer or other processing of personal data regarding individuals in the European Union, including personal health
data, is subject to the European Union General Data Protection Regulation (EU) 2016/679, or the GDPR, which took effect across all member
states of the European Union, or EU, in May 2018 and similar legislation in the United Kingdom. The GDPR is wide-ranging in scope
and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other
sensitive data, obtaining consent of the individuals to whom the personal data relates, establishing a legal basis for processing, providing
information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality
of personal data that requires the adoption of administrative, physical and technical safeguards, providing notification of data breaches
to appropriate data protection authorities or data subjects, establishing means for data subjects to exercise rights in relation to their
personal data and taking certain measures when engaging third-party processors. The GDPR increases our obligations with respect to clinical
trials conducted in the EU by expanding the definition of personal data to include coded data and requiring changes to informed consent
practices and more detailed notices for clinical trial subjects and investigators. In addition, the GDPR also imposes strict rules on
the transfer of personal data to countries outside the European Economic Area, or EEA, including the United States and, as a result,
increases the scrutiny for transfers of personal data from clinical trial sites located in the EU to the United States. The United Kingdom
and Switzerland have adopted similar restrictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further, Brexit and ongoing developments in the United Kingdom have
created uncertainty with regard to data protection regulation in the United Kingdom.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Privacy
and data security requirements are also either in place or underway in the United States. There are a broad variety of data protection
laws that may be applicable to our activities, and a range of enforcement agencies at both the state and federal levels that can review
companies for privacy and data security concerns based on general consumer protection laws. The Federal Trade Commission and state attorneys
general can all be aggressive in reviewing privacy and data security protections for consumers. New laws also are being considered or
have been implemented at both the state and federal levels. For example, the California Consumer Privacy Act of 2018, or the CCPA, which
became effective on January 1, 2020, requires companies that process information on California residents to make new disclosures to consumers
about their data collection, use and sharing practices, provides such individuals with new data privacy rights (including the ability
to opt out of certain disclosures of personal information), imposes new operational requirements for covered businesses, provides a private
right of action for data breaches and creates a statutory damages framework. Virginia became the second state to adopt a comprehensive
privacy legislation on March 2, 2021 with enactment of the Virginia Consumer Data Protection Act. Many other states are considering similar
legislation, and a broad range of legislative measures also have been introduced at the federal level. Although there are limited exemptions
for clinical trial data under the CCPA, the CCPA and other similar laws could impact our business activities depending on how it is interpreted
and exemplifies the vulnerability of our business to the evolving regulatory environment related to personal data.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
regulations promulgated pursuant to the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended, establish
privacy and security standards that limit the use and disclosure of individually identifiable health information, or protected health
information, and require the implementation of administrative, physical and technological safeguards to protect the privacy of protected
health information and ensure the confidentiality, integrity and availability of electronic protected health information. These provisions
may be applicable to our business or that of our collaborators, service providers, contractors or consultants. Determining whether protected
health information has been handled in compliance with applicable privacy standards and our contractual obligations can be complex and
may be subject to changing interpretation. If we are unable to properly protect the privacy and security of protected health information,
we could be found to have violated these privacy and security laws and/or breached certain contracts with our business partners (including
as a business associate). Further, if we fail to comply with applicable privacy laws, such as, to the extent applicable, HIPAA privacy
and security standards, we could face significant civil and criminal penalties. In the United States, the Department of Health and Human
Services&rsquo; and state attorney&rsquo;s general enforcement activity can result in financial liability and reputational harm, and
responses to such enforcement activity can consume significant internal resources. In addition, state attorneys general are authorized
to bring civil actions seeking either injunctions or damages in response to violations that threaten the privacy of state residents.
We cannot be sure how these regulations will be interpreted, enforced or applied to our operations. In addition to the risks associated
with enforcement activities and potential contractual liabilities, our ongoing efforts to comply with evolving laws and regulations at
the federal and state level may be costly and require ongoing modifications to our policies, procedures and systems.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the breadth and depth of changes in data protection obligations, preparing for and complying with the GDPR, CCPA and similar laws&rsquo;
requirements are rigorous and time-intensive and require significant resources and a review of our technologies, systems and practices,
as well as those of any third-party collaborators, service providers, contractors or consultants that process or transfer personal data.
Changes involving the GDPR, CCPA or other laws or regulations associated with the enhanced protection of certain types of sensitive data,
such as healthcare data or other personal information from our clinical trials, could require us to change our business practices and
put in place additional compliance mechanisms, may interrupt or delay our development, regulatory and commercialization activities and
increase our cost of doing business, and could expose us to government enforcement actions, regulatory investigations, private litigation
and significant fines, penalties and remediation costs and could have a material adverse effect on our business, financial condition
or results of operations. Additionally, any failure by our third-party collaborators, service providers, contractors or consultants to
comply with applicable law, regulations or contractual obligations related to data privacy or security could result in proceedings against
us by governmental entities or others, fines, reputational harm and other liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may publish privacy policies and other documentation regarding our collection, processing, use and disclosure of personal information
and/or other confidential information. Although we endeavor to comply with our published policies and other documentation, we may at
times fail to do so or may be perceived to have failed to do so. Moreover, despite our efforts, we may not be successful in achieving
compliance if our employees or vendors fail to comply with our published policies and documentation. Such failures can subject us to
potential foreign, local, state and federal action if they are found to be deceptive, unfair, or misrepresentative of our actual practices.
Moreover, subjects about whom we or our partners obtain information, as well as the providers who share this information with us, may
contractually limit our ability to use and disclose the information. Claims that we have violated individuals&rsquo; privacy rights or
failed to comply with data protection laws or applicable privacy notices even if we are not found liable, could be expensive and time-consuming
to defend and could result in adverse publicity that could harm our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is possible that new and existing laws may be interpreted and applied in a manner that is inconsistent with our practices and our efforts
to comply with the evolving data protection rules may be unsuccessful. If so, this could result in government-imposed fines, or penalties
or orders requiring that we change our practices, which could adversely affect our business. We must devote significant resources to
understanding and complying with this changing landscape. Failure to comply with federal, state and foreign laws regarding privacy and
security of personal information could expose us to government-imposed fines and penalties under such laws, penalties or orders requiring
that we change our practices, claims for damages or other liabilities, regulatory investigations and enforcement actions, litigation
and significant costs for remediation, reputational harm, diminished profits and earnings, additional reporting requirements and/or oversight,
any of which could adversely affect our business, our results of operations or prospects. We also face a threat of consumer class actions
related to these laws and the overall protection of personal data. Even if we are not determined to have violated these laws, government
investigations into these issues typically require the expenditure of significant resources and generate negative publicity. Any of the
foregoing could have a materially adverse effect on our reputation and our business, financial condition, results of operations or prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are subject to the U.K. Bribery Act, the U.S. Foreign Corrupt Practices Act and other anti-corruption laws, as well as export control
laws, import and customs laws, trade and economic sanctions laws and other laws governing our operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operations are subject to anti-corruption laws, including the U.K. Bribery Act 2010, or the U.K. Bribery Act, the U.S. Foreign Corrupt
Practices Act of 1977, or the FCPA, the U.S. domestic bribery statute contained in 18 &sect;201, the U.S. Travel Act, and other anti-corruption
laws that apply in countries where we do business. The U.K. Bribery Act, the FCPA and these other laws generally prohibit us and our
employees and intermediaries from authorizing, promising, offering, or providing, directly or indirectly, improper or prohibited payments,
or anything else of value, to government officials or other persons to obtain or retain business or gain some other business advantage.
Under the U.K. Bribery Act, we may also be liable for failing to prevent a person associated with us from committing a bribery offense.
We and our commercial partners operate in a number of jurisdictions that pose a high risk of potential U.K. Bribery Act or FCPA violations,
and we participate in collaborations and relationships with third parties whose corrupt or illegal activities could potentially subject
us to liability under the U.K. Bribery Act, FCPA or local anti-corruption laws, even if we do not explicitly authorize or have actual
knowledge of such activities. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our
international operations might be subject or the manner in which existing laws might be administered or interpreted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also subject to other laws and regulations governing our international operations, including regulations administered by the governments
of the United Kingdom and the United States, and authorities in the European Union, including applicable export control regulations,
economic sanctions and embargoes on certain countries and persons, anti-money laundering laws, import and customs requirements and currency
exchange regulations, collectively referred to as the Trade Control laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including the
U.K. Bribery Act, the FCPA or other legal requirements, including Trade Control laws. If we are not in compliance with the U.K. Bribery
Act, the FCPA and other anti-corruption laws or Trade Control laws, we may be subject to criminal and civil penalties, disgorgement and
other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our business, financial condition, results
of operations and liquidity. Likewise, any investigation of any potential violations of the U.K. Bribery Act, the FCPA, other anti-corruption
laws or Trade Control laws by United Kingdom, United States or other authorities could also have an adverse impact on our reputation,
our business, results of operations and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
relationships with customers, physicians and third-party payors will be subject, directly or indirectly, to federal and state healthcare
fraud and abuse laws, false claims laws, health information privacy and security laws and other healthcare laws and regulations. If we
are found in violation of these laws and regulations, we may be required to pay a penalty or be suspended from participation in federal
or state healthcare programs, which may adversely affect our business, financial condition and results of operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we obtain FDA approval for our product candidates and begin commercializing them in the United States, our operations will be directly,
or indirectly through our prescribers, customers and purchasers, subject to various federal and state fraud and abuse laws and regulations,
including, without limitation, the federal Anti-Kickback Statute, the federal civil and criminal false claims laws and Physician Payments
Sunshine Act of 2010 and regulations. These laws will impact, among other things, our proposed sales, marketing and educational programs.
In addition, we may be subject to patient privacy laws by both the U.S. federal government and the states in which we conduct our business.
The laws that will affect our operations include, but are not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting,
    receiving, offering or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly,
    in cash or in kind, in return for either the referral of an individual, or the purchase, leasing, furnishing or arranging for the
    purchase, lease or order of a good, facility, item or service reimbursable under a federal healthcare program, such as the Medicare
    and Medicaid programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one
    hand, and prescribers, purchasers and formulary managers on the other. The PPACA amended the intent requirement of the federal Anti-Kickback
    Statute, such that a person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal
    civil and criminal false claims laws and civil monetary penalty laws which prohibit, among other things, individuals or entities
    from knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid or other government
    payors that are false or fraudulent. The PPACA provides, and recent government cases against pharmaceutical and medical device manufacturers
    support the view that federal Anti-Kickback Statute violations and certain marketing practices, including off-label promotion, may
    implicate the False Claims Act of 1863;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit,
    among other things, a person from knowingly and willfully executing a scheme or from making false or fraudulent statements to defraud
    any healthcare benefit program, regardless of the payor (e.g., public or private);</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA
    (as amended by the Health Information Technology for Economic and Clinical Health Act of 2009), and their implementing regulations,
    which impose certain requirements relating to the privacy, security and transmission of individually identifiable health information
    without appropriate authorization by entities subject to the rule, such as health plans, health care clearinghouses and health care
    providers, and their respective business associates that perform certain functions or activities that involve the use or disclosure
    of protected health information on their behalf;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal
    transparency laws, including the federal Physician Payment Sunshine Act, that require certain manufacturers of drugs, devices, biologics
    and medical supplies for which payment is available under Medicare, Medicaid or the Children&rsquo;s Health Insurance Program, with
    specific exceptions, to report annually to the CMS information related to: (i) payments or other &ldquo;transfers of value&rdquo;
    made to physicians and teaching hospitals and (ii) ownership and investment interests held by physicians and their immediate family
    members;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal
    consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm
    consumers; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">state
    and foreign law equivalents of each of the above federal laws, state and local laws that require drug manufacturers to report information
    related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures, and state
    and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each
    other in significant ways and may not have the same effect, thus complicating compliance efforts.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Efforts
to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve
substantial costs. Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it
is possible that some of our business activities could be subject to challenge under one or more of such laws. It is possible that governmental
authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving
applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws
or any other governmental regulations that may apply to us, we may be subject to significant criminal, civil and administrative sanctions
including monetary penalties, damages, fines, disgorgement, individual imprisonment, and exclusion from participation in government funded
healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate
integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, reputational harm, and we may be required
to curtail or restructure our operations, any of which could adversely affect our ability to operate our business and our results of
operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
risk of our being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the
regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Any action against us for violation
of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&rsquo;s
attention from the operation of our business. The shifting compliance environment and the need to build and maintain robust and expandable
systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the possibility that
a healthcare company may run afoul of one or more of the requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur
substantial costs.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the
generation, handling, use, storage, treatment, manufacture, transportation and disposal of, and exposure to, hazardous materials and
wastes, as well as laws and regulations relating to occupational health and safety. We contract with third parties that conduct operations
on our behalf that involve the use of hazardous and flammable materials, including chemicals and biologic materials. Our contractors
also produce and dispose of hazardous waste products. We cannot eliminate the risk of contamination or injury from these materials. In
the event of contamination or injury resulting from our contractors&rsquo; use of hazardous materials, we could be held liable for any
resulting damages and any liability could exceed our resources, and our clinical trials or regulatory approvals could be suspended. We
also could incur significant costs associated with civil or criminal fines and penalties. Our third-party contractors may not carry specific
biological or hazardous waste insurance coverage, and their property, casualty and general liability insurance policies specifically
exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we maintain workers&rsquo; compensation insurance for certain costs and expenses that we may incur due to injuries to our employees
resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against
potential liabilities. We do not maintain insurance for toxic tort claims that may be asserted against us in connection with our storage
or disposal of biologic, hazardous or radioactive materials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations,
which have tended to become more stringent over time. These current or future laws and regulations may impair our research, development
or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions
or liabilities, which could adversely affect our business, financial condition, results of operations and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Computer
system failures, cyber-attacks or deficiencies in our or related parties&rsquo; cyber security could result in a material disruption
of our product development programs, compromise sensitive information related to our business or trigger contractual and legal obligations,
any of which could potentially expose us to liability or reputational harm or otherwise adversely affect our business and financial results.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have implemented our security measures designed to protect the information (including but not limited to intellectual property, proprietary
business information and personal information) in our possession, custody or control. Our internal computer systems and those of current
and future third parties (such as vendors, CROs, collaborators or others) on which we rely may fail and are vulnerable to breakdown,
breach, interruption or damage from computer viruses, computer hackers, malicious code, employee error or malfeasance, theft or misuse,
denial-of-service attacks, sophisticated nation-state and nation-state-supported actors, unauthorized access, natural disasters, terrorism,
war, telecommunication and electrical failures or other compromise. Despite our security practices, there is a risk that we may be subject
to phishing and other cyberattacks in the future. The risk of a security breach or disruption, particularly through cyber-attacks or
cyber intrusion, including by computer hackers, foreign governments and cyber terrorists, has generally increased as the number, intensity
and sophistication of attempted attacks and intrusions from around the world have increased.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be able to anticipate all types of security threats, and we may not be able to implement preventive measures effective against
all such security threats. The techniques used by cyber criminals change frequently, may not be recognized until launched, and can originate
from a wide variety of sources, including outside groups such as external service providers, organized crime affiliates, terrorist organizations
or hostile foreign governments or agencies. Our information technology and other internal infrastructure systems, including corporate
firewalls, servers, leased lines and connection to the Internet, face the risk of systemic failure that could disrupt our operations.
If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development
programs and our business operations. For example, the loss of clinical trial data from completed or future clinical trials could result
in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely
on third parties for the manufacture of our product candidates or any future product candidates and to conduct clinical trials, and similar
events relating to their computer systems could also have a material adverse effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate
use, disclosure of or access to confidential or proprietary information, we could incur liability, our competitive position could be
harmed and the further development and commercialization of our product candidates or any future product candidates could be hindered
or delayed. If we were to experience a significant cybersecurity breach of our information systems or data, the costs associated with
the investigation, remediation and potential notification of the breach to counterparties, data subjects, regulators or others could
be material. In addition, our remediation efforts may not be successful. Moreover, if the information technology systems of our vendors,
CROs, collaborators or other contractors or consultants become subject to disruptions or security breaches, we may have insufficient
recourse against such third parties and we may have to expend significant resources to mitigate the impact of such an event, and to develop
and implement protections to prevent future events of this nature from occurring. If we do not allocate and effectively manage the resources
necessary to build and sustain the proper technology and cybersecurity infrastructure, we could suffer significant business disruption,
including transaction errors, supply chain or manufacturing interruptions, processing inefficiencies, data loss or the loss of or damage
to intellectual property or other proprietary information. Furthermore, any such event that leads to unauthorized access, use, or disclosure
of personal information, including personal information regarding clinical trial participants or employees, could harm our reputation,
compel us to comply with federal and/or state breach notification laws and foreign law equivalents, cause us to breach our contractual
obligations, subject us to mandatory corrective action, and otherwise subject us to liability under laws, regulations and contracts that
protect the privacy and security of personal information, which could result in significant legal and financial exposure and reputational
damages. As cyber threats continue to evolve, we may be required to incur significant additional expenses in order to enhance our protective
measures or to remediate any information security vulnerability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial exposure from the events referenced above could either not be insured against or not be fully covered through any insurance
that we maintain. There can be no assurance that the limitations of liability in our contracts would be enforceable or adequate or would
otherwise protect us from liabilities or damages as a result of the events referenced above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, in response to the ongoing COVID-19 pandemic, varying parts of our workforce are currently working remotely on a part or full-time
basis. This could increase our cyber security risk, create data accessibility concerns, and make us more susceptible to communication
disruptions. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations or
prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to the Ownership of Our Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
do not know whether an active, liquid and orderly trading market will develop for our ADSs or what the market price of our ADSs will
be. As a result, it may be difficult for ADS holders to sell their ADSs.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to this offering, there has been no public market for our ADSs, although our ordinary shares have been admitted to trading on the Main
Market of the London Stock Exchange. We cannot predict the extent to which an active market for our ADSs will develop or be sustained
after this offering, or how the development of such a market might affect the market price for our ADSs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
this offering and after our ADSs begin trading on Nasdaq, our ordinary shares will continue to be traded on the Main Market of the London
Stock Exchange. We cannot predict the effect of this dual listing on the value of our ADSs and ordinary shares. However, the dual listing
of our ADSs and ordinary shares may dilute the liquidity of these securities in one or both markets and may adversely affect the development
of an active trading market for our ADSs. The price of our ADSs could also be adversely affected by trading in our ordinary shares on
the Main Market of the London Stock Exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Holders
of our ADSs may experience substantial dilution upon the exercise of outstanding options, warrants and convertible loan notes.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">As of May 6, 2022, there
were 72,400,000 ordinary shares issuable upon the exercise of share options at exercise prices of between $0.056 and $0.191
per ordinary share, of which 14,437,500 are currently exercisable and 57,962,500 are exercisable between July 6, 2021 and January
31, 2032. In addition, there were 36,659,090 ordinary shares that currently may be issued upon the exercise of warrants to purchase ordinary
shares at exercise prices of between $0.034 and $0.17 per ordinary share. The exercise of such options and warrants will
result in dilution of your investment. As a result of this dilution, you may receive significantly less than the full purchase price
you paid for our securities in the event of liquidation.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Holders
of our ADSs have fewer rights than our shareholders and must act through the depositary to exercise their rights.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of our ADSs do not have the same rights as our shareholders and may only exercise their voting rights with respect to the underlying
ordinary shares in accordance with the provisions of the deposit agreement. Holders of the ADSs will appoint the depositary or its nominee
as their representative to exercise the voting rights attaching to the ordinary shares represented by the ADSs. When a general meeting
is convened, if you hold ADSs, you may not receive sufficient notice of a shareholders&rsquo; meeting to permit you to withdraw the ordinary
shares underlying your ADSs to allow you to vote with respect to any specific matter. We will make all commercially reasonable efforts
to cause the depositary to extend voting rights to you in a timely manner, but we cannot assure you that you will receive voting materials
in time to instruct the depositary to vote, and it is possible that you, or persons who hold their ADSs through brokers, dealers or other
third parties, will not have the opportunity to exercise a right to vote. Furthermore, the depositary will not be liable for any failure
to carry out any instructions to vote, for the manner in which any vote is cast or for the effect of any such vote. As a result, you
may not be able to exercise your right to vote and you may lack recourse if your ADSs are not voted as you request. In addition, in your
capacity as an ADS holder, you will not be able to call a shareholders&rsquo; meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
rights of our shareholders may differ from the rights typically offered to shareholders of a U.S. corporation.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are incorporated under the laws of Guernsey. The rights of holders of ordinary shares and, therefore, certain of the rights of any potential
future holders of ADSs, are governed by the laws of Guernsey, including the provisions of the Guernsey Companies Law, and by our Memorandum
and Articles of Incorporation, or Articles. These rights differ in certain respects from the rights of shareholders in typical U.S. corporations.
See &ldquo;Description of Share Capital and Memorandum and Articles of Incorporation &mdash;-Differences in Corporate Law&rdquo; in this
report for a description of the principal differences between the provisions of the Guernsey Companies Law applicable to us and, for
example, the Delaware General Corporation Law relating to stockholders&rsquo; rights and protections.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our shareholders, cause
us to incur debt or assume contingent liabilities and subject us to other risks.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to continue to evaluate various acquisitions and strategic partnerships, including licensing or acquiring complementary drugs,
intellectual property rights, technologies or businesses. Any potential acquisition or strategic partnership may entail numerous risks,
including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased
    operating expenses and cash requirements;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    assumption of additional indebtedness or contingent liabilities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">assimilation
    of operations, intellectual property and drugs of an acquired company, including difficulties associated with integrating new personnel;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    diversion of our management&rsquo;s attention from our existing drug programs and initiatives in pursuing such a strategic partnership,
    merger or acquisition;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">retention
    of key employees, the loss of key personnel and uncertainties in our ability to maintain key business relationships;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">risks
    and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing
    drugs or drug candidates and regulatory approvals; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    inability to generate revenue from acquired technology and/or drugs sufficient to meet our objectives in undertaking the acquisition
    or even to offset the associated acquisition and maintenance costs.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>As
an FPI, we are exempt from a number of rules under the U.S. securities laws and are permitted to file less information with the SEC than
U.S. public companies</I>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an FPI, as defined in the SEC rules and regulations and, consequently, we are not subject to all of the disclosure requirements applicable
to companies organized within the United States. For example, we are exempt from certain rules under the Exchange Act, that regulate
disclosure obligations and procedural requirements related to the solicitation of proxies, consents or authorizations applicable to a
security registered under the Exchange Act. In addition, our officers and directors are exempt from the reporting and &ldquo;short-swing&rdquo;
profit recovery provisions of Section 16 of the Exchange Act and related rules with respect to their purchases and sales of our securities.
Moreover, we are not required to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. public
companies. Accordingly, there may be less publicly available information concerning our company than there is for U.S. public companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
an FPI, we will file an annual report on Form 20-F within four months of the close of each fiscal year ended March 31 and reports on
Form 6-K relating to certain material events promptly after we publicly announce these events. However, because of the above exemptions
for FPIs, our ADS holders will not be afforded the same protections or information generally available to investors holding shares in
public companies organized in the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>While
we are an FPI, we are not subject to certain Nasdaq corporate governance rules applicable to U.S. listed companies.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are entitled to rely on a provision in Nasdaq&rsquo;s corporate governance rules that allows us to follow the laws of Guernsey and rules
applicable to companies admitted to listing on the standard segment of the Official List of the FCA and to trading on the Main
Market of the London Stock Exchange, including, but not limited to, the Listing Rules and the Disclosure Guidance and Transparency Rules,
or DTRs, of the FCA with regard to certain aspects of corporate governance. This allows us to follow certain corporate governance practices
that differ in significant respects from the corporate governance requirements applicable to U.S. companies listed on Nasdaq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
example, we have elected to rely on the exemption allowing us to follow the laws of Guernsey and rules applicable to companies admitted
to listing on the standard segment of the Official List of the FCA and to trading on the Main Market of the London Stock Exchange
instead of Nasdaq regulations that require a listed U.S. company to (i) have a majority of the board of directors consist of independent
directors, (ii) require non-management directors to meet on a regular basis without management present and (iii) promptly disclose any
waivers of the code for directors or executive officers that should address certain specified items.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with our Nasdaq listing, our audit committee is required to comply with the provisions of Section 301 of the Sarbanes-Oxley
Act and Rule 10A-3 of the Exchange Act, both of which are also applicable to Nasdaq-listed U.S. companies. Because we have elected to
rely on the exemption allowing us to follow the laws of Guernsey and rules applicable to companies admitted to listing on the standard
segment of the Official List of the FCA and to trading on the Main Market of the London Stock Exchange, however, our audit committee
is not subject to additional Nasdaq requirements applicable to listed U.S. companies, including an affirmative determination that all
members of the audit committee are &ldquo;independent,&rdquo; using more stringent criteria than those applicable to us as an FPI. Furthermore,
Nasdaq&rsquo;s corporate governance rules require listed U.S. companies to, among other things, seek shareholder approval for the implementation
of certain equity compensation plans and issuances of ordinary shares, however as an FPI, we may elect to follow the laws of Guernsey
and rules applicable to companies admitted to listing on the Main Market of the London Stock Exchange in lieu of these Nasdaq requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may lose our FPI status, which would then require us to comply with the Exchange Act&rsquo;s domestic reporting regime and cause us to
incur significant legal, accounting and other expenses.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
an FPI, we are not required to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act applicable
to U.S. domestic issuers. We may no longer be an FPI as early as September 30, 2021 (the end of our second fiscal quarter in the fiscal
year following this Nasdaq listing), which would require us to comply with all of the periodic disclosure and current reporting requirements
of the Exchange Act applicable to U.S. domestic issuers as of April 1, 2022. In order to maintain our current status as an FPI, either
(a) a majority of our outstanding voting securities must be either directly or indirectly owned of record by non-residents of the United
States or (b)(i) a majority of our executive officers or directors cannot be U.S. citizens or residents, (ii) more than 50% of our assets
must be located outside the United States and (iii) our business must be administered principally outside the United States. If we lose
our status as an FPI, we would be required to comply with the Exchange Act reporting and other requirements applicable to U.S. domestic
issuers, which are more detailed and extensive than the requirements for FPIs. We may also be required to make changes in our corporate
governance practices in accordance with various SEC and Nasdaq rules. The regulatory and compliance costs to us under U.S. securities
laws if we are required to comply with the reporting requirements applicable to a U.S. domestic issuer may be significantly higher than
the cost we would incur as an FPI. As a result, we expect that a loss of FPI status would increase our legal and financial compliance
costs and is likely to make some activities highly time consuming and costly. We also expect that if we were required to comply with
the rules and regulations applicable to U.S. domestic issuers, it would make it more difficult and expensive for us to obtain director
and officer liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage.
These rules and regulations could also make it more difficult for us to attract and retain qualified members of our board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are an emerging growth company within the meaning of the Securities Act of 1933, or the Securities Act, and will take advantage
of certain reduced reporting requirements.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an EGC, as defined in the JOBS Act. For as long as we continue to be an EGC, we may take advantage of exemptions from various reporting
requirements that are applicable to other public companies that are not EGCs, including not being required to comply with the auditor
attestation requirements of Section 404 of the Sarbanes-Oxley Act, or Section 404, exemptions from the requirements of holding a nonbinding
advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. As an EGC,
we are required to report only two years of financial results and selected financial data compared to three and five years, respectively,
for comparable data reported by other public companies. We may take advantage of these exemptions until we are no longer an EGC. We could
be an EGC for up to five years, although circumstances could cause us to lose that status earlier, including if the aggregate market
value of our ADSs held by non-affiliates exceeds $700 million as of any September 30 (the end of our second fiscal quarter) before that
time, in which case we would no longer be an EGC as of the following December 31 (our fiscal year-end). We cannot predict if investors
will find our ADSs less attractive because we may rely on these exemptions. If some investors find our ADSs less attractive as a result,
there may be a less active trading market for our ADSs and the price of our ADSs may be more volatile in the event that we decide to
make an offering of our ADSs following our Nasdaq listing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we fail to establish and maintain proper internal controls, our ability to produce accurate financial statements or comply with applicable
regulations could be impaired.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
404(a) of the Sarbanes-Oxley Act, or Section 404(a), requires that beginning with our second annual report following our IPO, management
assess and report annually on the effectiveness of our internal control over financial reporting and identify any material weaknesses
in our internal control over financial reporting. Although Section 404(b) of the Sarbanes-Oxley Act, or Section 404(b), requires our
independent registered public accounting firm to issue an annual report that addresses the effectiveness of our internal control over
financial reporting, we have opted to rely on the exemptions provided in the JOBS Act, and consequently will not be required to comply
with SEC rules that implement Section 404(b) until such time as we are no longer an EGC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect our first Section 404(a) assessment will take place for our annual report for the fiscal year ending March 31, 2023. The presence
of material weaknesses could result in financial statement errors which, in turn, could lead to errors in our financial reports, delays
in our financial reporting, which could require us to restate our operating results or our auditors may be required to issue a qualified
audit report. We might not identify one or more material weaknesses in our internal controls in connection with evaluating our compliance
with Section 404 (a). In order to maintain and improve the effectiveness of our disclosure controls and procedures and internal control
over financial reporting, we will need to expend significant resources and provide significant management oversight.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Implementing
any appropriate changes to our internal control may require specific compliance training of our directors and employees, entail substantial
costs in order to modify our existing accounting systems, take a significant period of time to complete and divert management&rsquo;s
attention from other business concerns. These changes may not, however, be effective in maintaining the adequacy of our internal control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
either we are unable to conclude that we have effective internal control over financial reporting or, at the appropriate time, our independent
auditors are unwilling or unable to provide us with an unqualified report on the effectiveness of our internal control over financial
reporting as required by Section 404(b), then in the event we have decided to make an offering of our ADSs following our Nasdaq listing,
investors may lose confidence in our operating results, the price of our ADSs could decline and we may be subject to litigation or regulatory
enforcement actions. In addition, if we are unable to meet the requirements of Section 404, we may not be able to remain listed on Nasdaq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
will incur significant increased costs as a result of operating as a company that publicly listed on Nasdaq in the United States, and
our management will be required to devote substantial time to new compliance initiatives.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a U.S. public company, and particularly after we no longer qualify as an EGC, we will incur significant legal, accounting and other expenses
that we did not incur previously. The Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act of 1987, the
listing requirements of Nasdaq and other applicable securities rules and regulations impose various requirements on non-U.S. reporting
public companies, including the establishment and maintenance of effective disclosure and financial controls and corporate governance
practices. Our senior management and other personnel will need to devote a substantial amount of time to these compliance initiatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming
and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director
and officer liability insurance, which in turn could make it more difficult for us to attract and retain qualified senior management
personnel or members for our board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">However,
these rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result,
their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result
in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance
practices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Section 404, we will be required to furnish a report by our senior management on our internal control over financial reporting. However,
while we remain an EGC, we will not be required to include an attestation report on internal control over financial reporting issued
by our independent registered public accounting firm. To prepare for eventual compliance with Section 404, once we no longer qualify
as an EGC, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly
and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and
adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve
control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting
and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able
to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by
Section 404. If we identify one or more material weaknesses, it could result in an adverse reaction in the financial markets due to a
loss of confidence in the reliability of our financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>ADSs
holders may not be entitled to a jury trial with respect to claims arising under the deposit agreement, which could augur less favorable
results to the plaintiff(s) in any such action.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
deposit agreement governing the ADSs representing our ordinary shares provides that holders and beneficial owners of ADSs irrevocably
waive the right to a trial by jury in any legal proceeding arising out of or relating to the deposit agreement or the ADSs, including
claims under federal securities laws, against us or the depositary to the fullest extent permitted by applicable law. If this jury trial
waiver provision is prohibited by applicable law, an action could nevertheless proceed under the terms of the deposit agreement with
a jury trial. To our knowledge, the enforceability of a jury trial waiver under the federal securities laws has not been finally adjudicated
by a federal court. However, we believe that a jury trial waiver provision is generally enforceable under the laws of the State of New
York, which govern the deposit agreement, by a court of the State of New York or a federal court, which have non-exclusive jurisdiction
over matters arising under the deposit agreement, applying such law. In determining whether to enforce a jury trial waiver provision,
New York courts and federal courts will consider whether the visibility of the jury trial waiver provision within the agreement is sufficiently
prominent such that a party has knowingly waived any right to trial by jury. We believe that this is the case with respect to the deposit
agreement and the ADSs. In addition, New York courts will not enforce a jury trial waiver provision in order to bar a viable setoff or
counterclaim sounding in fraud or one which is based upon a creditor&rsquo;s negligence in failing to liquidate collateral upon a guarantor&rsquo;s
demand, or in the case of an intentional tort claim (as opposed to a contract dispute), none of which we believe are applicable in the
case of the deposit agreement or the ADSs. No condition, stipulation or provision of the deposit agreement or ADSs serves as a waiver
by any holder or beneficial owner of ADSs or by us or the depositary of compliance with any provision of the federal securities laws.
If you or any other holder or beneficial owner of ADSs brings a claim against us or the depositary in connection with matters arising
under the deposit agreement or the ADSs, you or such other holder or beneficial owner may not be entitled to a jury trial with respect
to such claims, which may have the effect of limiting and discouraging lawsuits against us and / or the depositary. If a lawsuit is brought
against us and / or the depositary under the deposit agreement, it may be heard only by a judge or justice of the applicable trial court,
which would be conducted according to different civil procedures and may augur different results than a trial by jury would have had,
including results that could be less favorable to the plaintiff(s) in any such action, depending on, among other things, the nature of
the claims, the judge or justice hearing such claims, and the venue of the hearing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Claims
of U.S. civil liabilities may not be enforceable against us.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are incorporated under the laws of Guernsey. Certain members of our board of directors and senior management are non-residents of the
United States, and all or a substantial portion of our assets and the assets of such persons are located outside the United States. As
a result, it may not be possible to serve process on such persons or us in the United States or to enforce judgments obtained in U.S.
courts against them or us based on civil liability provisions of the securities laws of the United States. As a result, it may not be
possible for investors to effect service of process within the United States upon such persons or to enforce judgments obtained in U.S.
courts against them or us, including judgments predicated upon the civil liability provisions of the U.S. federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
&ldquo;Description of Share Capital and Memorandum and Articles of Incorporation&mdash;Enforcement of Civil Liabilities.&rdquo; Additionally,
it may be difficult to assert securities law claims in actions originally instituted outside of the United States. Foreign courts may
refuse to hear a securities law claim because foreign courts may not be the most appropriate forum in which to bring such a claim. Even
if a foreign court agrees to hear a claim, it may determine that the law of the jurisdiction in which the foreign court resides, and
not U.S. law, is applicable to the claim. Further, if U.S. law is found to be applicable, the content of applicable U.S. law must be
proved as a fact, which can be a time-consuming and costly process, and certain matters of procedure would still be governed by the law
of the jurisdiction in which the foreign court resides.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
rights afforded to shareholders are governed by Guernsey law. Not all rights available to shareholders under English law or U.S. law
will be available to shareholders.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
rights afforded to shareholders will be governed by Guernsey law and by our Articles, and these rights differ in certain respects from
the rights of shareholders in typical English companies and U.S. corporations. In particular, Guernsey law significantly limits the circumstances
under which shareholders of companies may bring derivative actions and, in most cases, only the corporation may be the proper claimant
or plaintiff for the purposes of maintaining proceedings in respect of any wrongful act committed against it. Neither an individual nor
any group of shareholders has any right of action in such circumstances. In addition, Guernsey law does not afford appraisal rights to
dissenting shareholders in the form typically available to shareholders of a U.S. corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
insolvency laws of Guernsey and other jurisdictions may not be as favorable to you as the U.S. bankruptcy laws.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are incorporated under the laws of Guernsey. In the event of a bankruptcy, insolvency or similar event, proceedings could be initiated
in Guernsey or another relevant jurisdiction. The bankruptcy, insolvency, administrative and other laws of our and our subsidiaries&rsquo;
jurisdictions of organization or incorporation may be materially different from, or in conflict with, each other and those of the United
States, including in the areas of rights of creditors, shareholders, priority of governmental and other creditors and duration of the
proceeding. The application of these laws, or any conflict among them, could call into question whether any particular jurisdiction&rsquo;s
law should apply, adversely affecting your ability to enforce your rights under the ordinary shares underlying our ADSs in those jurisdictions
or limit any amounts that you may receive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are a passive foreign investment company, there could be adverse U.S. federal income tax consequences to U.S. holders.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Internal Revenue Code of 1986, or the Internal Revenue Code, we will be a PFIC for any taxable year in which (1) 75% or more of our
gross income consists of passive income or (2) 50% or more of the average quarterly value of our assets consists of assets that produce,
or are held for the production of, passive income. For purposes of these tests, passive income includes dividends, interest, gains from
the sale or exchange of investment property and certain rents and royalties. In addition, for purposes of the above calculations, a non-U.S.
corporation that directly or indirectly owns at least 25% by value of the shares of another corporation is treated as if it held its
proportionate share of the assets and received directly its proportionate share of the income of such other corporation. If we are a
PFIC for any taxable year during which a U.S. Holder (as defined below under &ldquo;Certain U.S. and Guernsey Tax Considerations-Material
U.S. Federal Income Tax Considerations for U.S. Holders&rdquo;) holds our shares, the U.S. Holder may be subject to adverse tax consequences
regardless of whether we continue to qualify as a PFIC, including ineligibility for any preferred tax rates on capital gains or on actual
or deemed dividends, interest charges on certain taxes treated as deferred, and additional reporting requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not believe that we were a PFIC for our taxable year ended March 31, 2020 but cannot provide any assurances regarding our PFIC status
for any past, current or future taxable years. The determination of whether we are a PFIC is a fact-intensive determination made on an
annual basis applying principles and methodologies which in some circumstances are unclear and subject to varying interpretation. In
particular, the characterization of our assets as active or passive may depend in part on our current and intended future business plans,
which are subject to change. In addition, for our current and future taxable years, the total value of our assets for PFIC testing purposes
may be determined in part by reference to the market price of our ordinary shares or ADSs from time to time, which may fluctuate considerably.
Under the income test, our status as a PFIC depends on the composition of our income which will depend on the transactions we enter into
in the future and our corporate structure. The composition of our income and assets is also affected by how, and how quickly, we spend
the cash we raise in any offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
certain circumstances, a U.S. Holder of shares in a PFIC may alleviate some of the adverse tax consequences described above by making,
where available, a qualified electing fund, or QEF, election to include in income its pro rata share of the corporation&rsquo;s income
on a current basis or a mark-to-market election. A U.S. Holder may make a QEF election with respect to our ordinary shares or ADSs only
if we agree to furnish such U.S. Holder annually with a PFIC annual information statement as specified in the applicable U.S. Treasury
Regulations. We currently do not intend to prepare or provide the information that would enable U.S. Holders to make a QEF election if
we are treated as a PFIC for any taxable year, and prospective investors should assume that a QEF election will not be available. A U.S.
Holder may be able to make a mark-to-market election with respect to our ADSs if our ADSs are treated as &ldquo;marketable stock.&rdquo;
Generally, stock will be considered marketable stock if it is &ldquo;regularly traded&rdquo; on a &ldquo;qualified exchange&rdquo; within
the meaning of applicable U.S. Treasury regulations. A class of stock is regularly traded during any calendar year during which such
class of stock is traded, other than in de minimis quantities, on at least 15 days during each calendar quarter. Our ADSs will be marketable
stock as long as they remain listed on Nasdaq and are regularly traded. There can be no assurance that out ADSs will be regularly traded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
further discussion of the PFIC rules and the adverse U.S. federal income tax consequences in the event we are classified as a PFIC, see
the section of this report entitled &ldquo;Certain U.S. and Guernsey Tax Considerations-Material U.S. Federal Income Considerations for
U.S. Holders.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>A
change in our tax residence could have a negative effect on our future profitability.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we are incorporated under the laws of Guernsey, our affairs are, and are intended to continue to be, managed and controlled in the United
Kingdom for tax purposes and therefore we are resident in the United Kingdom for U.K. and Guernsey tax purposes. It is possible that
in the future, whether as a result of a change in law or the practice of any relevant tax authority or as a result of any change in the
conduct of our affairs or for any other reason, we could become, or be regarded as having become, a resident in a jurisdiction other
than the United Kingdom. If we cease to be a U.K. tax resident, we may be subject to a charge to U.K. corporation tax on chargeable gains
on our assets and to unexpected tax charges in other jurisdictions on our income. Similarly, if the tax residency of any of our subsidiaries
were to change from their current jurisdiction for any of the reasons listed above, we may be subject to a charge to local capital gains
tax on the assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may be unable to use net operating loss and tax credit carryforwards and certain built-in losses to reduce future tax payments or benefit
from favorable U.K. tax legislation.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a U.K. resident trading entity, we are subject to U.K. corporate taxation. Due to the nature of our business, we have generated losses
since inception. As of March 31, 2021, we had cumulative carryforward tax losses of $9,411,521. Subject to any relevant restrictions,
we expect these to be available to carry forward and offset against future operating profits. As a company that carries out extensive
research and development activities, we benefit from the U.K. research and development tax credit regime for small and medium-sized companies,
whereby we are able to surrender the trading losses that arise from our qualifying research and development activities for a payable
tax credit of up to 33.35% of eligible research and development expenditures. Qualifying expenditures largely comprise employment costs
for research staff, consumables and certain internal overhead costs incurred as part of research projects. Certain subcontracted qualifying
research expenditures are eligible for a cash rebate of up to 21.67%. The majority of our pipeline research, clinical trials management
and manufacturing development activities are eligible for inclusion within these tax credit cash rebate claims. Our ability to continue
to claim payable research and development tax credits in the future may be limited because we may no longer qualify as a small or medium-sized
company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may benefit in the future from the United Kingdom&rsquo;s &ldquo;patent box&rdquo; regime, which allows certain profits attributable
to revenues from patented products to be taxed at an effective rate of 10%. We are the exclusive licensee or owner of several patent
applications which, if issued, would cover our product candidates, and accordingly, future upfront fees, milestone fees, product revenues
and royalties could be taxed at this tax rate. When taken in combination with the enhanced relief available on our research and development
expenditures, we expect a long-term lower rate of corporation tax to apply to us. If, however, there are unexpected adverse changes to
the U.K. research and development tax credit regime or the &ldquo;patent box&rdquo; regime, or for any reason we are unable to qualify
for such advantageous tax legislation, or we are unable to use net operating loss and tax credit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Changes
and uncertainties in the tax system in the countries in which we have operations could materially adversely affect our financial condition
and results of operations and reduce net returns to our shareholders.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
tax position could be adversely impacted by changes in tax rates, tax laws, tax practice, tax treaties or tax regulations or changes
in the interpretation thereof by the tax authorities in the United Kingdom, the United States and other jurisdictions as well as being
affected by certain changes currently proposed by the Organization for Economic Co-operation and Development and their action plan on
Base Erosion and Profit Shifting. Such changes may become more likely as a result of recent economic trends in the jurisdictions in which
we operate, particularly if such trends continue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
actual effective tax rate may vary from our expectation and that variance may be material. A number of factors may increase our future
effective tax rates, including: (1) the jurisdictions in which profits are determined to be earned and taxed; (2) the resolution of issues
arising from any future tax audits with various tax authorities; (3) changes in the valuation of our deferred tax assets and liabilities;
(4) increases in expenses not deductible for tax purposes, including transaction costs and impairments of goodwill in connection with
acquisitions; (5) changes in the taxation of share-based compensation; (6) changes in tax laws or the interpretation of such tax laws,
and changes in generally accepted accounting principles; and (7) challenges to the transfer pricing policies related to our structure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
tax authority may disagree with tax positions that we have taken, which could result in increased tax liabilities. For example, Her Majesty&rsquo;s
Revenue &amp; Customs, or HMRC, the U.S. Internal Revenue Service, or IRS, or another tax authority could challenge our allocation of
income by tax jurisdiction and the amounts paid between our affiliated companies pursuant to our intercompany arrangements and transfer
pricing policies, including methodologies for valuing developed technology and amounts paid with respect to our intellectual property
development. Similarly, a tax authority could assert that we are subject to tax in a jurisdiction where we believe we have not established
a taxable connection, often referred to as a &ldquo;permanent establishment&rdquo; under international tax treaties, and such an assertion,
if successful, could increase our expected tax liability in one or more jurisdictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
tax authority may take the position that material income tax liabilities, interest and penalties are payable by us, for example where
there has been a technical violation of contradictory laws and regulations that are relatively new and have not been subject to extensive
review or interpretation, in which case we expect that we might contest such assessment. High-profile companies can be particularly vulnerable
to aggressive application of unclear requirements. Many companies must negotiate their tax bills with tax inspectors who may demand higher
taxes than applicable law appears to provide. Contesting such an assessment may be lengthy and costly and if we were unsuccessful in
disputing the assessment, the implications could increase our anticipated effective tax rate, where applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="cr_006"></A>CAUTIONARY
STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus contains statements that constitute forward-looking statements. Many of the forward-looking statements contained in this prospectus
can be identified by the use of forward-looking words such as &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;could,&rdquo; &ldquo;estimate,&rdquo;
&ldquo;expect,&rdquo; &ldquo;intend,&rdquo; &ldquo;plan,&rdquo; &ldquo;potential&rdquo; and &ldquo;should,&rdquo; among others.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forward-looking
statements appear in a number of places in this prospectus and include, but are not limited to, statements regarding our intent, belief,
or current expectations. Forward-looking statements are based on our management&rsquo;s beliefs and assumptions and on information currently
available to our management. Such statements are subject to substantial risks and uncertainties, and actual results may differ materially
from those expressed or implied in the forward-looking statements due to various important factors, including, but not limited to, those
identified under &ldquo;Risk Factors.&rdquo; In light of the significant uncertainties in these forward-looking statements, you should
not regard these statements as a guarantee by us or any other person that we will achieve our objectives and plans in any specified time
frame, or at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forward-looking
statements include, but are not limited to, statements about:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    development of product candidates, including statements regarding the timing of initiation, completion and the outcome of clinical
    studies or trials and related preparatory work, the period during which the results of the trials will become available and our research
    and development programs;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain and maintain regulatory approval of our product candidates in the indications for which we plan to develop them,
    and any related restrictions, limitations or warnings in the label of an approved drug or therapy;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    plans to research, develop, manufacture and commercialize our product candidates;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing of our regulatory filings for our product candidates;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    size and growth potential of the markets for our product candidates;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to raise additional capital;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    impact of COVID-19 on our business and operations;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    commercialization, marketing and manufacturing capabilities and strategy;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    expectations regarding our ability to obtain and maintain intellectual property protection;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to attract and retain qualified employees and key personnel;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to contract with third party suppliers and manufacturers and their ability to perform adequately;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    estimates regarding future revenue, expenses and needs for additional financing; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    developments in the United States, European Union and other jurisdictions.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forward-looking
statements speak only as of the date they are made, and we do not undertake any obligation to update them in light of new information
or future developments or to release publicly any revisions to these statements in order to reflect later events or circumstances or
to reflect the occurrence of unanticipated events.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, statements that &ldquo;we believe&rdquo; and similar statements reflect our beliefs and opinions on the relevant subject. These
statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms
a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate
that we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain,
and investors are cautioned not to unduly rely upon these statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should read this prospectus and the documents that we reference in this prospectus and have filed as exhibits to the registration statement,
of which this prospectus is a part, completely and with the understanding that our actual future results may be materially different
from what we expect. We qualify all of our forward-looking statements by these cautionary statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="cr_007"></A>MARKET
and industry DATA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
industry data and market data included in this prospectus were obtained from independent third-party surveys, market research, publicly
available information, reports of governmental agencies, and industry publications and surveys. All of the market data used in this prospectus
involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. We believe that the
information from these industry publications and surveys included in this prospectus is reliable. The industry in which we operate is
subject to a high degree of uncertainty and risk due to a variety of factors, including those described in &ldquo;Risk Factors.&rdquo;
These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties
and by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="cr_008"></A>TRADEMARKS,
SERVICE MARKS AND TRADENAMES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Solely
for convenience, the trademarks, service marks, logos and trade names referred to in this prospectus are without the &reg; and &trade;
symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable
law, our rights or the rights of the applicable licensors to these trademarks, service marks, and trade names. For the avoidance of doubt,
&ldquo;OKYO,&rdquo; the OKYO logo and other trademarks or service marks of OKYO Pharma Limited appearing in this prospectus are the property
of OKYO or our subsidiary. This prospectus contains additional trademarks, service marks, and trade names of others, which are the property
of their respective owners. All trademarks, service marks, and trade names appearing in this prospectus are, to our knowledge, the property
of their respective owners. We do not intend our use or display of other companies&rsquo; trademarks, service marks, copyrights, or trade
names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="cr_009"></A>EXCHANGE
RATE INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fluctuations
in the exchange rate between Pounds Sterling and the U.S. dollar will affect the U.S. dollar amounts received by potential future owners
of our ADSs on conversion of dividends, if any, paid in Pounds Sterling on the ordinary shares and will affect the potential future U.S.
dollar price of our ADSs on Nasdaq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below shows the period end, average, high and low exchange rates of U.S. dollars per Pound Sterling for the periods shown. Average
rates are computed by using the noon buying rate of the Federal Reserve Bank of New York for the U.S. dollar on the last business day
of each month during the relevant year indicated or each business day during the relevant month indicated. The rates set forth below
are provided solely for your convenience and may differ from the actual rates used in the preparation of our consolidated financial statements
included in this registration statement and other financial data appearing in this registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; font-weight: bold; border-bottom: Black 1.5pt solid">Year Ended March 31,</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Period End</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Average Rate for Period</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">High</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Low</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD COLSPAN="13" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(U.S. dollars per pound Sterling)</B></FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 36%; text-align: left">2016</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">1,4381</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">1.5080</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">1.5882</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">1.3867</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.2537</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3087</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.4800</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.2118</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.4027</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.4264</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3265</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.2398</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3032</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.4332</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.2524</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3142</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.4540</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.2712</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3349</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.1492</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3795</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3074</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.4106</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.2129</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>Month, 2021</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Period End</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>High</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Low</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt"><B>(U.S. dollars per Pound Sterling)</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 64%"><FONT STYLE="font-size: 10pt">April 2020 </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><FONT STYLE="font-size: 10pt">1.2602</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><FONT STYLE="font-size: 10pt">1.2617</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><FONT STYLE="font-size: 10pt">1.2228</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">May 2020 </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.2320</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.2509</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.2129</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">June 2020 </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.2369</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.2758</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.2279</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">July 2020 </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.3133</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.3133</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.2469</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">August 2020 </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.3375</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.3375</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.3043</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">September 2020 </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.2921</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.3416</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.2706</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">October 2020 </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.2933</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.3143</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.2890</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">November 2020 </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.3338</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.3378</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.2904</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">December 2020 </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.3662</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.3662</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.3197</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">January 2021 </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.3723</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.3729</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.3522</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">February 2021 </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.3947</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.3644</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.4106</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">March 2021 </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.3795</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.3999</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.3722</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">April 2021 </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.3838</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.3977</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.3734</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">May 2021 </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.4188</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.4188</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.3873</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">June 2021 </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.3806</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.4179</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.3806</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">July 2021 </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.3913</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.3966</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.3615</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">August 2021 </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.3747</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.3929</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.3625</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">September 2021 </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.3470</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.3862</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.3439</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">October 2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.3804</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.3821</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.3569</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">November 2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.3252</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.3679</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.3252</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">December 2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.3500</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.3500</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.3188</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">January 2022 </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.3439</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.3724</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1.3385</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">February 2022 </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.3419</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.3636</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.3360</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">March 2022</P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">1.3152</P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">1.3365</P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">1.3044</P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">April 2022</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.2565</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.3116</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.2443</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">May 2022 (to May 6, 2022)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.2344</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.2523</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.2334</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><B>On May 6, 2022 the
exchange rate published by the Federal Reserve Bank of New York was $1.2344 per &pound;1.00.</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
presented on a constant currency basis in this prospectus is calculated by translating current year results at prior year average exchange
rates. Management reviews and analyzes business results excluding the effect of foreign currency translation because they believe this
better represents our underlying business trends.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="cr_010"></A>PRICE
RANGE OF OUR ORDINARY SHARES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ordinary shares have been trading on the Main Market of the London Stock Exchange under the symbol &ldquo;OKYO&rdquo; since July 17,
2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The following table presents,
for the periods indicated, the reported high and low sale prices, including intra-day sales, of our ordinary shares on the Main Market
of the London Stock Exchange in Pounds Sterling and U.S. dollars. For the convenience of the reader, we have translated Pounds Sterling
amounts in the table below into U.S. dollars at the noon buying rate of the Federal Reserve Bank of New York on May 6, 2022 which
was &pound;1.00 to $1.2344.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Price Per<BR> Ordinary Share &pound;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Price Per<BR> Ordinary Share $</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">High</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Low</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">High</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Low</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Year Ended March 31, 2023</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 40%">First Quarter (to May 6, 2022)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">0.063</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">0.061</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">0.077</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">0.075</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Year Ended March 31, 2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">First Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.078</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.060</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.096</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.073</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Second Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.065</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.040</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.080</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.049</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Third Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.085</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.041</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.105</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.051</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Fourth Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.083</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.048</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.102</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.059</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Year Ended March 31, 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">First Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.055</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.017</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.068</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.021</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Second Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.180</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.053</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.222</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.065</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Third Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.121</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.071</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.149</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.088</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Fourth Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.120</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.076</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.148</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.094</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Year Ended March 31, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">First Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.021</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.011</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.026</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.014</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Second Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.059</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.021</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.073</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.025</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Third Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.043</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.017</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.053</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.021</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Fourth Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.023</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.013</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.028</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.015</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">On May 12, 2022, the last
reported sale price of our ordinary shares on the Main Market of the London Stock Exchange was &pound;0.0613 per ordinary share
($0.076 per ordinary share based on the exchange rate set forth above).</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="us_001"></A>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
estimate that the net proceeds from this offering will be approximately $1.8 million, or approximately $2.2 million if
the underwriters exercise their over-allotment option in full, after deducting the underwriting discounts and commissions and estimated
offering expenses payable by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
intend to use the net proceeds as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approximately
    $0.75 million to advance OK-101 to the filing of an IND to treat DED, and approximately $1.0 million to fund the</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">initial Phase 2 clinical trial of OK-101 in DED
    patients; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    remainder to fund working capital and other general corporate purposes.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
expected use of the net proceeds from this offering represents our intentions based upon our current plans and business conditions. We
may also use a portion of the net proceeds to in-license, acquire, or invest in additional products or assets, businesses, or technologies,
although currently we have no specific agreements, commitments, or understandings in this regard. As of the date of this prospectus,
we cannot predict with certainty all of the particular uses for the net proceeds to be received upon the closing of this offering or
the amounts that we will actually spend on the uses set forth above. Predicting the costs necessary to develop product candidates can
be difficult. The amounts and timing of our actual expenditures and the extent of clinical development may vary significantly depending
on numerous factors, including the progress of our development efforts, the status of and results from ongoing clinical trials or clinical
trials we may commence in the future, as well as any collaborations that we may enter into with third parties and any unforeseen cash
needs. As a result, our management will retain broad discretion over the allocation of the net proceeds from this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
anticipate that our existing cash resources, together with the net proceeds from the offering, will enable us to fund our operating expenses
and capital expenditure requirements for at least the 12 months after the date of this prospectus. We have based this estimate on assumptions
that may prove to be incorrect, and we could use our available capital resources sooner than we currently expect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pending
their use, we plan to invest the net proceeds from the offering in short- and intermediate-term interest-bearing obligations and certificates
of deposit. The goal with respect to the investment of these net proceeds is capital preservation and liquidity so that such funds are
readily available to fund our operations.</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="cr_011"></A>DIVIDEND
POLICY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never paid or declared any cash dividends on our ordinary shares, and we do not anticipate paying any cash dividends on our ordinary
shares in the foreseeable future. We intend to retain all available funds and any future earnings to fund the development and expansion
of our business. Pursuant to the Guernsey Companies Law, we may only pay a dividend if the directors who authorize the dividend make
a prior solvency statement in statutory form.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="cr_012"></A>CAPITALIZATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should read the information in this &ldquo;Capitalization&rdquo; section together with &ldquo;Selected Consolidated Financial Data,&rdquo;
&ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo; and our consolidated financial
statements and the related notes appearing elsewhere in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The table below sets forth our
cash and short-term deposits and short-term investments and capitalization as of September 30, 2021 derived from our unaudited
consolidated financial statements included elsewhere in this prospectus:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
    an actual basis; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">on an adjusted basis to give effect to the sale by
us of 625,000 ADSs (representing 40,625,000 ordinary shares) at an initial public offering price of $4.00 per ADS
in this offering, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us
in connection with this offering</P>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30, 2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Actual</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As Adjusted</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">$</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents</TD><TD STYLE="width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; border-bottom: Black 2.5pt double; text-align: right">5,184,149</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; border-bottom: Black 2.5pt double; text-align: right"><P STYLE="margin: 0">7,007,849</P></TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total interest bearing loans and borrowings</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">535,497</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">535,497</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-decoration: underline">Equity:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Share premium</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">122,750,523</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">125,844,566</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Other reserves</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,592,995</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(9,863,339</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Accumulated loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(109,199,246</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(109,199,246</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total shareholders&rsquo; equity</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,958,282</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6,781,982</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total capitalization</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,493,779</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,317,479</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table above excludes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">72,400,000
    ordinary shares issuable upon the exercise of share options at exercise prices of between $0.056 and $0.191 per ordinary
    share of which 14,437,500 ordinary shares are currently exercisable and 57,962,500 are exercisable between July 6, 2022 and January
    31, 2032;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36,659,090 ordinary shares
    that currently may be issued upon the exercise of warrants to purchase ordinary shares at exercise prices of between $0.034
    and $0.17 per ordinary share.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="us_002"></A>DILUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you invest in our ADSs in this offering, your interest will be diluted to the extent of the difference between the initial public offering
price per ADS paid by purchasers in this offering and our pro forma as adjusted net tangible book value per ADS after completion of this
offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
September 30, 2021, we had a historical net tangible book value of $0.0036 per ordinary share (equal to $0.2345 per ADS).
Net tangible book value per ordinary share represents the amount of our total assets less our total liabilities, excluding goodwill and
other intangible assets, divided by the total number of our ordinary shares outstanding as of September 30, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">After giving effect to the
sale by us of 625,000 ADSs (representing 40,625,000 ordinary shares) at an initial public offering price of $4.00
per ADS in this offering, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable
by us in connection with this offering, our as adjusted net tangible book value as of September 30, 2021 would have been $4.96
million, (equal to $0.3115 per ADS). This represents an immediate increase in net tangible book value of $0.0012 per ordinary
share (equal to $0.077 ADS) to existing shareholders and an immediate dilution of $0.0567 per ordinary share (equal to
$3.6885 per ADS) to new investors purchasing ADSs in this offering. Dilution per ADS or ordinary share to new investors is determined
by subtracting the as adjusted net tangible book value per ADS or ordinary share after this offering from the assumed initial public
offering price per ADS paid by new investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table illustrates this dilution to new investors purchasing ADSs in this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">As of</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September <BR>30, 2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">per ADS</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: left">Initial public offering price</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right"></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">4.00</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Historical net tangible book value per ADS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.23</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Increase in historical net tangible book value per ADS attributable to this offering</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.08</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">As adjusted net tangible book value per ADS after this offering</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.31</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Dilution per ADS to new investors in this offering</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3.69</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">If the underwriters exercise
in full their over-allotment option to purchase an additional 93,750 ADSs, our as adjusted net tangible book value after this
offering would be $0.005 per ordinary share (equal to $0.33 per ADS), representing an immediate increase in as adjusted net tangible
book value of $0.001 per ordinary share (equal to $0.09 per ADS) to existing shareholders and immediate dilution of $0.06 per ordinary
share (equal to $3.67 per ADS).</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The following table summarizes,
as of September 30, 2021, on the as adjusted basis described above, the number of ADSs purchased from us, the total consideration paid
to us and the average price paid by new investors purchasing ADSs in this offering. The table below is based on an initial public offering
price of $4.00 per ADS in this offering, before deducting the estimated underwriting discounts and commissions and estimated offering
expenses payable by us in connection with this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>Ordinary Shares</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>Average Price per</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>Average</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Purchased(1)</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Total Consideration</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>Ordinary</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>Price per</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Number</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Percent</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Amount</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Percent</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Share</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>ADS</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="21" STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>(in thousands, except percentages and per share data)</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 28%"><FONT STYLE="font-size: 10pt">Existing shareholders</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 10pt">1,374,415,468</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 10pt">97</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 10pt">99,956,678</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 10pt">98</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 10pt">0.073</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">New investors</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">40,625,000</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">3</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">2,500,000</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">2</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-size: 10pt">0.062</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-size: 10pt">4.00</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Total</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">1,415,040.468</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">100</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">102,456,678</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">100</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 29px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Including
    ordinary shares in the form of ADSs.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The table above assumes no exercise
of the underwriters&rsquo; over-allotment option in this offering. If the underwriters exercise in full their over-allotment option to
purchase an additional 93,750 ADSs, the following will occur:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    percentage of our ordinary shares held by existing shareholders will remain at 97% of the total number of our ordinary shares
    outstanding after this offering; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    percentage of our ordinary shares held by new investors will remain at approximately 3% of the total number of our ordinary
    shares outstanding after this offering.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table above excludes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">72,400,000
    ordinary shares issuable upon the exercise of share options at exercise prices of between $0.056 and $0.191 per ordinary
    share of which 14,437,500 ordinary shares are currently exercisable and 57,962,500 are exercisable between July 6, 2022 and January
    31, 2032;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36,659,090
    ordinary shares that currently may be issued upon the exercise of warrants to purchase ordinary shares at exercise prices of between
    $0.034 and $0.17 per ordinary share.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that share options or warrants are exercised, or we issue additional ADSs or ordinary shares in the future, there will be
further dilution to investors participating in this offering. In addition, we may choose to raise additional capital because of market
conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans. If
we raise additional capital through the sale of equity or convertible debt securities, the issuance of these securities could result
in further dilution to our shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="cr_013"></A>SELECTED
CONSOLIDATED FINANCIAL DATA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables set forth our selected consolidated financial data for the periods indicated. We have derived the consolidated statement
of comprehensive income for the years ended March 31, 2021, and 2020 and the consolidated balance sheet data as of March 31, 2021,
and 2020 from our audited consolidated financial statements included elsewhere in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain our books and records in Pounds Sterling, and we prepare our financial statements in accordance with IFRS as issued by the IASB.
We report our financial results in U.S. dollars.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Six
    Months Ended<BR> September 30,</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Years
    Ended <BR> March 31,</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(unaudited)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(unaudited)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="14" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    statement of operations data:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 44%; text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development expenses</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(479,700</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(37,622</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(173,821</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(518,098</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and Administrative expenses</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,254,393</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(517,825</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,192,385</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,016,548</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    Loss</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,734,092</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(555,447</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,366,207</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,534,646</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    expense</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,021</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(69,608</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12,294</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(85,701</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
    Before taxation</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,735,114</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(625,055</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,378,501</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,620,347</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
    (expense)/credits</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">188,761</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(87</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24,994</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">76,289</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    Loss</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,546,353</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(625,142</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,353,507</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,544,059</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
    and diluted loss per share</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.01</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<BR> September
    30,</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of March
    31,</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">(unaudited)</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Consolidated balance sheet:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%; font-size: 10pt; text-align: left">Cash and cash equivalents</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 14%; font-size: 10pt; text-align: right">5,184,149</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 14%; font-size: 10pt; text-align: right">6,889,329</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 14%; font-size: 10pt; text-align: right">235,485</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Total assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,624,610</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">7,091,322</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">598,743</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Total liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">666,328</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,771,913</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">738,857</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">Share capital</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">122,750,523</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">111,629,173</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">112,079,983</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Other reserves</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(8,592,995</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(306,012</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(9,787,395</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Retained earnings</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(109,199,246</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(106,003,753</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(102,432,702</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Total Equity (Deficit)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">4,958,282</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">5,319,408</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">(140,114</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="cr_014"></A>MANAGEMENT&rsquo;S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>AND
RESULTS OF OPERATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following discussion of our financial condition and results of operations should be read in conjunction with the audited consolidated
historical financial statements as at March 31, 2021, 2020 and 2019.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following discussion includes forward-looking statements that reflect our plans, estimates and beliefs and involves risks and uncertainties.
Our actual results could differ materially from those discussed in these statements. Factors that could cause or contribute to these
differences include, but are not limited to, those discussed below and elsewhere in this registration statement, particularly in &ldquo;Risk
Factors&rdquo; and elsewhere in this prospectus.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We are a preclinical biopharmaceutical
company developing next-generation therapeutics to improve the lives of patients suffering from inflammatory eye diseases and ocular
pain. Our research program is focused on a novel G Protein-Coupled Receptor, or GPCR, which we believe plays a key role in the
pathology of these inflammatory eye diseases of high unmet medical need. Our therapeutic approach is focused on targeting inflammatory
and pain modulation pathways that drive these conditions. We are presently developing OK-101, our lead preclinical product candidate,
for the treatment of dry-eye disease. We also plan to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis
and allergic conjunctivitis. We have also been evaluating OK-201, a bovine adrenal medulla, or BAM, lipidated-peptide preclinical analogue
candidate for the treatment of neuropathic ocular pain, and plan on maintaining this drug candidate at the exploratory level while we
focus our primary energy on the OK-101 program.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 21, 2018, we announced that we successfully obtained (via assignment from Panetta Partners Limited, a related party) a license
from OTT to patents owned or controlled by OTT and a sub-license from OTT to certain patents licensed by OTT from TMC to support our
ophthalmic disease drug programs. These licenses gave us the right to exploit the IP estate which is directed to compositions-of-matter
and methodologies for treating ocular inflammation, DED with chemerin or lipid-linked chemerin analogues. We also have a license from
TMC to a separate IP estate for treating symptoms of ocular neuropathic pain and uveitis associated pain. On August 6, 2019, we signed
a collaborative agreement with TMC on a research program focused on ocular neuropathic pain.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 7, 2021 we announced the appointment of Mr. Gabriele Cerrone as Non-Executive Chairman and Director, and Gary S. Jacob,
Ph.D. as Chief Executive Officer and Director. The addition of these two individuals is a significant step for us, highlighting a careful
realignment of the strategic focus of our research and development program. We believe this realignment will allow us to file IND applications
on our drug candidates from with FDA in the shortest time possible.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Foreign
currency translations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Items
included in the financial statements are measured using the currency of the primary economic environment in which the entity operates
(the functional currency). The consolidated financial statements are presented in U.S. dollars, which is our presentation currency.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Foreign
exchange gains and losses resulting from the settlement of foreign currency transactions and from the translation at year-end exchange
rates of monetary assets and liabilities denominated in foreign currencies are recognized in the income statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements of overseas subsidiary undertakings are translated into U.S. dollars on the following basis:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets
    and liabilities at the rate of exchange ruling at the year-end date.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Profit
    and loss account items at the average rate of exchange for the year.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchange
differences arising from the translation of the net investment in foreign entities, borrowings and other currency instruments designated
as hedges of such investments, are taken to equity (and recognized in the statement of comprehensive income) on consolidation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Components
of Our Results of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Revenues</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products in the
near future. If our development efforts for our product candidates are successful and result in regulatory approval, we may generate
revenue in the future from product sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Operating
Expenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Research
and Development Expenses</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">R&amp;D
expenses consist primarily of costs incurred in connection with the R&amp;D of our product candidates and are expensed as incurred. These
expenses consist of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses
    incurred under agreements with CROs, CMOs, as well as investigative sites and consultants that conduct our preclinical studies and
    other scientific development services;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing
    scale-up expenses and the cost of acquiring and manufacturing materials for preclinical studies;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">employee-related
    expenses, including salaries, related benefits, travel and share-based compensation expense for employees engaged in R&amp;D functions;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    related to compliance with regulatory requirements;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">facilities
    costs, depreciation and other expenses, which include rent and utilities; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fees
    for maintaining our third-party licensing agreements.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognize external development costs based on an evaluation of the progress to completion of specific tasks using information provided
to us by our service providers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
direct R&amp;D expenses are tracked on a program-by-program basis for our product candidates and consist primarily of external costs,
such as fees paid to outside consultants, CROs and CMOs in connection with our preclinical development, manufacturing and clinical development
activities. Our direct R&amp;D expenses by program also include fees incurred under our license agreements. We do not allocate employee
costs or facility expenses, including depreciation or other indirect costs, to specific programs because these costs are deployed across
multiple programs and, as such, are not separately classified. We use internal resources primarily to oversee the R&amp;D as well as
for managing our preclinical development, process development, manufacturing and clinical development activities. These employees work
across multiple programs and, therefore, we do not track their costs by program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below summarizes our R&amp;D expenses incurred by program:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six months ended<BR>
    September 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended<BR> March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Direct research and development expense by program:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 44%; font-size: 10pt">OK-101</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">365,668</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">37,622</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">170,417</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">449,580</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">OK-201</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">114,032</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,404</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">68,518</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Total direct research and development expense</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">479,700</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">37,622</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">173,821</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">518,098</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total research and development expense</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">479,700</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">37,622</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">173,821</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">518,098</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">R&amp;D
activities are central to our business model. Product candidates in later stages of clinical development generally have higher development
costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical
trials and related product manufacturing expenses. As a result, we expect that our R&amp;D expenses will increase substantially over
the next several years as we increase personnel costs and prepare for regulatory filings related to our product candidates. We also expect
to incur additional expenses related to milestone, royalty payments and maintenance fees payable to third parties with whom we have entered
into license agreements to acquire the rights related to our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
successful development and commercialization of our product candidates is highly uncertain. At this time, we cannot reasonably estimate
or know the nature, timing and costs of the efforts that will be necessary to complete the preclinical and clinical development of any
of our product candidates or when, if ever, material net cash inflows may commence from any of our product candidates. This uncertainty
is due to the numerous risks and uncertainties associated with development and commercialization, including the uncertainty of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope, progress, outcome and costs of our preclinical development activities, clinical trials and other R&amp;D activities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    an appropriate safety profile with IND- and CTA-enabling studies;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">successful
    patient enrollment in, and the initiation and completion of, clinical trials;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing, receipt and terms of any marketing approvals from applicable regulatory authorities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    commercial manufacturing capabilities or making arrangements with third-party manufacturers;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">development
    and timely delivery of commercial-grade drug formulations that can be used in our clinical trials and for commercial launch;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining,
    maintaining, defending and enforcing patent claims and other intellectual property rights;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    and changing government regulation;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">launching
    commercial sales of our product candidates, if and when approved, whether alone or in collaboration with others; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining
    a continued acceptable safety profile of the product candidates following approval.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may never succeed in achieving regulatory approval for any of our product candidates. We may obtain unexpected results from our clinical
trials. We may elect to discontinue, delay or modify clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>General
and Administrative Expenses</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist primarily of salaries, related benefits, travel and share-based compensation expense for personnel
in executive, finance and administrative functions. General and administrative expenses also include professional fees for legal, consulting,
accounting and audit services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support our continued
research activities and development of our product candidates. We also anticipate that we will incur increased accounting, audit, legal,
regulatory, compliance, director and officer insurance costs, as well as investor and public relations expenses associated with being
a public company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Other
Income (Expense)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
expense consists of an impairment of a loan to West African Minerals Ltd, a related party as well as lease liability interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Results
of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
results of operations that follow reflect the historic periods under review and should not be taken as indicative of future performance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The following tables summarizes
our results of operations for the six months ended September 30, 2021 and 2020 and for the years ended March 31, 2021
and 2020:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six months Ended
    September 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Operating Expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 46%; font-size: 10pt; text-align: left">Research and development</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 14%; font-size: 10pt; text-align: right">(479,700</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 14%; font-size: 10pt; text-align: right">(37,622</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 14%; font-size: 10pt; text-align: right">(442,078</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1.5pt">General and administrative</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(2,254,393</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(517,825</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(1,736,568</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1.5pt">Total operating expenses</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(2,734,093</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(555,447</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(2,178,646</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Other income/ (Expense)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,021</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(69,608</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">68,587</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">Tax credit</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">188,761</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(87</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">188,848</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1.5pt">Net loss</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(2,546,353</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(625,142</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(1,921,211</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Other comprehensive loss:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1.5pt">Foreign currency translation adjustment</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">37,845</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">12,479</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">25,366</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total comprehensive loss</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(2,508,508</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(612,663</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(1,895,845</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Year Ended March 31,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Change</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating Expenses:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left">Research and development</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">(173,821</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">(518,098</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">344,277</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">General and administrative</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(3,192,385</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(1,016,548</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(2,175,837</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Total operating expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(3,366,206</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(1,534,646</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(1,831,560</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Other income/ (expense)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(12,295</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(85,701</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">73,407</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Tax (expense)/ credit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">24,994</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">76,289</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(51,295</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Net loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(3,353,507</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(1,544,059</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(1,809,448</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Other comprehensive loss:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Foreign currency translation adjustment</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">346,365</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">86,654</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">259,711</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total comprehensive loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">(3,007,142</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">(1,457,405</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">(1,549,737</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Research and Development Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Research and development
activities were $479,700 for the six months ended September 30, 2021 compared to $37,622 for the six months ended September 30,
2020. The increase of $442,078 is due to an increase in R&amp;D activity in 2021 after the temporary pause in R&amp;D activity in
2020 while the Scientific Advisory Board and management team were established.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Research and development activities
were $173,821 for the year ended March 31, 2021 compared to $518,098 for the year ended March 31, 2020. The decrease of $344,277 is due
to the temporary pause in R&amp;D activity in 2020 while the Scientific Advisory Board and team were established.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>General and Administrative Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">General and administrative
expenses were $2,254,393 and $517,825 for the six months ended September 30, 2021 and 2020. The increase is predominantly due to the
establishment of a management team and an increase in activity in the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">General and administrative expenses
were $3,192,385 and $1,016,548 for the year ended March 31, 2021 and 2020. The increase of $2,175,837 is predominantly due to bonuses
accrued of approximately $1,200,000, additional share-based payment charges of approximately $485,000, additional legal and audit costs
of approximately $142,000 and realized foreign exchange approximately $466,000 offset by savings of approximately $103,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Since our inception, we have
not generated any revenue and have incurred operating losses and negative cash flows from our operations. We have funded our operations
to date primarily with proceeds from the sale of ordinary shares and convertible loan notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="background-color: white">The
COVID-19 outbreak in the United States has caused business disruptions. The extent of the impact of COVID-19 on our operational and financial
performance will depend on certain developments, including the duration and spread of the outbreak, and impact on our clinical trials,
employees and vendors, all of which are uncertain and cannot be predicted. The economic effects of the outbreak could also have an adverse
effect on our ability to raise additional capital. At this point, the extent to which COVID-19 may impact our future financial condition
or results of operations is uncertain. There has not been a material impact on our financial statements for the period ending
September 30, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Through September 30,
2021, we received net cash proceeds of $1,460,910  from the exercise of warrants. Cash received from these
financings are invested in a money market fund with a view of liquidity and capital preservation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Cash Flows</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The following table summarizes
our cash flows for each of the periods presented:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Six
    Months Ended<BR> September 30,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<BR> March 31,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: left">Net cash used in operating activities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">(3,044,672</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">(551,175</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">(1,600,198</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">(1,202,065</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Net cash used in investing activities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(49,842</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(18,114</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(132,668</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Net cash provided by/ (used in) financing activities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,446,335</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7,819,867</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7,826,939</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">963,310</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Effect of exchange rate changes on cash and cash equivalents</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(106,844</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">7,206</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">445,216</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(20,708</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net decrease in cash and cash equivalents</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">(1,598,335</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">7,218,850</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">6,208,627</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">(371,423</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.25pt"><I>Net Cash Used in Operating
Activities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.25pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Our use of cash in each of
the six months ended September 30, 2021 and 2020 resulted primarily from our net losses, adjusted for non-cash charges and changes in
components of working capital. Net cash used in operating activities of $3,044,672 during the six months ended September 30, 2021 increased
by $2,493,497 compared to the six months ended September 30, 2020. The increase in net cash used in operating activities was primarily
due to the increased activity in the company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Our use of cash in each of the
years ended March 31, 2021 and 2020 resulted primarily from our net losses, adjusted for non-cash charges and changes in components of
working capital. Net cash used in operating activities of $1,600,198 during the year ended March 31, 2021 increased by $398,133 compared
to the year ended March 31, 2020. The increase in net cash used in operating activities was primarily due an increase in accruals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Net Cash Used in Investing Activities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended September 30, 2021,
no cash was used for investing activity. In the six months ended September 30, 2020, we used $49,842 of cash in investing activities
for the purchases of property and equipment and a loan to West African Minerals Ltd&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">During the year ended March 31,
2021 we used $18,114 of cash in investing activities for the purchases of property and equipment and a loan to West African Minerals Ltd.
During the year ended March 31, 2020, $132,668 was used for the same reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Net Cash Provided by Financing Activities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">During the six months ended
September 30, 2021 and 2020, net cash provided by financing activities was $1,446,335 and $7,819,867, respectively, consisting of net
cash proceeds from our sale and issuance of ordinary shares, entering into fixed term convertible loan agreements and the exercise of
warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">During the year ended March 31,
2021, and 2020, net cash provided by financing activities was $7,826,939 and $963,310, respectively, consisting of net cash proceeds from
our sale and issuance of ordinary shares and entering into fixed term convertible loan agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Funding Requirements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We expect our expenses to increase
substantially in connection with our ongoing activities, particularly as we advance the preclinical activities, manufacturing and clinical
trials of our product candidates. In addition, following our Nasdaq listing, we expect to incur additional costs associated with operating
as a public company. Our expenses will also increase as we:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
    regulatory approvals for any product candidates that successfully complete clinical trials;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish
    a sales, marketing and distribution infrastructure in anticipation of commercializing any product candidates for which we may obtain
    marketing approval and intend to commercialize on our own or jointly;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">hire
    additional clinical, medical and development personnel;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">expand
    our infrastructure and facilities to accommodate our growing employee base; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain,
    expand and protect our intellectual property portfolio.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that our existing cash, will enable us to fund our operating expenses and capital expenditure requirements for the foreseeable
future. We have based these estimates on assumptions that may prove to be wrong, and we could utilize our available capital resources
sooner than we expect. If we receive regulatory approval for our other product candidates, we expect to incur significant commercialization
expenses related to product manufacturing, sales, marketing and distribution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical product candidates,
we are unable to estimate the exact amount of our working capital requirements. Our future funding requirements will depend on and could
increase significantly as a result of many factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope, progress, outcome and costs of our preclinical development activities, clinical trials and other R&amp;D activities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs, timing, receipt and terms of any marketing approvals from applicable regulatory authorities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of future activities, including product sales, marketing, manufacturing and distribution, for any of our product candidates
    for which we receive marketing approval;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    revenue, if any, received from commercial sale of our products, should any of our product candidates receive marketing approval;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs and timing of hiring new employees to support our continued growth;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending
    intellectual property-related claims; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    extent to which we acquire technologies.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
such time, if ever, that we can generate product revenue sufficient to achieve profitability, we expect to finance our cash needs through
equity offerings. To the extent that we raise additional capital through the sale of equity, your ownership interest will be diluted.
If we raise additional funds through other third-party funding, collaboration agreements, strategic alliances, licensing arrangements
or marketing and distribution arrangements, we may have to relinquish valuable rights to our technologies, future revenue streams, research
programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds
through equity financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization
efforts or grant rights to develop and market products or product candidates that we would otherwise prefer to develop and market ourselves.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Borrowings</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 29, 2020, we entered into a fixed term unsecured loan agreement with existing shareholders for $606,980 at an interest rate of 20%
per annum to be repaid no later than 48 months after the date of the agreement. On May 4, 2021, $167,434 of the fixed term loan agreement
plus the associated interest accrued, was converted and 62,920,000 shares were issued accordingly at a price of $0.006 per share. On
February 24, 2022, all remaining fixed term loan agreements plus the associated interest accrued were converted and 165,176,000 shares
were issued accordingly at a price of $0.006 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 27, 2020, we entered into a fixed term unsecured loan agreement with existing shareholders for $4,828,250 at an interest
rate of 2.15% per annum to be repaid no later than 36 months after the date of the agreement. On May 4, 2021, the fixed term loan agreement
plus the associated interest accrued, was converted and 43,889,863 shares were issued accordingly at a price of $0.117
per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 17, 2020, we entered into a fixed term unsecured loan agreement with existing shareholders for $1,982,485 at an interest
rate of 2.15% per annum to be repaid no later than 36 months after the date of the agreement. On May 4, 2021 the fixed term loan agreement
plus the associated interest accrued, was converted and 18,021,226 shares were issued accordingly at a price of $0.117 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 3, 2020, we entered into a fixed term unsecured loan agreement with existing shareholders for $689,750 at an interest rate
of 2.15% per annum to be repaid no later than 36 months after the date of the agreement. On May 4, 2021 the fixed term loan agreement
plus the associated interest accrued, was converted and 6,269,980 shares were issued accordingly at a price of $0.117 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Off-Balance
Sheet Arrangements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contractual
Obligations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The following table summarizes
our contractual commitments and obligations as of September 30, 2021 and March 31, 2021.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">As at September 30, 2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Payments
    Due by Period</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Total</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Less
    than <BR>
    1 Year</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Between
    1<BR>
    and 3<BR>
    Years</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Between
    <BR>
    3 and <BR>
    5 Years</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 44%"><FONT STYLE="font-size: 10pt">Borrowings</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-size: 10pt">$&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">429,025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-size: 10pt">$&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">429,025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">Operating lease obligations</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">81,782</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">34,530</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">47,251</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Total</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">510,807</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">34,530</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">47,251</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">&nbsp;$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">429,025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">As at March 31, 2021</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Payments Due by Period</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Less than <BR> 1 Year</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Between <BR> 1 and <BR> 3 Years</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Between <BR> 3 and <BR> 5 Years</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 44%">Borrowings</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">8,370,836</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">8,370,836</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Operating lease obligations</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">106,668</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">42,056</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">64,612</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Total</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">8,477,504</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">42,056</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">64,612</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">8,370,836</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Quantitative
and Qualitative Disclosures about Market Risk</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exposed to market risks in the ordinary course of our business, which are principally limited to interest rate fluctuations and foreign
currency exchange rate fluctuations. We maintain significant amounts of cash and cash equivalents that are in excess of federally insured
limits in various currencies, placed with one or more financial institutions for varying periods according to expected liquidity requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Interest
Rate Risk</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
exposure to interest rate sensitivity is impacted by changes in the underlying U.S. and U.K. bank interest rates. Our surplus cash and
cash equivalents have been invested in interest-bearing savings and money market accounts from time to time. We have not entered into
investments for trading or speculative purposes. Due to the conservative nature of our investment portfolio, which is predicated on capital
preservation of investments with short-term maturities, we do not believe an immediate one percentage point change in interest rates
would have a material effect on the fair market value of our portfolio, and therefore we do not expect our operating results or cash
flows to be significantly affected by changes in market interest rates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Foreign
Currency Exchange Risk</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain our consolidated financial statements in the functional currency pounds Sterling. Monetary assets and liabilities denominated
in currencies other than the functional currency are translated into the functional currency at rates of exchange prevailing at the balance
sheet dates. Non-monetary assets and liabilities denominated in foreign currencies are translated into the functional currency at the
exchange rates prevailing at the date of the transaction. Exchange gains or losses arising from foreign currency transactions are included
in the determination of net income (loss) for the respective periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
financial reporting purposes, our consolidated financial statements are prepared using the functional currency, and translated into the
U.S. dollar. Assets and liabilities are translated at the exchange rates at the balance sheet dates and revenue and expenses are translated
at the average exchange rates and shareholders&rsquo; equity is translated based on historical exchange rates. Translation adjustments
are not included in determining net income (loss) but are included in foreign exchange adjustment to accumulate other comprehensive loss,
a component of shareholders&rsquo; equity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently engage in currency hedging activities in order to reduce our currency exposure, but we may begin to do so in the future.
Instruments that may be used to hedge future risks may include foreign currency forward and swap contracts. These instruments may be
used to selectively manage risks, but there can be no assurance that we will be fully protected against material foreign currency fluctuations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Critical
Accounting Policies and Significant Judgments and Estimates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
consolidated financial statements are prepared in accordance with IFRS as issued by the IASB. The preparation of our consolidated
financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets,
liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in our consolidated financial statements. We
base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the
circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are
not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ
from these estimates under different assumptions or conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
our significant accounting policies are described in more detail in our consolidated financial statements, we believe that the following
accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Accrued
Research and Development Expenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the process of preparing our consolidated financial statements, we are required to estimate our accrued R&amp;D expenses. This
process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed
on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been
invoiced or otherwise notified of actual costs. We make estimates of our accrued expenses as of each balance sheet date in the consolidated
financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of these estimates
with the service providers and make adjustments if necessary. Examples of estimated accrued R&amp;D expenses include fees paid to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vendors
    in connection with preclinical development activities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CROs
    and investigative sites in connection with preclinical studies and clinical trials; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CMOs
    in connection with drug substance and drug product formulation of preclinical study and clinical trial materials.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
base our expenses related to preclinical studies on our estimates of the services received and efforts expended pursuant to quotes and
contracts with multiple research institutions and CROs that conduct and manage preclinical studies and clinical trials on our behalf.
The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows.
There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of
the expense. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion
of clinical trial milestones. In accruing service fees, we estimate the time period over which services will be performed and the level
of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate,
we adjust the accrual or the amount of prepaid expenses accordingly. Although we do not expect our estimates to be materially different
from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing
of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there
have not been any material adjustments to our prior estimates of accrued R&amp;D expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Valuation
of Share-Based Compensation and Tranche Obligations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Share-Based
Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognize compensation expense for equity option awards based on the grant date fair value of the option award. For equity option awards
that vest based on a service condition, the share-based compensation expense is recognized on a straight-line basis over the requisite
service period. For equity option awards that contain both performance and service conditions, we recognize share-based compensation
expense ratably over the requisite service period when the achievement of a performance-based milestone is probable based on the relative
satisfaction of the performance condition as of the reporting date. We use the fair value of our ordinary shares to determine the fair
value of the equity option awards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, the share-based option awards granted to our employees and directors have been in the form of time and/or performance vesting share
options and have been reported in our consolidated statements of operations as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six Months Ended
    September&nbsp;30,</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 44%">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Options charge</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">831,903</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">11,077</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">550,138</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">36,340</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
calculation of the fair value of equity-settled share-based awards and the resulting charge to the statement of comprehensive income
requires assumptions to be made regarding future events and market conditions. These assumptions include the future volatility of the
Company&rsquo;s ordinary share price. These assumptions are then applied to a recognized valuation model in order to calculate
the fair value of the awards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
employees, directors or advisers are rewarded using share-based payments, the fair value of the employees&rsquo;, directors&rsquo; or
advisers&rsquo; services are determined by reference to the fair value of the share options / warrants awarded. Their value is appraised
at the date of grant and excludes the impact of any nonmarket vesting conditions (for example, profitability and sales growth targets).
Warrants issued in association with the issue of convertible loan notes are also considered as share based payments and a share-based
payment charge is calculated for these too.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with IFRS 2, a charge is made to the statement of comprehensive income for all share-based payments including share options
based upon the fair value of the instrument used. A corresponding credit is made to a reserve, or Share Based Payment Reserve, in the
case of options / warrants awarded to employees, directors or advisers, and ordinary shares to be issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reserve
in the case of warrants issued in association with the issue of convertible loan notes, net of deferred tax where applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
vesting periods or other vesting conditions apply, the expense is allocated over the vesting period, based on the best available estimate
of the number of share options / warrants expected to vest. Non-market vesting conditions are included in assumptions about the number
of options / warrants that are expected to become exercisable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimates
are subsequently revised, if there is any indication that the number of share options / warrants expected to vest differs from previous
estimates. No adjustment is made to the expense or share issue cost recognized in prior periods if fewer share options ultimately are
exercised than originally estimated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
exercise of share options / warrants, the proceeds received are allocated to share capital with any excess being recorded as share premium.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
share options are cancelled, this is treated as an acceleration of the vesting period of the options. The amount that otherwise would
have been recognized for services received over the vesting period is recognized immediately within the statement of comprehensive income.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect the impact of our share-based compensation expense for share option awards granted to employees, directors and other service providers
to grow in future periods due to the potential increases in the value of our ordinary shares and headcount.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
conducting the valuations, we considered all objective and subjective factors that we believed to be relevant for each valuation conducted,
including our best estimate of our business condition, prospects and operating performance at each valuation date. Within the valuations
performed, a range of factors, assumptions and methodologies were used. The significant factors included:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    lack of an active public market for our ordinary shares;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    results of operations, financial position and the status of our research and preclinical development efforts;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    material risks related to our business;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    business strategy;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    market performance of publicly traded companies in the life sciences and biotechnology sectors;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    prices paid in recent transactions involving our ordinary shares;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    likelihood of achieving a liquidity event for the holders of our ordinary shares, such as an IPO, given prevailing market conditions;
    and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    recent contemporaneous valuations of our ordinary shares prepared in accordance with methodologies outlined in the practice aid.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
dates of our valuations have not always coincided with the dates of our share grants. In determining the value of our ordinary shares
set forth in the table above, our board of directors considered, among other things, the most recent sale and issuance of our ordinary
shares, our stage of R&amp;D, our operating and financial performance and current business conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimates of fair value of our ordinary shares are highly complex and subjective. There are significant judgments and estimates inherent
in the determination of the fair value of our ordinary shares. These judgments and estimates include assumptions regarding our future
operating performance, and the determinations of the appropriate valuation methods. The assumptions underlying these valuations represent
management&rsquo;s best estimates, which involve inherent uncertainties and the application of management judgment. If we had made different
assumptions, our stock-based compensation expense, net loss and net loss per share could have been materially different. If we had made
different assumptions, our net loss and net loss per ordinary share could have been materially different.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Taxation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tax expense for a period represents the total of current taxation and deferred taxation. The charges in respect of current taxation are
based on the estimated taxable profit for the relevant year. Taxable profit for the year is based on the profit as shown in the income
statement, as adjusted for items of income or expenditure which are not deductible or chargeable for tax purposes. The current tax liability
for the year is calculated using tax rates which have either been enacted or substantively enacted at the relevant balance sheet date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax is provided in full, using the liability method on temporary differences arising between the tax base of assets and liabilities and
their carrying values in the financial statements. The deferred tax is not accounted for if it arises from initial recognition of an
asset or liability in a transaction other than a business combination that at the time of the transaction affects neither accounting
nor taxable profit or loss. Deferred tax is determined using tax rates which have been enacted or substantively enacted at the balance
sheet date and are expected to apply when the related deferred tax asset is realized, or the deferred income tax liability is settled.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets are recognized to the extent that it is probable that future taxable profits will be available against which the temporary
differences can be utilized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax is provided on temporary differences arising on investments in subsidiaries and associates, except where the timing of the reversal
of the temporary difference is controlled by the group and it is probable that the temporary difference will not reverse in the foreseeable
future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="cr_015"></A>Business</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We are a preclinical biopharmaceutical
company developing next-generation therapeutics to improve the lives of patients suffering from inflammatory eye diseases and ocular
pain. Our research program is focused on a novel G Protein-Coupled Receptor, or GPCR, which we believe plays a key role in the
pathology of these inflammatory eye diseases of high unmet medical need. Our therapeutic approach is focused on targeting inflammatory
and pain modulation pathways that drive these conditions. We are presently developing OK-101, our lead preclinical product candidate,
for the treatment of dry-eye disease. We also plan to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis
and allergic conjunctivitis. We have also been evaluating OK-201, a bovine adrenal medulla, or BAM, lipidated-peptide preclinical analogue
candidate for the treatment of neuropathic ocular pain, and plan on maintaining this drug candidate at the exploratory level while we
focus our primary energy on the OK-101 program. We are planning to file an IND on OK-101 to treat DED in the third
or fourth quarter of 2022 (see Figure 1).</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Figure
1.</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> OKYO Pipeline</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="form424b4_002.jpg" ALT="" STYLE="height: 287px; width: 540px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
evidence from over 40 years of scientific literature suggests inflammation as the most common underlying cause of DED. An increase in
the levels of inflammatory cytokines in both conjunctiva and tears is known to cause the chronic inflammation associated with DED. Consequently,
development of new therapeutic agents that target inflammatory pathways is crucial in improving symptoms in DED patients. On February
21, 2018, we announced that we successfully obtained (via assignment from Panetta Partners Limited, a related party) a license from OTT
to patents owned or controlled by OTT and a sub-license from OTT to certain patents licensed by OTT from TMC to support our ophthalmic
disease drug programs. These licenses gave us the right to exploit the IP estate which is directed to compositions-of-matter and methodologies
for treating ocular inflammation, DED with chemerin or lipid-linked chemerin analogues. We also have a license from TMC to a separate
IP estate for treating symptoms of ocular neuropathic pain, uveitis and associated pain. The scope of our use of the TMC IP granted to
us through the sublicense with OTT is commensurate with the scope of use of the IP granted to OTT from TMC. This intellectual property
forms the basis of our OK-101 program, which is discussed in greater detail below</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>OK-101</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OK-101,
our lead preclinical product candidate, is focused on keratoconjunctivitis sicca, commonly referred to as DED, which is a multifactorial
disease caused by an underlying inflammation resulting in the lack of lubrication and moisture in the surface of the eye. DED is one
of the most common ophthalmic conditions encountered in clinical practice. Symptoms of DED include constant discomfort and irritation
accompanied by inflammation of the ocular surface, visual impairment and potential damage to the ocular surface. There are presently
approximately 20 million people suffering from DED in the U.S. alone (Farrand et al. AJO 2017; 182:90), with the disease affecting approximately up to
34% of the population aged 50+ (Dana et al. AJO 2019; 202:47), and with women representing approximately two-thirds of those affected
(Matossian et al. J Womens Health (Larchmt) 2019; 28:502&ndash;514). Prevalence of DED is anticipated to increase substantially in the
next 10-20 years due to aging populations in the U.S., Europe, Japan and China and use of contact lenses in the younger population. We
believe this increase in prevalence of dry eye syndrome represents a major expanding economic burden to public healthcare. According
to Market Research Report, Dry Eye Syndrome, December 2020, the global DED market in 2019 was approximately $5.22 billion, with the market
size expected to reach $6.54 billion by 2027. In addition, DED causes approximately $3.8 billion annually in healthcare costs and represents
a major economic burden to public healthcare, accounting for more than $50 billion to the U.S. economy annually.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">At present, there are essentially
three major prescription drugs used to treat DED: 1) Restasis (cyclosporine), 2) Xiidra (lifitegrast), and 3) Tyrvaya (Varenicline).
However, DED continues to be a major unmet medical need due to the large number of patients not well served by the treatments available
to them through the medical community. The development of new drugs to treat DED has been particularly challenging due to the heterogeneous
nature of the patient population suffering from DED, and due to the difficulties in demonstrating an improvement in both signs and symptoms
of the disease in well-controlled clinical trials. The evidence from over 40 years of scientific literature, however, suggests inflammation
as the most common underlying cause of DED. Consequently, development of new therapeutic agents that target inflammatory pathways is
crucial in improving symptoms in DED patients. OK-101 is focused on an anti-inflammatory pathway for treating dry eye.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OK-101
is designed to target a chemokine-like receptor 1, or CMKLR1, or CHEMR23, which is a G protein-coupled receptor expressed on macrophages,
neutrophils, monocytes, plasmacytoid/myeloid dendritic cells, natural killer cells and nonhemopoietic cell types, such as endothelial
and epithelial cells (See Figure 2).</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Activation of CMKLR1 by its endogenous
peptide ligand chemerin is known to modulate inflammation, but natural ligands for CMKLR1 have short half-lives due to rapid inactivation.
Discovery of OK-101, a stable, high potency CMKLR1 agonist by On Target Therapeutics (Note: technology licensed to OKYO Pharma) provided
an important step toward the development of a new class of anti-inflammatory therapeutics that can be applied to the treatment of ophthalmic
diseases including DED, uveitis and ocular pain.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><IMG SRC="form424b4_003.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
2</B>. OK-101 binds to CHEMR23 receptor producing an anti-inflammatory response</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
key driver in the development of OK-101 to treat DED, uveitis and other ocular conditions was an analysis of the inherent advantages
and difficulties associated with the treatment of ocular conditions. One of the major issues with topical administration of any drug
designed for treating DED is the requirement that the drug have adequate drug &lsquo;residence&rsquo; time at the ocular site to afford
a pharmacologic benefit before being washed out through natural processes of tear enhancement and lacrimal tear drainage. The drug candidates
we have developed are designed to combat washout by including a lipid &lsquo;anchor&rsquo; within the candidate drug molecule to enhance
the residence time of the drug in the eye. We refer to our candidates for DED as &ldquo;lipidated-chemerin&rdquo; analogues to highlight
this pharmacologic characteristic. Figure 3 shows the significance of including a lipid anchor in the &ldquo;chemerin&rdquo; molecule
on drug potency and wash resistance conducted in a series of <I>in vitro</I> studies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="form424b4_005.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
3</B> shows the significance of including a lipid anchor in the &ldquo;chemerin&rdquo; molecule on drug potency and wash resistance conducted
in a series of <I>in vitro</I> studies. HEK293 cells were transiently transfected with cDNAs encoding human chemerin receptor CMKLR1.
Twenty-four hours after transfection, cells were stimulated with increasing concentrations of OK-101 for 15 min and luciferase activity
was determined as described (<I>Doyle J et al, J. Biol. Chem. 2014). </I>Data points represent the mean S.E. from at least three independent
experiments, each performed in triplicate. A lipidated stable chemerin analog showed higher potency against human chemerin receptor than
the corresponding non-lapidated peptide (Figure 3 top panel). Signaling of lipidated stable chemerin analog persisted despite serial
washes, whereas activity of the non-lipidated peptide was markedly diminished (Figure 3 bottom panel).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
potency of OK-101 was first determined in a cell-based PathHunter&reg; &beta;-Arrestin assay. This assay monitors the activation of a
GPCR in a homogenous, non-imaging assay format using a technology developed by DiscoverX called Enzyme Fragment Complementation (EFC)
with &beta;-galactosidase (&beta;-Gal) as the functional reporter. The enzyme is split into two inactive complementary portions (EA for
Enzyme Acceptor and PK for ProLink) expressed as fusion proteins in the cells. EA is fused to &beta;-Arrestin and PK is fused to human
Chemokine-like receptor 1, CMKLR1. Activation of CMKLR1-PK induces &beta;-Arrestin-EA recruitment, forcing complementation of the two
&beta;-galactosidase enzyme fragments (EA and PK). The resulting functional enzyme hydrolyzes substrate to generate a chemiluminescent
signal, which is measured using chemiluminescent PathHunter&reg; Detection Reagents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assay
Design: PathHunter cell lines co-expressing the ProLink&trade; (PK) tagged GPCR (human Chemokine-like receptor 1, CMKLR1) and the Enzyme
Acceptor (EA) tagged &beta;-Arrestin were expanded from freezer stocks according to standard procedures. Cells were seeded in a total
volume of 20 &mu;L into white walled, 384-well microplates and incubated at 37&deg;C for the appropriate time prior to testing. For agonist
potency determination, cells were treated with various concentrations of peptide to induce response and incubated at 37&deg;C for 90
minutes. Assay signal was generated through a single addition of 12.5 or 15 &mu;L (50% v/v) of PathHunter Detection reagent cocktail,
followed by a one-hour incubation at room temperature. Microplates were read following signal generation with a PerkinElmer EnvisionTM
instrument for chemiluminescent signal detection. Compound activity was analyzed using CBIS data analysis suite (ChemInnovation, CA).
Figure 4 below shows the agonist activity of OK-101 against human chemerin receptor CMKLR1 determined using PathHunter&reg; &beta;-Arrestin
assay. OK-101 was shown to have a sub-nanomolar EC50 potency.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><IMG SRC="form424b4_007.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
4.</B> Agonist activity of OK-101 using PathHunter&reg; &beta;-Arrestin assay</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
further characterize the potential efficacy of OK-101 to treat DED, OK-101 was tested in a mouse model of acute DED. Animals were
divided into five separate cohorts that included: 1) non-stressed control animals untreated throughout the study, 2) animals treated
with scopolamine to induce acute DED, 3) animals treated with scopolamine to induce acute DED and treated with 0.1% cyclosporine as a
positive control, 4) animals treated with scopolamine to induce acute DED and treated with phosphate buffer solution (the vehicle used
for OK-101 delivery), and 5) animals treated with scopolamine to induce acute DED and treated with OK-101 in phosphate buffered solution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Animals
in cohorts 1) and 2) were left untreated with test agents throughout the 5-day period, whereas animals in cohorts 3), 4) and 5) were
treated with either cyclosporine, or CS, vehicle or OK-101, respectively, twice a day during the 5-day period <I>via </I>bilateral topical
administration of the respective agents. On the fifth day, all of the animals were assessed for efficacy by evaluating corneal permeability,
a measure of dry-eye effectiveness, in live animals, as well as by exploring the impact of respective treatments on immune response.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Figure
5 shows the results from this animal study. Animals induced with scopolamine to generate acute DED showed a dramatic, statistically significant
increase in corneal permeability relative to na&iuml;ve non-stressed animals. The addition of cyclosporine to scopolamine-induced DED
animals showed a statistically significant reduction of permeability (p &le; 0.001). Notably, OK-101 demonstrated a dramatic reduction
of DED-induced corneal permeability as well (p &le; 0.001). OK-101&rsquo;s effect in reducing DED-induced corneal permeability was virtually
identical to that of the cyclosporine positive control and close to the baseline corneal permeability observed in non-stressed control
animals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="chart_ogd.jpg" ALT="" STYLE="height: 366px; width: 600px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
5</B>. Effect of various treatments on mouse corneal permeability. Corneal permeability was measured using Oregon Green Dextran (OGD)
staining followed by imaging. CS was positive control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the in-life portion of the study, immunohistochemistry was performed on frozen sections of enucleated mouse eyes to measure CD4+ T-cell
infiltration into the conjunctival epithelium of the eye (Figure 6). Animals induced to develop acute DED and not treated with drug (Vehicle
animals) showed significant infiltration of CD4+ T cells within the conjunctival epithelium, whereas OK-101 demonstrated a statistically
significant (p &le; 0.01) reduction in dry-eye-induced enhancement of CD4+ T-cells. In fact, the level of CD4+ T cells observed in OK-101
treated animals was equivalent to the CD4+ T cell level observed in na&iuml;ve untreated animals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><IMG SRC="form424b4_008.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
6</B>. CD4+ T cells in the conjunctival epithelium after acute DED induction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immunohistochemistry
was also performed on enucleated intact conjunctiva of mouse eyes fixed in 10% formalin, embedded in paraffin, and sectioned and stained.
DED typically leads to a loss of goblet cell density as was observed following induction of DED in the mice administered Vehicle (Figure
7). Whereas administration of OK-101 significantly rescued the DED-induced loss of Goblet Cells.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="form424b4_009.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
7</B>. Goblet Cell density following acute DED induction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">In addition, in a separate
set of animal model experiments, we evaluated pain-reducing activity of OK-101 in a ciliary nerve ligation mouse model of corneal neuropathic
pain. Neuropathic corneal pain is a severe, chronic and debilitating disease with no FDA approved commercially available treatments currently
available for this condition. In collaboration with Pedram Hamrah, MD, Professor of Ophthalmology, cornea specialist, and clinician-scientist
at Tufts Medical Center, Boston, we demonstrated that OK-101 suppresses neuropathic corneal pain in a mouse model of neuropathic corneal
pain developed in Dr. Hamrah&rsquo;s laboratory. OK-101 was topically administered to mice in comparison to the positive control gabapentin
which was administered via intraperitoneal injection. Pain relief was evaluated by an eye-wipe count, and OK-101 was shown to reduce
corneal pain similar to that of gabapentin (Figure 8), a commonly used oral drug for neuropathic pain. Notably, the drug concentration
of OK-101 used in this study was identical to that used in mouse models of DED that demonstrated ocular anti-inflammatory activity. OK-101
had no effect on corneal epithelial integrity compared to gabapentin or balanced salt solution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="margin: 0pt; font: 12pt Times New Roman, Times, Serif; text-align: center"><IMG SRC="image_004.jpg" ALT="Chart&#10;&#10;Description automatically generated" STYLE="height: 272px; width: 497px"></P>

<P STYLE="font: italic 9pt Times New Roman, Times, Serif; color: #44546A; margin: 0pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: normal 9pt Times New Roman, Times, Serif; margin: 0pt; color: rgb(68,84,106); text-align: justify"><FONT STYLE="color: Black"><B>Figure
8.</B> <I>OK-101 ameliorates neuropathic corneal pain in a mouse model of ciliary nerve ligation</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">A separate series of experiments
were also performed to evaluate ocular tolerance of OK-101 in rabbits <I>via</I> repeated ocular instillation followed by clinical ophthalmic
observations. Rabbit ocular tolerance tests on OK-101 showed no adverse signs such as inflammation, chemosis or hyperemia and no signs
of local irritation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">Based on the results
from the DED animal model and ocular tolerance studies, we are moving forward with plans to file an IND in the third or fourth
quarter of 2022 on OK-101 to treat DED to enable us to begin clinical trials soon thereafter. During the second quarter of 2021 we
successfully manufactured a 25-gram batch of OK-101 drug substance needed for initiating the IND-enabling studies that were begun
during the summer of 2021. To support this work, we also signed an agreement in June 2021 with Ora, a major CRO
specializing in ophthalmic drug development who is providing the following services:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preparation
    of the OK-101 pre-IND briefing document</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Support
    in requesting and preparing for the OK-101 pre-IND meeting with FDA</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Support
    for regulatory publishing and submission of IND in eCTD format</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Providing
    quality oversight for development of topical formulation for OK-101</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Providing
    quality oversight for development and qualification of a drug stability analysis method for OK-101 along with conducting stability
    studies to establish formulated drug product is stable for at least 90 days</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Support
    for completing animal toxicology studies in two animal species</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Outlook
and Strategy for Development of OK-101 to Treat DED</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development of new drugs to treat DED has been particularly challenging due to the heterogeneous nature of the patient population suffering
from DED, and due to the difficulties in demonstrating an improvement in both signs and symptoms of the disease in well-controlled clinical
trials. The evidence from over 40 years of scientific literature, however, suggests inflammation as the most common underlying cause
of DED. Consequently, development of new therapeutic agents that target inflammatory pathways is looking to be an attractive approach
in improving symptoms in DED patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">We are committed
to a major effort to finish all IND enabling activities, and plan to to file an IND on OK-101 to treat DED in the
third or fourth quarter of 2022. These activities include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completing
    topical</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> formulation of the OK-101 drug product
    and initial stability studies</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finalizing
    the bioanalytical</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> method development to support
    the OK-101 clinical program</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completing
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">batch manufacture of cGMP OK-101 for clinical
    trials</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completing
    toxicokinetic</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> method development</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completing
    toxicology</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> studies in rabbits and dogs</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completing
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">stability studies of formulated OK-101</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">We announced on December 6,
2021, based on consultations with our clinical CRO, Ora Inc., that we are planning to commence the first human study with OK-101
in the fourth quarter of 2022, and because the drug is designed to be administered topically, we plan to skip the standard
Phase 1 studies typically expected with orally delivered or injectable drug candidates in non-life-threatening conditions. This
first trial is planned to be a Phase 2 efficacy clinical trial in DED patients and is anticipated to be conducted in approximately 200
to 250 DED patients. The study is being designed in conjunction with, and will be managed and monitored by Ora Inc. The Phase
2 trial is expected to be completed in 6-8 months from enrollment of the first patient.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">On February 15, 2022, we announced
the successful completion of the pre-IND meeting facilitated by Ora with the FDA regarding development plans for OK-101 to treat DED.
Both nonclinical and clinical development milestones were covered in the pre-IND meeting, with the FDA agreeing that our first human
trial would be a Phase 2 safety and efficacy trial in DED patients. The FDA also provided guidance on the planned protocol
for this trial in DED patients, concurring with our decision to designate co-primary efficacy endpoints covering both
a sign and a symptom of DED in the clinical protocol of the trial. The decision to designate efficacy endpoints as primary endpoints
in this trial is highly significant as should this trial meet its prespecified primary endpoints, this result could accelerate the timeline
to an NDA filing with the FDA. We are presently on track with our pre-IND work on OK-101 and are planning to file the IND to treat DED
in the third or fourth quarter of 2022, followed by the planned commencement of a Phase 2 trial in DED patients in the fourth quarter
of 2022.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Additional
Applicable Disease Indications for OK-101 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ophthalmic
diseases</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
second related ophthalmic disease indication that is the target of our chemerin-based technology is uveitis. Uveitis is the third leading
cause of blindness worldwide. The most common type of uveitis is an inflammation of the iris called iritis (anterior uveitis). Uveitis
can damage vital eye tissue, leading to permanent vision loss. Uveitis is currently treated with corticosteroid eyedrops and injections
that reduce inflammation, however, the long-term use of corticosteroids causes increased risk of cataracts and glaucoma, requiring close
monitoring for the drug&rsquo;s potential side effects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
we are in the clinic evaluating OK-101 to treat dry eye, we will also undertake the clinical plan to explore the drug candidate&rsquo;s
potential to suppress the inflammation associated with uveitis. In support of this plan, we will also be exploring preclinical development
of OK-101 for the uveitis indication by first establishing &lsquo;proof-of-concept&rsquo; for this indication utilizing animal model
studies of anterior uveitis to evaluate the potential of OK-101 to suppress the inflammation associated with uveitis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
third related ophthalmic disease indication that is the target of our chemerin-based technology is allergic conjunctivitis. Allergic
conjunctivitis is inflammation of the conjunctiva caused by an allergic reaction that affects about 20% of the global population and
is typically treated with antihistamines, mast cell stabilizers and corticosteroids. Although there are effective drugs for the treatment
of ocular allergies, about one third patients do not respond adequately to the currently marketed drugs. Further, patients who display
poor response to antihistamines appear to suffer from chronic and seasonal allergies. There is a lack of an optimal treatment for the
perennial and severe forms of ocular allergies. We plan on conducting &lsquo;proof-of-concept&rsquo; studies using OK-101 for the treatment
of chronic and seasonal allergic conjunctivitis using a conjunctival allergen challenge animal model to investigate the potential of
OK-101 to suppress the inflammation associated with allergic conjunctivitis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Non-ophthalmic
conditions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 19, 2021, we announced that we submitted a patent application to the United States Patent and Trademark Office covering the use
of chemerin and chemerin analogues including OK-101 to treat the cytokine release syndrome associated with COVID-19
infections and other conditions such as acute respiratory distress syndrome (ARDS). On January 15, 2021 we signed a research and material
transfer agreement with the University of Alabama at Birmingham to evaluate the potential of chemerin analogs to minimize the inflammation
triggered by SARS-CoV-2 in a model of lung inflammation. <I>Ex vivo</I> lung tissue will be experimentally induced to produce inflammation,
and during the course of inflammation in the absence and presence of a chemerin analogue, respectively, a panel of cytokines including
TNF&alpha;, IL-6, IL-1&beta; will be measured. Currently, experiments are underway at the University of Alabama, but there is nothing
to report yet on the results of this study. Assuming the results are encouraging, our plan is to advance this program as a potential
prophylaxis to treat COVID-19 infections, and other conditions such as acute respiratory distress syndrome (ARDS). We plan this work
to be under the direction of Dr. Napoleone Ferrara, a member of our Scientific Advisory Board.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>OK-201</I></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">On May 1, 2018, we
obtained a license agreement from Tufts Medical Center for the right to exploit all the intellectual property claimed in patent application
PCT/US2016/0611101 &lsquo;Lipidated BAM8-22 and methods of using same&rsquo; including claims covering composition-of-matter and methodology
for treating symptoms of neuropathic chronic pain, ocular pain and uveitis-associated pain. OKYO began an effort to explore BAM8-22 analogs
that have potential to ameliorate inflammation and neuropathic pain. OK-201 is the lead compound from the license agreement with Tufts
Medical Center and was the focus of the Company&rsquo;s initial efforts to develop a lipidated BAM8-22 analogue to treat neuropathic
pain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="text-align: justify; margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in">On August 6, 2019,
we signed a&nbsp;collaborative agreement with Tufts Medical Center, Boston and Pedram Hamrah, MD, Professor of Ophthalmology at
Tufts University School of Medicine, Boston, MA to evaluate OKYO&rsquo;s BAM8-22 analogues, including OK-201, as non-opioid analgesics
to suppress corneal neuropathic pain using a mouse ocular pain model developed in Dr. Hamrah&rsquo;s laboratory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">On April 28, 2021 we
announced positive results of OK-201, a non-opioid analgesic drug candidate delivered topically in Dr. Hamrah&rsquo;s mouse
neuropathic corneal pain model, as a potential drug to treat acute and chronic ocular pain. Importantly, OK-201 demonstrated a
reduced corneal pain response equivalent to that of gabapentin, a commonly used oral drug for neuropathic pain. These observations
demonstrated preclinical &lsquo;proof-of-concept&rsquo; for the topical administration of OK-201 as a potential non-opioid analgesic
for ocular pain. Current treatments for corneal pain are limited to short term NSAIDs, steroids, and oral gabapentin and opioids in
severe cases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">Although the results with
OK-201 were encouraging, due to subsequent success obtained with OK-101 (see section on OK-101) in follow-on animal model studies utilizing
the same mouse neuropathic corneal pain model as for OK-201, we have decided to maintain this drug candidate at the exploratory level
while we focus our primary energy on the OK-101 program to treat DED, based on OK-101&rsquo;s combination of anti-inflammatory and ocular
pain-reducing activities in animal models of these conditions.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Intellectual Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; margin: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; background-color: white">We
consider the protection of our proprietary technologies and products, as well as our ability to maintain patent protection that covers
the composition of matter of our product candidates, their methods of use, and other related technologies and inventions, to be a critical
element in the success of our business. As of April 22, 2022, our owned and licensed intellectual property included 8 issued
patents and 15 pending patent applications in the U.S. and abroad.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; margin: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued
United States patent directed to lipidated chemerin fragments or analogs has a statutory expiration date of March 13, 2034, with potential
patent term extension available until 2039, following the grant of marketing authorization. Issued United States patent directed
to methods of using lipidated chemerin fragments or analogs for treating neuropathic pain has a statutory expiration date of March
13, 2034 (plus 187 days of patent term adjustment, or PTA), with potential patent term extension available until 2039, following
the grant of marketing authorization. Issued United States patent directed to methods of using lipidated chemerin fragments or analogs
for treating DED has a statutory expiration date of January 23, 2037, with potential patent term extension available until 2041,
following the grant of marketing authorization. We have pending patent applications for lipidated chemerin fragments or analogs and methods
of use thereof that, if issued, would be expected to expire in the United States and in countries outside of the United States between
2034 and 2043, excluding any patent term adjustment that might be available following the grant of the patent and any patent term extensions
that might be available following the grant of marketing authorizations.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">Issued United States patent
directed to lipidated BAM8-22 peptides or analogs and methods of use thereof has a statutory expiration date of November 9, 2036 (plus
70 days of PTA), with potential patent term extension available until 2042, following the grant of marketing authorization. We have
pending patent applications for lipidated BAM8-22 peptides or analogs and methods of use thereof that, if issued, would be expected to
expire in the United States and in countries outside of the United States between 2036 and 2040, excluding any patent term adjustment
that might be available following the grant of the patent and any patent term extensions that might be available following the grant
of marketing authorizations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">We plan
to protect our intellectual property position by, among other things, licensing or filing our own U.S. and foreign patent applications
related to our proprietary technologies and products, and any inventions or improvements that are important to the development and implementation
of our business. We also may seek patent protection, if available, with respect to biomarkers and diagnostic methods that may be used
to determine optimal patient populations for use of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">Wherever possible, we seek
to protect our inventions by filing U.S. patent applications as well as foreign counterpart applications in select countries. Because
patent applications in the U.S. are maintained in secrecy for at least 18 months after the applications are filed, and since publication
of discoveries in the scientific or patent literature often lags behind actual discoveries, we cannot be certain that we were the first
to make the inventions covered by each of our issued or pending patent applications, or that we were the first to file for protection
of inventions set forth in such patent applications. Our planned or potential products may be covered by third-party patents or other
intellectual property rights, in which case continued development and marketing of our products would require a license. Required licenses
may not be available to us on commercially acceptable terms, if at all. If we do not obtain these licenses, we could encounter delays
in product introductions while we attempt to design around the patents, or we could find that the development, manufacture or sale of
products requiring such licenses are not possible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">In addition
to patent protection, we also rely on know-how, trade secrets and the careful monitoring of proprietary information, all of which can
be difficult to protect. We seek to protect some of our proprietary technologies and processes by entering into confidentiality agreements
with our employees, consultants, and contractors. These agreements may be breached, we may not have adequate remedies for any breach and
our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our employees or our consultants
or contractors use intellectual property owned by others in their work for us, disputes may also arise as to the rights in related or
resulting know-how and inventions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>License Agreement for OK-101</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">OTT and TMC entered into a license
agreement on April 3, 2017, or the Master License, pursuant to which OTT licensed exclusive rights to certain patent applications
that describe and claim lipidated chemerin peptides and their uses in DED, or Chemerin. The Master License remains in effect until
they royalty term has expired with respect to all licensed products in all countries. The Master License may be terminated by either
party in the event of a material breach and in addition, OTT may terminate the Master License at any time upon 90 days&rsquo; notice.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 22, 2017, OTT entered into a license and sublicense agreement with Panetta Partners Limited, one of our principal stockholders,
relating to Chemerin, or the Chemerin License Agreement, which was licensed from OTT and sublicensed from TMC. On May 1,
2018, we entered into an assignment of the Sublicense with Panetta Partners Limited. Under the terms of the Chemerin License Agreement,
we have exclusive rights to Chemerin. Specifically, we have the benefit of the exclusive worldwide rights to a U.S. patent application
(which if issued would expire in 2036). In addition, we have exclusive worldwide rights to a Patent Cooperation Treaty, or PCT, patent
which has been nationalized in the U.S., Europe, Japan, Australia and Canada and if issued it would expire in 2037. The Chemerin License
Agreement provides for the payment by us of up to $4.9 million in development milestone payments and up to $37 million in sales milestones
as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Development
milestone payments being:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$300,000
    upon first patient enrolled in a Phase I clinical trial;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$600,000
    upon first patient enrolled on a Phase II clinical trial;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1,500,000
    upon first patient enrolled in a Phase III clinical trial; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2,500,000
    upon first commercial sale of a licensed product.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
milestones payments as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2,000,000
    on first achievement of annual net sales of $50,000,000;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$4,000,000
    on first achievement of annual net sales of $100,000,000;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$6,000,000
    on first achievement of annual net sales of $250,000,000;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$10,000,000
    on first achievement of annual net sales of $500,000,000; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$15,000,000
    on first achievement of annual net sales of $1,000,000,000.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
above payments equate to low and declining single digit percentage royalties on net sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that we have novel composition-of-matter coverage on the lipidated chemerin peptide lead analogues and novel method-of-use claims
in treating DED and other ophthalmic diseases. Each patent office has different patentability requirements but we believe that the license
patent applications 16/070,467 (U.S. patent application entitled &ldquo;Compounds and methods for treating inflammation&rdquo;; applicant:
Tufts Medical Center / Trustees of Tufts College) and PCT/US2017/014605 (U.S. patent application entitled &ldquo;Compounds and methods
for treating inflammation&rdquo;; applicant Tufts Medical Center / Trustees of Tufts College) contain patentable subject matter. The
process for issuance of a patent involves a correspondence with each local patent office in the jurisdictions in which the patent application
is filed. That process, patent prosecution, involves a discussion of any relevant prior art and typically a discussion of the scope of
the claims. The patent prosecution process can take several years depending on the jurisdiction and is not in the control of the patent
owner, but in the control of the local patent office.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
subject matter of the licensed IP may have been developed with government financial assistance and are subject to certain federal regulations
under the Bayh-Dole Act of 1980. In particular, the federal government retains a &ldquo;nonexclusive, nontransferable, irrevocable, paid-up
license&rdquo; for its own benefit to inventions produced with its financial assistance. The Bayh-Dole Act also provides federal agencies
with &ldquo;march-in rights&rdquo; and allows the government certain rights to require products to be manufactured in the United States.
March-in rights allow the government, in specified circumstances, to require the contractor or successors in title to the patent to grant
a &ldquo;nonexclusive, partially exclusive, or exclusive license&rdquo; to a &ldquo;responsible applicant or applicants.&rdquo; If the
patent owner refuses to do so, the government may grant the license itself.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>OK-201</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
entered into a license agreement with TMC on May 1, 2018 relating to intellectual property and proprietary technology for the use of
certain lipidated BAM peptides in the treatment of neuropathic pain. Under the terms of the license agreement, we have acquired an exclusive
license to certain patents (pending and issued), inventions (including future patent filings on lipidated BAM molecules related to the
licensed patents. The license agreement requires an upfront license fee of $15,000 (&pound;11,000), which has been paid by us and annual
maintenance fees of $15,000 (&pound;11,000) commencing on the first anniversary of the license agreement. The maintenance fees decrease
to $10,000 after the three year anniversary until the first commercial sale. The license agreement also provides for further development
and sales milestone payments and royalties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 23, 2021, we announced that patent No. 10,899,796 entitled &ldquo;Compounds and Methods for Treating Pain&rdquo; was issued
by the United States Patent and Trademark Office. The patent is directed to a class of BAM peptides linked to specific lipids that demonstrate
potential for treating symptoms of neuropathic pain, ocular pain, ocular inflammation and/or DED. The work recited in this patent lays
out the potential of this class of lipidated BAM analogues as non-opioid analgesics for ocular pain management without the side effects
and potential abuse associated with opioid medications and is the foundation of our OK-201 program. In addition to the license from TMC
we have a collaboration agreement with TMC pursuant to which TMC has agreed to make available the services of Dr Pedram Hamrah M.D. as
principal investigator and nominated reach associate to carry out investigative and research studies in furtherance of our OK-201 corneal
neuropathic pain program. The patent will expire in early 2036.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Government
Regulation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Overview</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Government
authorities in most jurisdictions extensively regulate the research, development, clinical testing, manufacture, distribution and marketing
of pharmaceutical products such as those that the company is developing. Obtaining regulatory approvals and ensuring subsequent compliance
with applicable laws and regulations requires the expenditure of substantial time and financial and managerial resources. Regulatory
requirements in different jurisdictions vary, and the timing and success of efforts to obtain regulatory approvals can be highly uncertain.
Development of a successful drug candidate, from identification of a candidate drug compound, through preclinical and clinical testing,
to filing of a marketing approval application, to registration, typically takes more than ten years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drug
development is a highly structured process divided into two major stages, preclinical and clinical. In the preclinical stage, the toxicology
and mode of action of an active compound is evaluated. The clinical stage is designed to prove the safety of any new pharmaceutical,
determine dosage requirements and, predominantly in the later phases, prove its therapeutic utility. This stage is carried out in three
phases, which, as a developer moves through the phases, require increasingly large, complex, expensive and time-consuming clinical studies.
During Phase 1, the product candidate is initially given to a small number of healthy human subjects or patients and tested for safety,
tolerance, absorption, metabolism, distribution and excretion. During Phase 2, additional trials are conducted in a larger, but still
relatively limited, patient population to verify that the product candidate has the desired effect and to identify optimal dosage levels.
Furthermore, possible adverse effects and safety risks are identified. The therapeutic utility of the product candidate for specific
targeted diseases is also studied in more depth. During Phase 3, trials are undertaken to further evaluate dosage, to provide statistically
significant evidence of clinical effectiveness and to further study the safety in an expanded patient population at multiple clinical
trial sites. Phase 3 trials may require several hundreds or thousands of patients and are therefore the most expensive and time-consuming
to conduct. At any time during one of the phases, a trial may produce a negative result, in which case the developer may choose to end
the development project or a regulator could force clinical trials to terminate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
completion of the Phase 3 trials, the developer submits all the preclinical and clinical trial documentation as well as extensive data
characterizing the manufacturing process to the regulator to seek regulatory approval to market the formulation as a pharmaceutical product.
The regulator reviews all the information related to the safety of the active compound, and whether the pharmacological effect claimed
by the developer on the proposed label can be substantiated by the results of the clinical trials. The regulator has the option to decide
to approve the application as requested, ask for changes to the claims made by the developer, ask for more information, require that
further clinical trials are undertaken, or refuse to approve the formulation for sale.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
after initial regulatory approval has been obtained, further studies, including Phase 4 post-approval safety studies, may be required
to provide additional data on safety and will be required to gain approval for the use of a product as a treatment for clinical indications
other than those for which the product was initially tested. There are also continuing, annual user fee requirements for any marketed
products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications
with clinical data. In addition, regulatory authorities require post-marketing reporting to monitor the adverse effects of the product.
Results of post-approval programs may limit or expand the further marketing of the products. Further, if there are any modifications
to the product, including changes in indication, manufacturing process or labeling, or a change in the manufacturing facility, an application
seeking approval of such changes or, as the case may be, notification, must be submitted to the relevant regulatory authorities before
the modified product can be commercialized. Moreover, an approved drug product may be subject to a REMS, which could impose a number
of post-approval obligations, including (among other things) a communication plan for physicians regarding safe use of the drug, distribution
and use restrictions, and/or periodic assessments of the effectiveness of the REMS. Finally, studies may be required as a contingency
of regulatory approval (post-approval commitments), and completion of these studies within a regulator mandated time frame may be required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>European
Union</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development, marketing and sale of medicinal products in the EU is subject to extensive pre- and post- marketing regulation by regulatory
authorities at both the EU and national levels. The requirements, regulatory approvals and processes governing the conduct of clinical
trials, product licensing, pricing and reimbursement vary from country to country, although there is some degree of EU wide harmonization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Clinical
Trials</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials of medicinal products in the EU must be conducted in accordance with EU and national regulations, focusing, in particular on traceability,
apply to clinical trials of advanced therapy medicinal products. If the sponsor of the clinical trial is not established within the EU,
it must appoint an entity within the EU to act as its legal representative. The sponsor must take out a clinical trial insurance policy
and, in most EU countries, the sponsor is liable to provide &lsquo;no fault&rsquo; compensation to any study subject injured in the clinical
trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to commencing a clinical trial, the sponsor must obtain a clinical trial authorization from the relevant regulatory authority, and a
positive opinion from an independent ethics committee. The application for a clinical trial authorization must include, among other things,
a copy of the trial protocol and an investigational medicinal product dossier containing information about the manufacture and quality
of the medicinal product under investigation. Currently, clinical trial authorization applications must be submitted to the regulatory
authority in each Member State in which the trial will be conducted. Under the new Regulation on Clinical Trials, which is currently
expected to take effect in 2019, there will be a centralized application procedure where one national authority takes the lead in reviewing
the application and the other national authorities have only a limited involvement. Any substantial changes to the trial protocol or
other information submitted with the clinical trial applications must be notified to or approved by the relevant competent authorities
and ethics committees. Medicines used in clinical trials must be manufactured in accordance with cGMP.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Marketing
Approval</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the EU medicinal products can only be commercialized after obtaining marketing authorization, or MA. There are three procedures for obtaining
marketing approvals: the centralized procedure, the decentralized procedure and the mutual recognition procedure/national procedure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Community marketing authorization, which is issued by the European Commission through the centralized procedure, based on the opinion
of the CHMP of the EMA, is valid throughout the entire territory of the EU. The centralized procedure is mandatory for certain types
of products, such as biotechnology medicinal products, orphan medicinal products, and medicinal products containing a new active substance
indicated for the treatment of AIDS, cancer, neurodegenerative disorders, diabetes, autoimmune and viral diseases. The centralized procedure
is optional for products containing a new active substance not yet authorized in the EU, or for products that constitute a significant
therapeutic, scientific or technical innovation or which are in the interest of public health in the EU.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketing
approvals obtained using the decentralized procedure are available for products not falling within the mandatory scope of the Centralized
Procedure. An identical dossier is submitted to the regulatory authorities of each of the Member States in which the marketing approval
is sought, one of which is selected by the applicant as the Reference Member State, or RMS. The competent authority of the RMS prepares
a draft assessment report, a draft summary of the product characteristics and a draft of the labeling and package leaflet, which are
sent to the other the concerned Member States, or CMSs, for their approval. A CMS can raise an objection, based on the assessment report,
the summary of product characteristics, the labeling and the package leaflet on the grounds of potential serious risk to public health.
If no such objections are raised the product will be granted a national marketing authorization in the RMS and all of the selected CMSs.
Where a product has already been authorized for marketing in a Member State, this decentralized procedure approval can be recognized
in other Member States through the mutual recognition procedure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketing
approvals obtained using the national procedure are issued by a single regulatory authority of one of the Member States and only apply
to the territory covered by the relevant regulatory authority. They are available for products not falling within the mandatory scope
of the centralized procedure. Once a product has been authorized for marketing in a Member State through the national procedure, any
application in another Member State must be by the mutual recognition procedure whereby the marketing approval can also be recognized
in other Member States through the mutual recognition procedure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the procedures described above, before granting the MA, the EMA or the relevant regulatory authority of the Member States of the EU makes
an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and therapeutic
utility.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holder of a marketing authorization in any Member State of the EU is subject to various obligations under applicable EU regulations,
such as pharmacovigilance obligations, requiring it to, among other things, report and maintain detailed records of adverse reactions,
and to submit periodic safety update reports to the regulatory authorities. The holder must also ensure that the manufacturing and batch
release of its product is in compliance with the applicable requirements. The marketing approval holder is further obligated to ensure
that the advertising and promotion of its products complies with applicable laws, which can differ from Member State to Member State
of the EU.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Data
Exclusivity</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 17pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MAAs
for generic medicinal products in the EU do not need to include the results of preclinical and clinical trials, but instead can refer
to the data included in the marketing approval of a reference product for which regulatory data exclusivity has expired. If a marketing
approval is granted for a medicinal product containing a new active substance, that product benefits from eight years of data exclusivity,
during which generic MAAs referring to the data of that product may not be accepted by the regulatory authorities, and a further two
years of market exclusivity, during which such generic products may not be placed on the market. The two-year period may be extended
to three years if during the first eight years a new therapeutic indication with significant clinical benefit over existing therapies
is approved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 17pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 17pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is a special regime for biosimilars, or biological medicinal products that are similar to a reference medicinal product but that do not
meet the definition of a generic medicinal product, for example, because of differences in raw materials or manufacturing processes.
For such products, the results of appropriate preclinical or clinical trials must be provided, and guidelines from the EMA detail the
type of quantity of supplementary data to be provided for different types of biological product. There are no such guidelines for complex
biological products, such as gene or cell therapy medicinal products, and so it is unlikely that biosimilars of those products will currently
be approved in the EU. However, guidance from the EMA states that they will be considered in the future in light of the scientific knowledge
and regulatory experience gained at the time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 17pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Orphan
Medicinal Products</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 17pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
EMA&rsquo;s Committee for Orphan Medicinal Products, or COMP, may recommend orphan medicinal product designation to promote the development
of products that are intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions affecting
not more than five in 10,000 persons in the EU. Additionally, designation is granted for products intended for the diagnosis, prevention
or treatment of a life-threatening, seriously debilitating or serious and chronic condition and when, without incentives, it is unlikely
that sales of the product in the EU would be sufficient to justify the necessary investment in developing the medicinal product. The
COMP may only recommend orphan medicinal product designation when the product in question offers a significant clinical benefit over
existing approved products for the relevant indication. Following a positive opinion by the COMP, the European Commission adopts a decision
granting orphan status. The COMP will reassess orphan status in parallel with EMA review of a marketing authorization application and
orphan status may be withdrawn at that stage if it no longer fulfills the orphan criteria (for instance because in the meantime a new
product was approved for the indication and no convincing data are available to demonstrate a significant benefit over that product).
Orphan medicinal product designation entitles a party to financial incentives such as reduction of fees or fee waivers and ten years
of market exclusivity is granted following marketing authorization. During this period, the competent authorities may not accept or approve
any similar medicinal product, unless it offers a significant clinical benefit. This period may be redacted to six years if the orphan
medicinal product designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not
to justify maintenance of market exclusivity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 17pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>United
States</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Standard
Procedure</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act of 1938 and its implementing regulations. The
process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and
regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements
at any time during the product development process, approval process or after approval, may subject an applicant to a variety of administrative
or judicial sanctions, such as the FDA&rsquo;s refusal to approve pending NDAs or BLAs, withdrawal of an approval, imposition of a clinical
hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions,
fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process required by the FDA before a drug may be marketed in the United States generally involves the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion
    of preclinical laboratory studies, animal studies and formulation studies in compliance with the FDA&rsquo;s good laboratory practice
    regulations;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    to the FDA of an IND, which the FDA must approve before human clinical trials may begin;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval
    of the human clinical trial by the institutional review board, or IRB, at each clinical site before each trial may be initiated;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance
    of adequate and well-controlled human clinical trials in accordance with applicable IND and other clinical trial-related regulations,
    sometimes referred to as GCPs to establish the safety and clinical utility of the proposed product candidate for its proposed indication;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    to the FDA of a BLA or NDA;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of an FDA pre-approval inspection of the production facility or facilities where the product is produced to assess compliance
    with the FDA&rsquo;s cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the product&rsquo;s
    identity, strength, quality, purity and potency;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    FDA audit of the preclinical and/or clinical trial sites that generated the data in support of the NDA; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
    review and approval of the BLA or NDA prior to any commercial marketing or sale of the product in the United States.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained
or if problems occur after the product reaches the market. Other potential consequences include, among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines,
    warning letters or holds on post-approval clinical trials;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product approvals;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    seizure or detention, or refusal to permit the import or export of products; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions
    or the imposition of civil or criminal penalties.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Clinical
Trials</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials involve the administration of the IND to human patients under the supervision of qualified investigators in accordance with GCP
requirements, which include the requirement that all research patients provide their informed consent in writing for their participation
in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the
parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any
subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, an IRB at each institution participating
in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution. Information about
certain clinical trials must be submitted within specific timeframes to the National Institutes of Health for public dissemination on
their website. Regulatory authorities, IRBs or the sponsor may suspend or terminate a clinical trial at any time on various grounds,
including a finding that the research patients are being exposed to an unacceptable health risk.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Marketing
Approval</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assuming
successful completion of the required clinical testing, the results of the preclinical studies and clinical trials, together with detailed
information relating to the product&rsquo;s chemistry, manufacture, controls, or CMC, and proposed labeling, among other things, are
submitted to the FDA as part of an NDA or BLA requesting approval to market the product for one or more indications. In most cases, the
submission of an NDA or BLA is subject to a substantial application user fee. Under the Prescription Drug User Fee Act guidelines that
are currently in effect, the FDA has a goal of 10 months from the date of filing of a standard NDA for a new molecular entity
to review and act on the submission. This review typically takes 12 months from the date the NDA is submitted to the FDA because
the FDA has approximately two months to make a filing decision.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, under the Pediatric Research Equity Act of 2003<B><I>, </I></B>certain NDAs or supplements to an NDA must contain data that
are adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations,
and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may, on
its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval
of the product for use in adults, or full or partial waivers from the pediatric data requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine
whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an
NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also
subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive
review. The FDA reviews an NDA to determine, among other things, whether the drug is safe and effective and whether the facility in which
it is manufactured, processed, packaged or held meets standards designed to assure the product&rsquo;s continued safety, quality and
purity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including
clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be
approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations
carefully when making decisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
approving a BLA or NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not
approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements
and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the
FDA may inspect one or more clinical trial sites to assure compliance with GCP requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
evaluating the NDA or BLA and all related information, including the advisory committee recommendation, if any, and inspection reports
regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a complete
response letter (which generally contains a statement of specific conditions that must be met in order to secure final approval
of the NDA and may require additional clinical or preclinical testing in order for the FDA to reconsider the application). Even
with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria
for approval. If and when those conditions have been met to the FDA&rsquo;s satisfaction, the FDA will typically issue an approval letter.
An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if the FDA approves a product, it may limit the approved indications for use of the product, require that contraindications, warnings
or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted
to further assess a drug&rsquo;s safety after approval, require testing and surveillance programs to monitor the product after commercialization,
or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS, which can materially
affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the
results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding
new indications, manufacturing changes, and additional labeling claims, are subject to further testing requirements and FDA review and
approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Orphan
Drug Designation</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Orphan Drug Act of 1983, the FDA may designate a biologic product as an &ldquo;orphan drug&rdquo; if it is intended to treat a rare
disease or condition (generally meaning that it affects fewer than 200,000 individuals in the United States, or more in cases in which
there is no reasonable expectation that the cost of developing and making a biologic product available in the United States for treatment
of the disease or condition will be recovered from sales of the product).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a product with orphan status receives the first FDA approval for the disease or condition for which it has such designation, the product
is entitled to orphan product exclusivity, meaning that the FDA may not approve any other applications to market the same drug or biologic
product for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product
with orphan exclusivity or if the party holding the exclusivity fails to assure the availability of sufficient quantities of the drug
to meet the needs of patients with the disease or condition for which the drug was designated. Competitors, however, may receive approval
of different products for the same indication for which the orphan product has exclusivity or obtain approval for the same product but
for a different indication for which the orphan product has exclusivity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Post-Approval
Requirements for the EU and United States</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA and the relevant regulatory authorities in the EU strictly regulate marketing, labeling, advertising and promotion of products that
are placed on the market in their respective territories. Drugs may be promoted only for the approved indications and in accordance with
the provisions of the approved label. The regulatory authorities actively enforce the laws and regulations prohibiting the promotion
of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register
their establishments with the relevant regulatory authorities and are subject to periodic unannounced inspections by them to confirm
compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior approval of the
relevant regulatory authorities before being implemented. Regulations laid down by the FDA and the regulatory authorities in the EU also
require investigation and correction of any deviations from the requirements of cGMP and impose reporting and documentation requirements
upon the marketing approval holder and any third-party manufacturers that the marketing approval holder may decide to use.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Other
Healthcare Laws in the EU and United States</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
company will also be subject to healthcare regulation and enforcement by the U.S. federal government and the states and governments in
the EU and any other countries in which the company conducts its business, including its research, and the marketing and distribution
of its product candidates and products once they have obtained marketing approval. Failure to comply with these laws, where applicable,
can result in the imposition of significant civil penalties, criminal penalties, exclusion from participating in health care programs,
additional reporting requirements and oversight if the company becomes subject to a corporate integrity agreement or similar agreement
to resolve allegations of non-compliance with these laws and other sanctions. The healthcare laws and regulations that may affect the
Company&rsquo;s ability to operate in the United States include: the federal fraud and abuse laws, including the federal anti-kickback
and false claims laws; federal data privacy and security laws; and federal transparency laws related to payments and/or other transfers
of value made to physicians and other healthcare professionals and teaching hospitals. Many US states have similar laws and regulations
that may differ from each other and federal law in significant ways. Moreover, several US states have enacted legislation requiring pharmaceutical
manufacturers to, among other things, establish marketing compliance programs, file periodic reports with the state, and make periodic
public disclosures on sales and marketing activities, and prohibiting certain other sales and marketing practices. Rules and legislation
covering more or less the same subject matter as those in the United States apply to in countries in the EU and to other countries. These
can differ between jurisdictions and can sometimes result in lower or higher exposure in those countries than in the United States. Where
a product is sold in a number of countries compliance efforts can therefore be complicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Coverage
and Reimbursement in the EU and United States</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of products developed from the Company&rsquo;s product candidates, if approved, will depend, in part, on the extent to which such
products will be covered by third party payors, such as government health care authorities, government health care programs, commercial
insurance and managed healthcare organizations. These third-party payors are increasingly limiting coverage or reducing reimbursements
for medical products and services. In the United States, no uniform policy of coverage and reimbursement for products exists among third
party payors. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. In addition, the U.S.
government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls,
restrictions on reimbursement and requirements for substitution of generic products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Governments
influence the price of medicinal products in the EU through their pricing and reimbursement rules and control of national healthcare
systems that fund a large part of the cost of those products to consumers. Some jurisdictions operate positive and negative list systems
under which products may only be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some
of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product candidate
to currently available therapies. Other Member States allow companies to fix their own prices for medicines but monitor and control company
profits. The downward pressure on healthcare costs in general in the EU governments influence the price of medicinal products through
their pricing and reimbursement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The adoption of price controls
and cost-containment measures, and the adoption of more restrictive policies in jurisdictions with existing controls and measures, could
further limit the Company&rsquo;s net revenue and results. Decreases in third party reimbursement for the Company&rsquo;s
product candidates or a decision by a third-party payor to not cover the Company&rsquo;s product candidates could reduce physician
usage of the Company&rsquo;s product candidates, once approved, and have a material adverse effect on the Company&rsquo;s
sales, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Privacy
and Data Protection Laws in Europe</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to European laws relating to our and our suppliers&rsquo;, partners&rsquo; and subcontractors&rsquo; collection, control,
processing and other use of personal data (i.e. any data relating to an identifiable living individual, whether that individual can be
identified directly or indirectly). We are subject to the supervision of local data protection authorities in those jurisdictions where
we are established, where we offer goods or services to EU residents and where we monitor the behavior of individuals in the EU (i.e.
undertaking clinical trials). We and our suppliers, partners and subcontractors process personal data including in relation to our employees,
employees of customers, clinical trial patients, healthcare professionals and employees of suppliers including health and medical information.
The data privacy regime in the EU includes the General Data Protection Regulation, or GDPR, the e-Privacy Directive (2002/58/EC) and
the e-Privacy Regulation (once in force) and the national laws and regulations implementing or supplementing each of them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
GDPR requires that personal data is only collected for specified, explicit and legal purposes as set out in the GDPR or local laws, and
the data may then only be processed in a manner consistent with those purposes. The personal data collected and processed must be adequate,
relevant and not excessive in relation to the purposes for which it is collected and processed, it must be held securely, not transferred
outside of the EEA, (unless certain steps are taken to ensure an adequate level of protection) and must not be retained for longer than
necessary for the purposes for which it was collected. In addition, the GDPR requires companies processing personal data to take certain
organizational steps to ensure that they have adequate records, policies, security, training and governance frameworks in place to ensure
the protection of data subject rights, including as required to respond to complaints and requests from data subjects. For example, the
GDPR requires us to make more detailed disclosures to data subjects, requires disclosure of the legal basis on which we can process personal
data, makes it harder for us to obtain valid consent for processing, will require the appointment of a data protection officer where
sensitive personal data (i.e., health data) is processed on a large scale, introduces mandatory data breach notification throughout
the EU and imposes additional obligations on us when we are contracting with service providers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, to the extent a company processes, controls or otherwise uses &ldquo;special category&rdquo; personal data (including patients&rsquo;
health or medical information, genetic information and biometric information), more stringent rules apply, further limiting the circumstances
and the manner in which a company is legally permitted to process that data. Finally, the GDPR provides a broad right for Member State
to create supplemental national laws which may result in divergence across Europe making it harder to maintain a consistent operating
model or standard operating procedures. Such laws, for example, may relate to the processing of health, genetic and biometric data, which
could further limit our ability to use and share such data or could cause our costs to increase, and harm our business and financial
condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
depend on a number of third parties in relation to the provision of our services, a number of which process personal data on our behalf.
With each such provider we enter into contractual arrangements to ensure that they only process personal data according to our instructions,
and that they have sufficient technical and organizational security measures in place. Where we transfer personal data outside the EU,
we do so in compliance with the relevant data export requirements from time to time. We take our data protection obligations seriously,
as any improper, unlawful or accidental disclosure, loss, alteration or access to, personal data, particularly sensitive personal data
(i.e., special category), could negatively impact our business and/or our reputation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also subject to EU laws on personal data export, as we may transfer personal data from the EU to other jurisdictions which are not
considered by the European Commission to offer adequate protection of personal data. Such transfers need to be legitimized by a valid
transfer mechanism under the GDPR. There is currently ongoing litigation challenging the commonly used transfer mechanisms, the EU Commission
approved model clauses. In addition, the U.S. Privacy Shield is currently under review by the European Commission. As such, it is uncertain
whether the Privacy Shield framework and/or model clauses will be invalidated in the near future. These changes may require us to find
alternative bases for the compliant transfer of personal data from the EU to the United States and we are monitoring developments in
this area. Invalidation of any mechanism on which we rely could require operational changes and increased costs and may lead to governmental
enforcement actions, litigation, fines and penalties or adverse publicity that could have an adverse effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
EU is in the process of replacing the e-Privacy Directive with a new set of rules taking the form of a regulation, which will be directly
implemented in the laws of each Member State, without the need for further enactment. The draft e-Privacy Regulation imposes strict opt-in
marketing rules with limited exceptions for business-to-business communications and alters rules on third-party cookies, web beacons
and similar technology. Regulation of cookies and web beacons may lead to broader restrictions on online research activities, including
efforts to understand users&rsquo; internet usage. The current draft also significantly increases fining powers to the same levels as
GDPR (i.e., the greater of 20 million Euros or 4% of total global annual revenue). While no official timeframe has been provided, commentators
have stated that the e-Privacy Regulation is likely to be agreed in 2019 and to come into force during the second half of 2020 or during
2021 following a transition period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are costs and administrative burdens associated with compliance with the GDPR and the resultant changes in the EU and EEA member states&rsquo;
national laws and the introduction of the e-Privacy Regulation once it takes effect. Any failure or perceived failure to comply with
global privacy laws carries with it the risk of significant penalties and sanctions of up to &euro;20 million or 4% of global turnover.
These laws or new interpretations, enactments or supplementary forms of these laws, could create liability for us, could impose additional
operational requirements on our business, could affect the manner in which we use and transmit patient information and could increase
our cost of doing business. Claims of violations of privacy rights or contractual breaches, even if we are not found liable, could be
expensive and time-consuming to defend and could result in adverse publicity that could harm our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Property,
Plant and Equipment</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
below table contains information regarding existing or planned material tangible fixed assets owned or leased by us and our subsidiary.
We believe that suitable additional or substitute space will be available as needed to accommodate any future expansion of our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Location</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tenure</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Principal
    use</B></FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Suite
    1405</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Graybar
    Building</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">420
    Lexington Ave</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
    York</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NY
    10170</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6
    months</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO
    Office</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="cr_016"></A>MANAGEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DIRECTORS,
SENIOR MANAGEMENT AND EMPLOYEES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The following table sets forth
information regarding our directors and senior management as of the date of this prospectus. The business address of all persons
identified below is Martello Court, Admiral Park, St. Peter Port, Guernsey GY1.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; width: 30%"><FONT STYLE="font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center; width: 14%"><FONT STYLE="font-size: 10pt"><B>Age</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; width: 52%"><FONT STYLE="font-size: 10pt"><B>Position</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Gabriele Cerrone</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">50</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Non-Executive</FONT><FONT STYLE="font-size: 10pt">
    Chairman</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Dr. Gary S. Jacob</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">75</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">CEO and Director</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Dr. Raj Patil</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">64</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Chief Scientific Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Keeren Shah</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">46</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Willy Simon</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">70</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Non-Executive Director</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">John Brancaccio</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">74</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Non-Executive Director</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Bernard Denoyer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">74</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Non-Executive Director</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Gabriele Cerrone</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Gabriele Cerrone has been the
Non-Executive Chairman of our company since January 2021. Mr. Cerrone is the Founder of Tiziana Life Sciences Limited and has
been its Executive Chairman since April 2014. Mr. Cerrone has founded 10 biotechnology companies in oncology, infectious diseases and
molecular diagnostics, and has listed seven of these companies on Nasdaq, two to the Main Market and AIM Market in London. Mr. Cerrone
co-founded Cardiff Oncology, Inc., an oncology company and served as its Co-Chairman; he was a co-founder and served as Chairman of both
Synergy Pharmaceuticals, Inc. and Callisto Pharmaceuticals, Inc. and was a Director of and led the restructuring of Siga Technologies,
Inc. Mr. Cerrone also co-founded FermaVir Pharmaceuticals, Inc. and served as Chairman of the Board until its merger in September 2007
with Inhibitex, Inc. Mr. Cerrone served as a director of Inhibitex, Inc. until its US$2.5bn sale to Bristol Myers Squibb Co in 2012.
Mr. Cerrone is the Executive Chairman and Founder of Nasdaq-listed Tiziana Life Sciences Limited, an oncology focused therapeutics company;
Co-Founder of Rasna Therapeutics Inc., a company focused on the development of therapeutics for leukaemias; Co-Founder of Hepion Pharmaceuticals,
Inc.; Executive Chairman and Co-Founder of Gensignia Life Sciences, Inc., a molecular diagnostics company focused on oncology using microRNA
technology; Non-Executive Chairman and Founder of Accustem Sciences Limited; and founder of BioVitas Capital Ltd. Mr. Cerrone graduated
from New York University&rsquo;s Stern School of Business with a master&rsquo;s degree in business administration (MBA).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dr.
Gary S. Jacob</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="background-color: white">Dr.
Gary S. Jacob has served as Chief Executive Officer and a director of our company since January 2021. </FONT>From <FONT STYLE="background-color: white">November
2018 to March 2020, Dr. Jacob was the Chief Executive Officer of Immuron Limited, an Australian microbiome biopharmaceutical company.
From July 2008 until December 2017, Dr. Jacob was President and Chief Executive Officer of Synergy Pharmaceuticals Inc., a biopharmaceutical
company, where he held various positions from July 2008 to November 2018</FONT> and he served as its Chairman from September 2013 to
November 2018. On December 12, 2018, Synergy Pharmaceuticals Inc. filed a petition for relief under Chapter 11 of the U.S. Bankruptcy
Code. <FONT STYLE="background-color: white">Since March 19, 2014, Dr. Jacob has been Chairman of the Board of Hepion Pharmaceuticals,
Inc., a biotechnology company, and earlier served as its Chief Executive Officer from May 15, 2013 until March 19, 2014. Dr. Jacob served
as Chief Executive Officer of Callisto Pharmaceuticals, Inc. from May 2003 until January 2013 and a director from October 2004 until
January 2013. Dr. Jacob also serves as a director of Virpax Pharmaceuticals, Inc., and Rasna Therapeutics, Inc., and is a past director
of Cardiff Oncology, Inc. Dr. Jacob has over 35 years of experience in the pharmaceutical and biotechnology industries across multiple
disciplines including research &amp; development, operations and business development. Prior to 1999, Dr. Jacob served as a Monsanto
Science Fellow, specializing in the field of glycobiology, and from 1997 to 1998 Dr. Jacob was Director of Functional Genomics, Corporate
Science &amp; Technology, at Monsanto Company. Dr. Jacob also served from 1990 to 1997 as Director of Glycobiology at G.D. Searle Pharmaceuticals
Inc. During the period of 1986 to 1990, he was Manager of the G.D. Searle Glycobiology Group at Oxford University, England</FONT>.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dr.
Raj Patil</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Dr.
Raj Patil has served as Chief Scientific Officer of our company since March 2021. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Patil has over 15 years of ophthalmic drug development experience, <FONT STYLE="background-color: white">including research &amp; development,
operations and business development. Dr. Patil </FONT>previously worked with Ora, as Vice President of Research &amp; Development,
where he was responsible for driving all anterior and posterior segment ocular research of Ora&rsquo;s R&amp;D Institute. From 2013 until
2018, Dr. Patil worked at iVeena Delivery Systems as Vice President of Advanced Ocular Delivery Systems. Dr. Patil&rsquo;s tenure at
iVeena included a two-year sabbatical in Singapore, where he served as an Associate Professor of Ophthalmology at DUKE/NUS Medical School,
and Principal Investigator at Singapore Eye Research Institute. From 2004 until 2013, Dr. Patil also held a number of leadership roles
at Alcon/Novartis Institute of Biomedical Research, including Associate Director of Research and Head of Molecular Pharmacology - glaucoma
and retina research. Prior to 2004, Dr. Patil served as an Associate Professor of Ophthalmology, Cell Biology &amp; Genetics at the University
of Nebraska Medical Centre in Omaha from 2001 until 2004, and as an Assistant Professor of Ophthalmology, Molecular Biology &amp; Pharmacology
at Washington University in St. Louis from 1992 until 2000. Dr. Patil received his PhD in Biochemistry from National Chemical Laboratory/University
of Pune, India, and completed his postdoctoral training in Biochemistry and Molecular Biology at the University of Michigan, Ann Arbor,
MI. He is the recipient of the Olga Keith Wiess Special Scholar Award from the Research to Prevent Blindness Foundation, and NIH Director&rsquo;s
New Innovator Award. Dr. Patil has authored over 50 peer-reviewed research articles, serves as reviewer and editorial board member for
numerous journals, and is frequently invited to lecture at academic and industry events.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Keeren
Shah</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Keeren
Shah has served as our Chief Financial Officer since August 2020. Ms. Shah currently also serves as the Finance Director of Tiziana Life
Sciences Limited, Accustem Sciences Limited and Rasna Therapeutics Inc., having previously served as the Group Financial Controller
for all businesses from June 2016 to July 2020. Prior to joining us, Ms. Shah spent 10 years at Visa, Inc. as a Senior Leader in its
finance team where she was responsible for key financial controller activities, financial planning and analysis, and core processes as
well as leading and participating in key transformation programmes and Visa Inc.&rsquo;s initial public offering. Before joining Visa,
Ms. Shah also held a variety of finance positions at other leading companies including Arthur Andersen and BBC Worldwide. She holds a
Bachelor of arts with honours in Economics and is a member of the Chartered Institute of Management Accountants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Willy
Simon</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Willy
Jules Simon has been a director of our company since November 2015. He is a banker and worked at Kredietbank N.V. and Citibank London
before serving as an executive member of the Board of Generale Bank NL from 1997 to 1999 and as the chief executive of Fortis Investment
Management from 1999 to 2002. He acted as chairman of Bank Oyens &amp; van Eeghen from 2002 to 2004. He was chairman of AIM-traded Velox3
plc (formerly 24/7 Gaming Group Holdings plc) until 2014 and had been a director of Playlogic Entertainment Inc., a Nasdaq OTC listed
company. Willy Simon has been the chairman of Bever Holdings, a company listed in Amsterdam, since 2006 and Chairman of Ducat Maritime
since 2015. He is also a non-executive director of Tiziana Life Sciences Limited.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>John
Brancaccio </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">John
Brancaccio, a retired CPA, has served as a director of our company since June 2020. From April 2004 until May 2017, Mr. Brancaccio was
the Chief Financial Officer of Accelerated Technologies, Inc., an incubator for medical device companies. Mr. Brancaccio served as a
director of Callisto Pharmaceuticals, Inc. from April 2004 until its merger with Synergy Pharmaceuticals, Inc. in January 2013 and has
been a director of Tamir Biotechnology, Inc. (formerly Alfacell Corporation) since April 2004, as well as a director of Hepion Pharmaceuticals,
Inc. since December 2013, Rasna Therapeutics, Inc. since September 2016, Cardiff Oncology, Inc. since December 2005 and Tiziana Life
Sciences Limited  since July 2020. Mr. Brancaccio served as a director of Synergy from July 2008 until April 2019. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Bernard Denoyer</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="background-color: white">Bernard
F. Denoyer has served as a director of our company since December 2021. Mr. Denoyer served as Senior Vice President, Finance and Secretary
of Synergy Pharmaceuticals, Inc, from July 2008 until his retirement in June 2017. Between 2004 and January 2013 Mr. Denoyer concurrently
served as Principal Financial Officer of Synergy&rsquo;s former parent company, Callisto Pharmaceuticals, Inc. From October 2000 to December
2003, Mr. Denoyer was an independent consultant. Prior to this, Mr. Denoyer served as Chief Financial Officer and Senior Vice President
of META Group, Inc. He is currently serving on the Board of Trustees for two not-for-profits, St. Edmunds Retreat, Inc. and Midwestern
Connecticut Council on Alcoholism, Inc.<FONT STYLE="background-color: white">.</FONT></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Scientific
Advisory Board</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors is assisted in its approach to its scientific strategy. Members of the Scientific Advisory Board are:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Professor
Napoleone Ferrara, MD - University of California&rsquo;s Moores Cancer Center in San Diego</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr
Ferrara is Senior Deputy Director for Basic Sciences at University of California&rsquo;s Moores Cancer Center in San Diego; and Distinguished
Professor of Pathology at the University of California&rsquo;s School of Medicine, also in San Diego. Dr Ferrara&rsquo;s research led
to the development of the anti-VEGF monoclonal antibody bevacizumab (Avastin&reg;) which was initially approved for the treatment of
colorectal cancer and is now one of the top ten selling global pharmaceutical products. Dr. Ferrara won the 2010 Lasker Award for his
work on VEGF.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Professor
Pedram Hamrah, MD, FRCS, FARVO &ndash; Tufts University School of Medicine, Boston, and Clinician-Scientist at Tufts Medical Center</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Hamrah is an ophthalmologist and cornea specialist, with a focus on corneal immunology and neuroscience, ocular imaging (immuno-imaging),
ocular surface diseases, and corneal neuropathic pain. He is currently on faculty at the departments of Ophthalmology and Bioengineering
at Tufts University, where he is the director of clinical research and director of the Center for Translational Ocular Immunology. In
addition, he is a faculty member at the immunology, neuroscience, and cell, molecular and developmental biology graduate programs at
the Sackler School of Graduate Biomedical Sciences at Tufts. Throughout his career, he has focused on discovery, patient care and teaching.
Dr. Hamrah currently serves on over a dozen editorial boards, is the associate editor for The Ocular Surface and TVST, section editor
for Eye, and assistant editor at Ocular Immunology and Inflammation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Foreign
Private Issuer Exemption</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an FPI as defined by the SEC. As a result, in accordance with Nasdaq listing requirements, we may rely on home country governance
requirements and certain exemptions thereunder rather than complying with Nasdaq corporate governance standards. While we voluntarily
follow most Nasdaq corporate governance rules, we may choose to take advantage of the following limited exemptions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exemption
    from filing quarterly reports on Form 10-Q containing unaudited financial and other specified information or current reports on Form
    8-K upon the occurrence of specified significant events.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exemption
    from Section 16 rules requiring insiders to file public reports of their stock ownership and trading activities and liability for
    insiders who profit from trades in a short period of time, which will provide less data in this regard than shareholders of U.S.
    companies that are subject to the Exchange Act.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exemption
    from the Nasdaq requirement requiring disclosure of any waivers of the code of business conduct and ethics for directors and officers.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exemption
    from the requirement that our board of directors have a remuneration committee that is composed entirely of independent directors
    with a written charter addressing the committee&rsquo;s purpose and responsibilities.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exemption
    from the requirement to have independent director oversight of director nominations.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to follow the laws of Guernsey and rules applicable to companies admitted to listing on the standard segment of the Official List
of the FCA and to trading on the Main Market of the London Stock Exchange in lieu of Nasdaq corporate governance requirements
as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    do not intend to follow Nasdaq Rule 5620(c) regarding quorum requirements applicable to meetings of shareholders. Such quorum requirements
    are not required under the laws of Guernsey. In accordance with generally accepted business practice, our Articles provide alternative
    quorum requirements that are generally applicable to meetings of shareholders.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    do not intend to follow Nasdaq Rule 5605(b)(2), which requires that independent directors regularly meet in executive sessions where
    only independent directors are present. Our independent directors may choose to meet in executive sessions at their discretion.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we may rely on certain home country corporate governance practices, we must comply with Nasdaq&rsquo;s Notification of Noncompliance
requirement (Nasdaq Rule 5625) and the Voting Rights requirement (Nasdaq Rule 5640). Further, we must have an audit committee that satisfies
Nasdaq Rule 5605(c)(3), which addresses audit committee responsibilities and authority and requires that the audit committee consist
of members who meet the independence requirements of Nasdaq Rule 5605(c)(2)(A)(ii).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to take all actions necessary for us to maintain compliance as an FPI under the applicable corporate governance requirements of
the Sarbanes-Oxley Act, the rules adopted by the SEC and Nasdaq listing rules. Accordingly, our shareholders will not have the same protections
afforded to shareholders of companies that are subject to all of the corporate governance requirements of Nasdaq. For an overview of
our corporate governance principles, see the section titled &ldquo;Description of Share Capital and Memorandum and Articles of Incorporation&mdash;Differences
in Corporate Law.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Code
of Business Conduct and Ethics</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to consummation of this initial public offering, we plan to adopt a Code of Business Conduct and Ethics applicable to our employees,
executive officers and directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Composition
of Our Board of Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors is currently composed of five members. Our board of directors has determined that, of our five directors, three of
these directors are &ldquo;independent&rdquo; as that term is defined under Nasdaq rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with our Articles, each of our directors for whom it is the third annual general meeting following the annual general meeting
at which they were elected or last re-elected, or who was appointed by the board since the previous annual general meeting, shall retire
from office but shall be eligible to stand for re-election. See &ldquo;Description of Share Capital and Memorandum and Articles of Incorporation&mdash;Articles&mdash;Board
of Directors.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commencing
with the 2021 annual general meeting, we adopted best practice for corporate governance in our country of incorporation so all
directors shall retire and stand for re-election at each annual general meeting (as opposed to reliance upon rotational reappointment).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
of our directors&rsquo; service contracts provide for benefits upon termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Committees
of Our Board of Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has three standing committees: an audit committee, a remuneration committee and a nominating committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Audit
Committee</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
audit committee, which consists of John Brancaccio, Bernard Denoyer and Willy Simon, assists the board of directors in overseeing
our accounting and financial reporting processes. Mr. Brancaccio serves as chairman of the audit committee. The audit committee consists
exclusively of members of our board who are financially literate, and Mr. Brancaccio is considered an &ldquo;audit committee financial
expert&rdquo; as defined by applicable SEC rules and has the requisite financial sophistication as defined under the applicable Nasdaq
rules and regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board has determined that all of the members of the audit committee satisfy the &ldquo;independence&rdquo; requirements set forth in
Rule 10A-3 under the Exchange Act. The audit committee will be governed by a charter that complies with Nasdaq rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
audit committee&rsquo;s responsibilities include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending
    the appointment of the independent auditor to the general meeting of shareholders;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    appointment, compensation, retention and oversight of any accounting firm engaged for the purpose of preparing or issuing an audit
    report or performing other audit services;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pre-approving
    the audit services and non-audit services to be provided by our independent auditor before the auditor is engaged to render such
    services;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluating
    the independent auditor&rsquo;s qualifications, performance and independence, and presenting its conclusions to the full board of
    directors on at least an annual basis;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and discussing with management and our independent registered public accounting firm our financial statements and our financial reporting
    process; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing,
    approving or ratifying any related party transactions.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Remuneration
Committee</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
remuneration committee consists of John Brancaccio, Bernard Denoyer and Willy Simon who serves as chairman of the remuneration
committee. Under SEC and Nasdaq rules, there are heightened independence standards for members of the remuneration committee, including
a prohibition against the receipt of any compensation from us other than standard board member fees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
remuneration committee&rsquo;s responsibilities include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying,
    reviewing and proposing policies relevant to the compensation and benefits of our directors and executive officers;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluating
    each executive officer&rsquo;s performance in light of such policies and reporting to the board; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing
    and administering our employee share option scheme or equity incentive plans in operation from time to time.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nominating
Committee</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">The
nominating committee consists of John Brancaccio, Willy Simon and Bernard Denoyer, who serves as chairman of the nominating committee.
The nominating committee&rsquo;s responsibilities include:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">drawing
    up selection criteria and appointment procedures for directors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending
    nominees for election to our board of directors and its corresponding committees;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">assessing
    the functioning of individual members of our board of directors and executive officers and reporting the results of such assessment
    to the board of directors; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing
    corporate governance guidelines.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Compensation
of Executive Officers and Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended March 31, 2021, the aggregate compensation accrued or paid to the members of our board of directors and our executive
officers for services in all capacities was $1.4 million and $0.1 million for the year ended March 31, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dr.
Gary S. Jacob Employment Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
entered into an employment agreement with Dr. Gary S. Jacob, our Chief Executive Officer, on December 21, 2020 and amended the
agreement on January 19, 2021. Pursuant to the agreement, Dr. Jacob has an annual salary of $350,000 and a cash bonus of up to 50% of
his annual salary based on annual performance goals. In addition, Dr. Jacob was granted options to purchase 40,000,000 ordinary shares.
The options will vest over 4 years in 4 equal tranches.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Jacob is also entitled to the same fringe benefits as we provide to our other executives from time to time and is eligible to receive
employee share incentives. If Dr. Jacob&rsquo;s employment with the company is terminated without cause, or if he resigns for good reason,
Dr. Jacob will also be entitled to receive severance equal to continuation of his base salary as then currently in effect for 12 months
following his date of termination and will be eligible for a pro-rated bonus and for reimbursement for medical coverage premiums for
6 months following his date of termination. Dr. Jacob&rsquo;s severance benefits are conditioned on, amongst other things, his
execution of our standard separation agreement and a general release of claims in our favor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
employment agreement provides that Dr. Jacob&rsquo;s employment with us is at-will. If required by us, the employment agreement further
provides that Dr. Jacob will resign from his position on our board of directors effective as of the date of his termination for any reason.
The employment agreement further contains a 12-month non-solicitation covenant by Dr. Jacob.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Gabriele
Cerrone Letter of Appointment</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
entered into an appointment agreement with Gabriele Cerrone on January 6, 2021 to serve as our Non-Executive Chairman. This agreement
entitles Mr. Cerrone to receive a consultancy fee of &pound;120,000 per year. On April 28, 2021 we entered into an agreement with the
Mr. Cerrone pursuant to which Mr. Cerrone was awarded a retrospective bonus of $627,273 for the financial year ended March 31,
2020 and a further bonus of $533,050 for the financial year ended March 31, 2021, in each case for services prior to his agreeing
to become a director of the Company, on condition that Mr. Cerrone agreed that Panetta Partners Limited and Planwise Group Limited exercise
a total of 147,969,396 warrants at exercise prices between $0.006 and $0.0189 (being all of the warrants held by Mr. Cerrone and his
associated entities). Mr. Cerrone also agreed that his accrued but unpaid compensation from January 1, 2021 to May 4, 2021 and through
to March 31, 2022, in the sum of $210,000 be waived and offset against the costs of the exercise of certain of the warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Employees</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2021 and 2020, we had 2 and 2 employees, respectively. All of our employees were based in the US. All of our employees
were engaged in either administrative or R&amp;D functions. None of our employees are covered by a collective bargaining agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Insurance
and Indemnification</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to our Articles, our directors (including any alternate director), secretary and other officer or employee for the time being shall be
indemnified out of the assets of the company to the fullest extent permitted by the Guernsey Companies Law from and against all actions,
costs, charges, losses, damages and expenses in respect of which they may lawfully be indemnified which they or any of them shall or
may incur or sustain by reason of any contract entered into or any act done, concurred in, or omitted, in or about the execution of their
duty or supposed duty or in relation thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain directors&rsquo; and officers&rsquo; insurance to insure such persons against certain liabilities. We have entered into a deed
of indemnity with each of our directors and executive officers prior to the filing of this registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insofar
as indemnification of liabilities arising under the Securities Act may be permitted to our board of directors, executive officers, or
persons controlling us pursuant to the foregoing provisions, we have been informed that, in the opinion of the SEC, such indemnification
is against public policy as expressed in the Securities Act and is therefore unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Total
Compensation for the Non-Executive Chairman Non-Executive Directors:</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below sets out the total remuneration received by the Non-Executive Chairman and the Non-Executive Directors for the year
ended March 31, 2021.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid">Name</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Position</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fees
    earned<BR> or paid in<BR> cash <BR> ($)<SUP>(1)</SUP></B></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Bonus<BR>
    earned or<BR> paid in cash <BR> ($)<SUP>(1)</SUP></B></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Options<BR>
    awarded <BR> ($)<SUP>(1) (2)</SUP></B></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total
    <BR> ($)<SUP>(1)</SUP></B></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 23%; text-align: left">Gabriele Cerrone</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 23%; text-align: center">Non-Executive Chairman</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">35,701</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">1,160,347</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">1,196,048</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Willy Simon</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">Non-Executive Director</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">41,866</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,075</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">43,941</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kunwar Shailubhai<SUP>(3)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">Non-Executive Director</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">36,969</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">17,119</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">54,088</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gregor MacRae<SUP>(4)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">Non-Executive Director</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">13,083</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">13,083</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">John Brancaccio</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">Non-Executive Director</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">31,000</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">-</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">16,000</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">47,000</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    amounts have been translated into U.S. dollars from Pounds Sterling based upon the exchange rate as certified by the Federal Reserve
    Bank of New York for customs purposes as of March 31, 2021. These translations are merely for the convenience of the reader and should
    not be construed as representations that the Pounds Sterling amounts actually represent such U.S. dollar amounts or could be converted
    into U.S. dollars at the rate indicated.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    the fair value of incentive stock options granted during the year to March 31, 2021 using the Black-Scholes model for computing stock-based
    compensation expense as of the date of grant.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Resigned
    June 17, 2021</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Resigned
    June 9, 2020</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Employee
Share Option Plan with Non-Employee Sub-Plan and US Sub-Plan </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
main features of the Unapproved Share Option Plan are summarized below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Eligibility</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
executive directors and employees of the Company and any of its subsidiaries are eligible to participate in the Unapproved Share Option
Plan. The Remuneration Committee selects the individuals to whom share options are to be granted from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Grant
of options</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
may be granted at such time or times as the Remuneration Committee (or the Board, excluding any interested Director, until a Remuneration
Committee is formally established) determines.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Exercise
price and adjustments to options</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the Ordinary Shares are admitted to trading on the Main Market of the London Stock Exchange, the exercise price per Ordinary Share may
not be less than the average of the middle market quotations for an Ordinary Share for the five dealing days immediately prior to the
date of grant. While the Ordinary Shares are not admitted to trading on the Main Market of the London Stock Exchange, the exercise price
will be the amount specified by the Remuneration Committee. If the Ordinary Shares are newly issued the exercise price may not, in any
event, be less than the nominal value of an Ordinary Share. In the event of any variation in the share capital of the Company the exercise
price and/or the number of Ordinary Shares comprised in each option may be adjusted as the Remuneration Committee determines. No adjustment
may be made which will reduce the exercise price below the nominal value of an Ordinary Share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Rights
and restrictions</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
option granted under the Unapproved Share Option Plan is not transferable. The option certificate will specify when the option will lapse,
and such date may not be later than the tenth anniversary of its date of grant. Except in the circumstances referred to below, an option
will only be exercisable on or after the date which is three years after the date of grant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the participant ceases to be employed by the Company by reason of injury, disability, ill-health or redundancy; or because the business
or company that employs them is transferred out of the ultimate ownership of the Company, his option may be exercised within six
months after such cessation or transfer provided that this limit may be further extended by the Remuneration Committee in the event that
any exercise of the options would trigger any requirement upon the holder to make a general offer to shareholders under Rule 9 of the
Takeover Code. In the event of the death of a participant, the personal representatives of a participant may exercise his option within
six months after the date of death. The extent to which an option may be exercised in these circumstances will be determined by reference
to any exercise conditions and time vesting provisions set out in the option certificate unless the Remuneration Committee decides otherwise
and is satisfied that any waiver of such provisions does not constitute a reward for failure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
cessation of employment for any other reason (or when a participant serves or has been served with, notice of termination of such employment),
the option will lapse unless the Remuneration Committee exercises its discretion to allow the exercise of the option for a period not
exceeding 6 months from the date of such cessation or notice. In such circumstances and where exercise is permitted, the extent to which
an option may be exercised will be determined by reference to any exercise conditions and time vesting provisions set out in the option
certificate unless the Remuneration Committee decides otherwise and is satisfied that any waiver of such provisions does not constitute
a reward for failure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Corporate
events</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options,
to the extent not already exercisable, will become exercisable immediately prior to a change in control of the Company, in the event
of a takeover of the Company, in the event that an officer becomes entitled or bound to acquire Ordinary Shares or in the event that
the court sanctions a compromise or arrangement for the reconstruction of the Company or its amalgamation with any other company. In
such event, all share options may be exercised for a limited period and will lapse to the extent not exercised. Options, to the extent
not already exercisable, will become exercisable in the event that the Company is proposed to be voluntarily wound up and all share options
may be exercised within a limited period in connection with the winding up, failing which they will lapse. In such circumstances and
where exercise is permitted, the extent to which an option may be exercised will be determined by reference to any exercise conditions
set out in the option certificate unless the Remuneration Committee decides otherwise and is satisfied that any waiver of such provisions
does not constitute a reward for failure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Performance
conditions</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise of share options may be subject to the satisfaction of such performance conditions, if any, as may be specified and subsequently
varied and/or waived by the Remuneration Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Issuance
of Ordinary Shares</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Ordinary Shares issued upon the exercise of share options granted under the Unapproved Share Option Plan will rank pari passu with the
Company&rsquo;s issued Ordinary Shares on the date of exercise, save as regards any rights arising by reference to a record date prior
to the date of such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Plan
limit</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
may not be granted under the Unapproved Share Option Plan if such grant would result in the total number of &ldquo;Dilutive Shares&rdquo;
exceeding 15% of the Company&rsquo;s issued share capital from time to time. &ldquo;Dilutive Shares&rdquo; means, on any date, all shares
of the Company which (a) have been issued, or transferred out of treasury, on the exercise of share options granted, or in satisfaction
of any other awards made, under any share incentive scheme (including the Unapproved Share Option Plan) in the shorter of the five years
ending on (and including) that date and the period since Admission; and (b) remain capable of issue, or transfer out of treasury, under
any subsisting share options granted by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Alternative
settlement on exercise</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Instead
of delivering the number of Ordinary Shares specified in the exercise notice, the Remuneration Committee may make a cash payment with
the option holder&rsquo;s consent or deliver Ordinary Shares equal to the value of the Ordinary Shares over which the option is exercised,
less the relevant exercise price, or may deliver a combination of the above two.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Alteration</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Remuneration Committee may alter the Unapproved Share Option Plan except that (apart from minor amendments to benefit the administration
of the Share Option Plan, to correct typographical or other errors, to take account of a change in legislation or to obtain or maintain
favorable tax, exchange control or regulatory treatment for participants or the Company) no alteration to the advantage of participants
or to the Unapproved Share Option Plan limit described above can be made without the prior approval of Shareholders in general meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
amendment may have a materially adverse effect on share options granted before the amendment without the relevant option holder&rsquo;s
consent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Termination
and Plan period</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Remuneration Committee may terminate or suspend the operation of the Unapproved Share Option Plan at any time, whereupon no further share
options shall be granted but in all other respects the provisions of the Unapproved Share Option Plan shall remain in force. In any event,
no share options may be granted after the date which is five years after the date the Unapproved Share Option Plan is adopted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="an_001"></A>RELATED
PARTY TRANSACTIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a description of related party transactions we have entered into with the beneficial owners of 3% or more of our ordinary
shares, which are our only voting securities, and senior management and members of our board of directors, for the three-year period
ended March 31, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Loan
to West African Minerals Ltd.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2018, we disposed of our Cameroon operations by way of an in specie distribution of all of our shares in Ferrum Resources Limited (renamed
West African Minerals Limited, or WAML) to our shareholders. As part of this transaction, we agreed to a deed of release with WAML whereby
we agreed to write off $17,056,070 of loans in exchange for shares in WAML to be distributed as part of the in-specie distribution. A
remaining amount of $3,400,000 is still outstanding from WAML, however, after careful consideration of the operations of WAML and its
subsidiaries, we decided to impair this receivable down to nil in 2018 as we do not expect to recover any of this outstanding debt. In
addition to the $3,400,000 outstanding there was a working capital loan advance of $600,000, which has been fully extended and also written
down to nil.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tiziana
Life Sciences Limited </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 1, 2018, we entered into a Shared Services Agreement with Tiziana Life Sciences Limited, or Tiziana, pursuant to which
we share premises and other resources. The agreement is renewed for successive three (3) month periods. For the years ended March 31,
2021 and 2020, we paid Tiziana $86,567 and $117,767, respectively, under the Shared Services Agreement. We share common officers and
directors with Tiziana, namely Gabriele Cerrone, Willy Simon and John Brancaccio.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Gabriele
Cerrone Letter of Appointment</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
entered into an appointment agreement with Gabriele Cerrone, on January 6, 2021, to serve as our non-executive chairman. This agreement
entitles Mr. Cerrone to receive a consultancy fee of &pound;120,000 per year. On April 28, 2021 we entered into an agreement with the
Mr. Cerrone pursuant to which Mr. Cerrone was awarded a retrospective bonus of $627,273 for the financial year ended March 31,
2020 and a further bonus of $533,050 for the financial year ended March 31, 2021, in each case for services prior to his agreeing
to become a director of the Company, on condition that Mr. Cerrone agreed that Panetta Partners Limited and Planwise Group Limited exercise
a total of 147,969,396 warrants at exercise prices between $0.006 and $0.0189 (being all of the warrants held by Mr. Cerrone and his
associated entities). Mr. Cerrone also agreed that his accrued but unpaid compensation from January 1, 2021 to May 4, 2021 and through
to March 31, 2022, in the sum of $210,000 be waived and offset against the costs of the exercise of certain of the warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Panetta
Partners Limited</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Non-Executive Chairman, Gabriele Cerrone, has a beneficial interest in Panetta Partners Limited, one of our principal stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 1, 2018 we entered into a Deed of Assignment with Panetta Partners Limited whereby we acquired the license and sub-license of certain
research and development assets in relation to our OK-101 product candidate for $2,793,488.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">We
have also entered into a Convertible Loan note agreement with Panetta Partners Limited, for a principal amount of $69,850, the conversion
rights attaching to which were exercised and the resulting ordinary shares issued on May 7, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Planwise Group Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">On May 7, 2021 we allotted and
issued 18,329,094 ordinary shares to Planwise Group Ltd, a company in which our Chairman, Gabriele Cerrone, has a beneficial interest,
as a commission of $36,880 upon the conversion of our convertible loan notes for which conversion took place on May 7, 2021.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Indemnity
Agreements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into deeds of indemnity with each of our directors and officers. See &ldquo;Management&mdash;Insurance and Indemnification.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Related
Person Transaction Policy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has adopted a written related person transaction policy, to be effective immediately upon the effectiveness of the
registration statement of which this prospectus forms a part, setting forth the policies and procedures for the review and approval or
ratification of related person transactions. This policy will cover, any transaction or proposed transactions between us and a related
person that are material to us or the related person, including without limitation, purchases of goods or services by or from the related
person or entities in which the related person has a material interest, indebtedness, guarantees of indebtedness and employment by us
of a related person. In reviewing and approving any such transactions, our audit and risk committee is tasked to consider all relevant
facts and circumstances, including, but not limited to, whether the transaction is on terms comparable to those that could be obtained
in an arm&rsquo;s length transaction and the extent of the related person&rsquo;s interest in the transaction. All of the transactions
described in this section occurred prior to the adoption of this policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="an_002"></A></B></FONT></P>


<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="a_001"></A>PRINCIPAL
SHAREHOLDERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The following table sets forth
information relating to the beneficial ownership of our ordinary shares as of May 12, 2022 by:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    person, or group of affiliated persons, known by us to own beneficially 5% or more of our outstanding ordinary shares; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    member of our board of directors and each of our executive officers.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The number of ordinary shares
beneficially owned by each entity, person, board member, or executive officer is determined in accordance with the rules of the SEC,
and the information is not necessarily indicative of beneficial ownership for any other purpose. Under such rules, beneficial ownership
includes any ordinary shares over which the individual has sole or shared voting power or investment power as well as any ordinary shares
that the individual has the right to acquire within 60 days of May 12, 2022 through the exercise of any option, warrant or other
right. Except as otherwise indicated, and subject to applicable community property laws, the persons named in the table have sole voting
and investment power with respect to all ordinary shares held by that person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The percentage of ordinary shares
beneficially owned before this offering is computed on the basis of 1,374,415,468 ordinary shares outstanding as of May 12, 2022.
Ordinary shares that a person has the right to acquire within 60 days of May 12, 2022 are deemed outstanding for purposes of computing
the percentage ownership of the person holding such rights, but are not deemed outstanding for purposes of computing the percentage ownership
of any other person, except with respect to the percentage ownership of all board members and executive officers as a group. Unless otherwise
indicated below, the address for each beneficial owner listed is Martello Court, Admiral Park, St. Peter Port, Guernsey,</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">Number of<BR> Ordinary<BR> Shares</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Percentage of <BR> Ordinary Shares <BR> Beneficially Owned</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid">Name and address of beneficial owner</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Beneficially <BR> Owned</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Before Offering</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">After Offering</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">5% or Greater Shareholders:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left">Panetta Partners Ltd</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">511,166,362</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">37.19</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><P STYLE="margin: 0">36.312</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Executive Officers and Directors:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gabriele Cerrone<SUP>(1)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">543,181,215</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">39.52</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0">38.539</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Gary S. Jacob<SUP>(2)</SUP></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0">10,000,000</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0">*</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0">*</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Willy
    Simon<SUP>(3)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,500,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0">*</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">John Brancaccio<SUP>(4)</SUP></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0">112,500</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0">*</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0">*</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Bernard Denoyer</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Raj Patil<SUP>(5)</SUP></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,250,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">*</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">*</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Keeren Shah<SUP>(6)</SUP></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">75,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">*</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">*</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    directors and officers as a group (7 persons)<SUP>(7)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">556,118,715</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates
    beneficial ownership of less than 1% of the total outstanding ordinary shares.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(1)</SUP></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of 511,166,362 ordinary shares owned by Panetta Partners Ltd and 32,014,853 ordinary shares owned by Planwise Group Ltd. Mr.
    Cerrone is the ultimate beneficial owner of the ordinary shares held by Planwise Group Ltd and Panetta Partners Ltd.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Consists
                                            of 10,000,000 stock options which are currently exercisable
                                            or exercisable within 60 days of May 12, 2022.</P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>(3)</SUP></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Consists of 1,500,000 stock options which are currently
    exercisable or exercisable within 60 days of May 12, 2022.</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>(4)</SUP></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Consists of 112,500 stock options which are currently exercisable
    or exercisable within 60 days of May 12, 2022.</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>(5)</SUP></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Consists of 1,250,000 stock options which are currently
    exercisable or exercisable within 60 days of May 12, 2022.</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>(6)</SUP></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Consists of 75,000 stock options which are currently exercisable
    or exercisable within 60 days of May 12, 2022.</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(7)</SUP></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Includes
                                            1,000,000 ordinary shares currently exercisable or exercisable within 60 days of May 12,
                                            2022.</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="a_002"></A>DESCRIPTION
OF SHARE CAPITAL AND MEMORANDUM AND ARTICLES OF INCORPORATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were originally incorporated in the British Virgin Islands as a British Virgin Islands Business Company on 4 July 2007 under the BVI
Business Companies Act 2004 with company number 1415559 under the name Jellon Enterprises, Inc.. Our legal and commercial name
was changed to Minor Metals &amp; Mining, Inc. on October 24, 2007, to Emerging Metals Limited on November 28, 2007, to West African
Minerals Corporation on December 9, 2011, and to OKYO Pharma Corporation on January 10, 2018. On March 9, 2018, shareholders approved
the cancellation of the Company&rsquo;s AIM listing and migration to Guernsey. On July 3, 2018, following the approval of the Guernsey
Companies Registry, the Company was registered under the Guernsey Companies Law under the name OKYO Pharma Limited, as a Guernsey company
with limited liability, an indefinite life and company number 65220. The Company is domiciled in Guernsey.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
registered office is located at Martello Court, Admiral Park, St. Peter Port, Guernsey, GY1 3HB and our telephone number is +44 (0) 20
7495 2379. Our website address is www.okyopharma.com. The reference to our website is an inactive textual reference only and the information
contained in, or that can be accessed through, our website is not a part of this registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Current
authorized share capital</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Current
issued share capital</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">As of May 12, 2022, our
issued share capital was 1,374,415,468 ordinary shares, no par value. Each issued ordinary share is fully paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Options</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">As of May 12, 2022, there
were vested options to purchase 14,437,500 ordinary shares outstanding with a weighted average exercise price of $0.074 per ordinary
share. The remaining options to purchase 57,962,500 ordinary shares vest between July 6, 2022 and August 31, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">As of May 12, 2022, there
were warrants to purchase 36,659,090 ordinary shares outstanding as follows:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">No. outstanding</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Exercise Price</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Exercise Price</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Final Exercise Date</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 23%; text-align: right">35,000,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 22%; text-align: right">0.062</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&pound;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 22%; text-align: right">0.045</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 22%; text-align: right">7/17/2023</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">909,090</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.038</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&pound;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0275</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">05/21/2023</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">750,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.192</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&pound;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.140</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">20/7/2022</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
to purchase 1,659,090 ordinary shares are exercisable immediately until the final exercise date. Warrants to purchase the remaining
35,000,000 ordinary shares are exercisable based on the achievement of milestones, with a final exercise date of July 17, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Information
about the Ordinary Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with our Articles, the following summarizes the rights of holders of our ordinary shares:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    holder of our ordinary shares is entitled to one vote per ordinary share on all matters to be voted on by shareholders generally;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    holders of the ordinary shares shall be entitled to receive notice of, attend, speak and vote at our general meetings; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">holders
    of our ordinary shares are entitled to receive such dividends as are recommended by our directors and declared by our shareholders.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Articles
</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are incorporated in Guernsey as a non-cellular company limited by shares under company number 65220. We are governed by our Articles
and the Guernsey Companies Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Articles were adopted by a special resolution of our shareholders at our annual general meeting held on September 25, 2020. The summary
below is not a complete copy of the terms of the Articles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Articles contain no specific restrictions on our purpose and therefore our purpose is unrestricted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Articles contain, among other things, provisions to the following effect:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Share
Capital</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
share capital currently consists of ordinary shares. Subject to the Guernsey Companies Law and to any rights attached to existing shares,
we may issue shares with such rights or restrictions as may be determined by the board. In addition, shares which are to be redeemed,
or are liable to be redeemed at our option or the holder of such shares may be issued with the board determining the terms and conditions
of such redemption.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of our issued and outstanding ordinary shares are fully paid. Holders of ordinary shares do not have conversion or redemption rights.
There are no provisions in our Articles discriminating against a shareholder as a result of such shareholder&rsquo;s ownership of a particular
number of shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Preferred
Shares</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors may provide for other classes of shares, including series of preferred shares. If any preferred shares are issued,
the rights, preferences and privileges of our ordinary shares will be subject to, and may be adversely affected by, the rights of holders
of such preferred shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Voting</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to any rights or restrictions attached to any shares, on a show of hands every shareholder who is present in person or by proxy at a
general meeting shall have one vote. On a poll, every shareholder present in person or by proxy at a general meeting shall have one vote
for every ordinary share held by such shareholder. A proxy need not be a shareholder of ours.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 89; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
shareholder shall not be entitled, in respect of any shares held by such shareholder, to vote (either personally or by proxy) at any
general meeting of ours unless all amounts payable by such shareholder in respect of that share in our capital have been paid or credited
as having been paid, or where such shareholder is in default of the provisions in the Articles requiring disclosure of ownership of shares
and we have served a direction notice on such shareholder advising such shareholder that such shares may not be voted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Variation
of Rights</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
or any of the rights, privileges or conditions attached to any class of shares in issue may only be varied with the consent in writing
of the holders of 75% in value of the issued shares of that class (excluding treasury shares) or with the sanction of a special
resolution passed at a separate general meeting of the holders of the shares of that class. A quorum for the separate class meeting is
two persons (in person or by proxy) holding one-third of the voting rights of the shares of that class or group.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Alteration
of capital</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may by ordinary resolution:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
consolidate and divide all or any of our share capital into shares of a larger amount than our existing shares;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
sub-divide all or any of our shares into shares of a smaller amount than is fixed by our Articles or by ordinary resolution;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
cancel any shares which, at the date of passing the resolution have not been taken up or agreed to be taken up;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
convert the whole, or any particular class, of our shares into redeemable shares;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
redesignate the whole, or any particular class, of our shares into shares of another class;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
covert all or any of our shares into shares of a nominal amount of a different currency, at the exchange rate; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
where our shares were expressed in a particular currency, denominate or redenominate it.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Dividends</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Subject to the Guernsey Companies Law, our directors may authorize dividends and distributions to be paid to Shareholders. If any share
is issued on terms providing that it shall rank for dividend or distribution as from a particular date, such share shall rank for dividend
or distribution accordingly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Our directors may direct that any dividend or distribution shall be satisfied wholly or partly by the distribution of assets, and in
particular of paid up shares, debentures, or other securities of any other company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
No dividend or distribution payable shall bear interest against us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
A transfer of shares shall not pass the right to any dividend or distribution declared thereon before the registration of the transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 90; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
All dividends or distribution unclaimed for a period of one year from the date on which such dividend or distribution was declared may
be invested or otherwise made use of by our directors for the benefit of until claimed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
All dividends or distribution unclaimed for a period of six years from the date on which such dividend or distribution was declared shall,
if our directors so resolve, be forfeited and shall revert to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
Subject to the Guernsey Companies Law or in the terms of issue of any share in our capital, for the purposes of making any distribution
or paying any dividend, our directors may determine that those persons who are entered on the register of members at the close of business
on a day determined by our directors shall be the persons who are entitled to receive such dividends or distributions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
Payments of dividends or distributions may be made by electronic transfer in such manner as agreed between the member and us or by cheque
or warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Transfer
of Ordinary Shares</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
shareholder may transfer all or any of their shares (i) in the case of certificated shares by transfer in writing in any usual or common
form or in any other form acceptable to our directors; and (ii) in the case of uncertificated shares, in the manner provided for in the
rules and procedures of the operator of the &ldquo;relevant system&rdquo; (i.e., the CREST System) and in accordance with and subject
to the CREST Regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
instrument of transfer of a certified share shall be signed by or on behalf of the transferor and, if the share is not fully paid, by
or on behalf of the transferee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors may, in its absolute discretion and without assigning any reason, decline to register any transfer of certificated
share or uncertified shares unless it is:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    respect of a share which is fully paid up;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    respect of a share in which we have no lien;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    respect of only one class of share;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    favor of a single transferee or not more than four joint transferees; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    relation to a certificated share, delivered for registration to our registered office (or such other place as our board of directors
    may from time to time determine) accompanied by the relevant share certificate(s) and such other evidence as our board of directors
    may reasonably require, to show the right of the transferor to make the transfer.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors shall not refuse to register any transfer or renunciation of partly paid shares which are listed on the Main Market
of the London Stock Exchange on the grounds that they are partly paid shares in circumstances where that refusal would prevent dealings
in any such shares from taking place on an open and proper basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Disclosure
of Ownership</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
directors may by notice in writing require a shareholder to disclose to us the identity of any person other than such shareholder who
has, or has had, at any time during the three years immediately preceding the date on which the notice is issued, any interest (whether
direct or indirect) in the shares held by such shareholder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 91; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a shareholder, or any other person appearing to be interested in shares held by that shareholder, has been issued with such a notice
and has failed in relation to any shares, or the Default Interests, to give the Company the information thereby required within the prescribed
period from the service of the notice, our directors may in their discretion serve a direction notice on such shareholder which may direct
that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
the shareholder shall not be entitled in respect of the Default Interests to be present or to vote (either in person or by proxy) at
any general meeting or at any separate meeting of the holders of any class of shares or on any poll or to exercise any other right conferred
by membership in relation to any such meeting or poll; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
where the Default Interests represent at least 0.25%. of the number of shares in issue of the class concerned:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
any dividend, distribution or other money payable in respect of the shares shall be withheld by us, which shall not have any obligation
to pay interest on it; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
no transfer of the Default Interests held by us shall be registered unless: (I) the shareholder is not themself in default as
regards supplying the information requested; and (II) the shareholder proves to the satisfaction of our directors that no person
in default as regards supplying such information is interested in any of the shares the subject of the transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Requirement
to disclose interests</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
shareholder shall be under an obligation to comply with the disclosure and notification requirements set out in Chapter 5 of the DTRs.
If the Company determines that a shareholder, or the Defaulting Member, has not complied with the provisions of Chapter 5 of the DTRs
with respect to some or all of such shares held by such Shareholder, or the Default Shares, we shall have the right by delivery of notice
to the Defaulting Member, or a Default Notice, to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
suspend the right of such Defaulting Member to vote on the Default Shares in person or by proxy at any meeting of ours; and/or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
(i) withhold, without any obligation to pay interest thereon, any dividend or other amount payable with respect to the Default Shares,
(ii) render ineffective any election to receive our shares instead of cash in respect of any dividend or part thereof, and/or (iii) prohibit
the transfer of any of our shares held by the Defaulting Member except with the consent of ours.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Pre-emptive
Rights</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
the laws of Guernsey nor the Articles provide shareholders with pre-emptive rights when new shares are issued by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Board
of Directors</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise determined by the company by ordinary resolution, the number of directors (other than any alternate directors) shall not be
less than one, but there shall be no maximum number of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
business and affairs of the Company shall be managed by, or under the direction or supervision of the our directors who may pay all expenses
incurred in promoting and registering the Company, and may exercise all such powers necessary for managing, and for directing and supervising
the management of, the our business and affairs as are not, by the Guernsey Companies Law or by the Articles, required to be exercised
by us in a general meeting, subject to the Articles, to the provisions of the Guernsey Companies Law and to such regulations as may be
prescribed by us by special resolution provided that such regulations are not inconsistent with the Articles or the provisions of the
Guernsey Companies Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 92; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the Articles, our directors may meet together for the dispatch of business, adjourn and otherwise regulate their meetings as they
think fit. The quorum necessary for the transaction of the business is two unless otherwise resolved by our directors. A meeting of our
directors at which a quorum is present shall be competent to exercise all powers and discretions for the time being exercisable by our
directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
director who is in any way, directly or indirectly, interested in a proposed transaction or arrangement with us, or in a transaction
or arrangement that has been entered into by us, must declare the nature and extent of such director&rsquo;s interest to our directors.
The declaration must be made at a meeting of our board of directors, or by written notice, or by general notice, in accordance with the
Guernsey Companies Law and the Articles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
directors shall have power at any time and from time to time to appoint any person to be a director, either to fill a casual vacancy
or as an addition to our existing directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the provisions of the Guernsey Companies Law and provided the director has disclosed their interest to our other directors, such director
notwithstanding their office may:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
be a party to, or otherwise interested in, any transaction or arrangement with us, or in which we are otherwise interested;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
act by themself or through their firm in a professional capacity for us be entitled to remuneration as if they were not a director;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
be a director or officer of, or employed by, or a party to any transaction or arrangement with, a shareholder of or otherwise directly
or indirectly interested in, any corporate entity promoted by us, or with which we have entered into any transaction with or are interested
in; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
not by reason of his office, be accountable to us for any benefit which such director derives from any such office or employment or from
any such transaction or arrangement or from any interest in any such body corporate and no such transaction or arrangement shall be liable
to be avoided on the ground of any such interest or benefit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
director shall be counted in the quorum at any meeting in relation to any resolution in respect of which such director has declared an
interest and may vote thereon.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
person must not be appointed as a director unless such person has consented in writing and submitted their declaration that they are
not ineligible to act as a director under the Guernsey Companies Law. A director need not be a shareholder but shall be entitled to receive
notice of and attend all of our general meetings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
person shall, unless recommended by our directors, be eligible for election to the office of director at any general meeting unless not
less than three nor more than 21 days before the date appointed for the meeting there shall have been left at our registered office a
notice in writing signed by a shareholder, their intention to propose such a person for election (this must be accompanied by that persons
willingness to be elected and their signed declaration).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
directors shall be paid such remuneration (by way of fee) for their services as may be determined by our directors in their absolute
discretion. Our directors shall also be entitled to be repaid all travelling, hotel and other expenses of travelling to and from board
meetings, committee meetings, general meetings, or otherwise incurred while engaged on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 93; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the provisions of the Guernsey Companies Law, every director shall have the power to purchase and maintain insurance for or for the
benefit of any persons who are or were at any time our directors, officers or employees (including any other company which is its holding
company or in which we have any direct or indirect interest in) against any liability incurred by such persons in respect of any act
or omission in the actual or purported execution and /or discharge of their duties or exercise or purported exercise of their powers
in relation to or in connection with their duties, powers or offices in relation to us or any other such company or subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
director may at any time by writing appoint any person to be their alternate director and may in like manner at any time terminate
such appointment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
office of director shall, ipso facto, be vacated if such director:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
resigns his office by writing under his hand and it is deposited at our registered office and we may agree to accept this at a later
date than specified;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
shall have absented themselves from meetings of the directors for six months in succession and all our other directors have resolved
that such director should vacate their office;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
becomes bankrupt, suspends payment or compounds with such director&rsquo;s creditors, or is adjudged insolvent or has his affairs declared
en d&eacute;sastre;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
dies;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
becomes ineligible to act as a director under the Guernsey Companies Law;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
is removed by resolution of our directors in writing signed by all of our other directors (being not less than two in number); or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
if we shall by ordinary resolution declare that such person shall cease to be a director.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Indemnity</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
directors (including any alternate director), secretary and other officer or employee for the time being shall be indemnified out of
the our assets to the fullest extent permitted by the Guernsey Companies Law from and against all actions, costs, charges, losses, damages
and expenses in respect of which they may lawfully be indemnified which they or any of them shall or may incur or sustain by reason of
any contract entered into or any act done, concurred in, or omitted, in or about the execution of their duty or supposed duty or in relation
thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Limitations
on the Rights to Own Our Securities</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not aware of any limitations on the rights to own our securities, including rights of non-resident or foreign shareholders to hold
or exercise voting rights on our securities, imposed by foreign law or by our Articles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>General
Meetings</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
annual general meeting of ours shall be held in each calendar year (provided that no more than fifteen months may elapse between one
annual general meeting and the next) at such time and place as may be determined by our directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 94; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
directors may convene a general meeting whenever they think fit. General meetings shall also be convened by the directors within 21
days of a requisition by our shareholders as provided for by the Guernsey Companies Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
special notice is required in accordance with the Guernsey Companies Law, not less than fourteen days&rsquo; notice in respect of all
general meeting shall be given to all Shareholders (other than those who, under the provisions of the Articles or otherwise, are not
entitled to receive notices from the Company).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Every
notice shall specify the place, the date and the time of the meeting and the general nature of the business of the meeting. Any general
meeting may be held in Guernsey, or elsewhere, as our directors may from time to time determine. There is no age limit at which a director
is required to retire.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the purpose of determining which persons are entitled to attend and vote at any general meeting and how many votes such persons may cast,
the Company may specify in the relevant notice of general meeting a time, not more than forty eight hours (excluding any days which are
not business days) before the time fixed for the meeting, by which a person must be entered on the register of members in order to have
the right to attend and vote at the meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
business shall be transacted unless the requisite quorum is present when the meeting proceeds to business. Two shareholders present in
person or by proxy and entitled to vote shall be a quorum, save where we only have one shareholder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
within half an hour from the time appointed for the general meeting a quorum is not present, if convened on the requisition of the shareholders
the meeting shall be dissolved. In any other case the meeting shall be adjourned to the same day in the next week at the same time and
place and no notice of such adjournment need be given. At any such adjourned meeting, those shareholders present in person or by proxy
shall be a quorum. If no shareholders are present at the adjourned meeting, the meeting shall be dissolved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Every
question submitted to a general meeting shall be determined in the first instance by a show of hands of the shareholders present in person
or by proxy or by attorney and entitled to vote, but a poll may be demanded by no fewer than five shareholders having the right to vote
on the resolution, or one or more of the shareholders present in person or by proxy representing at least 10%. of the total voting
rights of all of the shareholders having the right to vote on the resolution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Corporate
representatives</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
corporation which is a shareholder may by resolution of its directors or other governing body authorize such person as it thinks fit
to act as its representative at any meeting of ours or of any class of shareholders, and the person so authorized shall be entitled to
exercise the same powers on behalf of the corporation which he represents as that corporation could exercise if it were an individual
shareholder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Borrowing
Powers</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the Articles and the Guernsey Companies Law, our board of directors may exercise all of the powers of the company to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">borrow
    money;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">indemnify
    and guarantee;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">mortgage
    or charge;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">create
    and issue debentures and other securities; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">give
    security either outright or as collateral security for any debt, liability or obligation of the company or of any third party.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 95; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Uncertificated
Shares</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the Guernsey Companies Law, our board of directors may permit title to shares of any class to be issued or held otherwise than by
a certificate and to be transferred by means of a &ldquo;relevant system&rdquo; (i.e., the CREST System) without a certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors may take such steps as it sees fit in relation to the evidencing of and transfer of title to uncertificated shares,
any records relating to the holding of uncertificated shares and the conversion of uncertificated shares to certificated shares, or vice-versa.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors may by notice to the holder of an uncertificated share, require that share to be converted into certificated form.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors may take such other action that the board considers appropriate to achieve the sale, transfer, disposal, forfeiture,
re-allotment or surrender of an uncertified share or otherwise to enforce a lien in respect of it.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Winding
up</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to any preferred, deferred or other special rights, or subject to such conditions or restrictions to which any shares in our capital
may be issued, on a winding-up or other return of capital, the holders of our ordinary shares are entitled to share in any surplus assets
pro rata to their holdings of such ordinary shares. A liquidator may, with the sanction of a special resolution of ours and any other
sanction required by the Guernsey Companies Law, divide amongst our shareholders in specie or in kind the whole or any part of our assets
(whether or not the assets shall consist of property of one kind or shall consist of property of different kinds), those assets to be
set at such value as such liquidator deems fair. A liquidator may also vest the whole or any part of our assets in trustees on trusts
for the benefit of the shareholders as the liquidator shall think fit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
the Company is proposed to be or is in the course of being wound up and the whole or part of its business or property is proposed to
be transferred or sold to another company the liquidator may, with the sanction of an ordinary resolution, receive in compensation for
the transfer or sale, shares, policies or other like interests in such other company for distribution among our shareholders or may enter
into any other arrangement whereby our shareholders may, in lieu of receiving cash, shares, policies or other like interests, or in addition
thereto, participate in the profits of or receive any other benefits from such company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Issue
of shares and share rights</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
directors may exercise the power of the company for an unlimited duration to issue an unlimited number of shares or grant rights to subscribe
for, or to convert any security into shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue shares which: (i) are redeemable shares; (ii) confer preferential rights to distribution of capital or income; (iii) do not
entitle the holder to voting rights; and (iv) entitle the holder to restricted voting rights. Our directors may issue shares which have
a nominal or par value, no par value, in any number they see fit and in fractions of a share. Subject to &ldquo;Variation of Rights&rdquo;
above, we may convert all or any classes of our shares into redeemable shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 96; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
directors may make arrangements on the issue of shares to distinguish between shareholders as to the amounts and the times of payments
of calls on their shares and issue shares that provide for the payment of dividends and distributions in differing proportions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Acquisition
of own shares</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the provisions of the Guernsey Companies Law and the rights of holders of any class of shares, we may purchase our own shares, including
redeemable shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Liens,
Calls on Shares and Forfeiture</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
respect of any shares we issue that are not fully paid, we will have a first and paramount lien on every share (not being a fully paid
share) for all moneys payable at a fixed time or called in respect of such share. Our board of directors may make calls upon shareholders
for any amounts unpaid in respect of their shares, subject to the terms of allotment (whether in respect of nominal value or premium).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a call remains unpaid after it has become due and payable, then, following notice by our board of directors requiring payment of the
unpaid amount together with any accrued interest and expenses incurred, such share may be forfeited by a resolution of our board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
shareholder whose shares have been forfeited will cease to be a shareholder in respect of such share, but will, notwithstanding the forfeiture,
remain liable to us for all moneys which at the date of forfeiture were presently payable together with interest. A forfeited share may
be sold, re-allotted or otherwise disposed of as our board of directors sees fit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Provisions
that Would Delay, Defer or Prevent a Change of Control</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no provisions in our Articles that would have the effect of delaying, deferring or preventing a change in control of us and that
would operate only with respect to a merger, acquisition or corporate restructuring involving us or any of our subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Other
Relevant Laws and Regulations</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Mandatory
Bid</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.K. City Code on Takeovers and Mergers, or Takeover Code, applies to the company. Under the Takeover Code, where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    person, together with persons acting in concert with them, acquires, whether by a series of transactions over a period of
    time or not, an interest in shares which (taken together with shares in which he is already interested, and in which persons acting
    in concert with them are interested) carry 30% or more of the voting rights of a company; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    person who, together with persons acting in concert with them, is interested in shares which in the aggregate carry not less
    than 30% of the voting rights of a company but does not hold shares carrying more than 50% of such voting rights and such person,
    or any person acting in concert with them, acquires an interest in any other shares which increases the percentage of shares
    carrying voting rights in which he is interested, such person shall, except in limited circumstances, be obliged to extend offers,
    on the basis set out in Rules 9.3, 9.4 and 9.5 of the Takeover Code, to the holders of any class of equity share capital, whether
    voting or non-voting, and also to the holders of any other class of transferable securities carrying voting rights. Offers for different
    classes of equity share capital must be comparable; the U.K. Panel on Takeovers and Mergers, or Takeover Panel, should be consulted
    in advance in such cases.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 97; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
offer under Rule 9 of the Takeover Code must be in cash and at the highest price paid for any interest in the shares by the person required
to make an offer or any person acting in concert with them during the 12 months prior to the announcement of the offer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Takeover Code, a &ldquo;concert party&rdquo; arises where persons acting together pursuant to an agreement or understanding (whether
formal or informal and whether or not in writing) cooperate, through the acquisition by them of an interest in shares in a company, to
obtain or consolidate control of the company. &ldquo;Control&rdquo; means holding, or aggregate holdings, of an interest in shares carrying
30% or more of the voting rights of the company, irrespective of whether the holding or holdings give <I>de facto</I> control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shareholder
Notification and Disclosure Requirements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholders
are obliged to comply with the shareholding notification and disclosure requirements set out in Chapter 5 of the DTRs. As the company
is classified as a &ldquo;non-UK issuer&rdquo; for the purposes of the DTRs, a shareholder is required pursuant to Rule 5 of the DTRs
to notify the company if, as a result of an acquisition or disposal of shares or financial instruments, the shareholder&rsquo;s percentage
of voting rights of the company reaches, exceeds or falls below 5%, 10%, 15%, 20%, 25%, 30%, 50% and 75%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
DTRs can be accessed and downloaded from the FCA&rsquo;s website at <U>https://www.handbook.fca.org.uk/handbook/DTR/</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholders
are urged to consider their notification and disclosure obligations carefully as a failure to make a required disclosure to the company
may result in disenfranchisement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 98; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Shareholder
rights under Guernsey Law</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of the rights of shareholders under the Guernsey Companies Law and other applicable laws in Guernsey. Prospective
shareholders are advised that this is not a complete statement of the rights of Shareholders under applicable law in Guernsey or under
the Articles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)
Company alterations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Guernsey Companies Law, it is possible for a Guernsey company to merge with another Guernsey company or an overseas company with
the approval by a special resolution of members, provided that there is a short form amalgamation process for amalgamations between a
company and its wholly-owned subsidiary or between two or more wholly- owned subsidiaries of the same company which does not require
a special resolution of the members of each company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Guernsey Companies Law, a compromise or arrangement is permitted between the company and its creditors or shareholders, or any class
thereof, whether for the purpose of facilitating the company&rsquo;s reconstruction or its merger with another company, or otherwise.
An application must be made to court which court will then order a meeting of the company&rsquo;s creditors or shareholders. It is necessary
for 75%. in value of the creditors or 75% of the voting rights of the shareholders, or class thereof, as the case may
be, to agree to the compromise or arrangement and if such compromise or arrangement is sanctioned by the court, it will be binding on
the creditors or shareholders, or class thereof, as appropriate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Guernsey Companies Law also requires the approval of the shareholders by special resolution for the removal of a company from the Guernsey
Register of Companies for the purpose of becoming registered as a company under the law of a district, territory or place outside Guernsey.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Guernsey Companies Law, amendments to a company&rsquo;s articles of incorporation so permitted may be authorized by way of a special
resolution of the company&rsquo;s shareholders (provided that certain provisions within a company&rsquo;s articles of incorporation can
be embedded with a higher voting threshold required for change).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)
Rights of dissent and appraisal</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Guernsey Companies Law contains rights of dissent (the granting of which is discretionary on the part of the court), which are applicable
where the company resolves to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
amalgamate with another corporation (other than vertical or horizontal short form amalgamations);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
transfer of its registration into another jurisdiction; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
carry out a takeover transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 99; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(c)
Shareholder derivative actions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
laws of Guernsey permit derivative actions to be brought by a shareholder, or such person as the court directs who, in the discretion
of the court, is a proper person to make an application to court to bring a derivative action. Under the laws of Guernsey, the complainant
must obtain permission of the court to commence a derivative action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(d)
Sale of undertaking</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Companies Law does not contain provisions in relation to shareholder authority for the sale of a company&rsquo;s undertaking and, accordingly,
the sale, lease or exchange of all or substantially all the property of the company will be governed by the articles of incorporation
of a company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(e)
Unfair prejudice</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
member of a company may apply to the court on the ground that the affairs of the company are conducted in a manner that is unfairly prejudicial
to the interests of members generally or of some part of its members (including at least themselves), or an actual or proposed
act or omission of the company is or would be so prejudicial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the court is satisfied that an application is well founded it may make such orders as it sees fit, which may include without limitation:
(a) requiring the company to refrain from doing or continuing to do an act, or require it to do any act which the applicant has complained
it has omitted to do; or (b) providing for the purchase of shares of any member of the company by other members of the company or by
the company itself (and the reduction of the company&rsquo;s capital accordingly).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Differences
in Corporate Law</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a non-cellular company limited by shares incorporated in Guernsey, we are governed by the Guernsey Companies Law. The applicable provisions
of the Guernsey Companies Law differ from laws applicable to U.S. corporations and their shareholders. Set forth below is a summary of
certain differences between the provisions of the Guernsey Companies Law applicable to us and the Delaware General Corporation Law relating
to shareholders&rsquo; rights and protections. This summary is not intended to be a complete discussion of the respective rights and
it is qualified in its entirety by reference to the laws of Guernsey and Delaware law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 100; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Guernsey
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shareholder
    Meetings</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 39%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
    a company&rsquo;s memorandum or articles of incorporation state otherwise, the directors are required to call a general meeting once
    the company receives requests to do so from shareholders who hold more than 10% of the capital of the company that carries the right
    of voting at general meetings (excluding any capital held as treasury shares).</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 37%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholders
    generally do not have the right to call meetings of shareholders unless that right is granted in the certificate of incorporation
    or bylaws.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    be held at such time or place as designated in the certificate of incorporation or the bylaws, or if not so designated, as determined
    by the board of directors</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
    the shareholders pass a resolution exempting the company from holding an annual general meeting, a company must hold a general meeting
    of its members within a period of 18 months beginning on the date on which it was incorporated and thereafter at least once every
    calendar year (with no more than 15 months elapsing between one annual general meeting and the next).</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    be held inside or outside Delaware</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notice:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
    to the articles of incorporation, a meeting may be held at any place in Guernsey or elsewhere.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;
    Whenever shareholders are required to take any action at a meeting, a written notice of the meeting shall be given which shall state
    the place, if any, date and hour of the meeting, and the means of remote communication, if any.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notice:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;
    A meeting must be called by at least 10 days&rsquo; notice or such longer period as provided by the articles of incorporation. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;
    A meeting may be called by shorter notice if all shareholders entitled to attend and vote so agree.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;
    The notice shall specify the date, time and place of the meeting, the information of any resolutions to be passed at the meeting
    and such other information as is required by the articles of incorporation.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shareholders&rsquo;
    Voting Rights</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
    the memorandum or articles of incorporation provide otherwise, directors are appointed by ordinary resolution of the shareholders.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
    limited exceptions, and unless the certificate of incorporation provides otherwise, shareholders may act by written consent to elect
    directors.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    shareholder may appoint another person or persons to be their proxy to exercise all or any of their rights to attend, speak and vote
    at a meeting.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
    stockholder entitled to vote may authorize another person or persons to act for such shareholder by proxy.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
    to the articles of incorporation, the quorum shall be two shareholders holding 5% of the total voting rights of the company between
    them.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    certificate of incorporation or bylaws may specify the number to constitute a quorum, but in no event shall a quorum consist of less
    than one-third of shares entitled to vote at a meeting. In the absence of such specifications, a majority of shares entitled to vote,
    present in person or represented by proxy, shall constitute a quorum.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
    to certain limited exceptions, a provision of the articles of incorporation is void to the extent that it would have the effect of
    excluding or making ineffective a demand for a poll at general meeting.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    certificate of incorporation may provide for cumulative voting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 101; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Guernsey</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Directors</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 39%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
    to the articles of incorporation, the board of directors must consist of at least one director and is not subject to a maximum number
    of directors.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 37%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    board of directors must consist of at least one director and is not subject to a maximum number of directors.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
    to the articles of incorporation, the board of directors may determine the remuneration or other benefits given to a director.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    number of directors shall be fixed by the bylaws, unless the certificate of incorporation fixes such number, in which case a change
    in the number shall be made only by amendment of the certificate of incorporation.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    person will cease to be a director if such person:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    classified board is permitted.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;
    provides written notice of their resignation to the company; </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    board of directors has the authority to fix the compensation of directors, unless otherwise restricted by the certificate of incorporation
    or bylaws.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;
    is removed in accordance with the memorandum and articles of incorporation; </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Removal</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;
    becomes ineligible to be a director under the laws of Guernsey; </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;
    dies; or </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;
    Any or all of the directors may be removed, with or without cause, by the holders of a majority of the shares entitled to vote unless
    the certificate of incorporation provides otherwise. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;
    otherwise vacates office in accordance with the memorandum and articles of incorporation.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;
    In the case of a classified board, shareholders may affect removal only for cause.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Interested
    Shareholders&rsquo; Transactions</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Guernsey Companies Law does not contain any specific prohibition on interested shareholder transactions.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Delaware General Corporation Law contains a business combination statute applicable to corporations whereby, unless the corporation
    has specifically elected not to be governed by such statute, it is prohibited from engaging in certain business combinations with
    an &ldquo;interested shareholder&rdquo; for three years following the date that such shareholder becomes an interested shareholder.
    An interested shareholder generally is a person or a group that owns at least 15% of the corporation&rsquo;s outstanding voting stock.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Interested
    Director Transactions</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    director must, immediately after becoming aware of the fact that such director is interested in a transaction or proposed transaction
    with the company, disclose to the board the nature and extent of such director&rsquo;s interest.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interested
    director transactions are permissible and may not be legally voided if:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
    to the memorandum and articles of incorporation, a director who is interested in a transaction may vote, attend board meetings, sign
    documents and do any other thing in such director&rsquo;s capacity as a director in relation to a transaction in which such director
    is interested as if such director was not interested in the transaction provided that such director has made the necessary declarations.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;
    the material facts of the director&rsquo;s interest are disclosed and a majority of the disinterested directors approve the transaction;
    </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    transaction in which a director is interested is voidable by the company at any time within 3 months of the date after which the
    transaction is disclosed to the board unless:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;
    the material facts of the director&rsquo;s interest are disclosed and a majority of the shareholders entitled to vote approve the
    transaction; or </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;
    the director&rsquo;s interest was disclosed at the time the transaction was entered into or a disclosure was not required (for example,
    if the transaction is entered into in the ordinary course of business and on usual terms and conditions);</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;
    the transaction is determined to have been fair to the corporation at the time it is authorized, approved or ratified by the board
    of directors, a committee thereof or the shareholders.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;
    the transaction is ratified by the shareholders; or</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;
    the company received fair value for the transaction.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 102; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Guernsey</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dividends</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 39%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    company may pay a dividend if the board of directors is satisfied on reasonable grounds that the company will, immediately after
    payment of the dividend, satisfy the statutory solvency test contained in the Guernsey Companies Law as well as any other requirement
    of the memorandum or articles of incorporation.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 37%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    board of directors may declare and pay dividends, subject to any restrictions contained in the certificate of incorporation, upon
    the shares of the corporation&rsquo;s capital stock either: out of its surplus or, in case there is no surplus, out of its net profits
    for the fiscal year in which the dividend is declared or the preceding fiscal year.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    dividend may be of such amount, be paid at such time and be paid to such members as the board of directors thinks fit; <I>provided
    </I>that the directors must not authorize a dividend in respect of some but not all of the shares in a class or that is of a greater
    value per share in respect of some shares of a class than in respect of other shares of that class.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
    to the articles of incorporation, there is no requirement for dividends to be paid out of a particular account or source.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Variation
    of Rights of Class of Shares</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    company may only vary the rights of a class of shareholders in accordance with the provisions of the articles of incorporation or,
    in the absence of such provisions, with the consent in writing from the holders of at least 75% in value of the issued shares of
    that class or by means of a special resolution passed by at least 75% in value of the issued shares of that class at a separate meeting
    of shareholders of that class.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    corporation may vary the rights of a class of shares with the approval of a majority of the outstanding shares of such class, unless
    the certificate of incorporation provides otherwise.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Mergers
    and Similar Arrangements</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
    to the articles of incorporation, a merger, consolidation, sale, lease or transfer of all or substantially all of the assets of a
    company may be negotiated and approved by the board of directors. Depending on the structure of such a transaction, a separate shareholder
    approval may be required.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
    the Delaware General Corporation Law, with certain exceptions, a merger, consolidation, sale, lease or transfer of all or substantially
    all of the assets of a corporation must be approved by the board of directors and a majority of the outstanding shares entitled to
    vote thereon.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If,
    within a period of four months after the date of an offer being made in respect of a transfer of shares, the offer is approved or
    accepted by the shareholders comprising not less than 90% in value of the shares affected, the offeree may, within two months immediately
    after the last day on which the offer can be approved or accepted, give notice to any dissenting shareholders of its desire to acquire
    the remaining shares. On the expiration of one month from the date of the notice to acquire, the offeror will be entitled to acquire
    the shares of the dissenting shareholder(s) by sending them a copy of the notice to acquire and by paying or transferring to them
    the consideration that such shareholder(s) are entitled to in respect of those shares, at which point the offeror shall be registered
    as the holder of those shares.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Delaware General Corporation Law also provides that a parent corporation may, by resolution of its board of directors, merge with
    any subsidiary of which it owns at least 90% of each class of capital stock without a vote by the shareholders of such subsidiary.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Appraisal
    Rights</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Guernsey Companies Law does not specifically provide for any appraisal rights of shareholders. The Guernsey Companies Law does, however,
    give the courts of Guernsey broad authority in respect of orders made pursuant to successful unfair prejudice claims under the Guernsey
    Companies Law.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    shareholder of a corporation participating in certain major transactions may, under certain circumstances, be entitled to appraisal
    rights under which the shareholder may receive cash in the amount of the fair value of the shares held by such shareholder in lieu
    of the transaction consideration.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 103; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Guernsey</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shareholder
    Suits</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 39%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    shareholder may commence or continue a claim as a representative of those with the same interests in the claim. Unless the court
    directs otherwise, any judgment in which a party is acting as a representative will be binding on all persons represented.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 37%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class
    actions and derivative actions generally are available to shareholders for, among other things, breach of fiduciary duty, corporate
    waste, and actions not taken in accordance with applicable law. In such actions, the court has discretion to permit the winning party
    to recover attorneys&rsquo; fees incurred in connection with such action.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derivative
    actions are also available to shareholders in respect of a cause of action arising from an actual or proposed act or omission involving:
    negligence, default, breach of duty and/or breach of trust by a director of the company.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
    are awarded by the court at its discretion. The normal order is for the winning party to recover its costs incurred in connection
    the action.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Limitations
    on Directors&rsquo; Liability and Indemnification of Directors and Officers</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    company may include in its articles of incorporation provisions limiting the liability of its directors (and officers or other persons);
    however, any provision that purports to exempt a director from any liability in connection with any negligence, default, breach of
    duty or breach of trust in relation to the company is void.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    corporation may include in its certificate of incorporation provisions limiting the personal liability of its directors to the corporation
    or its shareholders for monetary damages for certain breaches of fiduciary duty. However, such provisions may not limit liability
    for any breach of the duty of loyalty, acts or omissions not in good faith or that involve intentional misconduct or a knowing violation
    of law, the authorization of unlawful dividends, stock purchases, or redemptions, or any transaction from which a director derived
    an improper personal benefit.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    provision by which a company directly or indirectly provides an indemnity for a director of the company, or any associated company,
    against any liability in connection with any negligence, default, breach of duty or breach of trust is void, except that:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    corporation may indemnify a director or officer of the corporation against expenses, judgments, fines and amounts paid in settlement
    actually and reasonably incurred in defense of any action, suit or proceeding by reason of such person&rsquo;s position if (i) the
    person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation
    and (ii) with respect to any criminal action or proceeding, the person had no reasonable cause to believe the conduct was unlawful.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;
    a company is not prevented from purchasing and maintaining for a director of the company, or any associated company, insurance against
    any such liability; and </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;
    such restriction does not apply to a qualifying third-party indemnity provision, which is a provision for indemnity against liability
    incurred by a director to a person other than the company or an associated company that does not provide any indemnity against a
    prescribed list of liabilities, including certain fines and penalties and liabilities incurred in defending certain proceedings.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 104; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Guernsey</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Directors&rsquo;
    Fiduciary Duties</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 39%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    duties of directors in Guernsey are generally owed to the company and its shareholders as a whole rather than to any other person
    or particular shareholders (subject to certain exceptions) and arise from customary laws, statutory laws and contractual obligations.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 37%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors
    of a Delaware corporation have a fiduciary duty to the corporation and its shareholders. This duty has two components: the duty of
    care and the duty of loyalty.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customary
    law duties of directors include:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;
    The duty of care requires that a director act in good faith, with the care that an ordinarily prudent person would exercise under
    similar circumstances. Under this duty, a director must inform themselves of, and disclose to shareholders, all material information
    reasonably available regarding a significant transaction. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;
    a duty to act in good faith, in the best interests of the company, and not for any collateral purpose; </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;
    The duty of loyalty requires that a director act in a manner he or she reasonably believes to be in the best interests of the corporation.
    He or she must not use their corporate position for personal gain or advantage. This duty prohibits self-dealing by a director
    and mandates that the best interest of the corporation and its shareholders take precedence over any interest possessed by a director,
    officer or controlling shareholder and not shared by the shareholders generally.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;
    a duty to exercise powers for a proper purpose. Even if a director is acting in good faith and in the best interests of the company,
    such director must nevertheless use their powers for the proper purpose for which they were conferred; </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;
    a duty to avoid and mitigate conflicts of interest; and </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;
    a duty to account for profits. As a fiduciary, a director may not take a personal profit from opportunities arising from such director&rsquo;s
    office, even if the director is acting honestly and in the best interests of the company. Any such profit must be paid to the company.
    A director&rsquo;s entitlement to remuneration and payment of expenses will be governed by the company&rsquo;s articles of incorporation.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    general, actions of a director are presumed to have been made on an informed basis, in good faith and in the honest belief that the
    action taken was in the best interests of the corporation. However, this presumption may be rebutted by evidence of a breach of one
    of the fiduciary duties. Should such evidence be presented concerning a transaction by a director, such director must prove the procedural
    fairness of the transaction, and that the transaction was of fair value to the corporation.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statutory
    duties of directors include:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;
    a general duty to manage the business and affairs of the company; and </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;
    the directors are responsible for considering a solvency test in various circumstances, including in authorizing distributions by
    the company to its shareholders.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 105; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Guernsey</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Inspection
    of Books and Records</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 39%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    register and index of members, register of directors, register of secretaries and copies of all resolutions of shareholders passed
    other than at general meetings and minutes of the proceedings of general meetings, in each case, in the last six years, must be open
    for the inspection by any shareholder of the company without charge during ordinary business hours. They must also be open to inspection
    by any other person upon payment of such fee as may be prescribed by the Guernsey Committee for Economic Development or such lesser
    fee as the company may request.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 37%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    shareholders have the right, upon written demand, to inspect or obtain copies of the corporation&rsquo;s shares ledger and its other
    books and records for any purpose reasonably related to such person&rsquo;s interest as a shareholder.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
    a company receives a request to inspect its records, the company must comply with that request or apply to the Guernsey courts for
    a direction not to comply.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amendments
    of Governing Documents</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
    to certain exceptions, such as the alteration of the statement of the company&rsquo;s name, a company may only make or alter a provision
    of its memorandum of incorporation in accordance with the terms of the memorandum of incorporation or by unanimous resolution of
    all of its shareholders.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendments
    to the certificate of incorporation require the affirmative vote of the holders of a majority of the outstanding shares entitled
    to vote thereon, unless the certificate of incorporation provides otherwise. Bylaws may be amended with the approval of a majority
    of the outstanding shares entitled to vote and may, if provided in the certificate of incorporation, also be amended by the board
    of directors.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    company may alter its articles of incorporation by means of a special resolution passed by at least 75% of the shareholders.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dissolution
    and Winding Up</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    company may be dissolved by means of a compulsory or voluntary winding up or a compulsory or voluntary striking off.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
    the board of directors approves the proposal to dissolve, dissolution must be approved by all of the shareholders. Only if the dissolution
    is initiated by the board of directors may it be approved by a simple majority of the corporation&rsquo;s outstanding shares.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
    application for voluntary winding up requires a special resolution of the members passed by a majority of at least 75%.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
    application for the voluntary striking off of a company must be made by the board of directors and be accompanied by a declaration
    of compliance confirming that all requirements of Guernsey law with respect to the striking off have been complied with.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 106; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Other
Guernsey Law Considerations</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registered
Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are required by the Guernsey Companies Law to keep a register of our shareholders. Under the laws of Guernsey, the ordinary shares are
deemed to be issued when the name of the shareholder is entered in our share register. The share register therefore is prima facie evidence
of the identity of our shareholders, and the shares that they hold. The share register generally provides limited, or no, information
regarding the ultimate beneficial owners of our ordinary shares. Our share register is maintained by our registrar, Computershare
Investor Services (Guernsey) Limited.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potential
future holders of our ADSs will not be treated as one of our shareholders and their names will therefore not be entered in our share
register. The depositary, the custodian or their nominees will be the holder of the shares underlying our ADSs. Potential future holders
of our ADSs have a right to receive the ordinary shares underlying their ADSs. For discussion on our ADSs and ADS holder rights, see
&ldquo;Description of the American Depositary Shares&rdquo; in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will perform all procedures necessary to update the share register to reflect any ordinary shares being sold in any potential offering,
including updating the share register with the number of ordinary shares to be issued to the depositary upon the closing of any such
offering in the future. We also are required by the Guernsey Companies Law to register a transfer of shares (or give the transferee notice
of and reasons for refusal as the transferee may reasonably request) as soon as practicable and in any event within two months of receiving
notice of the transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We,
any of our shareholders, or any other affected person may apply to the court for rectification of the share register if:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    name of any person, without sufficient cause, is entered in or omitted from our register of members; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">default
    is made or unnecessary delay takes place in entering on the register the fact of any person having ceased to be a member or on which
    we have a lien, provided that such delay does not prevent dealings in the shares taking place on an open and proper basis.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
shareholder may transfer all or any of his shares (i) in the case of certificated shares by transfer in writing in any usual or
common form or in any other form acceptable to the Directors; and (ii) in the case of uncertificated shares, in the manner provided for
in the rules and procedures of the operator of the relevant system and in accordance with and subject to the CREST Regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
instrument of transfer of a certified share shall be signed by or on behalf of the transferor and, if the share is not fully paid, by
or on behalf of the transferee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board may, in its absolute discretion and without assigning any reason, decline to register any transfer of certificated share or uncertified
shares unless it is:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    respect of a share which is fully paid up;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    respect of a share in which the Company has no lien;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    respect of only one class of share;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    favor of a single transferee or not more than four joint transferees; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    relation to a certificated share, delivered for registration to the registered office of the Company (or such other place as the
    Board may from time to time determine) accompanied by the relevant share certificate(s) and such other evidence as the Board may
    reasonably require to prove the right of the transferor to make the transfer.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board shall not refuse to register any transfer or renunciation of partly paid shares which are listed on the Main Market of the London
Stock Exchange on the grounds that they are partly paid shares in circumstances where that refusal would prevent dealings in any such
shares from taking place on an open and proper basis</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 107; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Distributions
and Dividends</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Subject to the Guernsey Companies Law, our directors may authorize dividends and distributions to be paid to shareholders. If any share
is issued on terms providing that it shall rank for dividend or distribution as from a particular date, such share shall rank for dividend
or distribution accordingly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Our directors may direct that any dividend or distribution shall be satisfied wholly or partly by the distribution of assets, and in
particular of paid-up shares, debentures, or other securities of any other company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
No dividend or distribution payable shall bear interest against us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
A transfer of shares shall not pass the right to any dividend or distribution declared thereon before the registration of the transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
Unless otherwise directed, any dividend or distribution may be paid by way of electronic transfer in such manner as agreed between the
shareholder and us or by cheque or warrant sent through the post to the registered address of such shareholder entitled thereto, or in
the case of joint holders to that one whose name stands first on our register of members in respect of the joint holding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
All dividends or distribution unclaimed for a period of one year from the date on which such dividend or distribution was declared may
be invested or otherwise made use of by our directors for our benefit until claimed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
All dividends or distribution unclaimed for a period of six years from the date on which such dividend or distribution was declared shall,
if our directors so resolve, be forfeited and shall revert to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
Subject to the Guernsey Companies Law or in the terms of issue of any share in our capital, for the purposes of making any distribution
or paying any dividend, our directors may determine that those persons who are entered on the register of members at the close of business
on a day determined by our directors shall be the persons who are entitled to receive such dividends or distributions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Limitation
on Owning Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Articles do not restrict in any way the ownership or voting of our shares by non-residents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Purchase
of Own Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Articles, a summary of which is provided above, do not prohibit us from purchasing our own shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Articles do not have conditions governing changes to our capital which are more stringent that those required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shareholder
Rights</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
rights granted under the Guernsey Companies Law, including the right to requisition a general meeting or require a resolution to be put
to shareholders at the annual general meeting, are only available to our members. For Guernsey law purposes, our members are the persons
who are registered as the owners of the legal title to the shares and whose names are recorded in our register of members. In the case
of shares held in a settlement system operated by the Depository Trust Company, or DTC, the registered member will be DTC&rsquo;s nominee,
Cede &amp; Co. If a person who holds their ADSs in DTC wishes to exercise certain of the rights granted under the Guernsey Companies
Law, they may be required to first take steps to withdraw their ADSs from the settlement system operated by DTC and become the registered
holder of the shares in our register of members. A withdrawal of shares from DTC may have tax implications, for additional information
on the potential tax implications of withdrawing your shares from the settlement system operated by DTC, see &ldquo;Material Tax Considerations&mdash;Guernsey
Taxation.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exchange
Controls and Other Limitations Affecting Security Holders</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Guernsey law, there are currently no restrictions on the export or import of capital, including foreign exchange controls or restrictions
that affect the remittance of dividends, interest or other payments to nonresidents holders of our ordinary shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 108; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Enforcement
of Civil Liabilities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
laws do not necessarily extend either to us or our officers or directors. We are incorporated under the laws of Guernsey. Some of our
directors and officers reside outside of the United States. Substantially all of the assets of both us and our directors and officers
are located outside the United States. As a result, it may not be possible for investors to effect service of process on either us or
our officers and directors within the United States, or to enforce against these persons or us, either inside or outside the United States,
a judgment obtained in a U.S. court predicated upon the civil liability provisions of the federal securities or other laws of the United
States or any State in the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have appointed OKYO Pharma US, Inc., as our agent to receive service of process with respect to any action brought against us in the
United States under the federal securities laws of the United States or of the laws of any state of the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
judgment of a U.S. court is not directly enforceable in Guernsey, but constitutes a cause of action which may be enforced by Guernsey
courts provided that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    applicable U.S. courts had jurisdiction over the case, as recognized under Guernsey law;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    judgment is given on the merits and is final, conclusive and non-appealable;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    judgment relates to the payment of a sum of money, not being taxes, fines or similar governmental penalties;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    defendant is not immune under the principles of public international law;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    same matters at issue in the case were not previously the subject of a judgment or disposition in a separate court;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    judgment was not obtained by fraud; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    recognition and enforcement of the judgment is not contrary to public policy in Guernsey.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Guernsey
courts award compensation for the loss or damage actually sustained by the plaintiff. Although punitive damages are generally unknown
to the Guernsey legal system, there is no prohibition on them either by statute or customary law. Whether a particular judgment may be
deemed contrary to Guernsey public policy depends on the facts of each case, though judgments found to be exorbitant, unconscionable,
or excessive will generally be deemed as contrary to public policy. Moreover, certain defendants may qualify for protection under Protection
of Trading Interests Act 1980, an act of the UK extended to Guernsey by the Protection of Trading Interests Act 1980 (Guernsey) Order,
1983. This Act provides that a qualifying defendant is not liable for multiple damages, in excess of that required for actual compensation.
A &ldquo;qualifying defendant&rdquo; for these purposes is a citizen of the UK and its Colonies (as defined in the Act), a corporation
or other limited liability entity organized under the laws of the UK, Guernsey or other territory for whose international relations the
UK is responsible or a person conducting business in Guernsey.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Guernsey
courts cannot enter into the merits of the foreign judgment and cannot act as a court of appeal or review over the foreign courts. It
is doubtful that an original action based on U.S. federal or state securities laws could be brought before Guernsey courts. In addition,
a plaintiff who is not resident in Guernsey may be required to provide a security bond in advance to cover the potential of the expected
costs of any case initiated in Guernsey. In addition, Clarivate has been further advised by our legal counsel in Guernsey that it is
uncertain as to whether the courts of Guernsey would entertain original actions or enforce judgments from U.S. courts against us or our
officers and directors which originated from actions alleging civil liability under U.S. federal or state securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 109; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="lp_001"></A>DESCRIPTION
OF THE AMERICAN DEPOSITARY SHARES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JPMorgan
Chase Bank, N.A., or JPMorgan,</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> as depositary, will issue the ADSs.
Each ADS will represent an ownership interest a designated number of ordinary shares which we will deposit with the custodian, as agent
of the depositary, under the deposit agreement among ourselves, the depositary and yourself as an ADR holder. In the future, each ADS
will also represent any securities, cash or other property deposited with the depositary but which they have not distributed directly
to you. Unless certificated ADRs are specifically requested by you, all ADSs will be issued on the books of our depositary in book-entry
form and periodic statements will be mailed to you which reflect your ownership interest in such ADSs. In our description, references
to American depositary receipts, or ADRs, shall include the statements you will receive which reflect your ownership of ADSs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
depositary&rsquo;s office is located at 383 Madison Avenue, Floor 11, New York, NY 10179.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may hold ADSs either directly or indirectly through your broker or other financial institution. If you hold ADSs directly, by having
an ADS registered in your name on the books of the depositary, you are an ADR holder. This description assumes you hold your ADSs directly.
If you hold the ADSs through your broker or financial institution nominee, you must rely on the procedures of such broker or financial
institution to assert the rights of an ADR holder described in this section. You should consult with your broker or financial institution
to find out what those procedures are.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
an ADR holder, we will not treat you as a shareholder of ours and you will not have any shareholder rights. The laws of Guernsey governs
shareholder rights. Because the depositary or its nominee will be the shareholder of record for the ordinary shares represented by all
outstanding ADSs, shareholder rights rest with such record holder. Your rights are those of an ADR holder. Such rights derive from the
terms of the deposit agreement to be entered into among us, the depositary and all registered holders from time to time of ADRs issued
under the deposit agreement. The obligations of our company, the depositary and its agents are also set out in the deposit agreement.
Because the depositary or its nominee will actually be the registered owner of the ordinary shares, you must rely on it to exercise the
rights of a shareholder on your behalf. The deposit agreement and the ADSs are governed by New York law. Under the deposit agreement,
as an ADR holder, you agree that any legal suit, action or proceeding against or involving us or the depositary, arising out of or based
upon the deposit agreement, the ADSs or the transactions contemplated thereby, may only be instituted in a state or federal court in
New York, New York, and you irrevocably waive any objection which you may have to the laying of venue of any such proceeding and irrevocably
submit to the exclusive jurisdiction of such courts in any such suit, action or proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of what we believe to be the material terms of the deposit agreement. Notwithstanding this, because it is a summary,
it may not contain all the information that you may otherwise deem important. For more complete information, you should read the entire
deposit agreement and the form of ADR which contains the terms of your ADSs. You can read a copy of the deposit agreement which is filed
as an exhibit to the registration statement of which this prospectus forms a part. You may also obtain a copy of the deposit agreement
at the SEC&rsquo;s Public Reference Room which is located at 100 F Street, NE, Washington, DC 20549. You may obtain information on the
operation of the Public Reference Room by calling the SEC at 1-800-732-0330. You may also find the registration statement and the attached
deposit agreement on the SEC&rsquo;s website at www.sec.gov.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Share
Dividends and Other Distributions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>How
will I receive dividends and other distributions on the ordinary shares underlying my ADSs?</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may make various types of distributions with respect to our securities. The depositary has agreed that, to the extent practicable, it
will pay to you the cash dividends or other distributions it or the custodian receives on ordinary shares or other deposited securities,
after converting any cash received into U.S. dollars (if it determines such conversion may be made on a reasonable basis) and, in all
cases, making any necessary deductions provided for in the deposit agreement. The depositary may utilize a division, branch or affiliate
of JPMorgan to direct, manage and/or execute any public and/or private sale of securities under the deposit agreement. Such division,
branch and/or affiliate may charge the depositary a fee in connection with such sales, which fee is considered an expense of the depositary.
You will receive these distributions in proportion to the number of underlying securities that your ADSs represent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 110; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as stated below, the depositary will deliver such distributions to ADR holders in proportion to their interests in the following manner:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Cash.
    </I>The depositary will distribute any U.S. dollars available to it resulting from a cash dividend or other cash distribution or
    the net proceeds of sales of any other distribution or portion thereof (to the extent applicable), on an averaged or other practicable
    basis, subject to (i) appropriate adjustments for taxes withheld, (ii) such distribution being impermissible or impracticable with
    respect to certain registered ADR holders, and (iii) deduction of the depositary&rsquo;s and/or its agents&rsquo; expenses in (1)
    converting any foreign currency to U.S. dollars to the extent that it determines that such conversion may be made on a reasonable
    basis, (2) transferring foreign currency or U.S. dollars to the United States by such means as the depositary may determine to the
    extent that it determines that such transfer may be made on a reasonable basis, (3) obtaining any approval or license of any governmental
    authority required for such conversion or transfer, which is obtainable at a reasonable cost and within a reasonable time and (4)
    making any sale by public or private means in any commercially reasonable manner. <I>If exchange rates fluctuate during a time when
    the depositary cannot convert a foreign currency, you may lose some or all of the value of the distribution.</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary
    Shares. In the case of a distribution in ordinary shares, the depositary will issue additional ADRs to evidence the number of ADSs
    representing such ordinary shares. Only whole ADSs will be issued. Any ordinary shares which would result in fractional ADSs will
    be sold and the net proceeds will be distributed in the same manner as cash to the ADR holders entitled thereto.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Rights
    to receive additional ordinary shares.</I> In the case of a distribution of rights to subscribe for additional ordinary shares or
    other rights, if we timely provide evidence satisfactory to the depositary that it may lawfully distribute such rights, the depositary
    will distribute warrants or other instruments in the discretion of the depositary representing rights to acquire additional ADRs.
    However, if we do not timely furnish such evidence, the depositary may:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
sell such rights if practicable and distribute the net proceeds in the same manner as cash to the ADR holders entitled thereto; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
if it is not practicable to sell such rights by reason of the non-transferability of the rights, limited markets therefor, their short
duration or otherwise, do nothing and allow such rights to lapse, in which case ADR holders will receive nothing and the rights may lapse.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Other
    Distributions.</I> In the case of a distribution of securities or property other than those described above, the depositary may either
    (i) distribute such securities or property in any manner it deems equitable and practicable or (ii) to the extent the depositary
    deems distribution of such securities or property not to be equitable and practicable, sell such securities or property and distribute
    any net proceeds in the same way it distributes cash.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Elective
    Distributions. </I>In the case of a dividend payable at the election of our shareholders in cash or in additional ordinary shares,
    we will notify the depositary at least 30 days prior to the proposed distribution stating whether or not we wish such elective distribution
    to be made available to ADR holders. The depositary shall make such elective distribution available to ADR holders only if (i) we
    shall have timely requested that the elective distribution is available to ADR holders, (ii) the depositary shall have determined
    that such distribution is reasonably practicable and (iii) the depositary shall have received satisfactory documentation within the
    terms of the deposit agreement including any legal opinions of counsel that the depositary in its reasonable discretion may request.
    If the above conditions are not satisfied, the depositary shall, to the extent permitted by law, distribute to the ADR holders, on
    the basis of the same determination as is made in the local market in respect of the ordinary shares for which no election is made,
    either (x) cash or (y) additional ADSs representing such additional ordinary shares. If the above conditions are satisfied, the depositary
    shall establish procedures to enable ADR holders to elect the receipt of the proposed dividend in cash or in additional ADSs. There
    can be no assurance that ADR holders generally, or any ADR holder in particular, will be given the opportunity to receive elective
    distributions on the same terms and conditions as the holders of ordinary shares.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 111; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the depositary determines in its discretion that any distribution described above is not practicable with respect to any specific registered
ADR holder, the depositary may choose any method of distribution that it deems practicable for such ADR holder, including the distribution
of foreign currency, securities or property, or it may retain such items, without paying interest on or investing them, on behalf of
the ADR holder as deposited securities, in which case the ADSs will also represent the retained items.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
U.S. dollars will be distributed by checks drawn on a bank in the United States for whole dollars and cents. Fractional cents will be
withheld without liability and dealt with by the depositary in accordance with its then current practices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
depositary is not responsible if it fails to determine that any distribution or action is lawful or reasonably practicable.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>There
can be no assurance that the depositary will be able to convert any currency at a specified exchange rate or sell any property, rights,
shares or other securities at a specified price, nor that any of such transactions can be completed within a specified time period. All
purchases and sales of securities will be handled by the Depositary in accordance with its then current policies, which are currently
set forth in the &ldquo;Depositary Receipt Sale and Purchase of Security&rdquo; section of www.adr.com/Investors/FindOutAboutDRs, the
location and contents of which the Depositary shall be solely responsible for.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Deposit,
withdrawal and Cancellation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>How
does the depositary issue ADSs?</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
depositary will issue ADSs if you or your broker deposit ordinary shares or evidence of rights to receive ordinary shares with the custodian
and pay the fees and expenses owing to the depositary in connection with such issuance. In the case of the ADSs to be issued under this
prospectus, we will arrange with the Selling Shareholders named herein to deposit such ordinary shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary
shares deposited in the future with the custodian must be accompanied by certain delivery documentation and shall, at the time of such
deposit, be registered in the name of the depositary, the custodian or a nominee of either.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
custodian will hold all deposited ordinary shares (including those being deposited by or on our behalf in connection with this offering
to which this prospectus relates) for the account and to the order of the depositary for the benefit of registered holders of ADRs, to
the extent not prohibited by law. ADR holders thus have no direct ownership interest in the ordinary shares and only have such rights
as are contained in the deposit agreement. The custodian will also hold any additional securities, property and cash received on or in
substitution for the deposited ordinary shares. The deposited ordinary shares and any such additional items are referred to as &ldquo;deposited
securities.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
each deposit of ordinary shares, receipt of related delivery documentation and compliance with the other provisions of the deposit agreement,
including the payment of the fees and charges of the depositary and any taxes or other fees or charges owing, the depositary will issue
an ADR or ADRs in the name or upon the order of the person entitled thereto evidencing the number of ADSs to which such person is entitled.
All of the ADSs issued will, unless specifically requested to the contrary, be part of the depositary&rsquo;s direct registration system,
and a registered holder will receive periodic statements from the depositary which will show the number of ADSs registered in such holder&rsquo;s
name. An ADR holder can request that the ADSs not be held through the depositary&rsquo;s direct registration system and that a certificated
ADR be issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>How
do ADR holders cancel an ADS and obtain deposited securities?</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
you turn in your ADR certificate at the depositary&rsquo;s office, or when you provide proper instructions and documentation in the case
of direct registration ADSs, the depositary will, upon payment of certain applicable fees, charges and taxes, deliver the underlying
ordinary shares to you or upon your written order. Delivery of deposited securities in certificated form will be made at the custodian&rsquo;s
office. At your risk, expense and request, the depositary may deliver deposited securities at such other place as you may request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 112; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
depositary may only restrict the withdrawal of deposited securities in connection with:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">temporary
    delays caused by closing our transfer books or those of the depositary or the deposit of ordinary shares in connection with voting
    at a shareholders meeting, or the payment of dividends;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    payment of fees, taxes and similar charges; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance
    with any U.S. or foreign laws or governmental regulations relating to the ADRs or to the withdrawal of deposited securities.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
right of withdrawal may not be limited by any other provision of the deposit agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Record
Dates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
depositary may, after consultation with us if practicable, fix record dates (which, to the extent applicable, shall be as near as practicable
to any corresponding record dates set by us) for the determination of the registered ADR holders who will be entitled (or obligated,
as the case may be):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    receive any distribution on or in respect of deposited securities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    give instructions for the exercise of voting rights;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    pay the fee assessed by the depositary for administration of the ADR program and for any expenses as provided for in the ADR;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    receive any notice or to act in respect of other matters; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    subject to the provisions of the deposit agreement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Voting
Rights</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>How
do I vote?</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you are an ADR holder and the depositary asks you to provide it with voting instructions, you may instruct the depositary how to exercise
the voting rights for the ordinary shares which underlie your ADSs. Subject to the next sentence, as soon as practicable after receipt
from us of notice of any meeting at which the holders of ordinary shares are entitled to vote, or of our solicitation of consents or
proxies from holders of ordinary shares, the depositary shall fix the ADS record date in accordance with the provisions of the deposit
agreement in respect of such meeting or solicitation of consent or proxy. The depositary shall, if we request in writing in a timely
manner (the depositary having no obligation to take any further action if our request shall not have been received by the depositary
at least 30 days prior to the date of such vote or meeting) and at our expense and provided no legal prohibitions exist, distribute to
the registered ADR holders a notice stating such information as is contained in the voting materials received by the depositary, stating
that that each registered holder of ADRs on the ADS record date will, subject to any applicable provisions of the laws of Guernsey, be
entitled to instruct the depositary as to the exercise of any voting rights pertaining to ordinary shares underlying such holder&rsquo;s
ADSs, and describing how you may instruct the depositary to exercise the voting rights for the ordinary shares which underlie your ADSs,
including instructions for giving a discretionary proxy to a person designated by us. For instructions to be valid, the depositary must
receive them in the manner and on or before the date specified. The depositary will try, as far as is practical, subject to the provisions
of or governing the underlying ordinary shares or other deposited securities, to vote or cause to be voted the ordinary shares or other
deposited securities as you instruct. The depositary will only vote or attempt to vote as you instruct. Holders are strongly encouraged
to forward their voting instructions to the depositary as soon as possible. Voting instructions will not be deemed to be received until
such time as the ADR department responsible for proxies and voting has received such instructions notwithstanding that such instructions
may have been physically received by the depositary prior to such time. The depositary will not itself exercise any voting discretion.
Furthermore, neither the depositary nor its agents are responsible for any failure to carry out any voting instructions, for the manner
in which any vote is cast or for the effect of any vote. Notwithstanding anything contained in the deposit agreement or any ADR, the
depositary may, to the extent not prohibited by law or regulations, or by the requirements of the stock exchange on which the ADSs are
listed, in lieu of distribution of the materials provided to the depositary in connection with any meeting of, or solicitation of consents
or proxies from, holders of deposited securities, distribute to the registered holders of ADRs a notice that provides such holders with,
or otherwise publicizes to such holders, instructions on how to retrieve such materials or receive such materials upon request (<I>i.e.</I>,
by reference to a website containing the materials for retrieval or a contact for requesting copies of the materials).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 113; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no guarantee that you will receive voting materials in time to instruct the depositary to vote and it is possible that you, or persons
who hold their ADSs through brokers, dealers or other third parties, will not have the opportunity to exercise a right to vote.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 16.7pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Reports
and Other Communications</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 16.7pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Will
ADR holders be able to view our reports?</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
depositary will make available for inspection by ADR holders at the offices of the depositary and the custodian the deposit agreement,
the provisions of or governing deposited securities, and any written communications from us which are both received by the custodian
or its nominee as a holder of deposited securities and made generally available to the holders of deposited securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
if we make any written communications generally available to holders of our ordinary shares, and we furnish copies thereof (or English
translations or summaries) to the depositary, it will distribute the same to registered ADR holders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 16.7pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fees
and Expenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 16.7pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>What
fees and expenses will I be responsible for paying?</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
depositary may charge each person to whom ADSs are issued, including, without limitation, issuances against deposits of ordinary shares,
issuances in respect of share distributions, rights and other distributions, issuances pursuant to a stock dividend or stock split declared
by us or issuances pursuant to a merger, exchange of securities or any other transaction or event affecting the ADSs or deposited securities,
and each person surrendering ADSs for withdrawal of deposited securities or whose ADSs are cancelled or reduced for any other reason,
$5.00 for each 100 ADSs (or any portion thereof) issued, delivered, reduced, cancelled or surrendered, as the case may be. The depositary
may sell (by public or private sale) sufficient securities and property received in respect of a share distribution, rights and/or other
distribution prior to such deposit to pay such charge.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following additional charges shall be incurred by the ADR holders, by any party depositing or withdrawing ordinary shares or by any party
surrendering ADSs and/or to whom ADSs are issued (including, without limitation, issuance pursuant to a stock dividend or stock split
declared by us or an exchange of stock regarding the ADSs or the deposited securities or a distribution of ADSs), whichever is applicable:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    fee of U.S.$1.50 per ADR or ADRs for transfers of certificated or direct registration ADRs;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    fee of up to U.S.$0.05 per ADS for any cash distribution made pursuant to the deposit agreement;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    aggregate fee of up to U.S.$0.05 per ADS per calendar year (or portion thereof) for services performed by the depositary in administering
    the ADRs (which fee may be charged on a periodic basis during each calendar year and shall be assessed against holders of ADRs as
    of the record date or record dates set by the depositary during each calendar year and shall be payable in the manner described in
    the next succeeding provision);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    fee for the reimbursement of such fees, charges and expenses as are incurred by the depositary and/or any of its agents (including,
    without limitation, the custodian and expenses incurred on behalf of holders in connection with compliance with foreign exchange
    control regulations or any law or regulation relating to foreign investment) in connection with the servicing of the ordinary shares
    or other deposited securities, the sale of securities (including, without limitation, deposited securities), the delivery of deposited
    securities or otherwise in connection with the depositary&rsquo;s or its custodian&rsquo;s compliance with applicable law, rule or
    regulation (which fees and charges shall be assessed on a proportionate basis against holders as of the record date or dates set
    by the depositary and shall be payable at the sole discretion of the depositary by billing such holders or by deducting such charge
    from one or more cash dividends or other cash distributions);</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 114; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    fee for the distribution of securities (or the sale of securities in connection with a distribution), such fee being in an amount
    equal to the $0.05 per ADS issuance fee for the execution and delivery of ADSs which would have been charged as a result of the deposit
    of such securities (treating all such securities as if they were ordinary shares) but which securities or the net cash proceeds from
    the sale thereof are instead distributed by the depositary to those holders entitled thereto;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">stock
    transfer or other taxes and other governmental charges;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SWIFT,
    cable, telex and facsimile transmission and delivery charges incurred at your request in connection with the deposit or delivery
    of ordinary shares, ADRs or deposited securities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">transfer
    or registration fees for the registration or transfer of deposited securities on any applicable register in connection with the deposit
    or withdrawal of deposited securities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    connection with the conversion of foreign currency into U.S. dollars, JPMorgan shall deduct out of such foreign currency the
    fees, expenses and other charges charged by it and/or its agent (which may be a division, branch or affiliate) so appointed in connection
    with such conversion; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fees
    of any division, branch or affiliate of the depositary utilized by the depositary to direct, manage and/or execute any public and/or
    private sale of securities under the deposit agreement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -36.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
facilitate the administration of various depositary receipt transactions, including disbursement of dividends or other cash distributions
and other corporate actions, the depositary may engage the foreign exchange desk within JPMorgan Chase Bank, N.A., or the Bank, and/or
its affiliates in order to enter into spot foreign exchange transactions to convert foreign currency into U.S. dollars. For certain currencies,
foreign exchange transactions are entered into with the Bank or an affiliate, as the case may be, acting in a principal capacity. For
other currencies, foreign exchange transactions are routed directly to and managed by an unaffiliated local custodian (or other third
party local liquidity provider), and neither the Bank nor any of its affiliates is a party to such foreign exchange transactions.</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif">
For further details see <U>www.adr.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will pay all other charges and expenses of the depositary and any agent of the depositary (except the custodian) pursuant to agreements
from time to time between us and the depositary. The charges described above may be amended from time to time by agreement between us
and the depositary. The right of the depositary to receive payment of fees, charges and expenses as provided above shall survive the
termination of the deposit agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
depositary may make available to us a set amount or a portion of the depositary fees charged in respect of the ADR program or otherwise
upon such terms and conditions as we and the depositary may agree from time to time. The depositary collects its fees for issuance and
cancellation of ADSs directly from investors depositing ordinary shares or surrendering ADSs for the purpose of withdrawal or from intermediaries
acting for them. The depositary collects fees for making distributions to investors by deducting those fees from the amounts distributed
or by selling a portion of distributable property to pay the fees. The depositary may collect its annual fee for depositary services
by deduction from cash distributions, or by directly billing investors, or by charging the book-entry system accounts of participants
acting for them. The depositary will generally set off the amounts owing from distributions made to holders of ADSs. If, however, no
distribution exists and payment owing is not timely received by the depositary, the depositary may refuse to provide any further services
to holders that have not paid those fees and expenses owing until such fees and expenses have been paid. At the discretion of the depositary,
all fees and charges owing under the deposit agreement are due in advance and/or when declared owing by the depositary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Payment
of Taxes</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any taxes or other governmental charges (including any penalties and/or interest) shall become payable by or on behalf of the custodian
or the depositary with respect to any ADR, any deposited securities represented by the ADSs evidenced thereby or any distribution thereon,
such tax or other governmental charge shall be paid by the holder thereof to the depositary and by holding or having held an ADR the
holder and all prior holders thereof, jointly and severally, agree to indemnify, defend and save harmless each of the depositary and
its agents in respect thereof. If an ADR holder owes any tax or other governmental charge, the depositary may (i) deduct the amount thereof
from any cash distributions, or (ii) sell deposited securities by public or private sale (after attempting by reasonable means to notify
the ADR holder hereof prior to such sale) and deduct the amount owing from the net proceeds of such sale. In either case the ADR holder
remains liable for any shortfall. If any tax or governmental charge is unpaid, the depositary may also refuse to affect any registration,
registration of transfer, split-up or combination of deposited securities or withdrawal of deposited securities until such payment is
made. If any tax or governmental charge is required to be withheld on any cash distribution, the depositary may deduct the amount required
to be withheld from any cash distribution or, in the case of a non-cash distribution, sell the distributed property or securities (by
public or private sale) in such amounts and in such manner as the depositary deems necessary and practicable to pay such taxes and distribute
any remaining net proceeds or the balance of any such property after deduction of such taxes to the ADR holders entitled thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 115; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
holding an ADR or an interest therein, you will be agreeing to indemnify us, the depositary, its custodian and any of our or their respective
officers, directors, employees, agents and affiliates against, and hold each of them harmless from, any claims by any governmental authority
with respect to taxes, additions to tax, penalties or interest arising out of any refund of taxes, reduced rate of withholding at source
or other tax benefit obtained.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Reclassifications,
Recapitalizations and Mergers</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we take certain actions that affect the deposited securities, including (i) any change in nominal value, split-up, consolidation, cancellation
or other reclassification of deposited securities or (ii) any distributions of ordinary shares or other property not made to holders
of ADRs or (iii) any recapitalization, reorganization, merger, consolidation, liquidation, receivership, bankruptcy or sale of all or
substantially all of our assets, then the depositary may choose to, and shall if reasonably requested by us:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">amend
    the form of ADR;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">distribute
    additional or amended ADRs;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">distribute
    cash, securities or other property it has received in connection with such actions;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sell
    any securities or property received and distribute the proceeds as cash; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">none
    of the above.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the depositary does not choose any of the above options, any of the cash, securities or other property it receives will constitute part
of the deposited securities and each ADS will then represent a proportionate interest in such property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amendment
and Termination</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>How
may the deposit agreement be amended?</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We may agree with the depositary
to amend the deposit agreement and the ADSs without your consent for any reason. ADR holders must be given at least 30 days&rsquo; notice
of any amendment that imposes or increases any fees or charges (other than stock transfer or other taxes and other governmental charges,
transfer or registration fees, SWIFT, cable, telex or facsimile transmission costs, delivery costs or other such expenses), or otherwise
prejudices any substantial existing right of ADR holders. Such notice need not describe in detail the specific amendments effectuated
thereby, however, it must identify to ADR holders a means to access the text of such amendment. If an ADR holder continues to
hold an ADR or ADRs after being so notified, such ADR holder is deemed to agree to such amendment and to be bound by the deposit agreement
as so amended. Any amendments or supplements which (i) are reasonably necessary (as agreed by us and the depositary) in order for (a)
the ADSs to be registered on Form F-6 under the Securities Act or (b) the ADSs or ordinary shares to be traded solely in electronic book-entry
form and (ii) do not in either such case impose or increase any fees or charges to be borne by ADR holders, shall be deemed not to prejudice
any substantial rights of ADR holders. Notwithstanding the foregoing, if any governmental body or regulatory body should adopt new laws,
rules or regulations which would require amendment or supplement of the deposit agreement or the form of ADR to ensure compliance therewith,
we and the depositary may amend or supplement the deposit agreement and the ADR at any time in accordance with such changed laws, rules
or regulations, which amendment or supplement may take effect before a notice is given or within any other period of time as required
for compliance. No amendment, however, will impair your right to surrender your ADSs and receive the underlying securities, except in
order to comply with mandatory provisions of applicable law.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 116; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>How
may the deposit agreement be terminated?</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
depositary may, and shall at our written direction, terminate the deposit agreement and the ADRs by mailing notice of such termination
to the registered holders of ADRs at least 30 days prior to the date fixed in such notice for such termination; provided, however, if
the depositary shall have (i) resigned as depositary under the deposit agreement, notice of such termination by the depositary shall
not be provided to registered holders unless a successor depositary shall not be operating under the deposit agreement within 60 days
of the date of such resignation, and (ii) been removed as depositary under the deposit agreement, notice of such termination by the depositary
shall not be provided to registered holders of ADRs unless a successor depositary shall not be operating under the deposit agreement
on the 120<SUP>th</SUP> day after our notice of removal was first provided to the depositary. After termination, the depositary&rsquo;s
only responsibility will be (i) to deliver deposited securities to ADR holders who surrender their ADRs, and (ii) to hold or sell distributions
received on deposited securities. As soon as practicable after the expiration of six months from the termination date, the depositary
will sell the deposited securities which remain and hold the net proceeds of such sales (as long as it may lawfully do so), without liability
for interest, in trust for the ADR holders who have not yet surrendered their ADRs. After making such sale, the depositary shall have
no obligations except to account for such proceeds and other cash.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Limitations
on Obligations and Liability to ADR holders</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Limits
on our obligations and the obligations of the depositary; limits on liability to ADR holders and holders of ADSs</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the issue, registration, registration of transfer, split-up, combination, or cancellation of any ADRs, or the delivery of any distribution
in respect thereof, and from time to time in the case of the production of proofs as described below, we or the depositary or its custodian
may require:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">payment
    with respect thereto of (i) any stock transfer or other tax or other governmental charge, (ii) any stock transfer or registration
    fees in effect for the registration of transfers of ordinary shares or other deposited securities upon any applicable register and
    (iii) any applicable fees and expenses described in the deposit agreement;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    production of proof satisfactory to it of (i) the identity of any signatory and genuineness of any signature and (ii) such other
    information, including without limitation, information as to citizenship, residence, exchange control approval, beneficial ownership
    of any securities, compliance with applicable law, regulations, provisions of or governing deposited securities and terms of the
    deposit agreement and the ADRs, as it may deem necessary or proper; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance
    with such regulations as the depositary may establish consistent with the deposit agreement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
issuance of ADRs, the acceptance of deposits of ordinary shares, the registration, registration of transfer, split-up or combination
of ADRs or the withdrawal of ordinary shares, may be suspended, generally or in particular instances, when the ADR register or any register
for deposited securities is closed or when any such action is deemed advisable by the depositary; provided that the ability to withdraw
ordinary shares may only be limited under the following circumstances: (i) temporary delays caused by closing transfer books of the depositary
or our transfer books or the deposit of ordinary shares in connection with voting at a shareholders meeting, or the payment of dividends,
(ii) the payment of fees, taxes, and similar charges, and (iii) compliance with any laws or governmental regulations relating to ADRs
or to the withdrawal of deposited securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
deposit agreement expressly limits the obligations and liability of the depositary, ourselves and each of our and the depositary&rsquo;s
respective agents, provided, however, that no disclaimer of liability under the Securities Act or the Exchange Act, to the extent applicable,
is intended by any provision of the deposit agreement. In the deposit agreement it provides that neither we nor the depositary nor any
such agent will be liable to registered holders or beneficial owners of ADSs if:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 117; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    present or future law, rule, regulation, fiat, order or decree of the United States, Guernsey, England and Wales or any other country
    or jurisdiction, or of any governmental or regulatory authority or securities exchange or market or automated quotation system, the
    provisions of or governing any deposited securities, any present or future provision of our charter, any act of God, war, terrorism,
    nationalization, expropriation, currency restrictions, work stoppage, strike, civil unrest, revolutions, rebellions, explosions,
    computer failure or circumstance beyond our, the depositary&rsquo;s or our respective agents&rsquo; direct and immediate control
    shall prevent or delay, or shall cause any of them to be subject to any civil or criminal penalty in connection with, any act which
    the deposit agreement or the ADRs provide shall be done or performed by us, the depositary or our respective agents (including, without
    limitation, voting);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it
    exercises or fails to exercise discretion under the deposit agreement or the ADRs including, without limitation, any failure to determine
    that any distribution or action may be lawful or reasonably practicable;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it
    performs its obligations under the deposit agreement and ADRs without gross negligence or willful misconduct; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it
    takes any action or refrains from taking any action in reliance upon the advice of or information from legal counsel, accountants,
    any person presenting ordinary shares for deposit, any registered holder of ADRs, or any other person believed by it to be competent
    to give such advice or information.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -36.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We,
the depositary and its agents may rely and shall be protected in acting upon any written notice, request, direction, instruction or document
believed by them to be genuine and to have been signed, presented or given by the proper party or parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
the depositary nor its agents have any obligation to appear in, prosecute or defend any action, suit or other proceeding in respect of
any deposited securities or the ADRs. We and our agents shall only be obligated to appear in, prosecute or defend any action, suit or
other proceeding in respect of any deposited securities or the ADRs, which in our opinion may involve us in expense or liability, if
indemnity satisfactory to us against all expense (including fees and disbursements of counsel) and liability is furnished as often as
may be required. The depositary and its agents may fully respond to any and all demands or requests for information maintained by or
on its behalf in connection with the deposit agreement, any registered holder or holders of ADRs, any ADRs or otherwise related to the
deposit agreement or ADRs to the extent such information is requested or required by or pursuant to any lawful authority, including without
limitation laws, rules, regulations, administrative or judicial process, banking, securities or other regulators. The depositary shall
not be liable for the acts or omissions made by, or the insolvency of, any securities depository, clearing agency or settlement system.
Furthermore, the depositary shall not be responsible for, and shall incur no liability in connection with or arising from, the insolvency
of any custodian that is not a branch or affiliate of JPMorgan Chase Bank, N.A. Notwithstanding anything to the contrary contained in
the deposit agreement or any ADRs, the depositary shall not be responsible for, and shall incur no liability in connection with or arising
from, any act or omission to act on the part of the custodian except to the extent that any registered holder of ADRs has incurred liability
directly as a result of the custodian having (i) committed fraud or willful misconduct in the provision of custodial services to the
depositary or (ii) failed to use reasonable care in the provision of custodial services to the depositary as determined in accordance
with the standards prevailing in the jurisdiction in which the custodian is located. The depositary shall not have any liability for
the price received in connection with any sale of securities, the timing thereof or any delay in action or omission to act nor shall
it be responsible for any error or delay in action, omission to act, default or negligence on the part of the party so retained in connection
with any such sale or proposed sale.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
depositary has no obligation to inform ADR holders or other holders of an interest in any ADSs about the requirements of the laws of
Guernsey, rules or regulations or any changes therein or thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 118; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
the depositary nor its agents will be responsible for any failure to carry out any instructions to vote any of the deposited securities,
for the manner in which any such vote is cast or for the effect of any such vote. The depositary may rely upon instructions from us or
our counsel in respect of any approval or license required for any currency conversion, transfer or distribution. The depositary shall
not incur any liability for the content of any information submitted to it by us or on our behalf for distribution to ADR holders or
for any inaccuracy of any translation thereof, for any investment risk associated with acquiring an interest in the deposited securities,
for the validity or worth of the deposited securities, for the credit-worthiness of any third party, for allowing any rights to lapse
upon the terms of the deposit agreement or for the failure or timeliness of any notice from us. The depositary shall not be liable for
any acts or omissions made by a successor depositary whether in connection with a previous act or omission of the depositary or in connection
with any matter arising wholly after the removal or resignation of the depositary. Neither the depositary nor any of its agents shall
be liable to registered holders or beneficial owners of interests in ADSs for any indirect, special, punitive or consequential damages
(including, without limitation, legal fees and expenses) or lost profits, in each case of any form incurred by any person or entity,
whether or not foreseeable and regardless of the type of action in which such a claim may be brought.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the deposit agreement each party thereto (including, for avoidance of doubt, each holder and beneficial owner and/or holder of interests
in ADRs) irrevocably waives, to the fullest extent permitted by applicable law, any right it may have to a trial by jury in any suit,
action or proceeding against the depositary and/or us directly or indirectly arising out of or relating to the ordinary shares or other
deposited securities, the ADSs or the ADRs, the deposit agreement or any transaction contemplated therein, or the breach thereof (whether
based on contract, tort, common law or any other theory).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
depositary and its agents may own and deal in any class of securities of our company and our affiliates and in ADSs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Disclosure
of Interest in ADSs</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that the provisions of or governing any deposited securities may require disclosure of or impose limits on beneficial or other
ownership of deposited securities, other ordinary shares and other securities and may provide for blocking transfer, voting or other
rights to enforce such disclosure or limits, you agree to comply with all such disclosure requirements and ownership limitations and
to comply with any reasonable instructions we may provide in respect thereof. We reserve the right to instruct you to deliver your ADSs
for cancellation and withdrawal of the deposited securities so as to permit us to deal with you directly as a holder of ordinary shares
and, by holding an ADS or an interest therein, you will be agreeing to comply with such instructions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Books
of Depositary</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
depositary or its agent will maintain a register for the registration, registration of transfer, combination and split-up of ADRs, which
register shall include the depositary&rsquo;s direct registration system. Registered holders of ADRs may inspect such records at the
depositary&rsquo;s office at all reasonable times, but solely for the purpose of communicating with other holders in the interest of
the business of our company or a matter relating to the deposit agreement. Such register may be closed at any time or from time to time,
when deemed expedient by the depositary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
depositary will maintain facilities for the delivery and receipt of ADRs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 119; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pre-release
of ADSs</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
its capacity as depositary, the depositary shall not lend ordinary shares or ADSs; provided, however, that the depositary may (i) issue
ADSs prior to the receipt of ordinary shares and (ii) deliver ordinary shares prior to the receipt of ADSs for withdrawal of deposited
securities, including ADSs which were issued under (i) above but for which ordinary shares may not have been received, each such transaction
a &ldquo;pre-release.&rdquo; The depositary may receive ADSs in lieu of ordinary shares under (i) above (which ADSs will promptly be
canceled by the depositary upon receipt by the depositary) and receive ordinary shares in lieu of ADSs under (ii) above. Each such pre-release
will be subject to a written agreement whereby the person/entity, or applicant to whom ADSs or ordinary shares are to be delivered (a)
represents that at the time of the pre-release the applicant or its customer owns the ordinary shares or ADSs that are to be delivered
by the applicant under such pre-release, (b) agrees to indicate the depositary as owner of such ordinary shares or ADSs in its records
and to hold such ordinary shares or ADSs in trust for the depositary until such ordinary shares or ADSs are delivered to the depositary
or the custodian, (c) unconditionally guarantees to deliver to the depositary or the custodian, as applicable, such ordinary shares or
ADSs, and (d) agrees to any additional restrictions or requirements that the depositary deems appropriate. Each such pre-release will
be at all times fully collateralized with cash, U.S. government securities or such other collateral as the depositary deems appropriate,
terminable by the depositary on not more than five (5) business days&rsquo; notice and subject to such further indemnities and credit
regulations as the depositary deems appropriate. The depositary will normally limit the number of ADSs and ordinary shares involved in
such pre-release at any one time to 30% of the ADSs outstanding (without giving effect to ADSs outstanding under (i) above), provided,
however, that the depositary reserves the right to change or disregard such limit from time to time as it deems appropriate. The depositary
may also set limits with respect to the number of ADSs and ordinary shares involved in pre-release with any one person on a case-by-case
basis as it deems appropriate. The depositary may retain for its own account any compensation received by it in conjunction with the
foregoing. Collateral provided in connection with pre-release transactions, but not the earnings thereon, shall be held for the benefit
of the ADR holders (other than the applicant).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Appointment</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the deposit agreement, each registered holder of ADRs and each person holding an interest in ADSs, upon acceptance of any ADSs (or any
interest therein) issued in accordance with the terms and conditions of the deposit agreement will be deemed for all purposes to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
    a party to and bound by the terms of the deposit agreement and the applicable ADR or ADRs; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">appoint
    the depositary its attorney-in-fact, with full power to delegate, to act on its behalf and to take any and all actions contemplated
    in the deposit agreement and the applicable ADR or ADRs, to adopt any and all procedures necessary to comply with applicable laws
    and to take such action as the depositary in its sole discretion may deem necessary or appropriate to carry out the purposes of the
    deposit agreement and the applicable ADR and ADRs, the taking of such actions to be the conclusive determinant of the necessity and
    appropriateness thereof.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -36.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Governing
Law</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
deposit agreement and the ADRs shall be governed by and construed in accordance with the laws of the State of New York. In the deposit
agreement, we have submitted to the jurisdiction of the courts of the State of New York and appointed OKYO Pharma US, Inc. as
an agent for service of process on our behalf. Notwithstanding the foregoing, any action based on the deposit agreement or the transactions
contemplated thereby may be instituted by the depositary in any competent court in Guernsey.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
holding an ADS or an interest therein, registered holders of ADRs and owners of ADSs each irrevocably agree that any legal suit, action
or proceeding against or involving us or the depositary, arising out of or based upon the deposit agreement, the ADSs or the transactions
contemplated thereby, may only be instituted in a state or federal court in New York, New York, and each irrevocably waives any objection
which it may have to the laying of venue of any such proceeding, and irrevocably submits to the exclusive jurisdiction of such courts
in any such suit, action or proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 120; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ORDINARY
SHARES AND ads</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">s <FONT STYLE="text-transform: uppercase"><A NAME="an_003"></A>ELIGIBLE
FOR FUTURE SALE</FONT></FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to this offering, no public market existed for our ADSs. Future sales of substantial amounts of ADSs in the public market, the availability
of ADSs for future sale or the perception that such sales may occur, however, could adversely affect the market price of our ADSs and/or
ordinary shares and also could adversely affect our future ability to raise capital through the sale of our ADSs and/or ordinary shares
or other equity-related securities at times and prices we believe appropriate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Based on the number of our ordinary
shares outstanding as of May 12, 2022, upon the closing of the offering, we will have 625,000 ADSs outstanding, representing
40,625,000 ordinary shares, and 1,415,040.468 ordinary shares outstanding (including ordinary shares in the form of ADSs).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of the ADSs sold in this offering will be freely tradable without restrictions or further registration under the Securities Act, except
for any shares sold to our &ldquo;affiliates,&rdquo; as that term is defined under Rule 144 under the Securities Act. The outstanding
ordinary shares held by existing shareholders are &ldquo;restricted securities,&rdquo; as that term is defined in Rule 144 under the
Securities Act. Restricted securities may be sold in the public market only if the offer and sale is registered under the Securities
Act or if the offer and sale of those securities qualifies for exemption from registration, including exemptions provided by Rules 144
or 701 promulgated under the Securities Act. Restricted securities may also be sold outside of the United States to non-U.S. persons
in accordance with Rule 904 of Regulation S under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the lock-up agreements described below and the provisions of Rule 144 or Regulation S under the Securities Act, as well as our insider
trading policy, these restricted securities will be available for sale in the public market at various times beginning at least 135 days
after the date of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rule
144</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, under Rule 144 as currently in effect, once we have been subject to public company reporting requirements for at least 90 days,
a person who is not deemed to have been one of our affiliates for purposes of the Securities Act at any time during the 90 days preceding
a sale and who has beneficially owned the shares proposed to be sold for at least six months, including the holding period of any prior
owner other than our affiliates, is entitled to sell such shares without complying with the manner of sale, volume limitation, or notice
provisions of Rule 144, subject to compliance with the public information requirements of Rule 144. If such a person has beneficially
owned the shares proposed to be sold for at least one year, including the holding period of any prior owner other than our affiliates,
then such person is entitled to sell such shares without complying with any of the requirements of Rule 144.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, under Rule 144, as currently in effect, our affiliates or persons selling shares on behalf of our affiliates are entitled to
sell upon expiration of the lock-up agreements described below, within any three-month period beginning 90 days after the date of this
prospectus, a number of shares that does not exceed the greater of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1%
    of the number of ADSs then outstanding, which will equal approximately shares immediately after this offering&#894; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    average weekly trading volume of our ADSs during the four calendar weeks preceding the filing of a notice on Form 144 with respect
    to such sale.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
under Rule 144 by our affiliates or persons selling shares on behalf of our affiliates are also subject to certain manner of sale provisions
and notice requirements and to the availability of current public information about us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rule
701</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rule
701 generally allows a shareholder who was issued shares pursuant to a written compensatory plan or contract and who is not deemed to
have been an affiliate of our company during the immediately preceding 90 days to sell these shares in reliance upon Rule 144, but without
being required to comply with the public information, holding period, volume limitation or notice provisions of Rule 144. Rule 701 also
permits affiliates of our company to sell their Rule 701 shares under Rule 144 without complying with the holding period requirements
of Rule 144. All holders of Rule 701 shares, however, are required by that rule to wait until 90 days after the date of this prospectus
before selling those shares pursuant to Rule 701.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Regulation
S</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulation
S provides generally that sales made in offshore transactions are not subject to the registration or prospectus-delivery requirements
of the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 121; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="an_004"></A>certain
U.S. AND GUERNSEY TAX CONSIDERATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Material
U.S. Federal Income Tax Considerations for U.S. Holders</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following discussion describes the material U.S. federal income tax consequences relating to the ownership and disposition of our ADSs
by U.S. Holders. This discussion applies to U.S. Holders that purchase our ADSs pursuant to this offering and hold such ADSs as capital
assets for U.S. federal income tax purposes. This discussion is based on the Internal Revenue Code, U.S. Treasury regulations promulgated
thereunder and administrative and judicial interpretations thereof, all as in effect on the date hereof and all of which are subject
to change, possibly with retroactive effect. This discussion does not address all of the U.S. federal income tax consequences that may
be relevant to specific U.S. Holders in light of their particular circumstances or to U.S. Holders subject to special treatment under
U.S. federal income tax law (such as certain financial institutions, insurance companies, dealers or traders in securities or other persons
that generally mark their securities to market for U.S. federal income tax purposes, tax-exempt entities or governmental organizations,
retirement plans, regulated investment companies, real estate investment trusts, grantor trusts, brokers, dealers or traders in securities,
commodities, currencies or notional principal contracts, certain former citizens or long-term residents of the United States, persons
who hold our ADSs as part of a &ldquo;straddle,&rdquo; &ldquo;hedge,&rdquo; &ldquo;conversion transaction,&rdquo; &ldquo;synthetic security&rdquo;
or integrated investment, persons that have a &ldquo;functional currency&rdquo; other than the U.S. dollar, persons who are subject to
the tax accounting rules of Section 451(b) of the Internal Revenue Code, persons that own directly, indirectly or through attribution
10% or more (by vote or value) of our equity, corporations that accumulate earnings to avoid U.S. federal income tax, partnerships and
other pass-through entities, and investors in such pass-through entities). This discussion does not address any U.S. state or local or
non-U.S. tax consequences or any U.S. federal estate, gift or alternative minimum tax consequences. Except as discussed below, this discussion
does not address U.S. federal income tax reporting obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
used in this discussion, the term &ldquo;U.S. Holder&rdquo; means a beneficial owner of our ADSs that is, for U.S. federal income tax
purposes, (1) an individual who is a citizen or resident of the United States, (2) a corporation (or entity treated as a corporation
for U.S. federal income tax purposes) created or organized in or under the laws of the United States, any state thereof, or the District
of Columbia, (3) an estate the income of which is subject to U.S. federal income tax regardless of its source or (4) a trust (x) with
respect to which a court within the United States is able to exercise primary supervision over its administration and one or more United
States persons have the authority to control all of its substantial decisions or (y) that has elected under applicable U.S. Treasury
regulations to be treated as a domestic trust for U.S. federal income tax purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an entity treated as a partnership for U.S. federal income tax purposes holds our ADSs, the U.S. federal income tax consequences relating
to an investment in such ADSs will generally depend upon the status and activities of such entity and the particular partner. Any such
entity and a partner in any such entity should consult its own tax advisor regarding the U.S. federal income tax consequences applicable
to it (and, as applicable, its partners) of the purchase, ownership and disposition of our ADSs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not sought, nor will we seek, a ruling from the IRS with respect to the matters discussed below. There can be no assurance that
the IRS will not take a different position concerning the tax consequences of the purchase, ownership or disposition of the ADSs or that
any such position would not be sustained. Persons considering an investment in our ADSs should consult their own tax advisors as to the
particular tax consequences applicable to them relating to the purchase, ownership and disposition of our ADSs, including the applicability
of U.S. federal, state and local tax laws and non-U.S. tax laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Passive
Foreign Investment Company Rules</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, a corporation organized outside the United States will be treated as a PFIC for any taxable year in which either (1) at least
75% of its gross income is &ldquo;passive income,&rdquo; referred to as the PFIC income test, or (2) on average at least 50% of its assets,
determined on a quarterly basis, are assets that produce passive income or are held for the production of passive income, referred to
as the PFIC asset test. Passive income for this purpose generally includes, among other things, dividends, interest, royalties, rents,
and gains from the sale or exchange of property that give rise to passive income. Assets that produce or are held for the production
of passive income generally include cash, even if held as working capital or raised in a public offering, marketable securities, and
other assets that may produce passive income. Generally, in determining whether a non-U.S. corporation is a PFIC, a proportionate share
of the income and assets of each corporation in which it owns, directly or indirectly, at least a 25% interest (by value) is taken into
account.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 122; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
PFIC status is determined on an annual basis and generally cannot be determined until the end of the taxable year, based on the nature
of our current and expected income and the current and expected value and composition of our assets, and while not free from doubt, we
do not believe we were a PFIC for our 2020 tax year and we do not expect to be a PFIC for our current taxable year. Nevertheless, there
can be no assurance that we will not be a PFIC in future taxable years. Furthermore, even if we determine that we are not a PFIC for
a taxable year, there can be no assurance that the IRS will agree with our conclusion and that the IRS would not successfully challenge
our position. Because of the uncertainties involved in establishing our PFIC status, our U.S. counsel expresses no opinion regarding
our PFIC status, and also expresses no opinion with respect to our predictions or past determinations regarding our PFIC status.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are a PFIC in any taxable year during which a U.S. Holder owns our ADSs, the U.S. Holder would be liable for additional taxes and
interest charges under the &ldquo;PFIC excess distribution regime&rdquo; upon (1) a distribution paid during a taxable year that is greater
than 125% of the average annual distributions paid in the three preceding taxable years, or, if shorter, the U.S. Holder&rsquo;s holding
period for our ADSs, and (2) any gain recognized on a sale, exchange or other disposition, including, under certain circumstances, a
pledge, of our ADSs, whether or not we continue to be a PFIC. Under the PFIC excess distribution regime, the tax on such distribution
or gain would be determined by allocating the distribution or gain ratably over the U.S. Holder&rsquo;s holding period for our ADSs.
The amount allocated to the current taxable year (<I>i.e</I>., the year in which the distribution occurs, or the gain is recognized)
and any year prior to the first taxable year in which we are a PFIC will be taxed as ordinary income earned in the current taxable year.
The amount allocated to other taxable years will be taxed at the highest marginal rates in effect for individuals or corporations, as
applicable, to ordinary income for each such taxable year, and an interest charge, generally applicable to underpayments of tax, will
be added to the tax.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are a PFIC for any taxable year during which a U.S. Holder holds our ADSs and one of our non-United States subsidiaries is also a
PFIC (<I>i.e</I>., a lower-tier PFIC), such U.S. Holder would be treated as owning a proportionate amount (by value) of the shares of
the lower-tier PFIC and would be taxed under the PFIC excess distribution regime on distributions by the lower-tier PFIC and on gain
from the disposition of shares of the lower-tier PFIC even though such U.S. Holder would not receive the proceeds of those distributions
or dispositions. Any of our non-United States subsidiaries that have elected to be disregarded as entities separate from us or as partnerships
for U.S. federal income tax purposes would not be corporations under U.S. federal income tax law and accordingly, cannot be classified
as lower-tier PFICs. However, a non-United States subsidiary that has not made the election may be classified as a lower-tier PFIC if
we are a PFIC during your holding period and the subsidiary meets the PFIC income test or PFIC asset test.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are a PFIC, a U.S. Holder will not be subject to tax under the PFIC excess distribution regime on distributions or gain recognized
on our ADSs if a valid &ldquo;mark-to-market&rdquo; election is made by the U.S. Holder for our ADSs. An electing U.S. Holder generally
would take into account as ordinary income each year, the excess of the fair market value of our ADSs held at the end of such taxable
year over the adjusted tax basis of such ADSs. The U.S. Holder would also take into account, as an ordinary loss each year, the excess
of the adjusted tax basis of such ADSs over their fair market value at the end of the taxable year, but only to the extent of the excess
of amounts previously included in income over ordinary losses deducted as a result of the mark-to-market election. The U.S. Holder&rsquo;s
tax basis in our ADSs would be adjusted annually to reflect any income or loss recognized as a result of the mark-to-market election.
Any gain from a sale, exchange or other disposition of our ADSs in any taxable year in which we are a PFIC would be treated as ordinary
income and any loss from such sale, exchange or other disposition would be treated first as ordinary loss (to the extent of any net mark-to-market
gains previously included in income) and thereafter as capital loss. If, after having been a PFIC for a taxable year, we cease to be
classified as a PFIC because we no longer meet the PFIC income or PFIC asset test, the U.S. Holder would not be required to take into
account any latent gain or loss in the manner described above and any gain or loss recognized on the sale or exchange of the ADSs would
be classified as a capital gain or loss.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 123; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
mark-to-market election is available to a U.S. Holder only for &ldquo;marketable stock.&rdquo; Generally, stock will be considered marketable
stock if it is &ldquo;regularly traded&rdquo; on a &ldquo;qualified exchange&rdquo; within the meaning of applicable U.S. Treasury regulations.
A class of stock is regularly traded during any calendar year during which such class of stock is traded, other than in de minimis quantities,
on at least 15 days during each calendar quarter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ADSs will be marketable stock as long as they remain listed on Nasdaq and are regularly traded. A mark-to-market election will not apply
to the ADSs for any taxable year during which we are not a PFIC, but will remain in effect with respect to any subsequent taxable year
in which we become a PFIC. Such election will not apply to any of our non-U.S. subsidiaries. Accordingly, a U.S. Holder may continue
to be subject to tax under the PFIC excess distribution regime with respect to any lower-tier PFICs notwithstanding the U.S. Holder&rsquo;s
mark-to-market election for our ADSs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tax consequences that would apply if we were a PFIC would also be different from those described above if a U.S. Holder were able to
make a valid QEF election. As we do not expect to provide U.S. Holders with the information necessary for a U.S. Holder to make a QEF
election, prospective investors should assume that a QEF election will not be available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
U.S. federal income tax rules relating to PFICs are very complex. Prospective U.S. investors are strongly urged to consult their own
tax advisors with respect to the impact of our possible PFIC status on the purchase, ownership and disposition of our ADSs, the consequences
to them of an investment in a PFIC, any elections available with respect to the ADSs and the IRS information reporting obligations with
respect to the purchase, ownership and disposition of ADSs of a PFIC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Distributions</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the discussion above under &ldquo;&mdash; Passive Foreign Investment Company Rules,&rdquo; a U.S. Holder that receives a distribution
with respect to our ADSs generally will be required to include the gross amount of such distribution in gross income as a dividend when
actually or constructively received by the U.S. Holder to the extent of the U.S. Holder&rsquo;s pro rata share of our current and/or
accumulated earnings and profits (as determined under U.S. federal income tax principles). To the extent a distribution received by a
U.S. Holder is not a dividend because it exceeds the U.S. Holder&rsquo;s pro rata share of our current and accumulated earnings and profits,
it will be treated first as a tax-free return of capital and reduce (but not below zero) the adjusted tax basis of the U.S. Holder&rsquo;s
ADSs. To the extent the distribution exceeds the adjusted tax basis of the U.S. Holder&rsquo;s ADSs, the remainder will be taxed as capital
gain. Because we may not account for our earnings and profits in accordance with U.S. federal income tax principles, U.S. Holders should
expect all distributions to be reported to them as dividends.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Distributions
on our ADSs that are treated as dividends generally will constitute income from sources outside the United States for foreign tax credit
purposes and generally will constitute passive category income. The amount of any dividend income paid in a currency other than the U.S.
dollar will be the U.S. dollar amount calculated by reference to the exchange rate in effect on the date of actual or constructive receipt,
regardless of whether the payment is in fact converted into U.S. dollars at that time. If the dividend is converted into U.S. dollars
on the date of receipt, a U.S. holder should not be required to recognize foreign currency gain or loss in respect of the dividend amount.
A U.S. Holder may have foreign currency gain or loss if the dividend is converted into U.S. dollars after the date of receipt.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 124; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Distributions paid on our ADSs
will not be eligible for the &ldquo;dividends received&rdquo; deduction generally allowed to corporate shareholders with respect to dividends
received from U.S. corporations under the Internal Revenue Code. Dividends paid by a &ldquo;qualified foreign corporation&rsquo;&rsquo;
to non-corporate U.S. Holders are eligible for taxation at a reduced capital gains rate rather than the marginal tax rates generally
applicable to ordinary income provided that a holding period requirement (more than 60 days of ownership, without protection from the
risk of loss, during the 121-day period beginning 60 days before the ex-dividend date) and certain other requirements are met. Each U.S.
Holder is advised to consult their tax advisors regarding the availability of the reduced tax rate on dividends to their
particular circumstances. However, if we are a PFIC for the taxable year in which the dividend is paid or the preceding taxable year
(see discussion above under &ldquo;&mdash; Passive Foreign Investment Company Rules&rsquo;&rsquo;), we will not be treated as a qualified
foreign corporation, and therefore the reduced capital gains tax rate described above will not apply.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
non-United States corporation (other than a corporation that is classified as a PFIC for the taxable year in which the dividend is paid
or the preceding taxable year) generally will be considered to be a qualified foreign corporation with respect to any dividend it pays
on ADSs that are readily tradable on an established securities market in the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amount of any dividend income that is paid in Pounds Sterling will be the U.S. dollar amount calculated by reference to the exchange
rate in effect on the date of receipt, regardless of whether the payment is in fact converted into U.S. dollars. If the dividend is converted
into U.S. dollars on the date of receipt (actual or constructive), a U.S. Holder should not be required to recognize foreign currency
gain or loss in respect of the dividend income. A U.S. Holder may have foreign currency gain or loss if the dividend is converted into
U.S. dollars after the date of receipt (actual or constructive).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Sale,
Exchange or Other Taxable Disposition of Our ADSs</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the discussion above under &ldquo;&mdash; Passive Foreign Investment Company Rules,&rdquo; a U.S. Holder generally will recognize
capital gain or loss for U.S. federal income tax purposes upon the sale, exchange or other disposition of our ADSs in an amount equal
to the difference, if any, between the amount realized (<I>i.e</I>., the amount of cash plus the fair market value of any property received)
on the sale, exchange or other disposition and such U.S. Holder&rsquo;s adjusted tax basis in the ADSs. Such capital gain or loss generally
will be long-term capital gain taxable at a reduced rate for non-corporate U.S. Holders or long-term capital loss if, on the date of
sale, exchange or other disposition, the ADSs were held by the U.S. Holder for more than one year. Any capital gain of a non-corporate
U.S. Holder that is not long-term capital gain is taxed at ordinary income rates. The deductibility of capital losses is subject to limitations.
Any gain or loss recognized from the sale or other disposition of our ADSs will generally be gain or loss from sources within the United
States for U.S. foreign tax credit purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Medicare
Tax</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
U.S. Holders that are individuals, estates or trusts and whose income exceeds certain thresholds generally are subject to a 3.8% tax
on all or a portion of their net investment income, which may include their gross dividend income and net gains from the disposition
of our ADSs. If you are a U.S. Holder that is an individual, estate or trust, you are encouraged to consult your tax advisors regarding
the applicability of this Medicare tax to your income and gains in respect of your investment in our ADSs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Information
Reporting and Backup Withholding</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
Holders may be required to file certain U.S. information reporting returns with the IRS with respect to an investment in our ADSs, including,
among others, IRS Form 8938 (Statement of Specified Foreign Financial Assets). In addition, each U.S. Holder who is a shareholder of
a PFIC must file an annual report containing certain information. U.S. Holders paying more than $100,000 for our ADSs may be required
to file IRS Form 926 (Return by a U.S. Transferor of Property to a Foreign Corporation) reporting this payment. Substantial penalties
and other adverse circumstances may be imposed upon a U.S. Holder that fails to comply with the required information reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 125; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
on and proceeds from the sale or other disposition of our ADSs generally have to be reported to the IRS unless the U.S. Holder establishes
a basis for exemption. Backup withholding may apply to amounts subject to reporting if the holder (1) fails to provide an accurate U.S.
taxpayer identification number or otherwise establish a basis for exemption, or (2) is described in certain other categories of persons.
However, U.S. Holders that are corporations generally are excluded from these information reporting and backup withholding tax rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Backup
withholding is not an additional tax. Any amounts withheld under the backup withholding rules generally will be allowed as a refund or
a credit against a U.S. Holder&rsquo;s U.S. federal income tax liability if the required information is furnished by the U.S. Holder
on a timely basis to the IRS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
Holders should consult their own tax advisors regarding the backup withholding tax and information reporting rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EACH
PROSPECTIVE INVESTOR IS URGED TO CONSULT ITS OWN TAX ADVISOR ABOUT THE TAX CONSEQUENCES TO IT OF AN INVESTMENT IN OUR ADSs IN LIGHT OF
THE INVESTOR&rsquo;S OWN CIRCUMSTANCES.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Guernsey
Tax Considerations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
summary below is based on current Guernsey law and published practice in Guernsey as of the date hereof, both of which are subject to
change, possibly with retrospective effect. This summary is intended as a general guide of certain Guernsey tax matters related to the
holders of ordinary shares of the Company (&ldquo;<B>Shareholders</B>&rdquo;) only and is not, is not intended to be nor should it be
construed to be, legal or tax advice or a summary of all tax matters in Guernsey.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholders,
whether corporations or individuals, that are not residents of Guernsey for tax purposes and who do not conduct business in Guernsey
through a permanent establishment situated in Guernsey, will not be subject to Guernsey income or Guernsey withholding tax. Any distributions
made by the Company to non-Guernsey tax resident Shareholders will not be subject to Guernsey income or Guernsey withholding tax.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Individual
Shareholders who are residents of Guernsey for tax purposes will generally be subject to Guernsey income tax at the individual standard
rate of 20% on distributions received from the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate
Shareholders that are residents of Guernsey for tax purposes (and which do not have exempt company status under the Income Tax (Exempt
Bodies) (Guernsey) Ordinance, 1989, as amended) will generally be subject to Guernsey income tax at the company standard rate, which
is currently 0%, on distributions received from the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Guernsey
does not currently levy capital gains tax (with the exception of a dwellings profit tax) and, therefore, Shareholders will not suffer
capital gains tax in Guernsey.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
stamp duty is chargeable in Guernsey on the issue, acquisition, transfer, conversion or redemption or other disposition of ordinary shares
of the Company (provided that it does not hold Guernsey real property).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Guernsey
has implemented through domestic legislation matters related to (i) the Foreign Account Tax Compliance Act, or FATCA, contained
in the United States Internal Revenue Code of 1986 and the Treasury Regulations promulgated thereunder and (ii) the Organization for
Economic Co-operation and Development&rsquo;s regime known as the Common Reporting Standard, or CRS. Pursuant
to FATCA and CRS, disclosure and reporting of information may be required, including disclosure of certain information about Shareholders,
their ultimate beneficial owners and/or controllers and their investment in the Company. You should consult your tax advisers regarding
the possible implications of FATCA, CRS and other similar regimes that may be relevant to your ownership and disposition of ordinary
shares of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 126; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="us_003"></A>UNDERWRITING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ThinkEquity
is acting as the representative of the underwriters of this offering, or the &ldquo;Representative. We have entered into an underwriting
agreement dated May 16, 2022 with the Representative. Subject to the terms and conditions of the underwriting agreement, we have
agreed to sell to each underwriter named below and each underwriter named below has severally and not jointly agreed to purchase from
us, at the public offering price per ADS less the underwriting discounts set forth on the cover page of this prospectus, the number of
ADSs listed next to its name in the following table:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriters</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    of ADSs</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 80%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ThinkEquity
    LLC</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">625,000<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">625,000</TD>
    <TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters are committed to purchase all ADSs offered by us other than those covered by the over-allotment option described below,
if any are purchased. The obligations of the underwriters may be terminated upon the occurrence of certain events specified in the underwriting
agreement. Furthermore, pursuant to the underwriting agreement, the underwriters&rsquo; obligations are subject to customary conditions,
representations and warranties contained in the underwriting agreement, such as receipt by the underwriters of officers&rsquo; certificates
and legal opinions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters are offering the ADSs subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal
matters by their counsel, and other conditions. The underwriters reserve the right to withdraw, cancel or modify offers to the public
and to reject orders in whole or in part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters propose to offer the ADSs offered by us to the public at the public offering price set forth on the cover of the prospectus.
After the ADSs are released for sale to the public, the underwriters may change the offering price and other selling terms at various
times.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Over-Allotment
Option</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have granted to the underwriters an option, exercisable for 45 days from the closing date of this offering, to purchase up to 93,750
additional ADSs (15% of the ADSs sold in this offering) from us to cover over-allotments, if any, at a price per ADS equal to the
public offering price, less the underwriting discounts and commissions. The underwriters may exercise the option solely for the purpose
of covering over-allotments, if any, in connection with this offering. To the extent the option is exercised, each underwriter must purchase
a number of additional ADSs approximately proportionate to that underwriter&rsquo;s initial purchase commitment set forth in the table
above. Any ADSs issued or sold under the option will be issued and sold on the same terms and conditions as the other ADSs that are the
subject of this offering. If this option is exercised in full, the total offering price to the public will be $2,875,000 and the
total net proceeds, before expenses, to us will be $2,673,750.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Discounts
and Commissions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Representative has advised us that the underwriters propose to offer the ADSs to the public at the public offering price per ADS set
forth on the cover page of this prospectus. The underwriters may offer ADSs to securities dealers at that price less a concession of
not more than $0.16 per ADS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the public offering price, underwriting discounts and commissions and proceeds before expenses to us assuming
both no exercise and full exercise by the underwriters of their over-allotment option:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Per ADS</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total Without Over-allotment Option</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total With Over-allotment Option</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; font-size: 10pt">Public offering price</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">4.00</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">2,500,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">2,875,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">Underwriting discounts and commissions (7.0%)<SUP>(1)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.28</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">175,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">201,250</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Proceeds, before expenses, to us</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">3.72</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">2,325,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">2,673,750</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have agreed to pay a non-accountable expense allowance to the Representative equal to 1% of the gross proceeds received in this offering
    (excluding proceeds received from exercise of the underwriters&rsquo; over-allotment option) which is not included in Underwriting
    discounts and commissions.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 127; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to reimburse the Representative for the fees and expenses of its legal counsel in connection with the offering in an amount
not to exceed $100,000, the fees and expenses related to the use of book building, prospectus tracking and compliance software for the
offering in the amount of $29,500, up to $15,000 for background checks of our officers and directors, out-of-pocket fees and expenses
of the Representative for marketing and roadshows for the offering not to exceed $20,000, data services and communications expenses in
the amount of $10,000, and up to $3,000 of the costs associated with preparing bound volumes of the public offering materials and any
commemorative mementos or lucite tombstones for the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
estimate the expenses of this offering payable by us, not including underwriting discounts and commissions, will be approximately $501,300.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Discretionary
Accounts</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters do not intend to confirm sales of the securities offered hereby to any accounts over which they have discretionary authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lock-Up
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to certain &ldquo;lock-up&rdquo; agreements, we and our executive officers, directors and certain shareholders, have agreed, subject
to limited exceptions, without the prior written consent of the Representative, not to directly or indirectly, offer, pledge, sell, contract
to sell, grant, lend, or otherwise transfer or dispose of, directly or indirectly, our common stock or any securities convertible into
or exercisable or exchangeable for our common stock, or the Lock-Up Securities, enter into any swap or other arrangement that transfers
to another, in whole or in part, any of the economic consequences of ownership of the Lock-Up Securities, make any demand for or exercise
any right or cause to be filed a registration statement, including any amendments thereto, with respect to the registration of any Lock-Up
Securities, or to enter into any transaction, swap, hedge or other arrangement relating to any Lock-Up Securities, subject to customary
exceptions, or publicly disclose the intention to do any of the foregoing, for a period of twelve months from the date of this prospectus,
with respect to our executive officers and directors, and six months from the date of this prospectus with respect to the shareholders
signing such agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Indemnification</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to indemnify the underwriters against liabilities relating to this offering arising under the Securities Act and the Exchange
Act, liabilities arising from breaches of some or all of the representations and warranties contained in the underwriting agreement,
and to contribute to payments that the underwriters may be required to make for these liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Electronic
Offer, Sale and Distribution of ADSs</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
prospectus in electronic format may be made available on the websites maintained by one or more underwriters or selling group members,
if any, participating in this offering and one or more of the underwriters participating in this offering may distribute prospectuses
electronically. The representative may agree to allocate a number of ADSs to underwriters and selling group members for sale to their
online brokerage account holders. Internet distributions will be allocated by the underwriters and selling group members that will make
internet distributions on the same basis as other allocations. Other than the prospectus in electronic format, the information on the
underwriters&rsquo; websites is not part of, nor incorporated by reference into, this prospectus or the registration statement of which
this prospectus forms a part, has not been approved or endorsed by us or any underwriter in its capacity as underwriter, and should not
be relied upon by investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Right
of First Refusal</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
a period of six months after the closing of this offering, the representative of the underwriters will have, subject to certain exceptions,
an irrevocable right of first refusal to act as sole and exclusive book-runner, sole and exclusive underwriter and/or sole and exclusive
or lead placement agent, at the representative&rsquo;s sole discretion, for each and every future public and private equity and debt
offering, including all equity linked financings, during such six month period, for us, or any successor to or any subsidiary of us,
on terms and conditions customary for the representative for such transaction, except for any financings done in the United Kingdom.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 128; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stabilization</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this offering, the underwriters may engage in stabilizing transactions, over-allotment transactions, syndicate-covering
transactions, penalty bids, and purchases to cover positions created by short sales which involves making bids for, purchasing and selling ADSs in the open market for the purpose of preventing or retarding
a decline in the market price of the ADSs and, indirectly, our ordinary shares while the offering is in progress.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stabilizing
transactions permit bids to purchase ADSs so long as the stabilizing bids do not exceed a specified maximum and are engaged in for
the purpose of preventing or retarding a decline in the market price of the ADSs and, indirectly, our ordinary shares while the
offering is in progress.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: White">Over-allotment
transactions involve sales by the underwriters of ADSs in excess of the number of ADSs the underwriters are obligated to purchase. This
creates a syndicate short position which may be either a covered short position or a naked short position. In a covered short position,
the number of ADSs over-allotted by the underwriters is not greater than the number of ADSs that they may purchase in the over-allotment
option. In a naked short position, the number of ADSs involved is greater than the number of ADSs that they purchase in the over-allotment
option. The underwriters may close out any short position by exercising their over-allotment option and/or purchasing ADSs in the open
market. The underwriters will not purchase ordinary shares in the open market to close out any such short position.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Syndicate
covering transactions involve purchases of ADSs in the open market after the distribution has been completed in order to cover syndicate
short positions. In determining the source of ADSs to close out the short position, the underwriters will consider, among other things,
the price of ADSs available for purchase in the open market as compared with the price at which they may purchase ADSs through exercise
of the over-allotment option. If the underwriters sell more ADSs than could be covered by exercise of the over-allotment option and,
therefore, have a naked short position, the position can be closed out only by buying ADSs in the open market. A naked short position
is more likely to be created if the underwriters are concerned that after pricing there could be downward pressure on the price of the
ADSs in the open market that could adversely affect investors who purchase in the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Penalty
bids permit the representative to reclaim a selling concession from a syndicate member when the ADSs originally sold by that syndicate
member are purchased in stabilizing or syndicate covering transactions to cover syndicate short positions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">These stabilizing transactions,
syndicate covering transactions and penalty bids may have the effect of raising or maintaining the market price of our ADSs and, indirectly,
our ordinary shares or preventing or retarding a decline in the market price of our ADSs and, indirectly, our ordinary shares. As a result,
the prices of our ADSs and ordinary shares in the open market may be higher than they would otherwise be in the absence of these transactions.
Neither we nor the underwriters make any representation or prediction as to the effect that the transactions described above may have
on the price of our ADSs or ordinary shares. These transactions may be affected in the over-the-counter market or otherwise and, if commenced,
may be discontinued at any time.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Passive
Market Making</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In connection with this
offering, underwriters and selling group members may engage in passive market making transactions in our ADSs on the Nasdaq Capital Market
in accordance with Rule 103 of Regulation M under the Exchange Act, during a period before the commencement of offers or sales of the
securities and extending through the completion of the distribution. This means that if the representatives of the underwriters&rsquo;
purchase ADSs in the open market in stabilizing transactions or to cover short sales, the representatives can require the underwriters
that sold those ADSs as part of the offering to repay the underwriting discount received by them. A passive market maker must display
its bid at a price not in excess of the highest independent bid of that security. However, if all independent bids are lowered below
the passive market maker&rsquo;s bid, then that bid must then be lowered when specified purchase limits are exceeded. Furthermore, stabilization
transactions will also need to comply with UK and EU laws, in particular the Market Abuse Regulation (Regulation (EU) 596/2014), which
is part of UK domestic law pursuant to the Market Abuse (Amendment) (EU Exit) Regulations (<I>SI 2019/310</I>).</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
Relationships</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters and their affiliates may in the future provide various advisory, investment and commercial banking and other services for
us in the ordinary course of business, for which they may receive customary fees and commissions. However, we have not yet had, and have
no present arrangements with any of the underwriters for any further services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 129; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pricing
of the Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
public offering price of the ADSs we are offering was negotiated between us and the underwriters based on the trading of our ordinary
shares prior to the offering, among other things. Other factors considered in determining the public offering price of the ADSs include
our history and prospects, the stage of development of our business, our business plans for the future and the extent to which they have
been implemented, an assessment of our management, general conditions of the securities markets at the time of the offering and such
other factors as were deemed relevant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Selling
Restrictions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities offered
by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be
offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with
the offer and sale of any such securities be distributed or published, in any jurisdiction, except under circumstances that will result
in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are
advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus.
This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in
any jurisdiction in which such an offer or a solicitation is unlawful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
we nor our underwriters can assure investors that an active trading market will develop for our ADSs in the United States, or that the
ADSs will trade in the public market at or above the initial public offering price after the U.S. offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you purchase ADSs or ordinary shares offered in this prospectus, you may be required to pay stamp taxes and other charges under the laws
and practices of the country of purchase, in addition to the offering price listed on the cover page of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 130; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities offered
by this prospectus in any jurisdiction where action for that purpose is required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
securities offered by this prospectus may not be offered or sold, directly or indirectly, nor may this prospectus or any other offering
material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction,
except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into
whose possession this prospectus comes are advised to inform themselves about and to observe any restrictions relating to the offering
and the distribution of this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any
securities offered by this prospectus in any jurisdiction in which such an offer or a solicitation is unlawful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notice
to prospective investors in Australia</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">does
    not constitute a disclosure document or a prospectus under Chapter 6D.2 of the Corporations Act 2001 (the &ldquo;<B>Corporations
    Act</B>&rdquo;);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">has
    not been, and will not be, lodged with the Australian Securities and Investments Commission (&ldquo;<B>ASIC</B>&rdquo;), as a disclosure
    document for the purposes of the Corporations Act and does not purport to include the information required of a disclosure document
    for the purposes of the Corporations Act; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">may
    only be provided in Australia to select investors who are able to demonstrate that they fall within one or more of the categories
    of investors, available under section 708 of the Corporations Act (&ldquo;<B>Exempt Investors</B>&rdquo;).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ordinary shares may not be directly or indirectly offered for subscription or purchased or sold, and no invitations to subscribe for
or buy the ordinary shares may be issued, and no draft or definitive offering memorandum, advertisement or other offering material relating
to any ordinary shares may be distributed in Australia, except where disclosure to investors is not required under Chapter 6D of the
Corporations Act or is otherwise in compliance with all applicable Australian laws and regulations. By submitting an application for
the ordinary shares, you represent and warrant to us that you are an Exempt Investor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
any offer of ordinary shares under this document will be made without disclosure in Australia under Chapter 6D.2 of the Corporations
Act, the offer of those securities for resale in Australia within 12 months may, under section 707 of the Corporations Act, require disclosure
to investors under Chapter 6D.2 if none of the exemptions in section 708 applies to that resale. By applying for the ordinary shares,
you undertake to us that you will not, for a period of 12 months from the date of issue of the ordinary shares, offer, transfer, assign
or otherwise alienate those ordinary shares to investors in Australia except in circumstances where disclosure to investors is not required
under Chapter 6D.2 of the Corporations Act or where a compliant disclosure document is prepared and lodged with ASIC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 131; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->127<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notice
to prospective investors in Canada</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ordinary shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as
defined in National Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted
clients, as defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale
of the ordinary shares must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements
of applicable securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus
(including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by
the purchaser within the time limit prescribed by the securities legislation of the purchaser&rsquo;s province or territory. The purchaser
should refer to any applicable provisions of the securities legislation of the purchaser&rsquo;s province or territory for particulars
of these rights or consult with a legal advisor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to section 3A.3 of National Instrument 33-105 Underwriting Conflicts (NI 33-105), the underwriters are not required to comply
with the disclosure requirements of NI 33-105 regarding underwriter conflicts of interest in connection with this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notice
to prospective investors in the EEA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In relation to each member
state of the EEA (each, a &ldquo;<B>Relevant State</B>&rdquo;), no securities have been offered or will be offered pursuant to the offering
to the public in that Relevant State prior to the publication of a prospectus in relation to the securities which has been approved by
the competent authority in that Relevant State or, where appropriate, approved in another Relevant State and notified to the competent
authority in that Relevant State, all in accordance with the EU Prospectus Regulation, except that offers of securities may be made to
the public in that Relevant State at any time under the following exemptions under the EU Prospectus Regulation:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(a) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">to any legal entity which is a qualified investor as defined under
    Article 2(e) of the EU Prospectus Regulation;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">(b) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">to fewer than 150 natural or legal persons (other than qualified
    investors as defined under the EU Prospectus Regulation), subject to obtaining the prior consent of the representatives for any such
    offer; or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">(c) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">in any other circumstances falling within Article 1(4) of the EU
    Prospectus Regulation,</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">provided that no such offer
of securities shall require us or any representative to publish a prospectus pursuant to Article 3 of the EU Prospectus Regulation or
supplement a prospectus pursuant to Article 23 of the EU Prospectus Regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">For the purposes of this
provision, the expression an &ldquo;offer to the public&rdquo; in relation to securities in any Relevant State means the communication
in any form and by any means of sufficient information on the terms of the offer and any securities to be offered so as to enable an
investor to decide to purchase or subscribe for any securities, and the expression &ldquo;EU Prospectus Regulation&rdquo; means Regulation
(EU) 2017/1129, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 132; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->128<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notice
to prospective investors in the UK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">No securities have been offered
or will be offered pursuant to the offering to the public in the UK prior to the publication of a prospectus in relation to the securities
which has been approved by the FCA, all in accordance with the UK Prospectus Regulation, except that offers of securities may be made
to the public in the UK at any time under the following exemptions under the UK Prospectus Regulation:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(a) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">to any legal entity which is a qualified investor as defined under
    Article 2(e) of the UK Prospectus Regulation;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">(b) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">to fewer than 150 natural or legal persons (other than qualified
    investors as defined under the UK Prospectus Regulation), subject to obtaining the prior consent of the representatives for any such
    offer; or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">(c) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">in any other circumstances falling within Section 86 of the FSMA,</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">provided that no such offer
of securities shall require us or any representative to publish a prospectus pursuant to Section 85 of the FSMA or supplement a prospectus
pursuant to Article 23 of the UK Prospectus Regulation. For the purposes of this provision, the expression an &ldquo;offer to the public&rdquo;
in relation to the securities in the UK means the communication in any form and by any means of sufficient information on the terms of
the offer and any securities to be offered so as to enable an investor to decide to purchase or subscribe for any securities, the expression
&ldquo;UK Prospectus Regulation&rdquo; means Regulation (EU) 2017/1129 as it forms part of UK domestic law by virtue of the European
Union (Withdrawal) Act 2018, as amended, and the expression &ldquo;FSMA&rdquo; means the UK Financial Services and Markets Act 2000,
as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In addition, in the UK, this
document is being distributed only to, and is directed only at, and any offer subsequently made may only be directed at persons who are
&ldquo;qualified investors&rdquo; (as defined in the Prospectus Regulation) (i) who have professional experience in matters relating
to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended,
or the Order, and/or (ii) who are high net worth companies (or persons to whom it may otherwise be lawfully communicated) falling within
Article 49(2)(a) to (d) of the Order (all such persons together being referred to as &ldquo;relevant persons&rdquo;) or otherwise in
circumstances which have not resulted and will not result in an offer to the public of securities in the UK within the meaning
of FSMA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Any person in the UK that
is not a relevant person should not act or rely on the information included in this document or use it as a basis for taking any action.
In the UK, any investment or investment activity that this document relates to may be made or taken exclusively by relevant persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notice
to prospective investors in Japan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ordinary shares have not been and will not be registered pursuant to Article 4, Paragraph 1 of the Financial Instruments and Exchange
Act. Accordingly, none of the ordinary shares nor any interest therein may be offered or sold, directly or indirectly, in Japan or to,
or for the benefit of, any &ldquo;resident&rdquo; of Japan (which term as used herein means any person resident in Japan, including any
corporation or other entity organized under the laws of Japan), or to others for re-offering or resale, directly or indirectly, in Japan
or to or for the benefit of a resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise
in compliance with, the Financial Instruments and Exchange Act and any other applicable laws, regulations and ministerial guidelines
of Japan in effect at the relevant time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="an_006"></A>Expenses
of This Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
estimate that our expenses in connection with this offering will be as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Amount</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 78%"><FONT STYLE="font-size: 10pt">SEC registration fee</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 18%; text-align: right"><FONT STYLE="font-size: 10pt">1,067</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">FINRA Filing Fee</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2,225</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Nasdaq Capital Market listing fee</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">55,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Printing and engraving expenses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">10,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Legal fees and expenses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">252,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Transfer agent and registrar fees and expenses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">7,500</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Accounting fees and expenses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">47,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">Miscellaneous costs</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">6,208</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Total</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">381,000</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
amounts in the table are estimates except the SEC registration fee, the listing fee, and the FINRA filing fee. We will pay all of the
expenses of this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 133; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->129<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="an_007"></A>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;Certain legal matters
with respect to English law and Guernsey law in connection with the validity of our ordinary shares registered hereby will be passed
upon for us by Orrick, Herrington &amp; Sutcliffe (UK) LLP, United Kingdom and Carey Olsen (Guernsey) LLP, Bailiwick of Guernsey,
respectively. Certain matters of U.S. federal law will be passed upon for us by Sheppard, Mullin, Richter &amp; Hampton LLP, New York,
New York. Certain legal matters respect will be passed upon for the underwriters by Dorsey &amp; Whitney LLP, New York, New York.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="an_008"></A>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The consolidated financial statements
of OKYO Pharma Limited as of March 31, 2021 and 2020, and for each of the years then ended, have been included herein and in the registration
statement in reliance on the report of Mazars LLP, an independent registered public accounting firm, appearing elsewhere herein, and
upon the authority of said firm as experts in accounting and auditing. The registered business address of Mazars LLP is 30 Old Bailey,
London. EC4M 7AU, United Kingdom.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="an_009"></A>SERVICE
OF PROCESS AND ENFORCEMENT OF LIABILITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are incorporated and currently existing under the laws of Guernsey. In addition, certain of our directors and officers reside outside
the United States, and most of the assets of our non-U.S. subsidiaries are located outside the United States. As a result, it may not
be possible for investors to effect service of process within the United States upon OKYO or those persons or to enforce against OKYO
or them, either inside or outside the United States, judgments obtained in U.S. courts, or to enforce in U.S. courts, judgments obtained
against them in courts in jurisdictions outside the U.S., in any action predicated upon civil liability provisions of the federal securities
laws of the United States. Both in original actions and in actions for the enforcement of judgments of U.S. courts, there is doubt as
to whether civil liabilities predicated solely upon the U.S. federal securities laws are enforceable in Guernsey. See &ldquo;Description
of Share Capital and Memorandum and Articles of Incorporation&mdash;Enforcement of Civil Liabilities.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="an_010"></A>WHERE
YOU CAN FIND ADDITIONAL INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have filed with the SEC a registration statement (including amendments and exhibits to the registration statement) on Form F-1 under
the Securities Act. This prospectus, which is part of the registration statement, does not contain all of the information in the registration
statement and its exhibits. For further information with respect to us and the ADSs offered by this prospectus, we refer you to the registration
statement and the exhibits and schedules to the registration statement. Statements contained in this prospectus as to the contents of
any contract or any other document referred to are not necessarily complete, and in each instance, we refer you to the copy of the contract
or other document filed as an exhibit to the registration statement. Each of these statements is qualified in all respects by the filed
exhibits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may review a copy of the registration statement, including exhibits and any schedule filed therewith, and obtain copies of such materials
at the SEC&rsquo;s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. You may obtain information on the operation of
the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains an Internet website (www.sec.gov) that contains reports,
proxy and information statements and other information regarding issuers, like us, that file electronically with the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
completion of this offering, we will be subject to the information reporting requirements of the Exchange Act applicable to FPIs. Accordingly,
we will be required to file reports and other information with the SEC, including annual reports on Form 20-F and reports on Form 6-K.
Those reports may be inspected without charge at the locations described above. As an FPI, we will be exempt from the rules under the
Exchange Act related to the furnishing and content of proxy statements, and our officers, directors and principal shareholders will be
exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. In addition, we will
not be required under the Exchange Act to file periodic reports and financial statements with the SEC as frequently or as promptly as
U.S. companies whose securities are registered under the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also maintain a website at www.okyopharma.com contained in, or accessible through, our website is not a part of this prospectus, and
the inclusion of our website address in this prospectus is an inactive textual reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 134; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->130<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="an_011"></A>INDEX
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OKYO
PHARMA LIMITED</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 91%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#an_012">Report of Independent Registered Public Accounting Firm</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#an_013">Consolidated Balance Sheets</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#an_014">Consolidated Statements of Comprehensive Income</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#an_015">Consolidated Statements of Changes in Shareholders&rsquo; Equity</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#an_016">Consolidated Statement of Cash Flows</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#an_017">Notes to Consolidated Financial Statements</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 135; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><A NAME="an_012"></A>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors and Shareholders of OKYO Pharma Limited</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Opinion
on the Consolidated Financial Statements</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have audited the accompanying consolidated balance
sheets of OKYO Pharma Limited and its subsidiary (the Group) as of March 31, 2021 and 2020, the related consolidated statements
of operations and comprehensive loss, shareholders&rsquo; equity, and cash flows for each of the two years in the period ended
March 31, 2021 and the related notes (collectively referred to as the consolidated financial statements). In our opinion, the consolidated
financial statements present fairly, in all material respects, the financial position of the Group as of March 31, 2021 and 2020,
and the results of its operations and its cash flows for each of the two years in the period ended March 31, 2021, in conformity
with International Financial Reporting Standards as issued by the International Accounting Standards Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Going Concern Uncertainty</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements
have been prepared assuming that the group will continue as a going concern. As discussed in Note 2 to the consolidated financial
statements, the group is pre-revenue and has suffered recurring losses from operations. The directors expect to incur further losses
and to require significant capital expenditure in continuing towards the clinical stage for their drug candidates. The directors have
prepared cash flow projections that include the costs associated with the continued clinical trials and additional investment to fund
operations. These projections indicate that the group will not be able to meet its liabilities as they fall due for a period beyond 12
months from the date of issue of these financial statements without raising additional finance. These conditions raise substantial doubt
about the group&rsquo;s ability to continue as a going concern. The consolidated financial statements do not include any adjustments that
might result from the outcome of this uncertainty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Basis for Opinion</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These consolidated financial statements are the responsibility
of the Group&rsquo;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.
We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required
to be independent with respect to the Group in accordance with the U.S. federal securities laws and the applicable rules and regulations
of the Securities and Exchange Commission and the PCAOB. The Group is not required to have, nor were we engaged to perform, an audit of
its internal control over financial reporting. As part of our audit procedures we are required to obtain an understanding of internal
control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Group&rsquo;s internal control
over financial reporting. Accordingly, we express no such opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We conducted our audits in accordance with the standards
of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated
financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess
the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures
that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the
consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by
management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide
a reasonable basis for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Mazars LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">London, England</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">January 26, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We have serviced the Group as auditors since 2019.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 136; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>OKYO
Pharma Limited </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="an_013"></A>Consolidated
Balance Sheets</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six months ended September 30, 2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(unaudited)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">$</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">$</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">$</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: center">ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Current assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%; text-align: left; padding-left: 10pt">Cash and cash equivalents</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">5,184,149</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">6,889,329</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">235,485</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Related party receivables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">95,789</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,664</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,190</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Taxation receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">208,901</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,322</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">74,387</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Prepayments and other receivables</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">49,726</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">43,371</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">236,947</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt">Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,538,565</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,986,686</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">568,009</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Property and Equipment, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,863</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,057</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">635</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Right of use asset</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">81,182</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">98,579</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">30,099</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt">Total non-current assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">86,045</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">104,636</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">30,734</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 20pt">Total assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,624,610</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,091,322</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">598,743</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 10pt">LIABILITIES AND SHAREHOLDERS&rsquo; EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Current liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Accounts payable and accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">556,643</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,673,154</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">663,282</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Related party payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,904</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43,886</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Lease liabilities - current</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">34,530</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">34,148</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,091</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt">Total current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">619,077</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,707,302</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">712,259</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Lease liabilities - non current</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">47,251</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">64,612</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">26,598</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Total liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">666,328</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,771,914</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">738,857</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Shareholders&rsquo; Equity:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Share capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">122,750,523</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">111,629,173</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">112,079,984</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Share options reserve</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,449,067</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">636,313</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">93,441</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Warrants reserve</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">649,096</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">861,214</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">639,903</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Convertible Loan Note reserve</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(554,627</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,370,836</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Foreign currency translation reserve</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,136,531</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,174,375</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,520,740</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Retained earnings</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(109,199,246</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(106,003,753</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(102,432,702</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Total shareholders&rsquo; equity</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,958,282</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,319,408</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(140,114</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 20pt">Total liabilities and shareholders&rsquo; equity</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,624,610</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,091,322</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">598,743</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 137; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>OKYO
Pharma Limited </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="an_014"></A>Consolidated
Statements of Operations and Comprehensive Loss</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Six months ended</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>September 30,</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021 (unaudited)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020 (unaudited)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">$</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">$</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">$</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">$</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Cost of revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Gross Profit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%">Research</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">(479,700</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">(37,622</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">(173,821</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(518,098</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Operating Expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,254,393</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(517,825</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,192,385</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,016,548</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total operating expenses</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(2,734,093</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(555,447</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(3,366,206</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,534,646</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Other income/(expense):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Finance Income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,123</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48,125</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Finance (expense)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,021</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(504</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,158</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Impairment</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(69,104</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(11,172</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(132,668</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Loss from operations before income taxes</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(2,735,114</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(625,055</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(3,378,501</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,620,347</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Income tax provision</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">188,761</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(87</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,994</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">76,289</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Loss for the year</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(2,546,353</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(625,142</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(3,353,507</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,544,059</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Other Comprehensive loss:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Currency translation</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">37,845</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">12,479</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">346,365</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">86,654</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Comprehensive loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(2,508,508</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(612,663</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(3,007,142</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,457,405</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Basic and diluted loss per share attributable to common shareholders</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.00</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.00</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.01</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.00</TD><TD STYLE="text-align: left">)</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 138; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>OKYO
Pharma Limited </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="an_015"></A>Consolidated
Statements of Shareholders&rsquo; Equity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">No. of Shares</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Share Capital</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Options reserve</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Warrant reserve</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Convertible Loan Note reserve</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Retained Earnings</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Translation Reserve</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Total Equity</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center">$</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center">$</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center">$</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center">$</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center">$</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center">$</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center">$</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 28%">Balance at 31 March 2019</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 5%; text-align: right">524,108,283</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 5%; text-align: right">111,741,860</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 5%; text-align: right">57,101</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 5%; text-align: right">30,242</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 5%; text-align: right">&mdash;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 5%; text-align: right">(100,888,643</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left">)</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 5%; text-align: right">(10,607,394</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left">)</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 5%; text-align: right">333,166</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif">Issue of share capital</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">112,188,766</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">965,171</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">965,171</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">Options charge</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">36,340</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">36,340</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">Warrants charge</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(627,047</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">609,661</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(17,386</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">Total transactions</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">338,124</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">36,340</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">609,661</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">984,125</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left">Comprehensive income</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">Loss for the period</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">(1,544,059</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">(1,544,059</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">Currency translation</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">86,654</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">86,654</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">Total comprehensive income</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(1,544,059</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">86,654</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(1,457,405</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Balance at 31 March 2020</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">636,297,049</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">112,079,984</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">93,441</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">639,903</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(102,432,702</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(10,520,740</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(140,114</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif">Issue of share capital</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">36,269,253</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">230,019</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">230,019</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">Options charge</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">550,138</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">550,138</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">Options exercised</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">250,000</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">15,870</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">(1,515</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">1,515</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">15,870</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">Options forfeiture</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">(5,751</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">(5,751</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">Warrants charge</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">(138,305</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">221,311</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">83,006</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">Convertible loan note issued</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">(558,395</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">8,151,777</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">7,593,382</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">Convertible loan note interest</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">219,059</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(219,059</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">Total transactions</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">(450,811</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">542,872</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">221,311</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">8,370,836</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">(217,544</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">8,466,664</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left">Comprehensive income</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">Loss for the period</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">(3,353,507</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">(3,353,507</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">Currency translation</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">346,365</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">346,365</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">Total comprehensive income</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(3,353,507</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">346,365</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(3,007,142</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 8pt Times New Roman, Times, Serif">Balance at 31 March 2021</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">672,816,302</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: right">111,629,173</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: right">636,313</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: right">861,214</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: right">8,370,836</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: right">(106,003,753</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: right">(10,174,375</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: right">5,319,408</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">Options charge</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">831,903</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">831,903</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">Options forfeiture</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">(19,149</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">(19,149</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">Warrants charge</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">34,970</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">34,970</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">Warrants Exercised</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">147,969,396</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">2,147,523</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">(847,864</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">1,299,658</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">Convertible loan note conversion</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">149,910,410</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">8,973,827</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">(8,973,827</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">Convertible loan note and warrant interest</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">91,911</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">557,229</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">(649,140</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: left">Transfer between equity reserves</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">508,865</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">(508,865</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">Total transactions</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">297,879,806</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">11,121,350</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">812,754</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">(212,118</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">(8,925,463</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">(649,140</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">2,147,383</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left">Comprehensive income</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">Loss for the period</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">(2,546,353</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">(2,546,353</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">Currency translation</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">37,844</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">37,844</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">Total comprehensive income</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">(2,546,353</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">37,844</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">(2,508,509</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: left">Balance at 30 September 2021 (unaudited)</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: right">970,696,108</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: right">122,750,523</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: right">1,449,067</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: right">649,096</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: right">(554,627</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: right">(109,199,246</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: right">(10,136,531</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: right">4,958,282</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 139; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>OKYO
Pharma Limited </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="an_016"></A>Consolidated
Statements of Cash Flows</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Six months ended</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>September 30,</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021<BR>
 (unaudited)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020<BR>
 (unaudited)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 44%; text-align: left">Loss from operations before income taxes</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(2,735,114</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(625,055</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(3,378,501</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(1,620,347</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">/Noncash license and corporate finance fee</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Share option charge</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">831,903</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,077</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">550,138</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,340</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Warrant charge</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">34,970</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37,831</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">83,006</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">42,846</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Depreciation of fixed assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,079</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">532</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,510</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">426</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Amortisation of right of use asset</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,997</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,708</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,601</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,553</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Loss on foreign exchange</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(15,263</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,056</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,915</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Impairment of loan to West African Minerals Ltd</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">69,104</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,171</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">132,668</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Options forfeiture</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(19,149</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,751</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Loss on disposal of right of use asset</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(818</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net (increase) in related party receivables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,807</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,476</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,862</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(543</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net (decrease)/increase in related party payables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28,748</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,208</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(46,311</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,049</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net /decrease/(increase) in operating assets/other receivables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(106,322</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">205,398</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">208,931</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(122,190</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net (decrease)/increase in trade and other payables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,108,328</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(320,172</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">886,093</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">271,218</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Cash inflow from taxation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">77,086</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">78,540</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Net cash used in operating activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,044,672</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(551,175</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,600,198</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,202,066</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>PPE</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,928</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,943</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Loan to West African Minerals Ltd</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(47,914</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(11,171</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(132,668</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Net cash used in investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(49,842</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(18,114</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(132,668</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Proceeds from issuance of ordinary shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">230,019</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">230,019</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">990,639</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Proceeds from issuance of convertible loan notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,593,380</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,593,380</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Processed from options exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,870</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Processed from warrants exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,460,910</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Loan to related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(518,000</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Loan repayment from related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">496,810</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Repayment of leasing liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(14,575</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,532</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(12,331</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,139</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Net cash provided by financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,446,335</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,819,867</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,826,938</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">963,310</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net increase/(decrease) in cash and cash equivalents</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,598,337</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,218,850</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,208,627</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(371,423</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Cash and cash equivalent, beginning of period</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,889,329</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">235,485</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">235,486</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">627,616</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Exchange difference</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(106,844</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,206</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">445,216</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(20,708</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Cash and cash equivalent, end of period</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,184,149</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,461,541</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,889,329</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">235,485</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 140; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="an_017"></A>1.
GENERAL INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OKYO
Pharma Limited (the &ldquo;Company&rdquo; or &ldquo;OKYO&rdquo;) is a company domiciled in Guernsey and listed on the standard market
of the London Stock Exchange (LON:OKYO).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is developing next-generation therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain.
Our goal is to develop first in class drug candidates that prevent the disease instead of controlling it, and we achieve this through
our collaboration with pioneer scientists in the field.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.
ACCOUNTING POLICIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal accounting policies applied in the preparation of these consolidated financial statements are set out below. These policies
have been applied consistently to all the years and periods presented unless otherwise stated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Basis
of preparation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements of the Group have been prepared in accordance with International Financial Reporting Standards (IFRS)
as issued by the International Accounting Standards Board (IASB), IFRIC interpretations and the Companies (Guernsey) Law 2008
as applicable to companies reporting under IFRS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Going
Concern</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group and Company incurred losses during the year and has net assets at the period ended September 30, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group and Company is in the early stages of developing its business focusing on drug candidates for the treatment of dry-eye, uveitis,
ocular and chronic pain and is in its pre-revenue R&amp;D stage. The Directors expect the Group and Company to incur further losses
and to require significant capital expenditure in continuing towards the clinical stage for these candidates. The Group and Company has
successfully secured additional investment funds to date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Directors have prepared cash flow projections that include the costs associated with the continued clinical trials and additional investment
to fund that operation. On the basis of those projections, the directors conclude that the company will not be able to meet its
liabilities as they fall due for a period beyond the next 12 months from the date when these financial statements are issued.
Consequently, in the opinion of the directors there is a material uncertainty that may cause significant doubt about the Group&rsquo;s
ability to continue as a going concern. Despite this material uncertainty, the Directors conclude that it is appropriate to continue
to adopt the going concern basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements do not include the adjustments that would be required if the going concern basis of preparation was considered inappropriate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 141; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Basis
of consolidation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiary
undertakings are all entities over which the Group exercises control. The Group has control when it can demonstrate all of the following:
(a) power over the investee; (b) exposure, or rights, to variable returns from its involvement with the investee; and (c) the ability
to use its power over the investee to affect the amount of the investor&rsquo;s return.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
existence and effect of both current voting rights and potential voting rights that are currently exercisable or convertible are considered
when assessing whether control of an entity is exercised. Subsidiaries are consolidated from the date at which the Group obtains control
and are de-consolidated from the date at which control ceases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inter-company
transactions, balances and unrealized gains on transactions between group companies are eliminated upon consolidation. Unrealized losses
are also eliminated. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted
by the Group.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Segment
reporting</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are reported in a manner consistent with the internal reporting provided to the Board. The Board allocates resources to and
assess the performance of the segments. The Board considers there to be only one operating segment being the research and development
of biotechnological and pharmaceutical products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Taxation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tax credit for the year represents the total of current taxation and deferred taxation. The credit in respect of current taxation is
based on the estimated taxable loss for the year. Taxable profit or loss for the year is based on the profit or loss as shown in the
statement of comprehensive income, as adjusted for items of income or expenditure which are not deductible or chargeable for tax purposes.
The current tax asset for the year is calculated using tax rates which have either been enacted or substantively enacted at the balance
sheet date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities
and their carrying amounts in the consolidated financial statements. Deferred tax is determined using tax rates (and laws) that have
been enacted or substantially enacted by the balance sheet date and expected to apply when the related deferred tax is realized, or the
deferred liability is settled. Deferred tax assets are recognized to the extent that it is probable that the future taxable profit will
be available against which the temporary differences can be utilized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and Development tax credits are provided for in the year that the costs are incurred. These are estimated based on eligible research
and development expenditure. Any difference rebated are recognized in the following year, when the cash is received from the UK tax authorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Functional
currency and foreign currency translation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Items
included in the financial statements of each of the Group&rsquo;s entities are measured using the currency of the primary economic environment
in which the entity operates (the functional currency), which is Pounds sterling.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements are presented in US dollars, which is the Group&rsquo;s presentation currency.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Foreign
exchange gains and losses resulting from the settlement of foreign currency transactions and from the translation at year-end exchange
rates of monetary assets and liabilities denominated in foreign currencies are recognized in the income statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 142; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements of overseas subsidiary undertakings are translated into US dollars on the following basis:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets
    and liabilities at the rate of exchange ruling at the year-end date.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Profit
    and loss account items at the average rate of exchange for the year.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchange
differences arising from the translation of the net investment in foreign entities, borrowings and other currency instruments designated
as hedges of such investments, are taken to equity (and recognized in the statement of comprehensive income) on consolidation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>License
fees</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
related to the acquisition of rights to a product or technology are capitalized as intangible assets if it is probable that future economic
benefits from the asset will flow to the entity and the cost of the asset can be reliably measured.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
made which provide the right to perform research are carefully evaluated to determine whether such payments are to fund research or acquire
an asset. License fees expenses are recognized as incurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Research
and development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
on-going research and development expenditure is currently expensed in the period in which it is incurred. Due to the regulatory environment
inherent in the development of the Group&rsquo;s products, the criteria for development costs to be recognized as an asset, as set out
in IAS 38 &lsquo;Intangible Assets&rsquo;, are not met until a product has been granted regulatory approval and it is probable that future
economic benefit will flow to the Group. The Group currently has no qualifying expenditure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Financial
instruments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group classifies a financial instrument, or its component parts, as a financial liability, a financial asset or an equity instrument
in accordance with the substance of the contractual arrangement and the definitions of a financial liability, a financial asset and an
equity instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group evaluates the terms of the financial instrument to determine whether it contains an asset, a liability or an equity component.
Such components shall be classified separately as financial assets, financial liabilities or equity instruments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument
of another entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Financial assets, initial recognition and measurement and subsequent measurement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial
recognition is at cost and subsequent measurement of financial assets depends on their classification. Financial assets such as receivables
and deposits are subsequently measured at amortized cost using the effective interest method, less loss allowance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group does not hold any financial assets at fair value through profit or loss or fair value through other comprehensive income.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Financial liabilities, initial recognition and measurement and subsequent measurement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 143; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
initial recognition, financial liabilities are measured at their fair value minus, if appropriate, any transaction costs that are directly
attributable to the issue of the financial liability. All financial liabilities are subsequently measured at amortized cost using the
effective interest method. Interest expense and foreign exchange gains and losses are recognized in profit or loss. Any gain or loss
on derecognition is also recognized in profit or loss.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group&rsquo;s financial liabilities include trade and other payables.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Impairment</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Impairment
of financial assets measured at amortized cost</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
each reporting date the Group recognizes a loss allowance for expected credit losses on financial assets measured at amortized cost.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
establishing the appropriate amount of loss allowance to be recognized, the Group applies either the general approach or the simplified
approach, depending on the nature of the underlying group of financial assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>General
approach</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
general approach is applied to the impairment assessment of refundable lease deposits and other refundable lease contributions, restricted
cash and cash and cash equivalents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the general approach the Group recognizes a loss allowance for a financial asset at an amount equal to the 12-month expected credit losses,
unless the credit risk on the financial asset has increased significantly since initial recognition, in which case a loss allowance is
recognized at an amount equal to the lifetime expected credit losses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Simplified
approach</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
simplified approach is applied to the impairment assessment of trade receivables.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the simplified approach the Group always recognizes a loss allowance for a financial asset at an amount equal to the lifetime expected
credit losses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Impairment
of non-financial assets </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-financial
assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-financial
assets are impaired when their carrying amount exceeds their recoverable amount. The recoverable amount is measured as
the higher of fair value less cost of disposal and value in use. The value in use is calculated as being net projected cash flows based
on financial forecasts discounted back to present value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Share
capital</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary
shares of the company are classified as equity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Property,
plant and equipment</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(i)
Recognition and measurement</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Items
of property, IT and equipment are measured at cost less accumulated depreciation and accumulated impairment losses. Costs include expenditures
that are directly attributable to the acquisition of the asset. Purchased software that is integral to the functionality of the related
equipment is capitalized as part of that equipment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
parts of an item of property, IT and equipment have different useful lives, they are accounted for as separate items (major components)
of property, IT and equipment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gains
and losses on disposal of an item of property, IT and equipment are determined by comparing the proceeds from disposal with the carrying
amount of property, IT and equipment, and are recognized in profit or loss. When revalued assets are sold, the amounts included in the
revaluation reserve are transferred to retained earnings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 144; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(ii)
</I>Depreciation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
is calculated on the depreciable amount, which is the cost of an asset, or other amount substituted for cost, less its residual value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
is recognized in profit or loss on a straight-line basis over the estimated useful life of each part of an item of property, IT and equipment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated useful lives for the current period and the comparative period are as follows.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 79%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IT
    and equipment</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3
    years</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fixtures
    and fittings</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5
    years</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
methods, useful lives and residual values are reviewed at each reporting date. Depreciation is allocated to the operating expenses line
of the income statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Leases</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
leases are accounted for by recognizing a right-of-use asset and a lease liability except for:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases
    of low value assets; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases
    with a duration of 12 months or less.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group has leases for its offices. Each lease is reflected on the balance sheet as a right-of-use asset and a lease liability. The Group
does not have any short-term leases or leases of low value assets. Variable lease payments which do not depend on an index or a rate
(such as lease payments based on a percentage of Group sales) are excluded from the initial measurement of the lease liability and asset.
The Group classifies its right-of-use assets in a consistent manner to its property, plant and equipment (see Note 11).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Measurement
and recognition of leases as a lessee</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
lease commencement date, the Group recognizes a right-of-use asset and a lease liability in its consolidated statement of financial
position. The right-of-use asset is measured at cost, which is made up of the initial measurement of the lease liability, any initial
direct costs incurred by the Group, an estimate of any costs to dismantle and remove the asset at the end of the lease, and any lease
payments made in advance of the lease commencement date (net of any incentives received).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group depreciates the right-of-use asset on a straight-line basis from the lease commencement date to the earlier of the end of the useful
life of the right-of-use asset or the end of the lease term. The Group also assesses the right-of-use asset for impairment when such
indicators exist.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the commencement date, the Group measures the lease liability at the present value of the lease payments unpaid at that date, discounted
using the Group&rsquo;s incremental borrowing rate because as the lease contracts are negotiated with third parties it is not possible
to determine the interest rate that is implicit in the lease. The incremental borrowing rate is the estimated rate that the Group would
have to pay to borrow the same amount over a similar term, and with similar security to obtain an asset of equivalent value. This rate
is adjusted should the lessee entity have a different risk profile to that of the Group.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 145; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
payments included in the measurement of the lease liability are made up of fixed payments (including in substance fixed), variable payments
based on an index or rate, amounts expected to be payable under a residual value guarantee and payments arising from options reasonably
certain to be exercised.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent
to initial measurement, the liability will be reduced by lease payments that are allocated between repayments of principal and finance
costs. The finance cost is the amount that produces a constant periodic rate of interest on the remaining balance of the lease liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fair
Value Measurement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
have assessed the categorization of the fair value measurements using the IFRS 13 fair value hierarchy. Categorization
within the hierarchy has been determined on the basis of the lowest level of input that is significant to the fair value measurement
of the relevant asset as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 - valued using quoted prices in active markets for identical assets;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 - valued by reference to valuation techniques using observable inputs other than quoted prices included within Level 1;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 - valued by reference to valuation techniques using inputs that are not based on observable market data.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Share
based payments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
calculation of the fair value of equity-settled share-based awards and the resulting charge to the statement of comprehensive
income requires assumptions to be made regarding future events and market conditions. These assumptions include the future volatility
of the company&rsquo;s share price. These assumptions are then applied to a recognized valuation model in order to calculate the fair
value of the awards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
employees, directors or advisers are rewarded using share-based payments, the fair value of the employees&rsquo;, directors&rsquo;
or advisers&rsquo; services are determined by reference to the fair value of the share options / warrants awarded. Their value is appraised
at the date of grant and excludes the impact of any nonmarket vesting conditions (for example, profitability and sales growth targets).
Warrants issued in association with the issue of Convertible Loan Notes are also considered as share based payments and a share-based
payment charge is calculated for these too.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with IFRS 2, a charge is made to the Statement of Comprehensive Income for all share-based payments including share options
based upon the fair value of the instrument used. A corresponding credit is made to a Share Based Payment Reserve, in the case of options
awarded to employees, directors, advisers, and other consultants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
vesting periods or other vesting conditions apply, the expense is allocated over the vesting period, based on the best available estimate
of the number of share options expected to vest. Non-market vesting conditions are included in assumptions about the number of
options that are expected to become exercisable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimates
are subsequently revised, if there is any indication that the number of share options expected to vest differs from previous estimates.
No adjustment is made to the expense or share issue cost recognized in prior periods if fewer share options ultimately are exercised
than originally estimated. Exercise of share options / warrants, the proceeds received are allocated to share capital with any excess
being recorded as share premium.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
share options are cancelled, this is treated as an acceleration of the vesting period of the options. The amount that otherwise would
have been recognized for services received over the remainder of the vesting period is recognized immediately within the Statement of
Comprehensive Income.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
share options are forfeited prior to the completion of the vesting or service period to which they relate, the forfeiture results in
the reversal of the previously recognized share-based payment cost.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 146; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
goods and services received in exchange for the grant of any share-based payment are measured at their fair value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
are issued by the Group in return for services and as part of a financing transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Warrants
issued in return for services.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
issued in return for services fall within scope of IFRS 2. The financial liability component is measured at fair value and charged to
the Consolidated Statement of Income. There is no remeasurement of fair value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Warrants
issued as part of a financing transaction.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
issued as part of a financing transaction fall outside the scope of IFRS 2. These are classified as equity instruments because a fixed
amount of cash is exchanged for a fixed amount of equity. The relative fair value is recognized within equity and is not remeasured.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Classification
of these instruments is governed by the so-called &lsquo;fixed&rsquo; test for non-derivatives, and the &lsquo;fixed for fixed&rsquo;
test for derivatives. Under the fixed test, a non-derivative contract will qualify for equity classification only where there is no contractual
obligation for the issuer to deliver a variable number of its own equity instruments. Under the fixed for fixed test, a derivative will
qualify for equity classification only where it will be settled by the issuer exchanging a fixed amount of cash or another financial
asset for a fixed number of its own equity instruments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
issued by the Group are classified as equity instruments because a fixed amount of cash is exchanged for a fixed amount of equity of
the Group. No other features exist that would result in financial liability classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Convertible
loan notes </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Where
there is no option to repay in cash or the Company has the choice of settlement, and the interest rate is fixed,</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group considers these to be convertible equity instruments and records the principal of the loan note as equity in a Convertible loan
note reserve. The accrued interest on the principal amount, for which there is no obligation to settle in cash, is also recorded in the
Convertible loan note reserve. Upon redemption of the instrument and the issue of share capital, the amount is reclassified from the
convertible loan note reserve to share capital and share premium.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Where
the above conditions are not met </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group considers these to be convertible debt instruments and records the principal of the loan note as a debt liability in the liabilities
section of the statement of financial position. The accrued interest on the principal amount is recorded in the income statement and
as an increase in the debt liability. Upon redemption of the instrument and the issue of share capital, the amount is reclassified from
the debt liability to share capital and share premium. Under IAS 32 the liability and equity components of convertible loan notes must
be presented separately on the statement of financial position. The Group has examined the terms of each issue of convertible loan notes
and determined their accounting treatment accordingly. Convertible loan notes are treated differently depending upon a number of factors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.
CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial information in accordance with generally accepted accounting practice, in the case of the Group being International
Financial Reporting Standards as adopted by the European Union, requires the Directors to make estimates and judgements that affect the
reported amount of assets, liabilities, income and expenditure and the disclosures made in the financial statements. Such estimates and
judgements must be continually evaluated based on historical experience and other factors, including expectations of future events.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following are considered to be critical accounting estimates:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Share-based
payments</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group accounts for share-based payment transactions for employees in accordance with IFRS 2 Share-based Payment, which requires the measurement
of the cost of employee services received in exchange for the options on our ordinary shares, based on the fair value of the award on
the grant date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Directors selected the Black-Scholes-Merton option pricing model as the most appropriate method for determining the estimated fair value
of our share-based awards without market conditions. For performance-based options that include vesting conditions relating to the market
performance of our ordinary shares, a Monte Carlo pricing model was used in order to reflect the valuation impact of price hurdles that
have to be met as conditions to vesting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
resulting cost of an equity incentive award is recognized as expense over the requisite service period of the award, which is
usually the vesting period. Compensation expense is recognized over the vesting period using the straight-line method.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
assumptions used for estimating fair value for share-based payment transactions are disclosed in note 16 to our consolidated financial
statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Warrants</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Directors selected the Black-Scholes-Merton option pricing model as the most appropriate method for determining the estimated fair value
of warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
assumptions used for estimating fair value for warrants are disclosed in note 9 to our consolidated interim financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 147; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following are considered to be critical accounting judgments:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are charged to expense as incurred and are typically made up of clinical and preclinical activities, drug development
and manufacturing costs, and third-party service fees, including for clinical research organizations and investigative sites. When entering
into agreements with third parties which provide the rights to conduct research into specific biological processes the Group accounts
for these agreements as an expense if the agreements are &lsquo;milestone&rsquo; in nature and relate to the Group&rsquo;s own research
and development costs. Such agreements involve periodic payments and are evaluated as representing payments made to fund research.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IFRS
16 defines the lease term as the non-cancellable period of a lease together with the options to extend or terminate a lease, if the lessee
were reasonably certain to exercise that option. This will take into account the length of time remaining before the option is exercisable,
current trading, future trading forecasts as to the ongoing profitability of the organization and the level and type of planned
future capital investment. The judgement is reassessed at each reporting period. A reassessment of the remaining life of the lease could
result in a recalculation of the lease liability and a material adjustment to the associated balances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group accounts for warrants based on whether they are issued in return for a service (within IFRS 2) or as part of a financing transaction
(outside the scope of IFRS 2).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
warrants issued as part of a financing transaction, the classification of these instruments is governed by the so-called &lsquo;fixed&rsquo;
test for non-derivatives, and the &lsquo;fixed for fixed&rsquo; test for derivatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.
CHANGES IN ACCOUNTING POLICIES AND PRIOR YEAR ADJUSTMENT</B>S</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Accounting
for warrants issued as part of a cash fundraise &ndash; Prior year adjustment</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ending March 31, 2021, the Group reviewed the accounting for warrants that were issued as part of a cash fundraise that took
place in March 2020. The accounting treatment of relative fair value was identified as the most appropriate methodology, rather than
the separate valuation of the warrants as a cost of fundraising. The impact of the change in accounting treatment resulted in an increase
in share capital of $1,435,508 and a corresponding reduction in the warrant reserve of $1,435,508.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.
OPERATING LOSS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
loss is stated after charging:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six months ended<BR> September
    30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended<BR> March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Group</I></FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021<BR>
    (unaudited)<BR> $</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020<BR>
    (unaudited)<BR> $</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021$</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020$</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 44%; text-align: left">Director fees including bonus</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">395,185</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">278,224</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">122,101</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Chairman&rsquo;s bonus</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,160,347</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Audit fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">58,874</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">53,402</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Audit-related assurance services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">33,295</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22,085</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">72,637</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Depreciation</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,165</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,240</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,512</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">212</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 148; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.
SEGMENTAL REPORTING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year under review management identified the Group&rsquo;s only operating segment as the research and development of biotechnological
and pharmaceutical products. This one segment is monitored, and strategic decisions are made based upon it and other non-financial data
collated from industry intelligence. The form of financial reporting reported to the Board is consistent with those presented in the
annual financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.
EMPLOYEES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">Year ended March 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2021</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2020</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt"><U>Group</U></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Staff costs comprised:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 68%; text-align: left">Directors&rsquo; salaries</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">1,438,571</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">122,101</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Wages and salaries</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">121,702</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">229,347</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Social security costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,543</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">68,740</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Recruitment Costs</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">12,922</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,582,739</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">420,188</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">The average monthly number of employees, including directors, employed by the group during the years
    ending March 31, 2021, and March 31, 2020 were:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Research and Development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Corporate and administration</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group and Company made $2,904 of payments to a defined contribution pension schemes on behalf of Directors or employees during the
year ending March 31, 2021 (March 31, 2020: $2,774)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 149; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.
REMUNERATION OF KEY MANAGEMENT PERSONNEL</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors
of the Group and Company received the following remuneration during the years ending March 31 2021 and 2020:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="30" STYLE="font-weight: bold; text-align: center">Year ended March 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Directors&rsquo;<BR> fees</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Bonus</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Salary</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share based payment expenses</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Directors&rsquo;<BR> fees</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Bonus</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Salary</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share based payment expenses</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 28%; text-align: left">G. Cerrone (1)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;35</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">1,160</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; font-weight: bold; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">G Jacob (2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">41</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">85</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">468</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">W Simon</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">42</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">41</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">K. Shailubhai</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">38</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">J Brancaccio (3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">G Macrae (4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">8</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">L Zambeletti (5)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">36</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">158</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,201</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">85</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">503</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">122</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">41</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold">$&rsquo;000</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Directors<BR> fees</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Bonus</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Salary</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share based<BR> payment<BR> expenses</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 44%; text-align: left">W Simon</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">42,017</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">4,424</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">K. Shailubhai</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">39,445</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,496</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Leopoldo Zambeletti (5)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48,532</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,742</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Gregor MacRae (4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">John Brancaccio (3)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">129,994</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">48,661</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gabriele
    Cerrone&rsquo;s bonus awarded for $1,160k was awarded on the basis of the co-invention of the use of Chemerin in the COVID-19
    indication when he was not a director or employee of the Company (now the subject of a patent application); work carried out in procuring,
    backing and completing the refinancing the Company in 2020 and actions taken to make new executive appointments and scientific advisory
    appointments to the Board with the result that the Company now has a clear and accelerated path to the clinic.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gary
    Jacob became an employee and Director of the Company on 7 January 2021</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
    Brancaccio was appointed as Director on 10 June 2020</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gregor
    Macrae was appointed as Director on 18 December 2019 and resigned on 10 June 2020</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leopoldo
    Zambeletti resigned as Director on 18 December 2019</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 150; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following share options were granted to Directors in the year:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">2021</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">2020</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">2019</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of <BR> options</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<BR> options</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of <BR> options</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%; text-align: left">W. Simon</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">2,000,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">L Zambeletti</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,500,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">K Shailubhai</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,500,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">J Brancaccio</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">450,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">G. Jacob</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">40,000,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">40,450,000</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">22,000,000</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
key management personnel of the Group are considered to be represented by the Directors and officers of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
director as yet benefitted from any increase in the value of share capital since issuance of the options and no director exercised share
options in the year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.
TAXATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">Year ended March 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2021</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2020</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold"><U>Group</U></TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 68%; text-align: left">Current year tax (credit)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">(24,952</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Adjustments due to R&amp;D Tax credit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(42</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(76,289</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total tax (credit) for the period</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(24,994</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(76,289</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">The tax charge for the year is different from the standard rate of corporation tax in the United Kingdom of 21.49%. The difference can be reconciled as follows:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Loss before taxation</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,378,501</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,620,347</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Loss charged at standard rate of corporation tax 19%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(641,915</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(307,866</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Tax losses arising in the year not recognized</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">660,594</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">340,114</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Expenses not deductible for taxation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">145</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Tax increase from effect of capital allowances and depreciation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(334</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">81</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Research and Development tax claim</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(43,432</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Adjustments due to R&amp;D Tax credit in prior periods</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(42</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(76,289</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Consolidation adjustment in relation to foreign exchange movements</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">135</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(32,504</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Loans written off</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total tax (credit) for the period</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(24,994</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(76,289</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
deferred tax asset has been recognized in respect of trading losses carried forward because of uncertainty as to when these losses
will be recoverable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group has tax losses of $9,411,521 (2020: $4,421,886) to carry forward for use against future profits<B>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 151; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.
FINANCE INCOME AND COSTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">Year ended March 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021<BR> $&rsquo;000</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020<BR> $&rsquo;000</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Group</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-decoration: underline; text-align: left">Finance Income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 68%; text-align: left; padding-bottom: 1.5pt">Finance income interest received on loan</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 12%; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 12%; text-align: right">48,125</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Total finance income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48,125</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-decoration: underline; text-align: left">Finance Expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Interest expense on lease liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,122</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,158</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total finance expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,122</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,158</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net finance expense recognized in Statement of Comprehensive Income</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,122</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">46,967</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.
PROPERTY, PLANT AND EQUIPMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Details
of the Group&rsquo;s property, plant and equipment are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid"><B>$000</B></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">IT equipment</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Cost</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 60%">At 1 April 2021</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">8,343</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">8,343</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Additions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Disposals</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Foreign exchange</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(203</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(203</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">At 30 September 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,140</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,140</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Depreciation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>At 1 April 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,286</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,286</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Charge in year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,079</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,079</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Foreign exchange</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(88</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(88</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">At 30 September 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,277</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,277</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Net Book Value as at 30 September 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,863</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,863</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$000</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IT
    equipment</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cost</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
    1 April 2020</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,257</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,257</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additions</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,944</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,944</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disposals</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
    exchange</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">142</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">142</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>At
    31 March 2021</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,343</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,343</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Depreciation</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
    1 April 2020</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">622</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">622</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Charge
    in year</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,593</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,593</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
    exchange</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>At
    31 March 2021</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,286</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,286</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Net
    Book Value as at 31 March 2021</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,057</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,057</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$000</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IT
    equipment</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cost</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
    1 April 2019</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,323</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,323</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additions</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disposals</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Foreign
    exchange</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(66</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(66</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>At
    31 March 2020</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,257</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,257</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Depreciation</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
    1 April 2019</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">218</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">218</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
    exchange</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Charge
    in year</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">416</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">416</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>At
    31 March 2020</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">622</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">622</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Net
    Book Value as at 31 March 2020</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">635</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">635</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 152; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.
OTHER RECEIVABLES </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six months ended<BR> September
    30, 2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold">$</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(unaudited)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Group</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%; text-align: left">Security deposit</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">4,500</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other receivables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,499</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">222,492</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">VAT receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,484</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,799</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,103</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Prepayments</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">33,742</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">21,072</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6,352</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">49,726</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">43,370</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">236,947</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no differences between the carrying amount and fair value of any of the trade and other receivables above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>13.
TRADE AND OTHER PAYABLES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six months ended<BR> September
    30, 2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold">$000</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(unaudited)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold">Group</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%; text-align: left">Trade payable</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">216,180</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">210,992</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">595,057</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Accruals</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">340,463</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">238,080</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,261</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Chairman&rsquo;s Bonus accrual</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,224,083</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Other creditors</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">27,964</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">556,643</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,673,154</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">663,282</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>14.
CAPITAL AND RESERVES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital
Management</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the purpose of the Group&rsquo;s capital management, capital includes called up share capital, share premium, share based payments for
options, share based payments for warrants and all other equity reserves attributable to the equity holders of the parent as reflected
in the statement of financial position.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s objectives when managing capital are to safeguard the Company&rsquo;s ability to continue as a going concern and to maximize
shareholder value through the optimization of the debt and equity balance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group manages its capital to maximize the return to the shareholders through the optimization of equity. The capital structure
of the Group at 31 March 2021 consists of equity attributable to equity holders of the Company, comprising issued capital, reserves and
retained deficit as disclosed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group manages its capital structure and makes adjustments to it, in light of economic conditions and the strategy approved by shareholders.
To maintain or adjust the capital structure, the Group may adjust the dividend payment to shareholders, return capital to shareholders
or issue new shares and release the Company&rsquo;s share premium account. No changes were made in the objectives, policies or processes
during the year ended 31 March 2021 and 31 March 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share
capital and premium</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue an unlimited number of nil par value shares of a single class. The Company may issue fractional
shares and a fractional share shall have the corresponding fractional rights, obligations and liabilities of a whole share of the same
class or series of shares. Shares may be issued in one or more series of shares as the Directors may by resolution determine from time
to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
share in the Company confers upon the shareholder:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    right to one vote at a meeting of the shareholders or on any resolution of shareholders;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    right to an equal share in any dividend paid by the Company; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    right to an equal share in the distribution of the surplus assets of the Company on its liquidation.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may by resolution of the Directors redeem, purchase or otherwise acquire all or any of the shares in the Company subject to regulations
set out in the Company&rsquo;s Articles of Incorporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 153; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Authorized</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue an unlimited number of nil par value shares of a single class.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Shares</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Share capital</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Issued ordinary shares of US$0.00 each</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; padding-bottom: 2.5pt">At 31 March 2018</TD><TD STYLE="width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; width: 16%; text-align: right">388,395,417</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; width: 16%; text-align: right">108,958,365</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Shares issued on lieu of fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">135,712,866</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,783,494</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">At 31 March 2019</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">524,108,283</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">111,741,860</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Shares issued - private placement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">112,188,766</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">965,171</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Relative fair value charge for warrants issued in conjunction with private placement</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(627,047</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>At 31 March 2020 (restated)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">636,297,049</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">112,079,984</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Shares issued - private placement</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">36,269,253</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">230,019</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Relative Fair value charge for warrants issued in conjunction with private placement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(138,305</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">CLNs issued in lieu of fundraising commission</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(558,395</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Options exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">250,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,870</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">At 31 March 2021</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">672,816,302</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">111,629,173</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Issuance
of ordinary shares</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
1 May 2018, the Company acquired the OK-101 Project and the BAM-8 Project. These acquisitions were settled via the issue of 135,000,000
Ordinary Shares credited fully paid at a price of 1.5 pence each.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
21 May 2018, the Company engaged Stockdale securities Ltd. &pound;2,500 of the corporate finance fee was satisfied by the issue to Stockdale
of 200,000 new ordinary at an issue price of 1.25p per ordinary share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
22 October 2018, 512,866 ordinary shares were issued at an issue price of 1.5p per ordinary share as part of an amendment to a collaboration
agreement with On Target Therapeutics LLC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2019, 36,363,636 ordinary shares were issued at an issue price of 1.1p per ordinary share by way of a placing of ordinary shares
to raise finance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2020, 75,825,130 ordinary shares were issued at an issue price of 1.1p per ordinary share by way of a further placing of ordinary
shares to raise finance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2020, 36,269,253 ordinary shares were issued at an issue price of 0.005p per ordinary share by way of a placing of ordinary shares
to raise finance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2021, 250,000 ordinary shares were issued in relation to an exercise of options at an issue price of 0. 045p per ordinary share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share
options reserve</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
reserves comprise the cumulative share-based payment charge on outstanding options in issue as at 31 March 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant&rsquo;s
reserve</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
reserves comprise the cumulative share-based payment charge on outstanding warrants in issue as at 31 March 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Directors paid no dividend during the year to 31 March 2021 and 31 March 2020<B>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>15.
SHARE OPTIONS AND WARRANTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Options</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates share-based payment arrangements to remunerate Directors and key employees in the form of a share option scheme. It
also issues options in lieu of fees to key suppliers and collaborators. The exercise price of the option is normally equal to the market
price of an ordinary share in the Company at the date of grant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <BR> Average <BR> exercise price <BR> (cents)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <BR> Average <BR> exercise price <BR> (cents)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 36%">Outstanding at 1 April</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">6.21</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">19,500,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">5.58</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">23,000,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.31</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">42,250,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Forfeited</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(6.21</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(750,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(5.58</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,500,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Exercised</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(6.21</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(250,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Outstanding at 31 March</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6.90</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">60,750,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5.58</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">19,500,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Exercisable at 31 March</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6.21</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">9,250,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5.58</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,875,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 154; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021 (unaudited)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020 (unaudited)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <BR> Average <BR> exercise
    price <BR> (cents)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <BR> Average <BR> exercise
    price <BR> (cents)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 36%">Outstanding at 1 April</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">6.90</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">19,500,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">5.58</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">23,000,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.68</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">750,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20.07</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Forfeited</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(6.06</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(750,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(5.83</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Outstanding at 30 September</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7.27</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">19,500,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6.35</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">23,000,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Exercisable at 30 September</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">8.35</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">9,500,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5.83</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,750,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
options were exercised during the six months ended 30 September 2021 and the year ended 31 March 2020. 250,000 options were exercised
during the year ended 31 March 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total outstanding fair value charge of the share option instruments is deemed to be approximately $2,019,165 (March 2021 $2,710,263,
March 2020: $495,243). A share-based payment charge for the six-month period ended September 30, 2021 of $617,793 (30 September 2020:
$8,586, March 2021: $522,615, March 2020: $37,495) has been expensed in the statement of comprehensive income.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average contractual life of options outstanding at September 30, 2021 is 7.99 years. (March 31, 2021: 8.97 years, March 2020:
5.27 years).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share
options outstanding at September 30, 2021 have the following expiry dates and exercise prices:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid">Grant Date</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center">Expiry Date</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center">Exercise Price</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: right">Share Options as at 30 September 2021<BR>
    (&lsquo;000)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 34%">6 July 2018</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 20%; text-align: center">6 July 2025</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 20%; text-align: center">4.5p</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 18%; text-align: right">2,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>20 August 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">19 August 2028</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">15.5p</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">750</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>6 January 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5 January 2031</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5p</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>12 January 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">11 January 2031</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">7.9p</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>15 April 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">15 April 2031</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">7.88p</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">31 August 2021</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">31 August 2031</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">4.9p</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">14,400</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Total</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">63,650</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Fair
value of options granted</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Directors have used the Black-Scholes option pricing model to estimate the fair value of most of the options applying the assumptions
below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historical
volatility relies in part on the historical volatility of a group of peer companies that management believes is generally comparable
to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not paid any dividends on share capital since its inception and does not anticipate paying dividends on its share capital
in the foreseeable future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has estimated a forfeiture rate of zero.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
model inputs for options granted during the six months ended 30 September 2021 valued under the Black Scholes Valuation model included:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 155; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: center">Grant Date</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt">(unaudited)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: center">31 August 2021</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: center">15 April 2021</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 56%; font-size: 10pt">Grant date share price</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 20%; font-size: 10pt; text-align: right">4.9p</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 20%; font-size: 10pt; text-align: right">7.65p</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">Exercise share price</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">4.9p</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">7.88p</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Vesting periods</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">25% each year</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">25% each year</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">Risk free rate <B>&nbsp;</B></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">0.30%</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">0.35%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Expected volatility</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">77.9%</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">80.2%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Option life</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 10pt">5 years</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 10pt">5 years</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
model inputs for options granted during the year ended 31 March 2021 valued under the Black Scholes Valuation model included:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>20
                                            August</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2020</B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6
                                            January</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2021</B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12
    January <BR>
    2021</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 43%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grant
    date share price</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.5</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">p</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.8</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">p</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.79</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">p</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise
    share price</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.5</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">p</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.5</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">p</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.79</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">p</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vesting
    periods</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25%
    each year</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25%
    each year </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33%
    in 6 months and 67% in 1 year</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
    free rate</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.15</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    volatility</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">77.4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-0.01</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.4%,
                                            0.6%</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">66.7%,
    83.7%</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6
    months to 1 year</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Option
    life</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5
    years</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">77.5</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.79</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">p</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Warrants</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the acquisition of the Chemerin project, the underlying scientific founders of the Chemerin Project (inukshuk Holdings), who
will continue to be involved in the development of the Project, received 35,000,000 warrants as consideration. The warrants are exercisable
at a price of 4.5 pence each and are split into four distinct tranches and each tranche becomes exercisable upon satisfaction of a specific
developmental milestone. The warrants are exercisable until 17 July 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2019, warrants were granted over 36,363,636 shares at an exercise price of 1.35p per share in connection with a private placement.
The warrants are exercisable until 19 May 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2020, warrants were granted over 40,000,000 shares at an exercise price of 0.55p per share in connection with a private placement.
The warrants are exercisable until 23 March 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2020, warrants were granted over 35,825,130 shares at an exercise price of 0.55p per share in connection with a private placement.
The warrants are exercisable until 28 May 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2020, warrants were granted over 36,174,870 shares at an exercise price of 0.55p per share in connection with a private placement.
The warrants are exercisable until 28 May 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2020, warrants were granted over 909,090 shares at an exercise price of 2.75p per share in in lieu of professional fees. The warrants
are exercisable until 21 May 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2020, warrants were granted over 750,000 shares at an exercise price of 14p per share in in lieu of broker fees. The warrants are
exercisable until 20 July 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <BR> Average <BR> exercise<BR> price <BR> (cents)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <BR> Average <BR> exercise<BR> price <BR> (cents)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 36%">Outstanding at 1 January</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">2.1</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">147,188,766</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">6.2</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">35,000,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.2</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37,83,3960</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">112,188,766</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Forfeited</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Outstanding at 31 December</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2.1</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">185,022,726</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2.1</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">147,188.766</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Exercisable at 31 December</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">149,568,181</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 156; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021 (unaudited)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020 (unaudited)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <BR> Average <BR> exercise
    price <BR> (cents)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <BR> Average <BR> exercise
    price <BR> (cents)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 36%">Outstanding at 1 April</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">2.07</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">185,022,726</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">1.94</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">147,188,766</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.78</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">76,605,760</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.78</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37,083,960</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.96</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(147,969,396</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Forfeited</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Outstanding at 30 September</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2.45</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">113,659,090</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1.94</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">184,272,726</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Exercisable at 30 September</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.85</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">78,659,090</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1.04</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">149,272,726</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Directors have estimated the fair value of the warrants in services provided using the Black-Scholes valuation model based on the assumptions
below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
model inputs for warrants granted during the six months ended 30 September 2021 valued under the Black Scholes Valuation model included:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">(unaudited)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7 May 2021</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 73%">Grant date share price</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 25%; text-align: right">7.25p</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Exercise share price</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">0.4p</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Vesting periods</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">Vesting market performance conditions</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify">Risk free rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">0.36%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Expected volatility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">80.6%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Expected life</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">3 years</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Directors have estimated the fair value of the warrants in services provided during the year ending 31 March 2020 using the Black-Scholes
valuation model based on the assumptions below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>July
    2020</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>May
    2020</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 51%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grant
    date share price</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.3p</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 30%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.8p</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise
    share price</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14p</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.8p</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vesting
    periods</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fully
    vested</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50%
    of these warrants shall only vest if the 5-day VWAP of the Company exceeds a 100% premium to the Exercise Price, and the remainder
    shall only vest if the 5-day VWAP of the Company exceeds a 200% premium to the Exercise Price</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
    free rate</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    volatility</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.68%</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">88.1%</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2
    years</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.95%</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">79.6%</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3
    years</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Option
    life</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.3p</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.8p</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
remaining fair value of the warrant instruments is deemed to be approximately $71,842 as at 30 September 2021 and $108,873 as at 31
March 2021 (2020: 118,658). For the consideration warrants, the charge has been expensed over the vesting period. For all other warrants,
the charge has been expensed over the service period. A share-based payment charge for the year of $83,006 (2020: $42,846) has been expensed
in the statement of comprehensive income. A share-based payment charge for the 6 months to 30 September 2021 of $34,970 (2020: 37,831)
has been expensed in the statement of comprehensive income.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 157; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>16.
</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONVERTIBLE INSTRUMENTS CLASSIFIED AS EQUITY
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2020, the Company decided to raise convertible equity finance from supportive existing shareholders. &pound;440,000 was raised from
the issuance of Convertible Loan Notes. The four year Loan Notes carry a coupon of 20% per annum and are convertible (together with all
accrued interest) into ordinary shares of nil par value each in the capital of the Company at a conversion price of 0.4p, they are not
convertible into cash. The Loan Notes are convertible at the election of the noteholder until the maturity date of the Notes, at which
point they will convert automatically, or at the election of the noteholder on completion of the next non-qualifying equity financing
or on the making of a takeover offer for the Company (as defined in the City Code on Takeovers and Mergers), and such election may be
made on an immediate basis or conditional on any such takeover offer being declared, or becoming, unconditional.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
May Convertible Loan Notes also have attached an obligation to receive warrants on a one for one basis when the notes convert.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&pound;26,400
of commission was due on these notes has been satisfied by the issuance of an identical convertible instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Between
July 2020 and September 2020, a further &pound;5,437,104 was raised from the issuance of Convertible Loan Notes. These three-year Loan
Notes are short term instruments and carry a coupon of 2.15% per annum and are convertible (together with all accrued interest) into
ordinary shares of nil par value each in the capital of the Company at a conversion price of 8.5p, they are not convertible into cash.
All conversion conditions are the same as the notes above. &pound;407,783 of commission was due on these notes has been satisfied by
the issuance of identical convertible instruments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
noteholders were offered the option to convert during the six months to September 30, 2021 and any conversions took place on 7 May, 2021.
Loan note holders were offered conversions including the full interest that would have been accrued had the note reached its full term.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amount of the Convertible Equity Instrument that was recorded in the convertible loan note reserve is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">30 September 2021 (unaudited)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">31 March 2021</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: justify">Par value of Convertible Loan Notes issued</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">7,593,381</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">7,593,381</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Plus: Par value of Convertible Loan Notes issued in lieu of fees</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">558,396</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">558,396</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">8,151,777</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">8,151,777</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accrued interest</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">776,289</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">219,059</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Conversion of Convertible Loan Notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,973,827</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Reallocation of the relative fair value of warrants issuable upon issuance of the Convertible Loan
    Note</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(508,865</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(554,627</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">8,370,836</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Transfer
between equity reserves</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
group has affected a transfer between reserves to reflect a change in the basis of estimation in connection with Convertible Loan Notes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>17.
</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LEASES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2020, the group terminated from its lease early resulting in the right of use asset of $27,069 and lease liability of $27,887
being written off to the profit and loss.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
new lease was subsequently entered into in January 2021. The initial recognition resulted in a right of use asset and a lease liability
of $104,377 respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 158; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">Right-of-use assets</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Property</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 80%; text-align: justify">At 1 April 2021</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">98,578</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Impact of Foreign exchange</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,400</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Depreciation</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(14,997</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">At 30 September 2021 (unaudited)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">81,182</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 80%; text-align: justify">At 1 April 2020</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">30,099</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Impact of Foreign exchange</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,030</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Depreciation of early terminated lease</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,060</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Early Termination write off</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(27,069</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Additions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">104,377</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Depreciation of new lease</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(5,799</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">At 31 March 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">98,579</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Property</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 80%; text-align: justify">At 1 April 2019</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">38,050</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Additions</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">At 30 March 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,050</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">At 1 April 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,537</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Charge in year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,553</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Foreign exchange movements</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(139</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">At 30 March 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,951</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt">Net book value as at 31 March 2020</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">30,099</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">Lease Liabilities</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0">30 September <BR> 2021</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">(unaudited)</P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">31 March<BR> 2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">31 March <BR> 2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">$</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: justify">At 1 April</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">98,760</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">31,689</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">35,513</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,021</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">740</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,160</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Lease payments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(15,596</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,542</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,139</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Foreign exchange movements</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,404</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,155</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Early Termination write off</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(27,887</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Additions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">104,378</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">382</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Lease payments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">81,781</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">98,760</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">31,689</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
liabilities are presented in the statement of financial position as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>30
    September <BR>
    2021 (unaudited)</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>31
    March <BR>
    2021</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>31
    March <BR>
    2020</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 52%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34,530</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34,148</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,091</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-current</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">47,251</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">64,612</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26,598</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">81.781</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">98,760</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31,689</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
lease liabilities are secured by the related underlying assets. Future minimum lease payments as at 31 September 2021 were as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="18" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Minimum lease payment due (unaudited)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Within 1 year</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">1-2 years</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2-5 years</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Over 5 years</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">30 September 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 35%; text-align: justify">Lease payments</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">35,999</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">35,999</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">12,002</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">84,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Finance charges</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,469</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(693</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(57</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,240</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt">Net present values</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">34,530</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">35,306</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">11,945</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">81,781</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 159; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18<B>.
</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BASIC AND DILUTED LOSS PER SHARE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
loss per share is calculated by dividing the loss attributable to equity holders of the Group by the weighted average number of ordinary
shares in issue during the year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six months ended<BR> September
    30</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<BR> March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021 (unaudited)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020 (unaudited)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 44%; text-align: left">(Loss) attributable to equity holders of the company ($)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(2,546,353</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(674,269</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(3,353,507</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(1,544,059</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Weighted average number of ordinary shares in issue</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">910,469,043</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">659,485,588</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">672,767,629</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">595,474,039</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">Basic and dilutive loss per share (cents per share)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(0.00</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(0.00</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(0.01</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(0.00</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the Group is reporting a loss from continuing operations for the period then, in accordance with IAS 33, the share options are not considered
dilutive because the exercise of the share options would have an anti-dilutive effect. The basic and diluted earnings per share as presented
on the face of the statement of comprehensive income are therefore identical. All earnings per share figures presented above arise from
continuing and total operations and therefore no earnings per share for discontinued operations are presented.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>19.
</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FINANCIAL INSTRUMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
main risks arising from the Group&rsquo;s financial instruments are liquidity risk, interest rate risk and credit risk. The Directors
regularly review and agree policies for managing each of these risks which are summarized below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidity
risk</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group&rsquo;s policy is to regularly monitor current and expected liquidity requirements to ensure that it maintains sufficient reserves
of cash to meet its liquidity requirements in the short and long term. The Group ordinarily finances its activities through cash generated
from by private and public offerings of equity and debt securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below summarizes the maturity profile of the Group and Company&rsquo;s financial liabilities based on contractual undiscounted
payments:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">Group</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">$</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Less than 3<BR> months</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">3 to 12<BR> months</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: justify">Trade and other payables</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">110,179</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">100,813</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">210,992</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Related party payables</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">110,179</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">100,813</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">210,992</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Group</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="10" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2020</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Less
    than 3<BR>
    months</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3
    to 12<BR>
    months</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 52%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade
    and other payables</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">141,564</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">481,343</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">622,907</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related
    party payables</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,790</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38,096</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43,886</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">147,443</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">519,439</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">666,793</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Credit
risk</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Credit
risk is managed on a Group basis. Credit risk arises principally from cash and cash equivalents and deposits with banks and financial
institutions.as well as outstanding receivables. The Group reviews its banking arrangements carefully to minimize such risks and
currently has no customers and therefore this risk is viewed as minimal. Management monitor loans between members of the Group as part
of their internal reporting and assess outstanding receivables for ability to be repaid.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Interest
rate risk</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group has limited exposure to interest-rate risk arising from its bank deposits. These deposit accounts are held at variable interest
rates based on Allied Irish Bank base rate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Directors do not consider the impact of possible interest rate changes based on current market conditions to be material to the net result
for the year or the equity position at the year-end for either the year ended 31 March 2021 or 31 March 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 160; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the Group is reporting a loss from continuing operations for the year and periods then, in accordance with IAS 33, the share options
are not considered dilutive because the exercise of the share options would have an anti-dilutive effect. The basic and diluted earnings
per share as presented on the face of the Comprehensive statement of income are therefore identical. All earnings per share figures presented
above arise from continuing and total operations and therefore no earnings per share for discontinued operations are presented.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>19.
RELATED PARTY TRANSACTIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
related party transactions occurred in the normal course of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">West
African Minerals Limited (&ldquo;WAML&rdquo;)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WAML
is a related party of the Company as it shares a common director, Willy Simon. In 2018, the Company disposed of its Cameroon operations
by way of an in specie distribution of all of its shares in Ferrum Resources Limited (renamed West African Minerals Limited) to shareholders.
As part of this transaction, the Group had agreed to a deed of release with WAML whereby it agreed to write off $17,056,070 of loans
in exchange for shares in WAML to be distributed as part of the in-specie distribution. A remaining amount of $3,400,000 was outstanding
from WAML, however, after careful consideration of the operations of WAML and its subsidiaries, the Company decided to impair this receivable
down to &pound;nil in 2018 as it does not expect to recover any of this outstanding debt. In addition to the $3,400,000 outstanding was
a working capital loan advance of $600,000 which has been impaired as the Group does not expect to recover any of this outstanding debt.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended March 31, 2021, the Group had funded $11,172 (2020: $132,668) towards this $600,000 loan facility and as at the year-end
no further amounts were payable under this facility. The amounts funded in the year have been immediately written off as the Group has
no reasonable expectation of recovering the contractual cash flows of the loan in its entirety.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended 31 March, 2020 and 31 March 2019, the Group had funded $132,668 and $365,477, respectively, towards this $600,000 loan
facility. As at the 31 March 2020 approximately $10,000 was still payable under this facility.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tiziana
Life Sciences PLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tiziana
Life Sciences PLC is a related party as it shares common Directors and officers. The Company share premises and other resources with
Tiziana Life Sciences PLC and there is a shared services agreement in place between Company and Tiziana Life Sciences PLC. As at 31<SUP>st
</SUP>March 2021, the Company had incurred $86,567 (2020: $117,767) worth of costs in relation to this agreement and at 31<SUP>st </SUP>March
2021 $26,224 was receivable from Tiziana Life Sciences PLC. At 31<SUP>st</SUP> March 2020, $43,886 was due to Tiziana Life Sciences PLC.
As at 30 September 2021, the Company had incurred $58,804 (30 September 2020: $54,092) worth of costs in relation to his agreement
and at 30 September 2020, $28,748 (30 September 2020: $13,833) was due to Tiziana Life Sciences PLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had also extended a short-term loan facility of &pound;400k to Tiziana Life Sciences PLC in 2018 with interest payable of 20%
per annum. This loan was fully repaid during the year to 31 March 2021, and no further amounts were owing. $21,190 was
due as of March 31, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Panetta
Partners Limited</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Panetta
Partners Limited is a related party as it is a shareholder of the Company and also a vendor. The Company has entered into a Deed of Assignment
with Panetta Partners whereby the Company has the licence and sub-licence of certain research and development assets in relation to the
Chemerin product, assigned to it.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gabriele
Cerrone, the Company&rsquo;s Non-Executive Chairman is also a director of Panetta Partners Ltd. As at 30 September 2021, there
is a balance due to the Group by the Non-Executive Chairman of $95,789 (unaudited) for the exercise of warrants belonging to Panetta
Partner Ltd. The balance is to be offset against fees earned by Gabriele Cerrone during the year to March 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 161; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>22.
COMMITMENTS AND CONTINGENCIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group&rsquo;s main financial commitments relate to the contractual payments in respect of its licensing agreements. Due to the uncertain
nature of scientific research and development and the length of time required to reach commercialization of the products of this
research and development, pre-clinical, clinical and commercial milestone obligations are not detailed until there is a reasonable certainty
that the obligation will become payable. Contractual commitments are detailed where amounts are known and certain.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BAM8
    &ndash; The Group are committed to paying an annual license maintenance fee until the first commercial sale. The annual license maintenance
    fee is $15,000 until May 2021, and $10,000 thereafter.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OK-101
    &ndash; The Group has retained the services of Ora, Inc., a world-class ophthalmology CRO to work with Group towards an IND
    submission for OK-101. As yet, there are no firm financial commitments for this contract.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group also has a commitment to issue the remaining warrants on a one-to-one basis when Convertible Loan Notes issued in May 2020
are converted. The warrants have the same exercise price as the Convertible Loan Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>23.
POST BALANCE SHEET EVENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
1 December 2021, the Group announced that Bernard Denoyer has been appointed as a Non-Executive Director of the Company with immediate
effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 162; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>625,000
</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>American Depositary Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>Representing
40,625,000 Ordinary Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT><IMG SRC="form424b4_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>OKYO
Pharma Limited</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 30%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-top: Black 1pt solid; font: 12pt Times New Roman, Times, Serif; width: 100%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt"><B>PROSPECTUS</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 12pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>ThinkEquity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
16, 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
and including June 10, 2022 (25 days after commencement of this offering), all dealers that effect transactions in these securities,
whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers&rsquo; obligation
to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 163; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>form424b4_001.jpg
<TEXT>
begin 644 form424b4_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !J 1H# 2(  A$! Q$!_\0
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M6;Y1@#T)S2.RG[*E-1BN>3^Y?Y_D?/DNC7#:\^D63#4+KS#'N@!(=Q][!/4
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M7BT0/S1VL&TD?[S$X_*B/L8.Z82]I)6:+/P!LI(]*UJ^92(YIXXD;U**2?\
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MT\S"IAJ<W=K4^<4^&GB]WV_V.R^[3Q@?^A5O:5\&-8N&5M3OK:SC[K%F5_Z
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MT@E?S"DLS. V,$C/3/&?I6W113;;=V"5M@HHHI %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
*%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>form424b4_012.jpg
<TEXT>
begin 644 form424b4_012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (" G # 2(  A$! Q$!_\0
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MAW0M+\/Z3':Z3&OD. YF!#-.<?>+#K_+TK6K"=2^BT1K"%M7N<=XX\ 6GBN
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MS,VJ2EI*YS8*2BB@8M%%% !1WHQ2T""EI*6@!13A2"E%)@.%+24M  *6DHI
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MLFV]S0*<*04\4 *M2*!G.!GUQS3!4@H 6BBD)H :0 <@ 'UQS32:4FF&@!,
M# 4 >@%-&!P !]!BE--H <#1@9S@9]<<TVG T +@9S@9]<<TX<C!Y![&FBG"
M@!RJJ_=51GK@8J10,YP,^N*:!3Q0,<45BI95)4Y4D9P?4>E*0",$ CT- HH
M3:I&,#'ICBDP!P  /0"G44 -I J@Y"@$]P*6B@0F:***!A2BDI: "BBE H 2
MG444 %.I*6D(44M)2T +129I<T %**2BD M%%% !2XI*6@ HHHQ0 E%+BC%
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M.M_X6?XT_P"@Y)_WYC_^)I/^%H>-/^@Y)_WYC_\ B:Y3%-/%,#KO^%H^-?\
MH.R?]^8__B:7_A:/C3_H.R?]^8__ (FN/I>E '7?\+1\:_\ 0=D_[\Q__$T\
M?%#QD?\ F.2?]^8__B:X_&:""IHL/4['_A9OC(_\QR3_ +\Q_P#Q-.C^)7C%
MADZY)_WYC_\ B:Y"/YR .M3B%TQ@@YZBBPF[(ZA_B5XR4\:Y)_WYC_\ B:7_
M (6=XO"\ZS)G_KE'_P#$UE1Z-(\'FF0;L9QBLJ?",R'J#CBIC*,FT@L['6Q_
M$KQBR _VW+S_ -,H_P#XF@?$SQ@DF'UN3;_UQC_^)KE[=!@DD_2F2A/.6/\
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MP:-=P[\T^UAAD8R2G!Z >E)0ZF3J)/78Z _$OQ@%XUN3/_7&/_XFG+\2_&)
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M$5U/L4IN!R.?:LHJ";I]R6[V<]D4%:=(&<#Y2?RH>2V?8$X:K=O;"]AN0DX
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M;V>SR-_4^]9.OL)[<IC/L*E2N['-"K+F/+[VU'F/(A_"J8;UK>N;)]D@&!Z
MUS\D;Q-M=2#2DCUZ4DU8<S#H*A=<#-2@9I&Z4K&A *4=:&&#2'([5)2U-E9R
MO!_.G>86^]5JYMD9MV,'U%4G1EZ<BM+LRO&6J&/C=Q1M&,U#(Y[9!%.28$ '
MK0A.+6HV6($$]#5;:15QB",4S9FBQ47H5NE2K)V/6AXO2HB"*"MR<G(II%-5
MO6I!S0%A@XJ1.>G-(5]JDC^[0)CE08.>M12_+QWSFIBXR >M)(@9?I5%0C?5
MD:SG'"_-Z4Z-#(YW\8/2ELBOFL&QG'&:GNW$84H1OSS2Y;+03E:=AL^V-0PS
MSV]*H@;Y,$D^]78-UQG.,@U/Y$0W#@ #H/6FMK!*22V*#QA5!%/@AE8B55&%
M.<9ZTZ>TE12^X, ,X]JDB-W%  (L@]/44FII:%^TBUN3.L<^U6R%')SZTRXB
MC52J/@8Y&>E4SYBL8Y,@]<&DV_, 3@$\TTFI7(2LBXDT2VP6%MLN,<>M-N98
MQ;JJDE\YJ6]LX(O)%M)O=NHW=O6F3W2FS6V:'$@/+4045==0G>Z:)646;0RB
M4,'^5L^GK1/%:!))UN/W^<C![UF\G@GI5JWN((K66.2#>[?=;TI3C?5;EQ]Z
M7O2 7UP;A)VD)=>!D=JGO9K:[E\U<JVWYCC&35'85C5CT-/:,*HYY(SBKBN7
M2PN7F3DNG4L07B0VTL9A#,WW6_NU&TLUW*GG2,[9"@L:BV8C#9!SV]*DCG9(
M7C &&(.>XJ7!)W2U$YN6YH16Z6%Y-%<2LK!-R[>]5'D\P!(MP)///6H3*QN%
MD=BV>"2:L75P/,Q#$L0V@<>OK5IV%#JI=?(<%%DSQW5N?-&" W:E35;E-/GL
M8V5;>5MQ7']:A:1IX_/EN/,F)P5;DXJ--C3*9#M0GD@=*CE3+BY2BH-K?^M1
M(D1\[FP1V]:T)Q!>)(UG (TB4;MQY-9^Y%,B!=V3\K'M4MO \L4SH1B,9;)J
MK$3BDEJ2Z5:07>II%<W @CP27/M4<GE-)*-WW20K#^*FVXYE/<+4^G2VUM>1
MRW=O]HA&=T><9XK.2:;DON*4K*RZE5XS& #CD<8J90@LW)"ELX'/(IDI#2NZ
M)MCR=HSG'M4*BM(OJ142OIH@!&[+=!UK3MIK"WU&.98W>W &0>N:RCT'N:VO
MM=C]@@MX;,"926>9C]X>E9S6PX6;LW8D,<6HSW$44OEK]Y W)/M6:SRAQ X.
MY#C!HMXYII6EA<*Z<@YP:,3I*)&SYI;(8]S5K160O93OS6NGL'E7*W!A(:(L
M.0PQQ3)(@)B@8$#O6B;P:C?F74YMK;-H91CI4=KI,U[%(8.64%B#_=]:44^5
M.2U(<E&>NR((XDD@; ^9>]5RA8A>U:NBZ<+[6H+260I"[8=AZ5/XALX-/U.:
MVLB9(%.%?U/>H<TI\G7<M1:=WL83L1\@[=ZE@FV$EP6]ZB1?GR_3/-:]M86U
MQ:RW E"E#PA[U;E9:D-7>B((]2DC7:J 9]:2/!E:2?&6YINH/YC1JJ;2!5=F
M8*%)S4\D8O;4'S/21?ALL[KB-@!V%1-<-(X8C@5);2JMF4+D>HS4=P83$!'C
M/M6?,[V9TU(QC3BD3.Z31@*![5>TW3U,32R#)SC%4M/C2290W1>:LZE?&T(C
M@;!(Y [45&V^5'-&GI<I:DH%RT2L=JU7BB"-D5"TCN^<DL:T([=UAW/U-6E9
M6%)<NA5GE. H-0,_%6XX1*YJ&ZM_+.5/%4E8FZO8J8+'@5-&6BXQ5FRC#-@B
MK5S HC(*X-)M%-ZV*R2Y4 <5;$FT#FL]?E-*TN :1#C<EN)1G.:AAF.XX)'-
M5WDW&GIE13':R-/[3N7#M49FV]*HE\$5)&=QR:+"2[EL3,1\HP:T;'=%+O=M
MQQTK,# =JMI<!P-IZ#I31$DF=1#K1BCVXR/Y50NM566<!3DFLV6=1"%4_,?2
MJC2@(6Z,.]"C9F7LH[ER<"0ECU-8&K+D+@<YK4BNVF4KMR0.HJ/[.)<&09]!
M5/5%0]UZG/K"P'7GTH,#XR>#6O-:*L@V?E56564@$5'+8[*;YM3+92#R,4E6
M+H8 JOTJ&:;'4.VX569:8 \?KBG&4?Q#%6T<VQ#);J^<C\JJO:,O*G-:0((X
M(I"N:6J#G9E!60\@U,A!J]Y8/49I18J_08^E/F*YD4]H(J*2'(X'-:G]FR@?
M*<_6H9+>2/[Z$>]%TRE+L9)4J>13D;!JY)$&%56B930:)DZ ,*1XR#E:CCDV
MGFM*$*Q [&DW8II/8SEA8R*".I[5IK;*8?NC(%-FA6,$KU'2HQ+(R<,1V-$H
MW5TQ2BXE&YA\M\KTI(X9)C\HS[FIW!)V'J:LVJ^2 -NXGBKBKK0ENQ#! \;8
MQDGTJO<&:.8L?E[#![5H.DJSK("NW[N,U!>Q.S(1]P\?2E"47;N:*,GH]B]:
M#S]./G=Q@GOCUJK%=.Q\L;>."?447JO!9(J_=;Y<^HJK#%*83(JG _B%5'GN
M^8SIQA+9"7C,UP2P (&!BHU.['J*OZ;':3&2.Z)\U_N$Y_SFJ=Q ;6Z,1<'!
M'(IIW;TV!65D2SW9D9&C385&*KL3)DL<MUS4DR*K?*VX>U2I+;>1'&\1#AP7
MD']VG\6HOA5D0QI&R.7?:P'RCUJ6PM1>WL5N94A\PXWN>!3[DVD=^QM59[;^
M$/UJ".&2=V6)"V!N..PIV&H\R5GJ^A;U#2KC39&CE*O'N(21#E7QZ53))VL>
M<<4&60A%9V*+T4G@48Y(['I4Q4DO>W'?HBU;WB6]E=6Y@5WFQMD/\-5!UHZK
M[K2XXJWJ0DDPQE/=3FK-W<&](G*(K$8(08'%0 X()^AIT0PTD7XBD%M2;3].
MFU&>1(#&#'$TK>8X7Y1UQGJ?:JQ'4?C36&.G:I!SM/J,5*3N[O08P_?!]13E
M.&--;A0?0XI?XOKD55A$\! G*GHX(_&FL,$4PD@!AU!!J>49)(Z9S^=389$^
M1O\ SJ>RN8[8R^9;I,'B*@-_"?45$WS1J?;!J-1D#W!HL2U?1D9ZBK*'ACC'
MRU6;[XJPGW#]*;!,CB<JZGK6[I6IVS7RMJJ-+#%$?+"CHW:L"/[ZU<L[A;::
M60PI* I&U^E*U]&#E+ELB[=-:120W*1R&7EI8Y!A<GIBIK'4&DG>XF 2V1"#
M&C8R/2LB8R21(S9()ZG^57'VGR;=65E"AF('0^E4[&E",;/GU2\_N\_ZU'O,
M8%::/='N.8QW%):O=W%Y#!&=\K' #GN:LZ7/IUWK$?\ ;#RK8Q*1^Z&3[56G
M^SQZBTEI*3'O+1D]0O;/O6>KD[;B@^:2B]"O?6TMI=R6\P E4_-CI4,8<MMC
MSGVJ>68/=M,Y+ACR:?:IF\6-&\L2-C<P^Z/6A)V][</W:EN[?H-.<D2-E\<4
ML<7D,?M"'+#C(J>YM5@OS#&_VAP?O+SFE<F[SYTF"@P!3Y5*^H2W4H:I_>46
M=>544L0&,8IT<4;1D9.X=ZL6=JUY*T,) VC))K-R25V*#?-H1>;Y> #^-+%9
MRWLN(OF;OS3[V1 OV8)^\0X)J72KTZ9<"7 8=P:K3=&<W*WNB?8)+-QYZ%6%
M6)I UO@#MUK4N[M-9BS&I!Q@#')K+O+:6V@*R1D<=:E2=]4-R4HKF6IF)*8W
M^4\U8DQ*O(XJO!;-,Q(. .IJ9H9$.TMQ3YTM!.#O<EM%59.N/2I[N7]T<D9[
M5FNY4X/&*C9V?[S<>]3RW=QI-L:6YICDGK3^!D4QCFJ"6C&*NYL58 J)<#I4
MX^Y[FDR60,"6IZ2;."*5UVBH&XIAN6C,![U$9&SD''TJ(/ZTO)H0-(NQ78P%
M<=.]-DG$C;%'!-0!0,4[8P.Y1TH;9*2-*W*Q-R,#%76 DB!3KZUGVSJYQ(.G
MI6C'F1"JC"UI?0Q<=1GV<!-YY-5'B$BD.N:O[Q$=K=/6J-U<Q1L1D9I7*5UL
M9#V;3RE0, '@U6N+"6#DC<OJ*WHR"N[IFF2\HU+D3-%5E<C9L#I49"MUJ+SP
M?:GAE8=:+B::8PQD'Y30)73K3SD=#FHR<T#1,EPN?F%7K>2-B &&:R@/:GH<
M&DXI@XG3PJ"O:B:%2IZ5BPW#IT<C\:M"_?H_S#U%8NF^@HIIE:ZLP"2@Q[55
M,(QC%;&5E7.:JS1'MUIQET9V1A=:&/+;!22!38Y&CD4 \&KKJPZBH!"&<MCD
M=*OU*Y7L3L2T1..U5O,*# 7(I\\P11R>>U1QMQDBJ7O(KETL20P/*WF$X]!5
M^W6,@K(/F!JM!,=P5.1UJ_<&..$D*Q8CTZ&ARY;)(PDFU9F/?74C2E%.$!ZC
MK5A-0C^PE)%)?&.1^M17,7G1F50 /3O5:,!B$?@8ZTTHO8Z%[FM^A/\ OKU!
M$"H''(')]*F$$EO8RI+,$8#A>.:HK(;>?,;$A3P:U]3>.[C@FF3;E< BJM)N
MR9E&R=]C+AGC$31RINX^4U&\)4J"X9FYK2LM&?4M.N;P31Q);@YW=ZSY;.>*
M,/)&5! (/M5<T>;EOJ%H*[W_  (5RCD'IWJ553>-Y.WU%1H[!63/WA@^]79+
MX7%G;6AMXHS!D>8H^9\^M,3:35OZ_P Q8I+)/-1X6G&/W;;MN*BM+EK9F8 D
M,I5ESC(-2W&G36ME;7CO$4N"VQ5<%EP<?,.U56'\78]?:B,E+6)FX=QG44J\
MC'<4$<_7K1R.1VIV&+GD-^=*  <=J,9/L:7JH/IUHL #K@]^/QI2Q4I*.JG!
MH(IP&[<O]X9%%A!.@#Y7[IZ4R/E2.XY%2#]Y;>Z\4Q,"5?1N*+ *RYS[C(IO
M\(;TYJ;' ]CBHPN"R_6BP!M^5A4Z_-"A]4_D:B3G'N*E@YC"^C$4K ,49C^C
M4U!\J_C3T'R-]134Z#ZFE81"W^L%3@8B/^Z:A/,AJQ+\L#>^ * ((AF1!3U^
M[.?\]:(!M9G/1%_6A!^X [NWZ"D(49:5$SP!TJ=24MY)N[' J*)2S.PZD[15
MJZ0>;';#A8ERYH8R""VFG4QPHSOM+L!V4=33(\JQ(P2.!2+(_FED8KQC@XXH
M') '/-+6XT]4+N.Y5'0'-6DN9IKO<"-Q&WI41S)<,SH$"X4A1TJS(L-MJ"?8
M)VE4$%9&7!]3Q2EM8<[*I9ZV^7_#&]!=V5MH<]U(XBU57VQQ;."M9<<ME</
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MPX ZFD Y1CIVZGTI2>PZ?SIK, /0#H*C+%S@=*0#RX'3K5JX>R:SMA#'(MP
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M-*P^8KJ9.U3I+*/X<T)BIT(]*U!L5+HKU4BIEN5<<T*%/44X01MVJ782:&L
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MTR1DI'GIN/09]ZB$@KOF\-1V?A/QR++4-9A@L)[9%L[A1!YV\KQ,F.2">""
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M#=GBFK>9Y*GZ4T72WTVQ5VJ/7J:F:P20@99?I6*E&,DGN7-<VVQ65A-(6<@
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MK9>WLH/$?B;4PHM[B#3+2ZB-O:K-Y+2JGFRI$2!D9_#<33]M(EQ;ZG"0KI\
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M8N,YX]:,]NAHL@L>BWWCC34TS4(+"\UZX-W:M:0VNH3AX+*-\;]AR2YP-H)
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MK7)6>L:MI]G+9V6J7MM:S9\R&&=D1\]<@'%5&>5K=+=I7,$9+)$6.U2>I Z
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M3"UQTL_9:K').33C3*YI%)6#%+MH%/45D)@J5(% Y-'"C)J&27/ HV%N/DE
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MHJ!W)J";7!Y":CI:0U+*$HHHJ0"DHHH 6BDHI +1249I""BBDS0 N:,TVBD
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MYE]J[X2;6IP_"^6_W;_>;]D;&VE2779WG./^/6V;&?J:TH/$-[*C1:5916B
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MX-5/+:-RDB,C \Y%- R_#=6XC/DR219ZQRX=#5*Y@B?Y]ODL?XD.4/\ A1+
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MK)+8Y:[2;4G=_@:<5_<7"FUM%<0/D^4APTY R<^W%:5I(FE0?VGJ #W+#;!
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MUK<U:XM/#B2Z-HN6NI/^/FX+9,8_N CT[GN:U(HX/ _A\:LT0DU"];;:1/\
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M9*\C (_ TRUOV:!P\C*VT)(H_C /&?I5VYEJ80DX2<&:%[H5Q<6<]_"H+VQ
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MIW5PT5M'8PGON=AU)KF4/>;7HO)=7\SH4HJ-GZOS9<U&.13''+<*S9+- /\
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%L9=3_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>form424b4_014.jpg
<TEXT>
begin 644 form424b4_014.jpg
M_]C_X  02D9)1@ ! 0$!( $@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (? _P# 2(  A$! Q$!_\0
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MG#_\57\R/]H77_/S-_W\-']H77_/S-_W\- ']-W_  NCP!_T.WA__P &</\
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M'_\ P9P__%5_,C_:%U_S\S?]_#1_:%U_S\S?]_#0!_3=_P +H\ ?]#MX?_\
M!G#_ /%4?\+H\ ?]#MX?_P#!G#_\57\R/]H77_/S-_W\-']H77_/S-_W\- '
M]-W_  NCP!_T.WA__P &</\ \51_PNCP!_T.WA__ ,&</_Q5?S(_VA=?\_,W
M_?PT?VA=?\_,W_?PT ?TW?\ "Z/ '_0[>'__  9P_P#Q5'_"Z/ '_0[>'_\
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M_P#P9P__ !5?S(_VA=?\_,W_ '\-']H77_/S-_W\- ']-W_"Z/ '_0[>'_\
MP9P__%4?\+H\ ?\ 0[>'_P#P9P__ !5?S(_VA=?\_,W_ '\-']H77_/S-_W\
M- ']-W_"Z/ '_0[>'_\ P9P__%4?\+H\ ?\ 0[>'_P#P9P__ !5?S(_VA=?\
M_,W_ '\-']H77_/S-_W\- ']-W_"Z/ '_0[>'_\ P9P__%4?\+H\ ?\ 0[>'
M_P#P9P__ !5?S(_VA=?\_,W_ '\-']H77_/S-_W\- ']-W_"Z/ '_0[>'_\
MP9P__%4?\+H\ ?\ 0[>'_P#P9P__ !5?S(_VA=?\_,W_ '\-']H77_/S-_W\
M- ']-W_"Z/ '_0[>'_\ P9P__%4?\+H\ ?\ 0[>'_P#P9P__ !5?S(_VA=?\
M_,W_ '\-']H77_/S-_W\- ']-W_"Z/ '_0[>'_\ P9P__%4?\+H\ ?\ 0[>'
M_P#P9P__ !5?S(_VA=?\_,W_ '\-']H77_/S-_W\- ']-W_"Z/ '_0[>'_\
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MJ5R"?,/JWO7E/]H77_/S-_W\- ']-W_"Z/ '_0[>'_\ P9P__%4?\+H\ ?\
M0[>'_P#P9P__ !5?S(_VA=?\_,W_ '\-']H77_/S-_W\- ']-W_"Z/ '_0[>
M'_\ P9P__%4?\+H\ ?\ 0[>'_P#P9P__ !5?S(_VA=?\_,W_ '\-']H77_/S
M-_W\- ']-W_"Z/ '_0[>'_\ P9P__%4?\+H\ ?\ 0[>'_P#P9P__ !5?S(_V
MA=?\_,W_ '\-']H77_/S-_W\- ']-W_"Z/ '_0[>'_\ P9P__%4?\+H\ ?\
M0[>'_P#P9P__ !5?S(_VA=?\_,W_ '\-']H77_/S-_W\- ']-W_"Z/ '_0[>
M'_\ P9P__%4?\+H\ ?\ 0[>'_P#P9P__ !5?S(_VA=?\_,W_ '\-']H77_/S
M-_W\- ']-W_"Z/ '_0[>'_\ P9P__%4?\+H\ ?\ 0[>'_P#P9P__ !5?S(_V
MA=?\_,W_ '\-']H77_/S-_W\- ']-W_"Z/ '_0[>'_\ P9P__%4?\+H\ ?\
M0[>'_P#P9P__ !5?S(_VA=?\_,W_ '\-']H77_/S-_W\- ']-W_"Z/ '_0[>
M'_\ P9P__%4?\+H\ ?\ 0[>'_P#P9P__ !5?S(_VA=?\_,W_ '\-']H77_/S
M-_W\- ']-W_"Z/ '_0[>'_\ P9P__%4?\+H\ ?\ 0[>'_P#P9P__ !5?S(_V
MA=?\_,W_ '\-']H77_/S-_W\- ']-W_"Z/ '_0[>'_\ P9P__%4?\+H\ ?\
M0[>'_P#P9P__ !5?S(_VA=?\_,W_ '\-']H77_/S-_WV: /Z=+GXN>"+/R_M
M'B_0X/,02)YFHPKN4]&&6Y'O4/\ PNCP!_T.WA__ ,&</_Q5?SP?'"YGA7P1
MLGF&?#MIG]X?[@]Z\P_M"Z_Y^9O^_AH _IN_X71X _Z';P__ .#.'_XJC_A=
M'@#_ *';P_\ ^#.'_P"*K^9'^T+K_GYF_P"_AH_M"Z_Y^9O^_AH _IN_X71X
M _Z';P__ .#.'_XJC_A='@#_ *';P_\ ^#.'_P"*K^9'^T+K_GYF_P"_AH_M
M"Z_Y^9O^_AH _IN_X71X _Z';P__ .#.'_XJC_A='@#_ *';P_\ ^#.'_P"*
MK^9'^T+K_GYF_P"_AH_M"Z_Y^9O^_AH _IN_X71X _Z';P__ .#.'_XJC_A=
M'@#_ *';P_\ ^#.'_P"*K^9'^T+K_GYF_P"_AH_M"Z_Y^9O^_AH _IN_X71X
M _Z';P__ .#.'_XJC_A='@#_ *';P_\ ^#.'_P"*K^9'^T+K_GYF_P"_AH_M
M"Z_Y^9O^_AH _IN_X71X _Z';P__ .#.'_XJC_A='@#_ *';P_\ ^#.'_P"*
MK^9'^T+K_GYF_P"_AH_M"Z_Y^9O^_AH _IN_X71X _Z';P__ .#.'_XJIIOB
MYX(M[>&>3Q?H<<,PS%(VHPA7'J#NYK^8O^T+K_GYF_[^&O5OBA<31_"OX;.L
M\JL;68'$A_O+[T ?T,?\+H\ ?]#MX?\ _!G#_P#%4?\ "Z/ '_0[>'__  9P
M_P#Q5?S(_P!H77_/S-_W\-']H77_ #\S?]_#0!_3=_PNCP!_T.WA_P#\&</_
M ,51_P +H\ ?]#MX?_\ !G#_ /%5_,C_ &A=?\_,W_?PT?VA=?\ /S-_W\-
M']-W_"Z/ '_0[>'_ /P9P_\ Q5'_  NCP!_T.WA__P &</\ \57\R/\ :%U_
MS\S?]_#1_:%U_P _,W_?PT ?TW?\+H\ ?]#MX?\ _!G#_P#%4?\ "Z/ '_0[
M>'__  9P_P#Q5?S(_P!H77_/S-_W\-']H77_ #\S?]_#0!_3=_PNCP!_T.WA
M_P#\&</_ ,51_P +H\ ?]#MX?_\ !G#_ /%5_,C_ &A=?\_,W_?PT?VA=?\
M/S-_W\- ']-W_"Z/ '_0[>'_ /P9P_\ Q5'_  NCP!_T.WA__P &</\ \57\
MR/\ :%U_S\S?]_#1_:%U_P _,W_?PT ?TW?\+H\ ?]#MX?\ _!G#_P#%4?\
M"Z/ '_0[>'__  9P_P#Q5?S(_P!H77_/S-_W\-']H77_ #\S?]_#0!_3JWQ:
M\$+9K=GQ=H8M6;:LQU"+83Z [L9J#_A='@#_ *';P_\ ^#.'_P"*K^>K5KB9
M?V<=&D$\N[^UI.?,/H/>O)O[0NO^?F;_ +^&@#^F[_A='@#_ *';P_\ ^#.'
M_P"*H_X71X _Z';P_P#^#.'_ .*K^9'^T+K_ )^9O^_AH_M"Z_Y^9O\ OX:
M/Z;O^%T> /\ H=O#_P#X,X?_ (JC_A='@#_H=O#_ /X,X?\ XJOYD?[0NO\
MGYF_[^&C^T+K_GYF_P"_AH _IN_X71X _P"AV\/_ /@SA_\ BJ/^%T> /^AV
M\/\ _@SA_P#BJ_F1_M"Z_P"?F;_OX:/[0NO^?F;_ +^&@#^F[_A='@#_ *';
MP_\ ^#.'_P"*H_X71X _Z';P_P#^#.'_ .*K^9'^T+K_ )^9O^_AH_M"Z_Y^
M9O\ OX: /Z;O^%T> /\ H=O#_P#X,X?_ (JC_A='@#_H=O#_ /X,X?\ XJOY
MD?[0NO\ GYF_[^&C^T+K_GYF_P"_AH _IN_X71X _P"AV\/_ /@SA_\ BJ/^
M%T> /^AV\/\ _@SA_P#BJ_F1_M"Z_P"?F;_OX:/[0NO^?F;_ +^&@#^F[_A=
M'@#_ *';P_\ ^#.'_P"*K7\/^./#OBUY4T37=.U=HAF1;&Z28K]=I.*_EZ_M
M"Z_Y^9O^_AK].?\ @B;+)-XL^(+22/(?L<8^9B?XUH _6BBBB@#RK]K'_DUG
MXR?]B9K/_I#-7\UE?TI_M8_\FL_&3_L3-9_](9J_FLH **** "BBB@ HHHH
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M>14 %%%% !1110 4444 %%%% !1110 4444 %?I[_P $2?\ D:OB#_UZ1_\
MH:U^85?I[_P1)_Y&KX@_]>D?_H:T ?K71110!Y5^UC_R:S\9/^Q,UG_TAFK^
M:ROZ4_VL?^36?C)_V)FL_P#I#-7\UE !1110 4444 %%%% !1110 4444 %%
M%% !7J?_ #;4W_8QI_Z(>O+*]3_YMJ;_ +&-/_1#T >64444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 >E_LY?\EB\/?]=OZ5P&M?\
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M[N2*U^T,&?8&(&2.#7,5G"2G%26S+G%PDXO=!1115D'J7QU^[X'_ .Q=M/\
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MB67BEIM,UWQ*;&VT=H$V0.5),A<#<< 'O7'?M"?LU_!+X1Z#K.AZ7\2[R_\
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M2BY3Y%Y>FJNOO6Q\,T4=.**LD**** /2_P!G+_DL7A[_ *[?TK@-:_Y#-_\
M]?$G_H1KO_V<O^2Q>'O^NW]*X#6O^0S?_P#7Q)_Z$: *=%%% !17UA_P3_\
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M645$H<\;2>ZDO_ GS-^MQWU371Q?_@*LEZ6%8Y8GWI***L04444 >E_LY?\
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MBBM2 HHHH ]8\2?\FY^$?^PG<_S:O)Z]8\2?\FY^$?\ L)W/\VKR>@ HHHH
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M17:#RPLA'[P%@3C'H:]I\2?!SQ)\1_VI/@=\5]#^Q2^ ;+1;4S:N][$B(PB
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M@]=U;_DVW1O^PM)_Z"*\BKUW5O\ DVW1O^PM)_Z"*\BH *_4/PU\==.^"/\
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M?^B'KRRO4_\ FVIO^QC3_P!$/0!Y91110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!Z7^SE_R6+P]_UV_I7 :U_R&;__ *^)/_0C7?\
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M\UE?TI_M8_\ )K/QD_[$S6?_ $AFK^:R@ HHHH **** "BBB@ HHHH ****
M"BBB@ KU/_FVIO\ L8T_]$/7EE>I_P#-M3_]C&G_ *(>@#RRBBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#TO]G+_DL7A[_KM_2N U
MK_D,W_\ U\2?^A&N_P#V<?\ DL7A[_KM_2N UK_D,W__ %\2?^A&@"G1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!ZQXD_P"3<_"/
M_83N?YM7D]>L>)/^3<_"/_83N?YM7D] !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!ZE\=?N^!_^Q=M/_0*\MKU+X[?=\#_]B[:?
M^@5Y;0 4444 %%%% !1110 4444 %%%% !1110 5ZS\4O^24?#3_ *]9O_0E
MKR:O6?BE_P DH^&G_7K-_P"A+0!Y-1110 4444 %%%% !1110 4444 %%%%
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MK?\ WX3_ .+H_P"'>/PW_P"@]K?_ 'X3_P"+KZ?HH ^8/^'>/PW_ .@]K?\
MWX3_ .+H_P"'>/PW_P"@]K?_ 'X3_P"+KZ?HH ^8/^'>/PW_ .@]K?\ WX3_
M .+KTWX<_P#!-CP3\1/"-WX3A\2ZI:6D%X-1\YX%+%MI3;C=TPQKU*O:OV9?
M^0IJ_P#US'\Z /F#_AREX(_Z'C5/_ 5?_BZ/^'*7@C_H>-4_\!5_^+K](Z*
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M'_0\:I_X"K_\77Z1T4 ?FY_PY2\$?]#QJG_@*O\ \71_PY2\$?\ 0\:I_P"
MJ_\ Q=?I'10!^;G_  Y2\$?]#QJG_@*O_P 71_PY2\$?]#QJG_@*O_Q=?I'1
M0!^;G_#E+P1_T/&J?^ J_P#Q='_#E'P1_P!#SJG_ ("K_P#%U^D=% 'Y\^*O
M^"0/A+Q=_97VGQGJ,(TZRCL(PENIW(@P&/S=:PO^'*7@C_H>-4_\!5_^+K](
MZ* /S<_X<I>"/^AXU3_P%7_XNC_AREX(_P"AXU3_ ,!5_P#BZ_2.B@#\W/\
MAREX(_Z'C5/_  %7_P"+H_X<I>"/^AXU3_P%7_XNOTCHH _-S_AREX(_Z'C5
M/_ 5?_BZ/^'*7@C_ *'C5/\ P%7_ .+K](Z* /S<_P"'*7@C_H>-4_\  5?_
M (NC_AREX(_Z'C5/_ 5?_BZ_2.B@#\W/^'*7@C_H>-4_\!5_^+H_X<I>"/\
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MW7]DO]BO0_V0/&&I'1M<NM9.M6_ER?:8@FP*=PQ@GTKZNKG[W_D<-._ZYO\
M^@F@#H**** ,'Q]_R(OB/_L&W/\ Z*:OB^OM#Q]_R(OB/_L&W/\ Z*:OB^@
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M&K;_ +ZH_P"%I^%?^@U;?]]4 =717*?\+3\*_P#0:MO^^J/^%I^%?^@U;?\
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M_(B^(_\ L&W/_HIJ^+Z^T/'W_(B^(_\ L&W/_HIJ^+Z "BBB@ HHHH ****
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MY5E."#ZBO</AA\>95FM-(\0[?+P(X[_/.>P<?UKP^C89F6-4:1V.%11DD^U
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M/,%?:7_"!^'/^@'I_P#X#K_A1_P@?AS_ * >G_\ @.O^% 'Q;Y@H\P5]I?\
M"!^'/^@'I_\ X#K_ (4?\('X<_Z >G_^ Z_X4 ?%OF"CS!7VE_P@?AS_ * >
MG_\ @.O^%'_"!^'/^@'I_P#X#K_A0!\6^8*/,%?:7_"!^'/^@'I__@.O^%'_
M  @?AS_H!Z?_ . Z_P"% 'Q;Y@H\P5]I?\('X<_Z >G_ /@.O^%'_"!^'/\
MH!Z?_P" Z_X4 ?%OF"CS!7VE_P ('X<_Z >G_P#@.O\ A1_P@?AS_H!Z?_X#
MK_A0!\6^8*/,%?:7_"!^'/\ H!Z?_P" Z_X4?\('X<_Z >G_ /@.O^% 'Q;Y
M@H\P5]I?\('X<_Z >G_^ Z_X4?\ "!^'/^@'I_\ X#K_ (4 ?%OF"CS!7VE_
MP@?AS_H!Z?\ ^ Z_X4?\('X<_P"@'I__ (#K_A0!\6^8*/,%?:7_  @?AS_H
M!Z?_ . Z_P"%'_"!^'/^@'I__@.O^% 'Q;Y@H\P5]I?\('X<_P"@'I__ (#K
M_A1_P@?AS_H!Z?\ ^ Z_X4 ?%OF"CS!7VE_P@?AS_H!Z?_X#K_A1_P ('X<_
MZ >G_P#@.O\ A0!\6^8*/,%?:7_"!^'/^@'I_P#X#K_A1_P@?AS_ * >G_\
M@.O^% 'Q;Y@H\P5]I?\ "!^'/^@'I_\ X#K_ (4?\('X<_Z >G_^ Z_X4 ?%
MOF"CS!7VE_P@?AS_ * >G_\ @.O^%'_"!^'/^@'I_P#X#K_A0!\6^8*/,%?:
M7_"!^'/^@'I__@.O^%'_  @?AS_H!Z?_ . Z_P"% 'Q;Y@H\P5]I?\('X<_Z
M >G_ /@.O^%'_"!^'/\ H!Z?_P" Z_X4 ?%OF"G5]*?&SPKHVE_#^_GL]+M+
M6=<8DAA56'X@5\XZ=876K7D-G90M<7,Q"HJC//O0!%'')<2+%#&TTK'"H@R3
M7T9\&_@XOA](]:UJ-9-3<9BA89$(_P :W?A1\*;;P+8"YN0L^L3#][+C.P?W
M5]*]$H 2EHHH **** "BBB@ HHHH *3 SG'-+10 4444 %%%% !1110 55U+
M3XM5L9K2?=Y4RE&VG!P?>K54=<U>#0=(O-1N<B"VB:5\=< 9IJ]]!.UM3CM)
M^!WA+2-!U;28[!IK;5/^/IIY"[OQQ\QYXJ'4O@)X0U73=,LKBQD9-.0QP2"5
MA)L/5"W4K[5PLGQ@^($>A)XX_L6R/@]R'^R%O]*$).!)]<<XK8^+_P >;CP9
MH^AR>'M/35+_ %%H9GCD.!!;NZJ7/O\ ,!^-=O)7YE:6OK]YR<U'E;:T]#N_
M"OPN\-^"[I;G1].CLYEB,(9/[I()'Y@4_2/AOH>A>*]0\0V-NT&HWP'V@JYV
M.?7;TS5W4M2U(^&/M>F6R7.I20JT43G"[CCJ?09_2O);?XV>(_!LWB'3O&-C
M:S:C86RW5NU@<I)NX"-Z'-8QC4JIR3O?\324J=.UT=[XM^"_A/QMK0U35M-6
M>[\ORY"&($JCH' ^]CWJIKGP#\%^()K22ZTL#[/;K:A8G**\8& K ?> 'K7+
M>%?BEXVM_$=OHWB?2;/[1JME]MTYK1N!G_EF_N*L^'?B-XTTSQQ_PCGBC3[*
M2XOK-[RQ^PMG9M.-C_XUKRUH[2V\_P B.:E+>._D=?:_!_PQ8Z]8:O;6 @N[
M.W-K'Y;$*8S_  LO0CZU7T7X*>&?#OB7^V]/@GMKK>9!&DS"($]<)G%<YH/Q
M"\9Z3\1M.T#Q796(MM821[1K)LO#LP</[8[U[!64W4INSENOP-(*$M4M@HHH
MKG-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N?O?^1PT[_KF_
M_H)KH*Y^]_Y'#3O^N;_^@F@#H**** ,'Q]_R(OB/_L&W/_HIJ^+Z^T/'W_(B
M^(_^P;<_^BFKXOH **** "BBB@ HHHH **** "BBB@ HHHH *]J_9E_Y"FK_
M /7,?SKQ6O:OV9?^0IJ__7,?SH ^A**** "BBB@ HHHH **** *]WI]K?;/M
M-M%<;#E?,0-@^HS4Z@*  ,"EHIAYA2,H92",@\$&EHI 5[/3[73U86UM%;AC
MEA$@7)]3BK%%%/<6VP4444AA1110 4444 8?C/\ Y%V[_P!W^M:L,J1VT&]U
M7*@#<<9XK*\9_P#(NW?^[_6OG?\ :#\81ZKXJCTVUUTZ5-X4M8]5DC6<1_:&
M)QY9]> >*WHTG6ERHRJ5%3CS,^I*:TBJ0"P!/3)KPO5_BMXJ\1ZMX:T[PA+I
M\,>K:*VI&\O$,@1EX("@C.3D=>U<U>>,/'/Q"N/AYJ6F:I9Z-+)=RV]U T!D
M61T.&8?,.#CIVK2.'D[7:7]?\ SE7BME?^O^"?3"S1R,RJZLR]0#DCZT/-'&
MRJ[JK-]T,0"?I7SQ?_%'5?#OB3Q3I^G6EN=8N-2AT^VGE8F/S)'";V7T&<X%
M:?B;7?%?AG4?"-MXG^P:C?S7CJMW9AHE*@9Y3G!_$U/L)?UZ7'[9'N]%?..A
M_&3QZT.C^)-4BTO_ (1R^U"33S9PJ1*,.0LF_/?'3';K4VL?'K5-#^)5A8'5
M]+U"PO+[["=+MK:3S("0-KF<C:WNH%5]6G=I:_\  %]8A:Y]#*ZMD!@2.N#3
MJ^5IOB!XT^%[^.-9U+6;+4;'^U$LK>(VK#R7D(57)!.0N0=H'.*T-*_:-UVU
MT?7[>:2WU^_@$:V6I0V<EK;L\CJ@5E?G@MGCKBG+"S6L=5I^/_#D_68;2T/H
M]=4M&OVLA<1F[5=YAW#<%]<>E6&D1/O,J_4XKY[^&T?B>/\ :#O_ /A*IK.Z
MOFT:-DGL4,:,I;."A)P1]:TOCY?75OKT,4%W/;QOI<V1$^.<]?K4JA>I[-/I
M^ER_;>ZY-=3W'SH]H;>NT]&SP:BFU"UMY DMS#&YZ*\@!KXTT/Q)K/A'X8:;
MX-UG5[J746N[6^TV]DD_>7%O(P+(3W(;</H*]*M_AMIOQ-^+/C)-8N-0S;0P
MK;M!<E!$2HY QUSS6GU91]YRT_X;_,RCB'+2,=3Z)HKPGX7^//$<7PA\13L&
MU[4]$DE@M9%^9IU7."?4C'XT[2_BWK,?PC;Q%_;&GZYJ1NHHF6&U:W%ON8!H
MW1B3N'K67U>5VEWL;*M%V]+GME]J%OIMLUQ=3);P+UDD. /QJ6*5)HUDC8.C
M#<K#H1ZU\[?''QMJ>J6?C/PY)#$;:SL+:Z@.2K&1\D@GTS45O\4_''P[T9K+
M7%TV^G;0X]0T[[,C((R %\M\D[NGWN/I5+#2<4T]7_P/\R772E:VA](TQIHU
MD5"ZAVZ*2,G\*^<8?B-\5I=8T[2GFT..?6-*?4X)Q"Q%H$ )1AGY\],\8K4\
M+_$R[\6>+/ ,US:1BYO(KF.=U8@!T'51Z'WI2P\HJ]TP5>,G:Q[[3'FCC95=
MU4MP QQGZ5X+HOQ>\4WC^,99)+=]0TT2"V\.?9&2Y55) DWDXD!'/ JCI?Q$
MU#7(O -W>ZE8Z]<WU^8Y9+6![;[,<#*,A).X=.?2D\/.-V^G^5_Z_ /;Q>Q]
M%T5X!K7Q8\:W5QKOB'1QIT/A?0KY;.:RN$+3W(#!7</G"XSTP:H:Q\:O&]Y)
MXEU71TTV'0]!-M*\5PC-+<QR$@J#_"1USSTI_5I^7]= ^L0/HZJL>J6DE])9
M)<1M=Q@,\(8;E!Z$BO/OB-\3KWP[\.;#6-,MHSJ6IF*&V28_)&\G=O4"O,/#
M>H^)?"_Q6\<WGB*[TM]5M]-A(O5W16Y'ECDIR1]!G-3&BY1<K_U=+]1RK*,K
M(^F68*,DX'J:%8,,@Y'J*^8;'XP>)/&>D>-?#=OKEA>ZC9V8NK?6+>QD@0*5
MSM,;G.??-4G^,?B_P=IOA_PU>^(--M]3?2SJ+:E+ITLJR(,;8A&A)W'/WL_A
M6WU2>W7^M2/K,/D?5E0SWEO:E1-/'"6^Z)'"Y^F:\S^#/Q0O_'G@[4KR^AWW
M>GR-%]I2!X8[G )#*C#('%<#X-\*Q?'C4/$^K>)KZ\9[.?[/9V]K,8EM0 ><
M=SGUK*-'67.[)%NLGRJ"NV?1LDJ11EW=40<EF.!20SQW$8DBD65#T9""#^(K
MP;P'+/XV^#-_9:W)JVK)IMY<6A.GE1=74<<C*H!) )P!WJK\$?$">%M!\<.T
MMWIUC82M-;Z-JC[KJS4KD!ST^8\@ GK5?5])6>J=OT$JVJTT9[[;ZE:W3S)#
M<1RM"=LH5@=A]#Z585UD4,K!E]0<BODS6-3GT?X:RZ =7CTGQ'XICN-7O+QI
MMCQ6X!*A2?XB<#'N:]I^ =U'JWP?T>.'4C?.L!B:Y$@=\\C)/K4U*/LTI7T;
M"G6YY<MCT:.\@FD:..:-Y%^\BN"1]12K=0-,T*S1M,O6,,-P_"OG74/#</@W
MXIPR>$;R_N+VUMI;G6I)Y3)$5P2 >,!L]A7,V&C3:-X8\'_$&'5KYO$.I7Z_
M:W:;,<R.W*;.P&<?A6GU=-73_K^D1[=IV:V/J];R!IS")HS,.3&'&X?A1]K@
M\_R/.C\[&?+W#=^5> >+O!MOH_Q5\/\ _"-7VHS^*KBZ^TW[O,7B2V.<AQC
MZC H^)?@NWTSQ]H$N@7VH3>-+R^$\A\XM$EL =X=<8"\C%3[&+M[VZOM_6A?
MM9*^FS/H6BFQ[O+7?R^!G'K3JY#I.,^+'AV]\5>#[C3;!0UQ,P4%N@&>M3?#
M_P"'>G> ]'CMX(UENV ::Y8?,[?T%=;10 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5D^+-$_P"$D\-ZCIF_RS=0M$']"1P:UJ*:;3NA
M-*2LSY6\4:E\0-)^$[^!!X%NM1N+<"U?48'7R7MU;[ZC.=VWMZU%KWP9\4>(
MO \VJ>$_$DA%\EK%_9U]IZF6(1R*2 Y.0!C..^*^KJ:D:QKA5"CT48KL^M-?
M#%+\;_><OU=/XG<XO4+KQ)X0^%YDM;8>(_$=K: 1PJHB$TF .G8"O&/#_A?Q
M%XT\$>(K'4O#6H:;XLU "[GU"_93%)(.1$F"2% &!7T[164*WLU9+6][FDJ*
MD]7H?/NA)XP\3^(K#Q)?>%IM+/AW3/L\=G-(-]Y< '[N#POUJ/X2ZIXI;6M5
MUSQ-X*U*/Q1>0NWG2.AMXE7[D,?/&>,G%?0U%4Z]TX\NY*HV:?,?/OPCU#Q/
MJ7CRYUCQ?X-U&UUFZW0QW3.K6UI #D*O.<G R<=J^@J**RJ3]I+FM8UIPY%:
M]PHHHK(T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y^]_Y'#3
MO^N;_P#H)KH*Y^]_Y'#3O^N;_P#H)H Z"BBB@#!\??\ (B^(_P#L&W/_ **:
MOB^OM#Q]_P B+XC_ .P;<_\ HIJ^+Z "BBB@ HHHH **** "BBB@ HHHH **
M** "O:OV9?\ D*:O_P!<Q_.O%:]J_9E_Y"FK_P#7,?SH ^A**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,3QBVWP]=GKA:XBT_9Z\
M(7E]K&JZQIT>M:AJ[^9+/=9)1=N BX/05VWC/_D7;O\ W?ZUKVO_ ![1?[@_
ME5QJ2A?E=B91C+XE<\R\&? 73O!>JV=W;:A<31V5M/:6T,GW8XI#G:/H<X^M
M5[CX!0Q^'M'L--UNZT^ZTN^:]ANU ).YLLI'H>E>M45?MIWYKZD>RA:UCRO5
MO@'INK-KEQ)J%PFH:C.EVETF ;>9"&5U_$#BH_\ A2<C66FSZMX@O=:U+397
MN$FD  <D<+M["O6**/;3M:X>RA>]CYP^#_P)N]0TFQN_$5_?PV<-W<7"Z',N
MU4D+G#Y],=!6_;_LQ6L.MV\[:_=/I=IJ/]I6UCY:Y20G)!?J1GM7M]+5O$U'
M)RON1'#TTDK'D?B#]GVVU_6=>N)-9N8[#5&6X^Q!05AN$(*RJ3Z$#BI[;X*7
M-]X5U30_$/B!]7AN@OD2I;+"]NZD%6!'4@@5ZK14^VJ=RO8PWL>8_#WX*GP7
MXHE\17NO7FMZK-:K:/)< !=BG(P.U;/CGX7V?CF^2ZN;F6!DMVMP(^F&.<UV
MM%3[6?-SWU*]G%1Y;:'DOC+]G/0O&FC>$K.ZN)X;CPW)&]M=Q'#N$Q\K>H-,
M\2? O4-2\7:GK6D^+;S1$U)$CNK>&,,& &/E.>#BO7:*J->I%))Z(ET8/H<=
MI?PWMO"O@=_#WARY?2CM.V[QO?>>KGU)KE='_9]LK/P7K>BWVJ3WMWJTPN9[
M]5$;"0?=95' Q7K=%)5IJ]GN4Z<'T/%[7]FVVEL];75O$%]JE[J]M';7%T^%
M.U,A2H['%2V/[.MO]CU*+5==O-5FGM%L+::4 &VMUZ*/4Y[U['15?6*CZD^Q
MAV.$C^$]E'KFD:E]JF\S3=,?2T7LR, "Q]^*S?#OP,T[PWJ&A7<%]</)I'GF
M+=T8R=<_2O3:*S]I.UKE>SCO8\CA^!^HCQ)?^(+CQ5/-K$D306EP(%46R$DX
MQGYNO>F>&?V=K+0Y=.O+G5KB]U.VOVU"6XVA!-(W8J. *]?HK1UZC5KD^QAO
M8\?UC]GF#4O$MY=0Z[>6>A:A<+=WVCQ@>7-(ISG/8$\D5K3? _2Y-/\ %=DE
MU-%!X@$(D5<?NA&<@+7I5%2ZU1VU&J4%T.*\5?"ZP\5^ XO#4\\L26Z((+I/
MOQNGW7'O7$+^S-:7UOKCZQX@O]4U/5H$BFO'(7:R  ,!^ XKVRBB-:<%:+"5
M*$G=H\D\*_ &+1]0UG4=3UJXU?4=5L_L4\IC6-0@7 *J.AQ6:O[.=U:VFGR6
MOBRYCUFRC:VCU"2W20FW)R(RIZXP.?:O;:*KZQ4O>Y/L8=CG/!/AJ^\-Z(++
M4]3_ +8GW9-P85BR/3 KAO%'P&EO-:U#4/#7B2[\+_VDFV]AMD#)(<8W ?PG
M%>N45$:LXR<D]RW3C)),\6\*_ W7?#O@=_"D?BB:"&UF,UCJENFVX)8[F\T9
MPW)-4M8^!.J0Z3-:PZE)J^J:U>QOJ^J7&$)A3 50H]@!7NU%7]8J7;OOJ9^P
MA:QQOBSX2>%O&FG_ &?5-'MKF1;8VL4SJ=T:E<<$'M3_  )\-=,^'7@U?#^B
MK]DA5&42I][<0?F^HS77T5ESRMRWT->2-^:VIXOX!^ &I^!=4GD7QC=ZC874
MSS7=O<P@M/NZ@OGIS4V@_LZV^CZY;23:[>7N@V,[7-AH\@&R"0G(.>X![5[%
M16LJ]23;;W,U1@K*VQXOX=^ >K^&?&.H:[:>-;R3^T+LW-Q#/"')&>(PV>%'
MI19_ '5]+\=:CXDL_&UXLFH3K+-#-"'P@S^[4Y^5>:]HHH^L5&V[[JVR#V,.
MPV-2L:J3N(&"?6G445SFX4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 5S][_R.&G?]<W_]!-=!7/WO_(X:=_US
M?_T$T =!1110!@^/O^1%\1_]@VY_]%-7Q?7VAX^_Y$7Q'_V#;G_T4U?%] !1
M110 4444 %%%% !1110 4444 %%%% !7K_[/-BVI7NIQI<S6A1 =\#;2W/>O
M(*]J_9E_Y"FK_P#7,?SH ]D_X1>?_H,ZA_W^-'_"+S_]!G4/^_QKH** .?\
M^$7G_P"@SJ'_ '^-'_"+S_\ 09U#_O\ &N@HH Y__A%Y_P#H,ZA_W^-'_"+S
M_P#09U#_ +_&N@HH Y__ (1>?_H,ZA_W^-'_  B\_P#T&=0_[_&N@HH Y_\
MX1>?_H,ZA_W^-'_"+S_]!G4/^_QKH** .?\ ^$7G_P"@SJ'_ '^-'_"+S_\
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M>?\ Z#.H?]_C1_PB\_\ T&=0_P"_QKH** .?_P"$7G_Z#.H?]_C1_P (O/\
M]!G4/^_QKH** .?_ .$7G_Z#.H?]_C1_PB\__09U#_O\:Z"B@#G_ /A%Y_\
MH,ZA_P!_C1_PB\__ $&=0_[_ !KH** .?_X1>?\ Z#.H?]_C1_PB\_\ T&=0
M_P"_QKH** .?_P"$7G_Z#.H?]_C1_P (O/\ ]!G4/^_QKH** .?_ .$7G_Z#
M.H?]_C1_PB\__09U#_O\:Z"B@#G_ /A%Y_\ H,ZA_P!_C1_PB\__ $&=0_[_
M !KH** .?_X1>?\ Z#.H?]_C1_PB\_\ T&=0_P"_QKH** .?_P"$7G_Z#.H?
M]_C1_P (O/\ ]!G4/^_QKH** .?_ .$7G_Z#.H?]_C1_PB\__09U#_O\:Z"B
M@#G_ /A%Y_\ H,ZA_P!_C1_PB\__ $&=0_[_ !KH** .?_X1>?\ Z#.H?]_C
M1_PB\_\ T&=0_P"_QKH** .?_P"$7G_Z#.H?]_C1_P (O/\ ]!G4/^_QKH**
M .?_ .$7G_Z#.H?]_C1_PB\__09U#_O\:Z"B@#G_ /A%Y_\ H,ZA_P!_C1_P
MB\__ $&=0_[_ !KH** .?_X1>?\ Z#.H?]_C1_PB\_\ T&=0_P"_QKH** .?
M_P"$7G_Z#.H?]_C1_P (O/\ ]!G4/^_QKH** .?_ .$7G_Z#.H?]_C1_PB\_
M_09U#_O\:Z"B@#G_ /A%Y_\ H,ZA_P!_C1_PB\__ $&=0_[_ !KH** .?_X1
M>?\ Z#.H?]_C1_PB\_\ T&=0_P"_QKH** .?_P"$7G_Z#.H?]_C1_P (O/\
M]!G4/^_QKH** .?_ .$7G_Z#.H?]_C1_PB\__09U#_O\:Z"B@#G_ /A%Y_\
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M@ HHHH *]J_9E_Y"FK_]<Q_.O%:]J_9E_P"0IJ__ %S'\Z /H2BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\,\>+O[MG_W_ /\ ZU'_  SQXN_NV?\ W_\ _K4 >:45Z7_PSQXN_NV?_?\
M_P#K4?\ #/'B[^[9_P#?_P#^M0!YI17I?_#/'B[^[9_]_P#_ .M1_P ,\>+O
M[MG_ -__ /ZU 'FE%>E_\,\>+O[MG_W_ /\ ZU'_  SQXN_NV?\ W_\ _K4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5S][_P CAIW_ %S?_P!!-=!7/WO_
M ".&G?\ 7-__ $$T =!1110!@^/O^1%\1_\ 8-N?_135\7U]H>/O^1%\1_\
M8-N?_135\7T %%%% !1110 4444 %%%% !1110 4444 %>U?LR_\A35_^N8_
MG7BM>U?LR_\ (4U?_KF/YT ?0E%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% &'XS_Y%V[_ -W^M:]K_P >T7^X/Y5D>,_^1=N_]W^M
M:]K_ ,>T7^X/Y4 2T444 %%%% !1110 4444 %%%% !1110 4444 <E\5O\
MD0=7_P"N1KY]^$/PFN/'4L-[?(T&BQ8R3P9R.P]J^H-;T:V\0:;-8W:EK>48
M=0>H]*FT_3[?2K*&TM8EAMX5"(BC  % "Z?80:79Q6MM$L,$:[511@ 58HHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M *"=]_W\'^%4;?21I?BZQQ<SW!>-_P#7,#C@].*Z^N?O?^1PT[_KF_\ Z":
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7_?%'_#2GAG_ )Y77_?%?-=% 'TI_P -*>&?^>5U_P!\4?\ #2GAG_GE=?\
M?%?-=% 'TI_PTIX9_P">5U_WQ1_PTIX9_P">5U_WQ7S710!]*?\ #2GAG_GE
M=?\ ?%'_  TIX9_YY77_ 'Q7S710!]*?\-*>&?\ GE=?]\4?\-*>&?\ GE=?
M]\5\UT4 ?2G_  TIX9_YY77_ 'Q1_P -*>&?^>5U_P!\5\UT4 ?2G_#2GAG_
M )Y77_?%'_#2GAG_ )Y77_?%?-=% 'O'C7X\>'_$GAB_TZVCN1/.FU-R<9KP
M2$-"L3*Q26/!5U."".X-/HH ^B/@W\8QK:Q:'K<JIJ"C$-PQP)@.Q]Z]FKX1
M^975T=HY%.Y74X*D="*^B/@W\91K2Q:'K<H34%&V&X;@3>Q]Z /9J*2EH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y^]_Y
M'#3O^N;_ /H)KH*Y^]_Y'#3O^N;_ /H)H Z"BBB@#!\??\B+XC_[!MS_ .BF
MKXOK[0\??\B+XC_[!MS_ .BFKXOH **** "BBB@ HHHH **** "BBB@ HHHH
M *]J_9E_Y"FK_P#7,?SKQ6O:OV9?^0IJ_P#US'\Z /H2BBO-/VCO&EY\/_@Q
MXGUNPR+RWM6\IEZJQ&,U48N<E%;O03:BKO8Z'5OBMX,T#5AIFI^*]&T_420!
M:7-]%'+D]/E+9KIX9H[B))8G62-QE74Y!'J#7R%\%?V2? GQ(^!>GZKXBLFU
M3Q+KML;J;6IW)GCD?D%3GC!-7/%WBK6/V8_#_@[X3^!GE\3>+M9F9;6XU1LK
M%&!DD^PKV*F"I>T>'HR;J)VU5D[7NT[Z)6ZGCT\;5]FL35BE3:OOJNUUU;OT
M/K2BOEOX?_'[Q[X;^(6H?#SXFVEA'K\FGR7VFW^GY\F;:I.TCZUYAH_[3'QY
M\3?"_4O&^GZ;HB:/HUQ*MP\N=]PJ,<[1VP.*B.65I7?,K:.]]'=M*WS5C5YC
M25ERN]VK6UT5_P M3[;OO%^B:;K5IH]WJUE;:M=@M;V,MPJS3 =2J$Y/X5L5
M\:M\7O\ A.OC1\$-4DT&P\W7M):[-Q*I,UNV#D(?2NR^#GQ]\4^-_!_Q6U+4
MEM1<^&[JYAL?*4@;45BN[UZ"E6R^I2I\[Z)M_*;CI\T%''TZM3D6S:2^<>;7
MY'TQ17Q!?_M<?$*#X(?#WQ196MA=Z[KNM2:?+;E2$=0/E ]#FMB']IGXF?"O
MXIVVA_$[3M-;3M2LWO+?^S<[H@HSM/J:N64XB/,FU=<RM?5\N]B%FE!I.SLT
MG>VRD[*_S/J3QA\._#?CZ&.+Q!H]KJB1\K]HC#$?2F>&]!\+?#V*'1-'M['2
M/-R\=G$51G]2%ZFOF'P-\;OCUXSM=+\=Z?X9TW4O!&I7'[K2X7VW:P%L!R3Q
MTKB_'4WQ1N/VWM*%E<6$=XUD9+.&4GRTLR06##^_BM:>7UG-X>I425I-J^SB
MKV:_KJ9U,PI*/MX4W)Z6=MTW:Z?]=.Y]PZ)XNT3Q)<7L&DZM9:E/8R>5=1VL
MZR- _P#=< _*>.AK59@BEF. .2:^$/#OQ>\4>%M!^+WB#POH>DVE[H>O0"_$
M"'-S"=PD=O<5Z[JW[0FL>*/B#\-O#_A-K2XM=;T^34=69QN,4(4=,=/FS6%3
M+:D7[FWY>XIZ^5MC6&8T[/GW5_G[W+]][?>>]:1XTT#Q!;W<^F:S87\%FYCN
M)+:Y1UA8=58@_*1[TR^\=^'-+CL)+S7-/M8]08):--=(HN&/0(2?F)]J^"M0
M\5>(_$'[.'Q:E\-Z?I>A0VNJW$>H&VW*TL(8[F!_OD58L/$WBGP[\,?@C'XI
MTW1M8BO;VUCTV216+P0$KM8G^_C%=D<I4G\7VDK==8\W]>1RSS3E=N7I)WZ>
MZ[?UYV/T)!R,CI2U\0?%+]K'XB6OQ=\0^&/#?]C:)#HC*D5KK1*2:@.YC8\8
M-?7'PU\37WC#P1I6K:E9+I]]<1!IK=)!(JMWPPX(KRZV"JT*4:T[6E]^NJ/2
MI8RE6K2HQWC^AT]%%%<!W&'XS_Y%V[_W?ZU\S?&S_DHUW_UQC_E7TSXS_P"1
M=N_]W^M>$?%;X=^)->\;7%]I^F-<6CPQA9 P&<"@#R2BNN_X5'XP_P"@,_\
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M &#_ &%J?_0;F_[]K1_86I_]!N;_ +]K6]10!@_V%J?_ $&YO^_:T?V%J?\
MT&YO^_:UO44 8/\ 86I_]!N;_OVM']A:G_T&YO\ OVM;U% &#_86I_\ 0;F_
M[]K1_86I_P#0;F_[]K6]10!@_P!A:G_T&YO^_:T?V%J?_0;F_P"_:UO44 8/
M]A:G_P!!N;_OVM']A:G_ -!N;_OVM;U% &#_ &%J?_0;F_[]K1_86I_]!N;_
M +]K6]10!@_V%J?_ $&YO^_:T?V%J?\ T&YO^_:UO44 8/\ 86I_]!N;_OVM
M']A:G_T&YO\ OVM;U% &#_86I_\ 0;F_[]K1_86I_P#0;F_[]K6]10!@_P!A
M:G_T&YO^_:T?V%J?_0;F_P"_:UO44 8/]A:G_P!!N;_OVM']A:G_ -!N;_OV
MM;U% &#_ &%J?_0;F_[]K1_86I_]!N;_ +]K6]10!@_V%J?_ $&YO^_:T?V%
MJ?\ T&YO^_:UO44 8/\ 86I_]!N;_OVM']A:G_T&YO\ OVM;U% &#_86I_\
M0;F_[]K1_86I_P#0;F_[]K6]10!@_P!A:G_T&YO^_:T?V%J?_0;F_P"_:UO4
M4 8/]A:G_P!!N;_OVM']A:G_ -!N;_OVM;U% &#_ &%J?_0;F_[]K1_86I_]
M!N;_ +]K6]10!@_V%J?_ $&YO^_:T?V%J?\ T&YO^_:UO44 8/\ 86I_]!N;
M_OVM']A:G_T&YO\ OVM;U% &#_86I_\ 0;F_[]K1_86I_P#0;F_[]K6]10!@
M_P!A:G_T&YO^_:T?V%J?_0;F_P"_:UO44 8/]A:G_P!!N;_OVM']A:G_ -!N
M;_OVM;U% &#_ &%J?_0;F_[]K1_86I_]!N;_ +]K6]10!@_V%J?_ $&YO^_:
MT?V%J?\ T&YO^_:UO44 8/\ 86I_]!N;_OVM']A:G_T&YO\ OVM;U% &#_86
MI_\ 0;F_[]K1_86I_P#0;F_[]K6]10!@_P!A:G_T&YO^_:T?V%J?_0;F_P"_
M:UO44 8/]A:G_P!!N;_OVM']A:G_ -!N;_OVM;U% &#_ &%J?_0;F_[]K1_8
M6I_]!N;_ +]K6]10!@_V%J?_ $&YO^_:UGPV-U9^,+$7%\]X&B?;O4#;\I]*
MZZN?O?\ D<-._P"N;_\ H)H Z"BBB@#!\??\B+XC_P"P;<_^BFKXOK[0\??\
MB+XC_P"P;<_^BFKXOH **** "BBB@ HHHH **** "BBB@ HHHH *]J_9E_Y"
MFK_]<Q_.O%:]J_9E_P"0IJ__ %S'\Z /H2BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%'_"\O!O_077_OV_^%?)VT>E&T>E 'UC_P +R\&_]!=?^_;_ .%'_"\O!O\
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M5/% 'F]%:O\ PB6O?] :\_[]FC_A$M>_Z UY_P!^S0!E45J_\(EKW_0&O/\
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MFK=%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !7/WO_ ".&G?\ 7-__ $$UT%<_>_\ (X:=_P!<W_\ 030!T%%%% &#X^_Y
M$7Q'_P!@VY_]%-7Q?7VAX^_Y$7Q'_P!@VY_]%-7Q?0 4444 %%%% !1110 4
M444 %%%% !1110 5[5^S+_R%-7_ZYC^=>*U[5^S+_P A35_^N8_G0!]"4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8?C/_D7;O\
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M?_T$T =!1110!@^/O^1%\1_]@VY_]%-7Q?7VAX^_Y$7Q'_V#;G_T4U?%^10
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MJ* /FW_A1NL_] ;_ ,F8O_BJ/^%&ZS_T!O\ R9B_^*KZ2HH ^;?^%&ZS_P!
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M?_09N?R%'_",7?\ T&;G\A70T4 <]_PC%W_T&;G\A1_PC%W_ -!FY_(5T-%
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MD*Z&B@#GO^$8N_\ H,W/Y"C_ (1B[_Z#-S^0KH:* .>_X1B[_P"@S<_D*/\
MA&+O_H,W/Y"NAHH Y[_A&+O_ *#-S^0H_P"$8N_^@S<_D*Z&B@#GO^$8N_\
MH,W/Y"C_ (1B[_Z#-S^0KH:* .>_X1B[_P"@S<_D*/\ A&+O_H,W/Y"NAHH
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MN^F5JQXP^,][I>L-I?A_PY/X@O+6S2_OPCA%@C8$J >['!X]JRCAJLG9+O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
1HH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>form424b4_002.jpg
<TEXT>
begin 644 form424b4_002.jpg
M_]C_X  02D9)1@ ! 0$!( $@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (? _P# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]3+Z]M]-L
MY[N[GCMK6WC:6::9@J1HHRS,3P  "23Z5R?_  NCP!_T.WA__P &</\ \57/
M?M7L4_9;^,;*2K#P;K)!'4?Z#-7\V7]H77_/S-_W\- ']-W_  NCP!_T.WA_
M_P &</\ \51_PNCP!_T.WA__ ,&</_Q5?S(_VA=?\_,W_?PT?VA=?\_,W_?P
MT ?TW?\ "Z/ '_0[>'__  9P_P#Q5'_"Z/ '_0[>'_\ P9P__%5_,C_:%U_S
M\S?]_#1_:%U_S\S?]_#0!_3=_P +H\ ?]#MX?_\ !G#_ /%4?\+H\ ?]#MX?
M_P#!G#_\57\R/]H77_/S-_W\-']H77_/S-_W\- ']-W_  NCP!_T.WA__P &
M</\ \51_PNCP!_T.WA__ ,&</_Q5?S(_VA=?\_,W_?PT?VA=?\_,W_?PT ?T
MW?\ "Z/ '_0[>'__  9P_P#Q5'_"Z/ '_0[>'_\ P9P__%5_,C_:%U_S\S?]
M_#1_:%U_S\S?]_#0!_3=_P +H\ ?]#MX?_\ !G#_ /%4?\+H\ ?]#MX?_P#!
MG#_\57\R/]H77_/S-_W\-']H77_/S-_W\- ']-W_  NCP!_T.WA__P &</\
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M'_\ P9P__%5_,C_:%U_S\S?]_#1_:%U_S\S?]_#0!_3=_P +H\ ?]#MX?_\
M!G#_ /%4?\+H\ ?]#MX?_P#!G#_\57\R/]H77_/S-_W\-']H77_/S-_W\- '
M]-W_  NCP!_T.WA__P &</\ \51_PNCP!_T.WA__ ,&</_Q5?S(_VA=?\_,W
M_?PT?VA=?\_,W_?PT ?TW?\ "Z/ '_0[>'__  9P_P#Q5'_"Z/ '_0[>'_\
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M_P#P9P__ !5?S(_VA=?\_,W_ '\-']H77_/S-_W\- ']-W_"Z/ '_0[>'_\
MP9P__%4?\+H\ ?\ 0[>'_P#P9P__ !5?S(_VA=?\_,W_ '\-']H77_/S-_W\
M- ']-W_"Z/ '_0[>'_\ P9P__%4?\+H\ ?\ 0[>'_P#P9P__ !5?S(_VA=?\
M_,W_ '\-']H77_/S-_W\- ']-W_"Z/ '_0[>'_\ P9P__%4?\+H\ ?\ 0[>'
M_P#P9P__ !5?S(_VA=?\_,W_ '\-']H77_/S-_W\- ']-W_"Z/ '_0[>'_\
MP9P__%4?\+H\ ?\ 0[>'_P#P9P__ !5?S(_VA=?\_,W_ '\-']H77_/S-_W\
M- ']-W_"Z/ '_0[>'_\ P9P__%4?\+H\ ?\ 0[>'_P#P9P__ !5?S(_VA=?\
M_,W_ '\-']H77_/S-_W\- ']-W_"Z/ '_0[>'_\ P9P__%4?\+H\ ?\ 0[>'
M_P#P9P__ !5?S(_VA=?\_,W_ '\-']H77_/S-_W\- ']-W_"Z/ '_0[>'_\
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MJ5R"?,/JWO7E/]H77_/S-_W\- ']-W_"Z/ '_0[>'_\ P9P__%4?\+H\ ?\
M0[>'_P#P9P__ !5?S(_VA=?\_,W_ '\-']H77_/S-_W\- ']-W_"Z/ '_0[>
M'_\ P9P__%4?\+H\ ?\ 0[>'_P#P9P__ !5?S(_VA=?\_,W_ '\-']H77_/S
M-_W\- ']-W_"Z/ '_0[>'_\ P9P__%4?\+H\ ?\ 0[>'_P#P9P__ !5?S(_V
MA=?\_,W_ '\-']H77_/S-_W\- ']-W_"Z/ '_0[>'_\ P9P__%4?\+H\ ?\
M0[>'_P#P9P__ !5?S(_VA=?\_,W_ '\-']H77_/S-_W\- ']-W_"Z/ '_0[>
M'_\ P9P__%4?\+H\ ?\ 0[>'_P#P9P__ !5?S(_VA=?\_,W_ '\-']H77_/S
M-_W\- ']-W_"Z/ '_0[>'_\ P9P__%4?\+H\ ?\ 0[>'_P#P9P__ !5?S(_V
MA=?\_,W_ '\-']H77_/S-_W\- ']-W_"Z/ '_0[>'_\ P9P__%4?\+H\ ?\
M0[>'_P#P9P__ !5?S(_VA=?\_,W_ '\-']H77_/S-_W\- ']-W_"Z/ '_0[>
M'_\ P9P__%4?\+H\ ?\ 0[>'_P#P9P__ !5?S(_VA=?\_,W_ '\-']H77_/S
M-_W\- ']-W_"Z/ '_0[>'_\ P9P__%4?\+H\ ?\ 0[>'_P#P9P__ !5?S(_V
MA=?\_,W_ '\-']H77_/S-_W\- ']-W_"Z/ '_0[>'_\ P9P__%4?\+H\ ?\
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M ,51_P +H\ ?]#MX?_\ !G#_ /%5_,C_ &A=?\_,W_?PT?VA=?\ /S-_W\-
M']-W_"Z/ '_0[>'_ /P9P_\ Q5'_  NCP!_T.WA__P &</\ \57\R/\ :%U_
MS\S?]_#1_:%U_P _,W_?PT ?TW?\+H\ ?]#MX?\ _!G#_P#%4?\ "Z/ '_0[
M>'__  9P_P#Q5?S(_P!H77_/S-_W\-']H77_ #\S?]_#0!_3=_PNCP!_T.WA
M_P#\&</_ ,51_P +H\ ?]#MX?_\ !G#_ /%5_,C_ &A=?\_,W_?PT?VA=?\
M/S-_W\- ']-W_"Z/ '_0[>'_ /P9P_\ Q5'_  NCP!_T.WA__P &</\ \57\
MR/\ :%U_S\S?]_#1_:%U_P _,W_?PT ?TW?\+H\ ?]#MX?\ _!G#_P#%4?\
M"Z/ '_0[>'__  9P_P#Q5?S(_P!H77_/S-_W\-']H77_ #\S?]_#0!_3JWQ:
M\$+9K=GQ=H8M6;:LQU"+83Z [L9J#_A='@#_ *';P_\ ^#.'_P"*K^>K5KB9
M?V<=&D$\N[^UI.?,/H/>O)O[0NO^?F;_ +^&@#^F[_A='@#_ *';P_\ ^#.'
M_P"*H_X71X _Z';P_P#^#.'_ .*K^9'^T+K_ )^9O^_AH_M"Z_Y^9O\ OX:
M/Z;O^%T> /\ H=O#_P#X,X?_ (JC_A='@#_H=O#_ /X,X?\ XJOYD?[0NO\
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MXR?]B9K/_I#-7\UE?TI_M8_\FL_&3_L3-9_](9J_FLH **** "BBB@ HHHH
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M>14 %%%% !1110 4444 %%%% !1110 4444 %?I[_P $2?\ D:OB#_UZ1_\
MH:U^85?I[_P1)_Y&KX@_]>D?_H:T ?K71110!Y5^UC_R:S\9/^Q,UG_TAFK^
M:ROZ4_VL?^36?C)_V)FL_P#I#-7\UE !1110 4444 %%%% !1110 4444 %%
M%% !7J?_ #;4W_8QI_Z(>O+*]3_YMJ;_ +&-/_1#T >64444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 >E_LY?\EB\/?]=OZ5P&M?\
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M[N2*U^T,&?8&(&2.#7,5G"2G%26S+G%PDXO=!1115D'J7QU^[X'_ .Q=M/\
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MB67BEIM,UWQ*;&VT=H$V0.5),A<#<< 'O7'?M"?LU_!+X1Z#K.AZ7\2[R_\
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M2BY3Y%Y>FJNOO6Q\,T4=.**LD**** /2_P!G+_DL7A[_ *[?TK@-:_Y#-_\
M]?$G_H1KO_V<O^2Q>'O^NW]*X#6O^0S?_P#7Q)_Z$: *=%%% !17UA_P3_\
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M645$H<\;2>ZDO_ GS-^MQWU371Q?_@*LEZ6%8Y8GWI***L04444 >E_LY?\
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MBBM2 HHHH ]8\2?\FY^$?^PG<_S:O)Z]8\2?\FY^$?\ L)W/\VKR>@ HHHH
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M17:#RPLA'[P%@3C'H:]I\2?!SQ)\1_VI/@=\5]#^Q2^ ;+1;4S:N][$B(PB
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M@]=U;_DVW1O^PM)_Z"*\BKUW5O\ DVW1O^PM)_Z"*\BH *_4/PU\==.^"/\
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M?^B'KRRO4_\ FVIO^QC3_P!$/0!Y91110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!Z7^SE_R6+P]_UV_I7 :U_R&;__ *^)/_0C7?\
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M\UE?TI_M8_\ )K/QD_[$S6?_ $AFK^:R@ HHHH **** "BBB@ HHHH ****
M"BBB@ KU/_FVIO\ L8T_]$/7EE>I_P#-M3_]C&G_ *(>@#RRBBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#TO]G+_DL7A[_KM_2N U
MK_D,W_\ U\2?^A&N_P#V<?\ DL7A[_KM_2N UK_D,W__ %\2?^A&@"G1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!ZQXD_P"3<_"/
M_83N?YM7D]>L>)/^3<_"/_83N?YM7D] !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!ZE\=?N^!_^Q=M/_0*\MKU+X[?=\#_]B[:?
M^@5Y;0 4444 %%%% !1110 4444 %%%% !1110 5ZS\4O^24?#3_ *]9O_0E
MKR:O6?BE_P DH^&G_7K-_P"A+0!Y-1110 4444 %%%% !1110 4444 %%%%
M!1110!Z[JW_)MNC?]A:3_P!!%>15Z[JW_)MNC?\ 86D_]!%>14 %%%% !111
M0 4444 %%%% !1110 4444 %?I[_ ,$2?^1J^(/_ %Z1_P#H:U^85?I[_P $
M2?\ D:OB#_UZ1_\ H:T ?K71110!QOQG\.VWB[X/>.M"O9'BL]4T&_LII(AE
ME22W=&('J QK\I/^'>/PW_Z#VM_]^$_^+K];_'W_ "(OB/\ [!MS_P"BFKXO
MH ^8/^'>/PW_ .@]K?\ WX3_ .+H_P"'>/PW_P"@]K?_ 'X3_P"+KZ?HH ^8
M/^'>/PW_ .@]K?\ WX3_ .+H_P"'>/PW_P"@]K?_ 'X3_P"+KZ?HH ^8/^'>
M/PW_ .@]K?\ WX3_ .+H_P"'>/PW_P"@]K?_ 'X3_P"+KZ?HH ^8/^'>/PW_
M .@]K?\ WX3_ .+H_P"'>/PW_P"@]K?_ 'X3_P"+KZ?HH ^8/^'>/PW_ .@]
MK?\ WX3_ .+H_P"'>/PW_P"@]K?_ 'X3_P"+KZ?HH ^8/^'>/PW_ .@]K?\
MWX3_ .+H_P"'>/PW_P"@]K?_ 'X3_P"+KZ?HH ^8/^'>/PW_ .@]K?\ WX3_
M .+KTWX<_P#!-CP3\1/"-WX3A\2ZI:6D%X-1\YX%+%MI3;C=TPQKU*O:OV9?
M^0IJ_P#US'\Z /F#_AREX(_Z'C5/_ 5?_BZ/^'*7@C_H>-4_\!5_^+K](Z*
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M'_0\:I_X"K_\77Z1T4 ?FY_PY2\$?]#QJG_@*O\ \71_PY2\$?\ 0\:I_P"
MJ_\ Q=?I'10!^;G_  Y2\$?]#QJG_@*O_P 71_PY2\$?]#QJG_@*O_Q=?I'1
M0!^;G_#E+P1_T/&J?^ J_P#Q='_#E'P1_P!#SJG_ ("K_P#%U^D=% 'Y\^*O
M^"0/A+Q=_97VGQGJ,(TZRCL(PENIW(@P&/S=:PO^'*7@C_H>-4_\!5_^+K](
MZ* /S<_X<I>"/^AXU3_P%7_XNC_AREX(_P"AXU3_ ,!5_P#BZ_2.B@#\W/\
MAREX(_Z'C5/_  %7_P"+H_X<I>"/^AXU3_P%7_XNOTCHH _-S_AREX(_Z'C5
M/_ 5?_BZ/^'*7@C_ *'C5/\ P%7_ .+K](Z* /S<_P"'*7@C_H>-4_\  5?_
M (NC_AREX(_Z'C5/_ 5?_BZ_2.B@#\W/^'*7@C_H>-4_\!5_^+H_X<I>"/\
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MW7]DO]BO0_V0/&&I'1M<NM9.M6_ER?:8@FP*=PQ@GTKZNKG[W_D<-._ZYO\
M^@F@#H**** ,'Q]_R(OB/_L&W/\ Z*:OB^OM#Q]_R(OB/_L&W/\ Z*:OB^@
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M&K;_ +ZH_P"%I^%?^@U;?]]4 =717*?\+3\*_P#0:MO^^J/^%I^%?^@U;?\
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M_(B^(_\ L&W/_HIJ^+Z^T/'W_(B^(_\ L&W/_HIJ^+Z "BBB@ HHHH ****
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MY5E."#ZBO</AA\>95FM-(\0[?+P(X[_/.>P<?UKP^C89F6-4:1V.%11DD^U
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M/,%?:7_"!^'/^@'I_P#X#K_A1_P@?AS_ * >G_\ @.O^% 'Q;Y@H\P5]I?\
M"!^'/^@'I_\ X#K_ (4?\('X<_Z >G_^ Z_X4 ?%OF"CS!7VE_P@?AS_ * >
MG_\ @.O^%'_"!^'/^@'I_P#X#K_A0!\6^8*/,%?:7_"!^'/^@'I__@.O^%'_
M  @?AS_H!Z?_ . Z_P"% 'Q;Y@H\P5]I?\('X<_Z >G_ /@.O^%'_"!^'/\
MH!Z?_P" Z_X4 ?%OF"CS!7VE_P ('X<_Z >G_P#@.O\ A1_P@?AS_H!Z?_X#
MK_A0!\6^8*/,%?:7_"!^'/\ H!Z?_P" Z_X4?\('X<_Z >G_ /@.O^% 'Q;Y
M@H\P5]I?\('X<_Z >G_^ Z_X4?\ "!^'/^@'I_\ X#K_ (4 ?%OF"CS!7VE_
MP@?AS_H!Z?\ ^ Z_X4?\('X<_P"@'I__ (#K_A0!\6^8*/,%?:7_  @?AS_H
M!Z?_ . Z_P"%'_"!^'/^@'I__@.O^% 'Q;Y@H\P5]I?\('X<_P"@'I__ (#K
M_A1_P@?AS_H!Z?\ ^ Z_X4 ?%OF"CS!7VE_P@?AS_H!Z?_X#K_A1_P ('X<_
MZ >G_P#@.O\ A0!\6^8*/,%?:7_"!^'/^@'I_P#X#K_A1_P@?AS_ * >G_\
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M\_R/.C\[&?+W#=^5> >+O!MOH_Q5\/\ _"-7VHS^*KBZ^TW[O,7B2V.<AQC
MZC H^)?@NWTSQ]H$N@7VH3>-+R^$\A\XM$EL =X=<8"\C%3[&+M[VZOM_6A?
MM9*^FS/H6BFQ[O+7?R^!G'K3JY#I.,^+'AV]\5>#[C3;!0UQ,P4%N@&>M3?#
M_P"'>G> ]'CMX(UENV ::Y8?,[?T%=;10 4444 %%%% !1110 4444 %%%%
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M(*]J_9E_Y"FK_P#7,?SH ]D_X1>?_H,ZA_W^-'_"+S_]!G4/^_QKH** .?\
M^$7G_P"@SJ'_ '^-'_"+S_\ 09U#_O\ &N@HH Y__A%Y_P#H,ZA_W^-'_"+S
M_P#09U#_ +_&N@HH Y__ (1>?_H,ZA_W^-'_  B\_P#T&=0_[_&N@HH Y_\
MX1>?_H,ZA_W^-'_"+S_]!G4/^_QKH** .?\ ^$7G_P"@SJ'_ '^-'_"+S_\
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M>?\ Z#.H?]_C1_PB\_\ T&=0_P"_QKH** .?_P"$7G_Z#.H?]_C1_P (O/\
M]!G4/^_QKH** .?_ .$7G_Z#.H?]_C1_PB\__09U#_O\:Z"B@#G_ /A%Y_\
MH,ZA_P!_C1_PB\__ $&=0_[_ !KH** .?_X1>?\ Z#.H?]_C1_PB\_\ T&=0
M_P"_QKH** .?_P"$7G_Z#.H?]_C1_P (O/\ ]!G4/^_QKH** .?_ .$7G_Z#
M.H?]_C1_PB\__09U#_O\:Z"B@#G_ /A%Y_\ H,ZA_P!_C1_PB\__ $&=0_[_
M !KH** .?_X1>?\ Z#.H?]_C1_PB\_\ T&=0_P"_QKH** .?_P"$7G_Z#.H?
M]_C1_P (O/\ ]!G4/^_QKH** .?_ .$7G_Z#.H?]_C1_PB\__09U#_O\:Z"B
M@#G_ /A%Y_\ H,ZA_P!_C1_PB\__ $&=0_[_ !KH** .?_X1>?\ Z#.H?]_C
M1_PB\_\ T&=0_P"_QKH** .?_P"$7G_Z#.H?]_C1_P (O/\ ]!G4/^_QKH**
M .?_ .$7G_Z#.H?]_C1_PB\__09U#_O\:Z"B@#G_ /A%Y_\ H,ZA_P!_C1_P
MB\__ $&=0_[_ !KH** .?_X1>?\ Z#.H?]_C1_PB\_\ T&=0_P"_QKH** .?
M_P"$7G_Z#.H?]_C1_P (O/\ ]!G4/^_QKH** .?_ .$7G_Z#.H?]_C1_PB\_
M_09U#_O\:Z"B@#G_ /A%Y_\ H,ZA_P!_C1_PB\__ $&=0_[_ !KH** .?_X1
M>?\ Z#.H?]_C1_PB\_\ T&=0_P"_QKH** .?_P"$7G_Z#.H?]_C1_P (O/\
M]!G4/^_QKH** .?_ .$7G_Z#.H?]_C1_PB\__09U#_O\:Z"B@#G_ /A%Y_\
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M@ HHHH *]J_9E_Y"FK_]<Q_.O%:]J_9E_P"0IJ__ %S'\Z /H2BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\,\>+O[MG_W_ /\ ZU'_  SQXN_NV?\ W_\ _K4 >:45Z7_PSQXN_NV?_?\
M_P#K4?\ #/'B[^[9_P#?_P#^M0!YI17I?_#/'B[^[9_]_P#_ .M1_P ,\>+O
M[MG_ -__ /ZU 'FE%>E_\,\>+O[MG_W_ /\ ZU'_  SQXN_NV?\ W_\ _K4
M>:45Z7_PSQXN_NV?_?\ _P#K4?\ #/'B[^[9_P#?_P#^M0!YI17>ZY\$?$WA
M_2[C4+L6OV>!=S[)LG'TQ7 JX9 W8C- "YQR>!7H7PG^$\_CN\6]OD:'18FR
M21@S'T'M[TOPG^%%QXZO%OKY&AT6)LDD8,Q'\(]O>OJ.PL8-,LXK6UB6&"-=
MJHHP * %L[.+3[6*V@01PQ*$1!T '05/110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5S][_P CAIW_ %S?_P!!-=!7/WO_
M ".&G?\ 7-__ $$T =!1110!@^/O^1%\1_\ 8-N?_135\7U]H>/O^1%\1_\
M8-N?_135\7T %%%% !1110 4444 %%%% !1110 4444 %>U?LR_\A35_^N8_
MG7BM>U?LR_\ (4U?_KF/YT ?0E%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% &'XS_Y%V[_ -W^M:]K_P >T7^X/Y5D>,_^1=N_]W^M
M:]K_ ,>T7^X/Y4 2T444 %%%% !1110 4444 %%%% !1110 4444 <E\5O\
MD0=7_P"N1KY]^$/PFN/'4L-[?(T&BQ8R3P9R.P]J^H-;T:V\0:;-8W:EK>48
M=0>H]*FT_3[?2K*&TM8EAMX5"(BC  % "Z?80:79Q6MM$L,$:[511@ 58HHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M *"=]_W\'^%4;?21I?BZQQ<SW!>-_P#7,#C@].*Z^N?O?^1PT[_KF_\ Z":
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7_?%'_#2GAG_ )Y77_?%?-=% 'TI_P -*>&?^>5U_P!\4?\ #2GAG_GE=?\
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M=N_]W^M>$?%;X=^)->\;7%]I^F-<6CPQA9 P&<"@#R2BNN_X5'XP_P"@,_\
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M &#_ &%J?_0;F_[]K1_86I_]!N;_ +]K6]10!@_V%J?_ $&YO^_:T?V%J?\
MT&YO^_:UO44 8/\ 86I_]!N;_OVM']A:G_T&YO\ OVM;U% &#_86I_\ 0;F_
M[]K1_86I_P#0;F_[]K6]10!@_P!A:G_T&YO^_:T?V%J?_0;F_P"_:UO44 8/
M]A:G_P!!N;_OVM']A:G_ -!N;_OVM;U% &#_ &%J?_0;F_[]K1_86I_]!N;_
M +]K6]10!@_V%J?_ $&YO^_:T?V%J?\ T&YO^_:UO44 8/\ 86I_]!N;_OVM
M']A:G_T&YO\ OVM;U% &#_86I_\ 0;F_[]K1_86I_P#0;F_[]K6]10!@_P!A
M:G_T&YO^_:T?V%J?_0;F_P"_:UO44 8/]A:G_P!!N;_OVM']A:G_ -!N;_OV
MM;U% &#_ &%J?_0;F_[]K1_86I_]!N;_ +]K6]10!@_V%J?_ $&YO^_:T?V%
MJ?\ T&YO^_:UO44 8/\ 86I_]!N;_OVM']A:G_T&YO\ OVM;U% &#_86I_\
M0;F_[]K1_86I_P#0;F_[]K6]10!@_P!A:G_T&YO^_:T?V%J?_0;F_P"_:UO4
M4 8/]A:G_P!!N;_OVM']A:G_ -!N;_OVM;U% &#_ &%J?_0;F_[]K1_86I_]
M!N;_ +]K6]10!@_V%J?_ $&YO^_:T?V%J?\ T&YO^_:UO44 8/\ 86I_]!N;
M_OVM']A:G_T&YO\ OVM;U% &#_86I_\ 0;F_[]K1_86I_P#0;F_[]K6]10!@
M_P!A:G_T&YO^_:T?V%J?_0;F_P"_:UO44 8/]A:G_P!!N;_OVM']A:G_ -!N
M;_OVM;U% &#_ &%J?_0;F_[]K1_86I_]!N;_ +]K6]10!@_V%J?_ $&YO^_:
MT?V%J?\ T&YO^_:UO44 8/\ 86I_]!N;_OVM']A:G_T&YO\ OVM;U% &#_86
MI_\ 0;F_[]K1_86I_P#0;F_[]K6]10!@_P!A:G_T&YO^_:T?V%J?_0;F_P"_
M:UO44 8/]A:G_P!!N;_OVM']A:G_ -!N;_OVM;U% &#_ &%J?_0;F_[]K1_8
M6I_]!N;_ +]K6]10!@_V%J?_ $&YO^_:UGPV-U9^,+$7%\]X&B?;O4#;\I]*
MZZN?O?\ D<-._P"N;_\ H)H Z"BBB@#!\??\B+XC_P"P;<_^BFKXOK[0\??\
MB+XC_P"P;<_^BFKXOH **** "BBB@ HHHH **** "BBB@ HHHH *]J_9E_Y"
MFK_]<Q_.O%:]J_9E_P"0IJ__ %S'\Z /H2BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KG[W_ )'#3O\ KF__ *":Z"N?O?\ D<-._P"N;_\ H)H Z"BB
MB@#!\??\B+XC_P"P;<_^BFKXOK[0\??\B+XC_P"P;<_^BFKXOH **** "BBB
M@ HHHH **** "BBB@ HHHH *]J_9E_Y"FK_]<Q_.O%:]J_9E_P"0IJ__ %S'
M\Z /H2BBB@ HHJ&[O(+"WDN+F5(((U+/)(P"J!W)H FHKRBS_:G^%E]KXT:'
MQEI[Z@9/+$>_C=Z9Z5ZI'(DT:O&RNC#*LIR"/45K4HU*5O:1:OW1E"K3J-J$
MD[=A]%%%9&H45S-U\2/#EEXTM?"<VIPQ^(+J(S0V)^^Z#&2/SKIJIQE%)M;D
MJ2;:3V"BDIDTR6\+RR-MC12S-Z #)-24245XQ=?MB?""RN98)O&MBDL3E'4D
M\,#@CI7J7AGQ1I7C'1X-5T:^AU"PG&8YX6W*:Z)X>M3CSS@TO-&$,12J2Y(3
M3?:YJT5D^*?%.E^"]!N]9UF[6QTVT0R37$GW44=S4OA_Q!8>*M%L]6TNX6[T
M^\B6:"=>CH1D$?A6/++EYK:&O-%2Y;ZFC1114E!1110!A^,_^1=N_P#=_K63
MJOQ4\->&;I=/U'4EM[N.-2T91CC(]A6MXS_Y%V[_ -W^M?,OQL4'XC7?'_+&
M/^5 'O'_  O+P;_T%U_[]O\ X4?\+R\&_P#077_OV_\ A7R=M'I1M'I0!]8_
M\+R\&_\ 077_ +]O_A1_PO+P;_T%U_[]O_A7R=M'I1M'I0!]8_\ "\O!O_07
M7_OV_P#A1_PO+P;_ -!=?^_;_P"%?)VT>E&T>E 'UC_PO+P;_P!!=?\ OV_^
M%'_"\O!O_077_OV_^%?)VT>E&T>E 'UC_P +R\&_]!=?^_;_ .%'_"\O!O\
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M5/% 'F]%:O\ PB6O?] :\_[]FC_A$M>_Z UY_P!^S0!E45J_\(EKW_0&O/\
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MFK=%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !7/WO_ ".&G?\ 7-__ $$UT%<_>_\ (X:=_P!<W_\ 030!T%%%% &#X^_Y
M$7Q'_P!@VY_]%-7Q?7VAX^_Y$7Q'_P!@VY_]%-7Q?0 4444 %%%% !1110 4
M444 %%%% !1110 5[5^S+_R%-7_ZYC^=>*U[5^S+_P A35_^N8_G0!]"4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8?C/_D7;O\
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M?_T$T =!1110!@^/O^1%\1_]@VY_]%-7Q?7VAX^_Y$7Q'_V#;G_T4U?%^10
M449%&10 449%&10 449%&10 449%&10 449%&10 449%&10 5[5^S+_R%-7_
M .N8_G7BN17M7[,G_(4U?_KF/YT ?0E%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% &'XS_ .1=N_\ =_K6O:_\>T7^X/Y5D>,_^1=N
M_P#=_K6O:_\ 'M#_ +@_E0!+1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 5S][_R.&G?]<W_]!-=!7/WO_(X:=_US?_T$T =!1110!F^)
MK%]4\-ZK9QIYDEQ:2PJF0-Q9" ,GIUKY_P#^%&ZS_P! ;_R9B_\ BJ^DJ* /
MFW_A1NL_] ;_ ,F8O_BJ/^%&ZS_T!O\ R9B_^*KZ2HH ^;?^%&ZS_P! ;_R9
MB_\ BJ/^%&ZS_P! ;_R9B_\ BJ^DJ* /FW_A1NL_] ;_ ,F8O_BJ/^%&ZS_T
M!O\ R9B_^*KZ2HH ^;?^%&ZS_P! ;_R9B_\ BJ/^%&ZS_P! ;_R9B_\ BJ^D
MJ* /FW_A1NL_] ;_ ,F8O_BJ/^%&ZS_T!O\ R9B_^*KZ2HH ^;?^%&ZS_P!
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M?_09N?R%'_",7?\ T&;G\A70T4 <]_PC%W_T&;G\A1_PC%W_ -!FY_(5T-%
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MD*Z&B@#GO^$8N_\ H,W/Y"C_ (1B[_Z#-S^0KH:* .>_X1B[_P"@S<_D*/\
MA&+O_H,W/Y"NAHH Y[_A&+O_ *#-S^0H_P"$8N_^@S<_D*Z&B@#GO^$8N_\
MH,W/Y"C_ (1B[_Z#-S^0KH:* .>_X1B[_P"@S<_D*/\ A&+O_H,W/Y"NAHH
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MN^F5JQXP^,][I>L-I?A_PY/X@O+6S2_OPCA%@C8$J >['!X]JRCAJLG9+O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
1HH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>form424b4_003.jpg
<TEXT>
begin 644 form424b4_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $- :@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[4JZIX8B==FD7BLSFV1$X\PAHQC ?&,O'C-:VDIH.N/<"UTV3RHL*TD@PI+
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5^12/F(R<YW>V[':FXV)C44G8Z6BJ7GZA_SXQ?\ @1_]C1Y^H?\ /C%_W_\
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M2,@>YI8($MXMBY/=F/5CW)]Z@:6:&6.2XE18W.W8!PIQG.?PJS'+%,-T4B.
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M^9$-TB;QE!ZD=J Y7V+-%-CD26-9(W5T895E.01ZBG4""BBB@ HHHH ****
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MN#VM9$1(;E_O/\Q'KBGPA4=/,!*A@6 [\\TT@/-CDCI^'?\ 6EPQE/&!UY[
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M_,7_ ,31]@OO^@Q<?]^8O_B:T:* ,[[!??\ 08N/^_,7_P 31]@OO^@Q<?\
M?F+_ .)K1HH SOL%]_T&+C_OS%_\339-,O)8GC?5[C:ZE3B*+H?^ UIT4 ,B
MC6&%(ESM10HSZ"GT44 %%%% !1110 4444 %%%% !1110 8%)@>E+10 F!1M
M%+10 FT4;1Z4M% "8'I2T44 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
F444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>form424b4_005.jpg
<TEXT>
begin 644 form424b4_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '@ :H# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MTKAH;C'Q$G@FF$KF4&(?V@Z;%\L?+Y.-K'.3USSGM7<T %%%% &9K7^KLO\
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M.\.ZA'Y,<P,#9CD?8K<=V_A^O:L[P88I=*EN(XYMTTF]I9KM;AY?E&"6'M@
M>E2>,[L6OAV9'M9;A)\Q,(7577()R-W!Z=*I^ H8XM(G99)Y)&EP[RHB9PH
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M_P")I/\ A)-.+E/])W@9*_9I,@>OW: -:BLK_A(;'^[=?^ LG_Q-'_"0V/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI]%>1?\ "Q?$=SX6T'6S';V-C/'*=0OEM&N%A=)"BAD#!E1L9+<XZ5/>>/\
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MNYNI9());A "(HMBQG<[%5]%RW ]JZ*B@ HHHH **** "BBB@ HHHH ****
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M<X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MUR!O!'YC@U6T#_D7[#_K@O\ *AM(LWLTBN;>*X,88AI(P<$G)P.U)H QX?L
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M/^N"_P J<=2M4LHY+FZMHC*A(S)@'Z9P:;H'/A^P(Z>0O\J -&BBB@ HHHH
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M)SO4#@Y]ZY[QU!!>V]A936$U_P"9([K!'<+#RJ$[BQ]/3UZ\5O:)<"ZT*PN
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MK]QXEN(;AIHX?FWAD^5!_#M[5UD=K%&^\@O)_?<Y/_UOPJC]@U?_ *#0_P#
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(LD4BE71AD,#U!H S/"TLT_A72Y)R6D:V0EFZGC@G\*UZ1$6-%1%"JHP !@
M4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
,4 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>form424b4_007.jpg
<TEXT>
begin 644 form424b4_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $9 9(# 2(  A$! Q$!_\0
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MH **Q[GQ3HUIK46D3WJ+>2#A<':#Z%N@/L:V* "BBB@ HHHH **** "BBB@
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M?6O8*YX^*=!'B/\ LWS!]L^YY_E_)N_YY^9TW?[.: -Z$R-!&9E"RE0753D
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M=GD8\*,GDUU6E:WIFN0/-I=]#=Q(VUFB;(!]* +]%%% !1110 4444 %%%%
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M'J[_ / **LS4/A_XDENX]6M_&=P^K6L+QVK2VJ!!NZA@.QP*]&HH \VT_P
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MR>PM?$EK\7=,.OZM'=&>TG:."V!6*(#'8]?QK(O[1[WQOXBN-2\+ZCJEG!*
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M&TQXH6@ALPX+,#U:0C@]./2NNHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ***Q/$"^(I1!#H5QIUHC[O/NKM&D:/IC8@(!/7J>W0T
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M^"RM8DB@@0(B(, #VJS110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5Y'=11ML=DS@'TYH TJ*** "BBFO(D8!D=5!. 6.,F@ DD2&-I)'5$499F.
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M=.)%>9P 7VR,H)QQT KIZP?!FBW/A[PI9:7=O$\\!DW-$25.Z1F&,@=B*WJ
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MU;\&Z%=:!HT\-\\+7=U>3WDHA)*(9'+;5) ) &.WK0!T-%%% !1110 4444
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M9QZ>ETCC[Q8OC\L5T=>>P_#O6K?4SJ,7C6]6Z-NMMO\ LL>/+4Y Q]>]7O\
MA$_%/_0]WG_@'%0!U\MS!#+%%+,B22DB-68 N1R<>M2UY]>?#W6[^^LKVY\:
MWKW%B[/;L+6,;&88/'?BKO\ PB?BG_H>[S_P#BH Z^XN8+2+S;B9(HP0-SL
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M+C4&U"^5YHY(54%PA 88]AC%><^$O!_BO6]3 T2TNX9$(5[@9C$0;N3QQ]*
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M&"C/ZYK;HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
IHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>chart_ogd.jpg
<TEXT>
begin 644 chart_ogd.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '; PH# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXY_\''_V%'_"K/\ J??'/_@X_P#L* /0**\__P"%6?\ 4^^.?_!Q_P#84?\
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M /0**\__ .%6?]3[XY_\''_V%'_"K/\ J??'/_@X_P#L* /0**\__P"%6?\
M4^^.?_!Q_P#84?\ "K/^I]\<_P#@X_\ L* /0**\_P#^%6?]3[XY_P#!Q_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 445GZYI<>M:)=Z?)P)HRJM
M_=;JI_ X- &A17#W.K7>I?#R. +C4[IAIKKGE9=VQS^09JKZAXJN-,U!M#T6
M?0;2'3(TCD;5;KRS(=HPJ '/ QR>,F@#T"BO.+[7KK6KSPIJ>E6L3WDWVE%B
M>7,:.%VDEAU48)XZCIUJ;4=<U&X\,:[::[863WFGRPJZPM)Y,JL5*D<AA^=
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M[^N ^"G_ "2/0_K<?^E$E '?T444 %%%% %#5]3M]#TJYU"=28XAN*H.7)X
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7 ?!3_DD>A_6X_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MT%Z<W0A7SC_M8Y_6K=5M/O%U#3;:\12JSQ+( >V1FK- !1110 4444 %>?\
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M")H[>Y!\Z4/F5V/5BQSDT 9]C_PG_FV_VG_A&OLN5\SR_/W[.^,\9Q5K3?\
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MCD4Q$F@SS7.@:?/.299+=&<GJ3@<UQ_Q3_YDK_L:['_V>N_551 B*%51@ #
M K@/BG_S)7_8UV/_ +/0,] HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HK(U74=3T\^9%86<UN98HD9[QD<EV5!E?
M+( #-ZG@?A6I$9#$AE54D*C>J-N /< X&1[X'TH ?1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y1J/\ R.?B
M;_K]B_\ 22WIM.U'_D<_$W_7[%_Z26]-H **** "BBB@ HHHH **** "LOQ-
M_P BIK'_ %XS?^@&M2LOQ-_R*FL?]>,W_H!H ]L'04M(.@I: "BBB@ HHHH
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MO/\ T;:UZ!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 >4:C_R.?B;_ *_8O_22WIM.U'_D<_$W_7[%_P"DEO3: "BBB@ HHHH
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M !1110 4444 &B?\E#L/^P5>?^C;6O0*\_T3_DH=A_V"KS_T;:UZ!0 4444
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M110 4444 %%%% !HG_)0[#_L%7G_ *-M:] KS_1/^2AV'_8*O/\ T;:UZ!0
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M% !67XF_Y%36/^O&;_T UJ5E^)O^14UC_KQF_P#0#0![8.@I:0=!2T %%%%
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M78_^SUZ!7G_Q3_YDK_L:['_V>@#T"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** .?\ '?\ R3WQ+_V"KK_T4U<_70>._P#DGOB7_L%77_HI
MJY^@ HHHH **** "BBB@ HHHH **** #1/\ DH=A_P!@J\_]&VM>@5Y_HG_)
M0[#_ +!5Y_Z-M:] H **** "BBB@ HHHH QGTZ>W\5)JELF^*Y@^SW2\ KMR
M4?D\]2#]14&K>!_#>N7IO-0TN.6X/WI%=T+?7:1G\:Z"B@"BVC::^E?V6UC
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M4BGNK#!'Y&O'XOAK\2-!BDT?PSXUMXM!9CL6X7]]$IZA3L;'_ 67GGBO9Z*
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M,!L@<_3/UKL*** "BBB@ K@/@I_R2/0_K<?^E$E=_7 ?!3_DD>A_6X_]*)*
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M._\ DGOB7_L%77_HIJY^N@\=_P#)/?$O_8*NO_135S] !1110 4444 %%%%
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M$"+-%.)/+!SC(!P#UP2,]:W* /,O$G@F23Q)>Z@OAB'78KPJX/\ :#6SP,
M0>0&4XSQSUK0U/1_[#^'$68[:SN].=;R%(&=D64-G8"Y+'.2O7G-=[6;J6@:
M7J]U:7.H6:7$MH^^ N3A3QVS@]!US0!R6I^#)K_P/I-K]EBNKRU<74UM-*T8
MG=@3(I88(.6.#ZBG^"O"[:;J\VH-X9M]$7RO*5/MSW,KDD$G.[:%X],UWE%
M!1110 4444 <_P"._P#DGOB7_L%77_HIJY^N@\=_\D]\2_\ 8*NO_135S] !
M1110 4444 %%%% !1110 4444 &B?\E#L/\ L%7G_HVUKT"O/]$_Y*'8?]@J
M\_\ 1MK7H% !1110 5Y?\4_^1A\/?]>M[_Z';5ZA7E_Q3_Y&'P]_UZWO_H=M
M0!Q]%%% !1110 4444 %%%% !1110 5Z!\)_^09KW_85_P#;:"O/Z] ^$_\
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M6]_]#MJ]0KR_XI_\C#X>_P"O6]_]#MJ ./HHHH **** "BBB@ HHHH ****
M"O0/A/\ \@S7O^PK_P"VT%>?UZ!\)_\ D&:]_P!A7_VV@H ] HHHH **** /
M*-1_Y'/Q-_U^Q?\ I);TVG:C_P CGXF_Z_8O_22WIM !1110 4444 %%%% !
M1110 5E^)O\ D5-8_P"O&;_T UJ5E^)O^14UC_KQF_\ 0#0![8.@I:0=!2T
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M10 5Z!\)_P#D&:]_V%?_ &V@KS^O0/A/_P @S7O^PK_[;04 >@4444 %%%%
M'E&H_P#(Y^)O^OV+_P!)+>FT[4?^1S\3?]?L7_I);TV@ HHHH **** "BBB@
M HHHH *R_$W_ "*FL?\ 7C-_Z :U*R_$W_(J:Q_UXS?^@&@#VP=!2T@Z"EH
M**** ,#QU_R3[Q+_ -@JZ_\ 135\/U]P>.O^2?>)?^P5=?\ HIJ^'Z "BBB@
M HHHH **** "BBB@ HHHH ]?_9R_Y*'??]@J3_T;%7U!7R_^SE_R4.^_[!4G
M_HV*OJ"@ K@/@I_R2/0_K<?^E$E=_7 ?!3_DD>A_6X_]*)* ._HHHH ****
M,#4?$5W8WTEO'X>U.Z1,8FA0%&X[<U5_X2V^_P"A4UG_ +X7_&K_ (LU.XTC
MPS>7EI@7" !&(R%)(&<>V:X>^G\6VTVJVX\2,\EE:)= ?9T7S5/WL''&* /3
M;69KBUBF>%X6=0QCD^\N>Q]ZEJCHLPN-#L9A)))YD"-OD.6;(')]ZO4 %4K[
M2-.U/!OK&VN&"E5:6%7*@^A(XJ[10!B1>&+.UL[."RFGLWM4*)-!L#D'[VX%
M2IS@'IU&:#X8M%C5+:YN[4>5Y,IAD&9ER3\Q8'G);D8/)YK;HH 9##';P1PP
MH$CC4*BCL!P!7!?%/_F2O^QKL?\ V>O0*\_^*?\ S)7_ &-=C_[/0!Z!1110
M!X?XF_Y'WQ)_U]P_^DL%9]:'B;_D??$G_7W#_P"DL%9] !1110 4444 %%%%
M !1110 5GZ[_ ,B]J?\ UZ2_^@&M"L_7?^1>U/\ Z])?_0#0!](4444 %%%%
M '/^._\ DGOB7_L%77_HIJY^N@\=_P#)/?$O_8*NO_135S] !1110 4444 %
M%%% !1110 4444 &B?\ )0[#_L%7G_HVUKT"O/\ 1/\ DH=A_P!@J\_]&VM>
M@4 %%%% !7E_Q3_Y&'P]_P!>M[_Z';5ZA7E_Q3_Y&'P]_P!>M[_Z';4 <?11
M10 4444 %%%% !1110 4444 %>@?"?\ Y!FO?]A7_P!MH*\_KT#X3_\ (,U[
M_L*_^VT% 'H%%%% !1110!Y1J/\ R.?B;_K]B_\ 22WIM.U'_D<_$W_7[%_Z
M26]-H **** "BBB@ HHHH **** "LOQ-_P BIK'_ %XS?^@&M2LOQ-_R*FL?
M]>,W_H!H ]L'04M(.@I: "BBB@# \=?\D^\2_P#8*NO_ $4U?#]?<'CK_DGW
MB7_L%77_ **:OA^@ HHHH **** "BBB@ HHHH **** /7_V<O^2AWW_8*D_]
M&Q5]05\O_LY?\E#OO^P5)_Z-BKZ@H *X#X*?\DCT/ZW'_I1)7?UP'P4_Y)'H
M?UN/_2B2@#OZ*** "BBB@#.UYM.30KPZMC[#Y9\X'/(]L<YSTK@KA]+UBUNI
MI[36K3^R[:..;RYU$L\#<@2#O@<D=:[KQ%I']NZ%<Z>)!&\B@HY&0&!R,^V1
M7$C2/%TUWJ\1TJVA&II'#)<FY5DC"KM+!1\QSVXX]Z /0K!;9=.MELP!:B)?
M*QTVXX_2K%5M/LTT_3K:S1BRP1+&&/? QFK- !1110 4444 %>?_ !3_ .9*
M_P"QKL?_ &>O0*\_^*?_ #)7_8UV/_L] 'H%%%% 'A_B;_D??$G_ %]P_P#I
M+!6?6AXF_P"1]\2?]?</_I+!6?0 4444 %%%% !1110 4444 %9^N_\ (O:G
M_P!>DO\ Z :T*S]=_P"1>U/_ *])?_0#0!](4444 %%%% '/^._^2>^)?^P5
M=?\ HIJY^N@\=_\ )/?$O_8*NO\ T4U<_0 4444 %%%% !1110 4444 %%%%
M !HG_)0[#_L%7G_HVUKT"O/]$_Y*'8?]@J\_]&VM>@4 %%%% !7E_P 4_P#D
M8?#W_7K>_P#H=M7J%>7_ !3_ .1A\/?]>M[_ .AVU ''T444 %%%% !1110
M4444 %%%% !7H'PG_P"09KW_ &%?_;:"O/Z] ^$__(,U[_L*_P#MM!0!Z!11
M10 4444 >4:C_P CGXF_Z_8O_22WIM.U'_D<_$W_ %^Q?^DEO3: "BBB@ HH
MHH **** "BBB@ K+\3?\BIK'_7C-_P"@&M2LOQ-_R*FL?]>,W_H!H ]L'04M
M(.@I: "BBB@# \=?\D^\2_\ 8*NO_135\/U]P>.O^2?>)?\ L%77_HIJ^'Z
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MSZT/$W_(^^)/^ON'_P!)8*SZ "BBB@ HHHH **** "BBB@ K/UW_ )%[4_\
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M-_R/OB3_ *^X?_26"L^@ HHHH **** "BBB@ HHHH *S]=_Y%[4_^O27_P!
M-:%9^N_\B]J?_7I+_P"@&@#Z0HHHH **** .?\=_\D]\2_\ 8*NO_135S]=!
MX[_Y)[XE_P"P5=?^BFKGZ "BBB@ HHHH **** "BBB@ HHHH -$_Y*'8?]@J
M\_\ 1MK7H%>?Z)_R4.P_[!5Y_P"C;6O0* "BBB@ KR_XI_\ (P^'O^O6]_\
M0[:O4*\O^*?_ ",/A[_KUO?_ $.VH X^BBB@ HHHH **** "BBB@ HHHH *]
M ^$__(,U[_L*_P#MM!7G]>@?"?\ Y!FO?]A7_P!MH* /0**** "BBB@#RC4?
M^1S\3?\ 7[%_Z26]-IVH_P#(Y^)O^OV+_P!)+>FT %%%% !1110 4444 %%%
M% !67XF_Y%36/^O&;_T UJ5E^)O^14UC_KQF_P#0#0![8.@I:0=!2T %%%%
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M\8?\\M#_ /!A-_\ &* .?HKH/^%>^,/^>6A_^#";_P",4?\ "O?&'_/+0_\
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MC#_H':'_ .#2;_Y&H_L3QA_T#M#_ /!I-_\ (U !HG_)0[#_ +!5Y_Z-M:]
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M "*FL?\ 7C-_Z :Z'_A%?&'_ #YZ'_X,YO\ Y'JIJ?@GQAJ.E7EC]FT./[3
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
<* "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>form424b4_008.jpg
<TEXT>
begin 644 form424b4_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $0 ;P# 2(  A$! Q$!_\0
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M<4DC179 QN7S.1TYQZUZM0 4444 %%%% !1110 4444 %%%% !1110 4444
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MS0!TP=6^ZP/T-+7G?PYL[.VO[MK:R\-V[- N6TC46N7//\0/0>]>B4 %%%%
M!1110!YUXY_Y*;\/O^OFY_\ 18KT6O.O'/\ R4WX??\ 7S<_^BQ7HM !1110
M 4444 %8_BBSU?4/#EY;:#J"V&I.G[F=EW $'./;/3/.,UL44 >%_P#")_''
M_H:;7_O^/_C='_")_''_ *&FU_[_ (_^-U[I10!X7_PB?QQ_Z&FU_P"_X_\
MC='_  B?QQ_Z&FU_[_C_ .-U[I10!X7_ ,(G\<?^AIM?^_X_^-T?\(G\<?\
MH:;7_O\ C_XW7NE% 'A?_")_''_H:;7_ +_C_P"-T?\ ")_''_H:;7_O^/\
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MN;B[T=+ B7?]T812XQSZ"O3:\X^&L4*W4US%-ICI<6^Z+[)?74SL%?:25FZ
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MEXKT[QGH2:OI@F6!G:,K,NUE8=1U/J* -VBBB@ HHHH **** "BBB@ HHHH
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M6E?5%?*_C7_DN6N?0?\ HM* %HHHH **** "BBB@ HHHH JZE_R"KS_KB_\
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M_P#$5EZ]J'CSQ/8+8ZSJZ7=LL@D$;;%&X @'A1ZFM:B@""W\5_$VTMHK:#Q
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M_P !O_LJ[#X8?%OQ1XL\=VFCZH;/[++'(S"*#:V50D<Y]10![U1110 4444
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M110 5Y;^T!_R3%_^OR'^M>I5Y;^T!_R3%_\ K\A_K0!\LK]T?2EI%^Z/I2T
M%%%% !1110 4444 %>B? S_DK-A_UPF_]%FO.Z]$^!G_ "5FP_ZX3?\ HLT
M?6=%%% !1110 4444 %<YXSMKK4M#FTN#2[B]BNXV61H+B.%X\8*X+\9)XSV
MKHZYKQKK4>FZ++;QZFMAJ$Z$VTC1NP)4@D$JIQGIGMG- &?X)M-?MKVY.L1:
MTD1B C.H:A!<*3GL(P"#[FG>.+V&2."V:TBU:P@F']K:?'&LTPB9#L8(>>&P
M>.<=*H>!=0U'4->NI[G7UOEFMS+/:H'\NVD+_*L6Y%.T+P2<Y/I75ZMX6T+7
M9DFU/2[:YF0861TPX'IN'.* ,;P#>))9WEK':1:=;).7L;#8L<T5N0 &=!]W
M<P8C//K720Z3IUO?27T-A;1W<F=\Z1*';/7+8R:BTG0=*T&%H=*T^"T1SE_*
M3!8^YZG\:T: *ITRP-G+9FRM_LTI+20^4NQR3DDC&"2>:EMK:"SMTM[:&.&&
M,82.-0JJ/8"I:* /.O'/_)3?A]_U\W/_ *+%>BUYUXY_Y*;\/O\ KYN?_18K
MT6@#E?B7_P DT\1_]>,G\J^:?"W_ " (?]]_YU]+?$O_ ))IXC_Z\9/Y5\T^
M%O\ D 0_[[_SH V:*** "BBB@ HHHH **** ,Q/^2C^%/^OV'_T:*^NJ^14_
MY*/X4_Z_8?\ T:*^NJ "BBB@ KY7\:_\ERUSZ#_T6E?5%?*_C7_DN6N?0?\
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MH:]GKSGQNJK\3/A]M4#_ $FYZ#_IF*]&H Y7XE_\DT\1_P#7C)_*OFGPM_R
M(?\ ??\ G7TM\2_^2:>(_P#KQD_E7S3X6_Y $/\ OO\ SH V:*** "BBB@ H
MHHH **** ,Q/^2C^%/\ K]A_]&BOKJOD5/\ DH_A3_K]A_\ 1HKZZH ****
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M,E_Z_9O_ &6@#U.BBB@ KRW]H#_DF+_]?D/]:]2KRW]H#_DF+_\ 7Y#_ %H
M^65^Z/I2TB_='TI: "BBB@ HHHH **** "O1/@9_R5FP_P"N$W_HLUYW7HGP
M,_Y*S8?]<)O_ $6: /K.BBB@ HHHH **** "BBB@ HHHH BN8?M%K-#G;YB,
MF<9QD8KS;3-,U*XTWPEX9DT^XAET2[2:[N'0^4$@#!"K=&\S(P >.<]*].HH
M XO7FFN]2T#Q';6-X\6DWD\5Q T#++Y;J8S(J]6 .#P.0<BJ=IX;U#Q WB+4
M1?ZEH7]JWD3V[P?NYO*BC" MD9 ;!.."!CUKT"B@#S"Y^$%S>7EK>7/CKQ#+
M<VA+6\KR*6B)&"5..,BK?_"L]7_Z*+XG_P"_XKT2B@#S6[^%%]?V<MI=^/O$
MD]O,I22*252KJ>H(Q6/#^S]I]M$(H?$^KQQCD*NP#^5>Q44 >0_\*%M/^AKU
MG\T_PH_X4+:?]#7K/YI_A7I4OB+2H(M5DDNPJ:2,WIVM^Z^0/SQS\I!XS6C#
M*D\,<T3;HY%#*?4$9% 'DG_"A;3_ *&O6?S3_"N8^('PMC\'^$+C6;;Q'JL\
ML4D2!)67:=SA3T^M>]7VIV>FFV%W,(OM4ZVT.03ND;.%X^AJEJ=QH.I-;:1J
M/V6[%Z[K%!(GF+(T7S,.XRN._<4 ><+\!K-E!_X2O6N1GJG^%+_PH6T_Z&O6
M?S3_  KUX# P.E85_P",-$TW6ET>YN9?M[!#Y4=M))@.<*254@9(/4T >??\
M*%M/^AKUG\T_PH_X4+:?]#7K/YI_A7KU% 'CP^ %@+N"[_X2C6/M$#!XI?DW
M(0<@@XXYK=_X5GJ__11?$_\ W_%>B44 >=_\*SU?_HHOB?\ [_BC_A6>K_\
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EDOX+4QCS+:W,Z$Y'\/"EB!ZUZM110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>form424b4_009.jpg
<TEXT>
begin 644 form424b4_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $X ;D# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *Y?Q]XQA\#^&)-5> W$[.(;>
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M611+,J]=H)YKR30IO!6C:UIFJ'QAH4LRASJ:FT&V=\DQM$,?NBN0/E[ 5O\
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MSXW21JQQZD9J>JNF_P#(*L_^N"?^@BK5 !1110 4444 %%%% !1110 4444
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M)&21D9SU'(Y -7:* /._^%'^ /\ H#R?^!4O_P 51_PH_P  ?] >3_P*E_\
MBJ]$HH \[_X4?X _Z \G_@5+_P#%4?\ "C_ '_0'D_\  J7_ .*KT2B@#SO_
M (4?X _Z \G_ (%2_P#Q5'_"C_ '_0'D_P# J7_XJO1** /._P#A1_@#_H#R
M?^!4O_Q5'_"C_ '_ $!Y/_ J7_XJO1** /._^%'^ /\ H#R?^!4O_P 51_PH
M_P  ?] >3_P*E_\ BJ]$HH \[_X4?X _Z \G_@5+_P#%4?\ "C_ '_0'D_\
M J7_ .*KT2N?\6>--&\%6=O=ZU++'%/)Y2&.,N=V,]J .;_X4?X _P"@/)_X
M%2__ !5'_"C_  !_T!Y/_ J7_P"*JM_POOP)_P _EY_X"M1_POOP)_S^7G_@
M*U 'H6F:;9Z/IEOIUA"(;2W0)%&"3M ^M6Z\R_X7WX$_Y_+S_P !6H_X7WX$
M_P"?R\_\!6H ]-HKS+_A??@3_G\O/_ 5J]"TS4;?5]*M-2M&9K:ZB6:(L,$J
MPR..W!H MT444 %%%% !1110 4444 %%%% !1110 5YG\>O^267?_7S#_P"A
M5Z97F7QZ_P"267?_ %\P_P#H5 'H>F_\@JS_ .N"?^@BK55=-_Y!5G_UP3_T
M$5:H **** "BBB@ K)\3W^J:9X=O+S1M/&H7\2;HK8MC?Z_7C)P.O2M:B@#P
MO_A;/Q*_Z)[+_P" L]+_ ,+9^)7_ $3V7_P%GKW.B@#PS_A;/Q*_Z)[+_P"
ML]'_  MGXE?]$]E_\!9Z]SHH \,_X6S\2O\ HGLO_@+/1_PMGXE?]$]E_P#
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M&OZ5\/[FYU#QG>ZI;B:(&VEMHT5B6X.5YXH ]MTW_D%6?_7!/_015JJNF_\
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MB@#Z(\&2>)9?#4$GBM+>/5&9BR0# 5>P;'&[Z<=*Z"OE?_A+OB=_T-'Z)_\
M$4G_  EOQ._Z&C]$_P#B* /JFBOF;PKXY\='XA:#I>J^()+BWNKE!)&JIAE)
MP0?E%?3- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %>^
M_P"0?<_]<F_D:^#8^A^M?>5]_P @^Y_ZY-_(U\&Q]#]: 'T444 %%%% !111
M0 4444 %=[\$_P#DK6E?[LW_ *+:N"KO?@G_ ,E:TK_=F_\ 134 ?75%%% !
M1110 4444 %%%% %>[L+/4(UCO;2"YC5@RK-&' /J >]2O%')"T+QHT3*59"
MH*D'J"/2GT4 0VMI;64"P6EO%;PKG$<2!%&?8<5YQ\>O^267?_7S#_Z%7IM>
M9?'K_DEEW_U\P_\ H5 'H>F_\@JS_P"N"?\ H(JU573?^059_P#7!/\ T$5:
MH ^4/$O_ "6KQ)_UT?\ ]EJ>H/$O_):?$G_71_\ V6IZ "E]J*2@ HHI>] "
M4M)10 M%%)0!#HO_ "5SPI_U\)_Z$:^KJ^4=%_Y*YX4_Z^$_]"-?5U !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %>^_Y!]S_ -<F_D:^
M#8^A^M?>5]_R#[G_ *Y-_(U\&Q]#]: 'T444 %%%% !1110 4444 %=[\$_^
M2M:5_NS?^BFK@J[WX)_\E:TK_=F_]%M0!]=4444 %%%% !1110!Y_P"*O%&K
MV?BY=(@U?1]!LUM!.+O4UW_:6+$%4&Y0-N!GG/(KI_#%W->Z*DT^L6.K2%V!
MNK% L1P>@ 9N1]:XKQIH6H?\)J-8@T;0]4MY;)8-NKW(4(ZL3^[!!QP1GUXK
ML/!_GCP^@N-.TVP<2,!!IL@>$#/4$ <^M &]14<\\5M \TSJD2#<S,< "N1M
MO'\-QX..O_V?*K/>-9P6I;#O)YIC4'(^7)Y/H,]<4 =E7F7QZ_Y)9=_]?,/_
M *%79:%KSZG>:CIUY:K;:CI\BK-&DF]&#+N5D; )!'L,$$5QWQZ_Y)9=_P#7
MS#_Z%0!Z%IO_ ""K/_K@G_H(JU573?\ D%6?_7!/_015J@#Y0\2_\EI\2?\
M71__ &6K%5_$O_):?$G_ %T?_P!EJ>@ I:** "BBDH ***6@ I*6B@"#1/\
MDKGA3_KX3_T(U]75\HZ+_P E<\*?]?"?^A&OJZ@ HHHH **** "BBB@ HJK)
MJ5A%(T<E[;(ZG!5I5!'X9IO]K:;_ -!"T_[_ "_XT 7**I_VMIO_ $$+3_O\
MO^-']K:;_P!!"T_[_+_C0!<HJG_:VF_]!"T_[_+_ (T^+4+*>01PWEO(YZ*D
MJDG\ : +-%%% !1110 4444 5[[_ )!]S_UR;^1KX-CZ'ZU]Y7W_ "#[G_KD
MW\C7P;'T/UH ?1110 4444 %%%% !1110 5WOP3_ .2M:5_NS?\ HIJX*N]^
M"?\ R5K2O]V;_P!%-0!]=4444 %%%% !112.P1&8@D 9P!DT >2^+[0WOQ0E
M6'PNOB=XM-C+6]W,L<=IEVP4W9!+<YXXP.:[_P )6KVF@1Q2:#;Z&V]C]BMY
M%=%R>N5 &3UKF;O3_!/C_7!<G5;H:G#%Y'D1W<EM*JY)P8SAOTKK]"T.U\.Z
M8+"SDN7A#EP;B9I6R?\ :;G% %?Q'#=W,5K#!I[7L'G"2:-9UCSM(*@[ARI/
M4>U>:Z6\Y\)6.J75LT%KI?BB:ZG8,)#L,\JL>.@4OR3V!->RTP0Q+&T:QH$;
M.5"C!SUX]Z .!@L?^$I\6^*;FQOY[6U:TM]/2^M'^8R*6=C&W3C<%/OFN#^+
M/@:ZT'P%<7TOBW7=219HE^SWDX:,Y;J1CJ*]ZAABMXEBAB2*->B(H4#\!7FO
MQZ_Y)9=_]?,/_H5 'H>F_P#(*L_^N"?^@BK55=-_Y!5G_P!<$_\ 015J@#Y0
M\2_\EJ\2?]='_P#9:L57\2_\EI\2?]='_DM3T +124M !1244 +244M "44M
M)0!#HG_)7/"G_7PG_H1KZNKY0T3_ )*YX4_Z^$_]"-?5] !1110 5A>*_%^C
M^#-+74-9G>.)W\N-40LSMUP /8$\^E;M>,?M(_\ (FZ3_P!A#_VF] &K_P -
M >!_^>FH?^ W_P!>C_AH#P/_ ,]-0_\  ;_Z]>-PZ7IY@C)L;<DHI.8QZ4_^
MRM._Y\+;_OV* +WB6[^$_B37[K5Y-4\06TUTYDE2.W4J6/4C/(^E9/\ 9OPE
M_P"@]XD_\!8_\*L?V5IW_/A;?]^Q1_96G?\ /A;?]^Q0!A^(;/P!#I+OX?U7
M6;C4 R[8[N!%0KGG)'M5O3K#X9/IEL^HZUK\=ZT:F=(;9"BOCD*2.1FM'^RM
M._Y\+;_OV*/[*T[_ )\+;_OV* *_]F_"7_H/>)/_  %C_P *Z'P;K7PJ\&:\
MFL6VHZ]<W4:E8Q-;J%7((/ QG@UC?V5IW_/A;?\ ?L4?V5IW_/C;?]^Q0![#
M_P - >!_^>FH?^ W_P!>C_AH#P/_ ,]-0_\  ;_Z]>/?V5I__/C;?]^Q5?4-
M-L$TVZ=+*W5EB8@B,9!Q0!]4:!X@TSQ/I,>IZ1<K<6LA(# $$$=00>016G7E
M?[/O_),O^WZ7^2UZI0 4444 5[[_ )!]S_UR;^1KX-CZ'ZU]Y7W_ "#[G_KD
MW\C7P;'T/UH ?1110 4444 %%%% !1110 5WOP3_ .2M:5_NS?\ HIJX*N]^
M"?\ R5K2O]V;_P!%-0!]=4444 %%%% !114-V[QV4[QDAUC8J57<0<<8'?Z4
M >?^.]=\.B_N=*U;08K^_BAA>Q1R%EN99'*JD1^\,$9+ \5K_#J4R^'[A'^V
MI-!=R6\UO=7?VGR'0@%$DZLO<9R>:\S?Q)XON9([F2?4Y;B$'RI3X1R\>>NT
MEN*]0^'D]]=>%Q-J/G?:7N)&<SV LW;)ZF,$]?7O0!U=%%% !7F7QZ_Y)9=_
M]?,/_H5>FUYE\>O^267?_7S#_P"A4 >AZ;_R"K/_ *X)_P"@BK55=-_Y!5G_
M -<$_P#015J@#Y0\2\?&GQ)_UT?^2U8JOXE_Y+5XD_ZZ/_[+5B@ HHHH ***
M* "DHI: "DHI: (-$_Y*YX4_Z^$_]"-?5U?*.B_\E<\*?]?"?^A&OJZ@ HHH
MH *\8_:1_P"1-TG_ +"'_M-Z]GKQC]I'_D3=)_["'_M-Z /.X?\ CWB_ZYK_
M "J2HX?^/>+_ '%_D*DH **** "DHI: $HHI: "JNI?\@N\_ZXM_*K55=2_Y
M!5Y_UQ?^5 'KO[/O_),A_P!?TO\ ):]4KRO]GW_DF0_Z_I?Y+7JE !1110!7
MOO\ D'W/_7)OY&O@V/H?K7WE??\ (/N?^N3?R-?!L?0_6@!]%%% !1110 44
M44 %%%% !7>_!/\ Y*UI7^[-_P"BFK@J[WX)_P#)6M*_W9O_ $4U 'UU1110
M 4444 %%%% 'DWQ,N-5L_$=K=.^K_8(3;26BZ<KM'O$O[[SE7DG9C;GCJ.M=
MIX(N-2O-'N[S45N4%S?SRVL=U_K(X"_R*P[<=NPXJAK>F^(],\62^(?#]G;:
MF+JU2UGM+BX\DQE&)#(V",'<<CVK2\&Z-?:-I$XU)XOMMY>37DT<))CB:1L[
M%)Y('KW.: -+69=6BLO^)-:VT]VS8'VF4I&@P?F. 2><# ]:YM?&U\O@R'4[
MG2/)U6>Z^PQ61D)#S>88\@XR4X+<#.T&M[7-3TVQACM=2N)K=;S=&CQ!P00,
MGYU^[]<BN#70-4TCPS:SSRWVH6VD:]]MM4D!>?[(,K@YY.-S-ZD8% '9Z!KE
MU>ZEJ>D:G%#%J&GLA9H20DT;C*NH;GU!]P>:Y+X]?\DLN_\ KXA_]"J_8:7#
MXM\0^)=0E6X32KNUAT^"5"T;3!-S,ZG@C#-M]#CO7 ?%GX<Z3X;\!7&HVE]J
MTTR31*$N;QI$Y;'W30![EIO_ ""K/_K@G_H(JU573?\ D%6?_7!/_015J@#Y
M0\2_\EI\2?\ 71_Y+4]0>)?^2U>)/^NC_P#LM3T +124M "4M%% !2444 +1
M110!!HG_ "5SPI_U\)_Z$:^KJ^4=$_Y*YX4_Z^$_]"-?5U !1110 5XQ^TC_
M ,B;I/\ V$/_ &F]>SUXO^TC_P B;I/_ &$/_:;T >>0?\>\7^XO\JDJ.'_C
MWB_W%_D*?0 M%)2T )12TE "T4E+0 55U+_D%W?_ %Q?^1JU574O^07=_P#7
M%_Y4 >N_L^_\DR'_ %_2_P EKU2O*_V??^29#_K^E_DM>J4 %%%% %>^_P"0
M?<_]<F_D:^#8^A^M?>5]_P @^Y_ZY-_(U\&Q]#]: 'T444 %%%% !1110 44
M44 %=[\$_P#DK6E?[LW_ **:N"KO?@G_ ,E:TK_=F_\ 134 ?75%%% !1110
M 4444 >:^+-0\8Z-XNCOH]6\/V6B/"T,/V^5T5G)7 90<E^N".,9S74>%+?6
M8AJ,FN:M:7MW+< ^3:9\JU 11L&>1Z\^M>=_$N^T/7YOM&FZ_P"'[BX2TELF
MM[V[">4696\R,\@."N#ZCOQ77?#>1+Z'6=7.HZ==7-_>"2:/3I?,B@VQJJKN
M.,M@ DX[T =Q1110 5YE\>O^267?_7S#_P"A5Z;7F7QZ_P"267?_ %\P_P#H
M5 'H>F_\@JS_ .N"?^@BK55=-_Y!5G_UP3_T$5:H ^4/$O\ R6KQ)_UT?_V6
MIZ@\2_\ ):?$G_71_P#V6K% !244M !1110 E+110 44E+0!!HO_ "5SPI_U
M\)_Z$:^KJ^4=$_Y*YX4_Z^$_]"-?5U !1110 5XQ^TC_ ,B;I/\ V$/_ &F]
M>SUXQ^TC_P B;I/_ &$/_:;T >=P_P#'O%_N+_(5)4</_'O%_N+_ "%24 )1
M2T4 %%%% !1110 55U+_ )!5W_UQ?^56:K:E_P @J[_ZXO\ RH ]=_9]_P"2
M9#_K^E_DM>J5Y7^S[_R3(?\ 7]+_ "6O5* "BBB@"O??\@^Y_P"N3?R-?!L?
M0_6OO*^_Y!]S_P!<F_D:^#8^A^M #Z*** "BBB@ HHHH **** "N]^"?_)6M
M*_W9O_135P5=[\$_^2M:5_NS?^BFH ^NJ*** "BBB@ HHHH \E\4RZ#=^*=/
MT;3M0\/Z/:312S7%^EO;R2/(K "(%@0IY))/)[5T?PVNFEL]7M!-8W<%E>F&
M+4+.!(ENAM4Y*I\NX9VDC@XKGO%_AC16\3V.@Z?9:%HOVR"2ZDOY[".1I"K
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M?^PA_P"TWH \[@_X]XO]Q?Y"GTR'_CWB_P!Q?Y"I* "DI:* $HI:* "BBB@
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M]LZ9_P _]O\ ]]4?VSIG_/\ P?\ ?5 %ZDJE_;.F9_X_[?\ [ZH_MG3/^?\
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MX 0B@C=[4_\ MG3/^?\ M_\ OJ@"[2U1_MG3/^?^#_OJC^V=,_Y_[?\ [ZH
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M#_#'_0N:1_X!1_\ Q-;5% &+_P (?X9_Z%W2/_ */_XFC_A#_#/_ $+ND_\
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M"[I/_@%'_P#$UM44 8O_  A_AC_H7-(_\ H__B:/^$/\,?\ 0N:1_P" 4?\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_004.jpg
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $0 ?$# 2(  A$! Q$!_\0
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M=*>RB-K?[Q'<"8[@43<<IM_#K3]>UN;39;&RLK9;G4;^1D@C=]B *,L['!P
M/09.10"I2;2[ZFU16)H>MSZC+?V-Y:I;ZG8.%FB23<C!AE'5L X(]1D8--\.
MZY=:O/J=O>64=K/87 @98YO,#94-G.!Z^E .E)7OT_4W:*BBN8)Y)8XIHY'A
M;;(J,"4.,X(['!K%\0:[>Z9J.E:?86,5U<:@TH7S9_*5=B[CSM/:@482E+E1
MOT5S^A>)AJ2ZE'J-LNG7.FRB.Y5Y@R*"-P8/QP1ZXK0BUW2;BQGO8-2M)K:
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M/^HC_P!T?RKR"TAU/3](TW5-&MI99[]+O3)O+4G8S3N8I#Z!3NYKV*D "C
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M@ HHZ44 %%%&><4 %%%% !111G% !1110 4444 %%%% !1110 4444 %%%%
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MH('F2>54DOYH\_9_^/>)=X0@!&)#$+DD'MTSFNJN-0L[2:&&YNH8I)CB-'<
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MS,%58L-P&TY V$G)'4503QE.\=D1HL[274/VD11.9&$)*@'Y5QNY)P<#CK0
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M>!8EBM2+N3.^,I*[L(\#J1@'D=1UZ5%IWA74;>Y:>>6S4M<6\S"$;5/EE]Q
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MY;[QQU^M."J#D*,_2EHH **** "BBB@ HHHH **** "BBB@ HJ&\:=+*=[5
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M)>7I,:C,BQ/QN'&#D<@@#\2:IWEAJL#L8-Q:XE;_ %#D%<LQW%L=!N''?:*
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M *ZC^1H//.;>VEC@CF=,1R?=.>M<QKG_ !_K_P!<A_,UV5Z'&GVQ8C&>%4#
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MY6M?,9E<RPI$W##[O)Z#CZ\C&: &ZI+K44=D]L"UP8)O.CB0&,R>42O7G[X
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ Q1110 4444 %%%% !1110 8HHHH **** "BBB@ HHHH *,8&!
M110 4444 %%%% !1110 4444 8EYXEBLM3GL7T^_9XQ%Y<BQ 1S/(V B,2 2
M.^< #/I4=YXNTZSC;>)3<)Q);@#<AQDC/W21D X)QD5K7UA;:C;&WNHR\>Y7
M&&*E64Y!!&""".HK/_X171BS%K0N6Z[YG;DXR1D\$X&3U.!G- $,OC#2()XH
MI)G!9MLAV-^Y.TL"W'3 /S=.#S4W_"5:*7"+>[F)8!4B=B<#)( '*X_BZ'L:
MC_X0[00SL+$@N^]L32#=G((/S<J=S9'0YZ5(/"NBB.2/['\LB-&<RN<(?X1S
MPO' ' [8H BC\8Z-*Y\NX8QC:?-,;!3E-XVY'S''&!DYXQ5BW\2Z/=3-#!>J
M\BQF4C8PP  3U'4 C*]1Z5&/">BK&(ULR$5550)7^7 (!'/#<_>Z].>!5FTT
M/3;%T>WM@CH68,78G+  DY/)( R30!2N?&6AV\#S+>K.L>XN( 7("J6/ Z\#
MH/Z&G)XKTZ2TU*=?.+:>',L.PAR%)&5S@')4]^.AQ20>#?#UM!)##ID:1R*%
M<*[<@*Z^OI(X_'V%6SH&F-#-$UMN6>)HI,R,2RLQ9N<YR22<]>: &:?X@L]0
MNVL@)8;U-WF6\B?,FT@')&5P<C!SSFJ-KXXT6>5XY9S;,LOE+YV,.=Q7JI..
M1SG!&1G&16G::)I]C()+>%DDSEG\URSG).6)/S<L>N>WH*HMX6MF^SC>H%N[
MO%B/&TL<MGGD$XR#U_+"944GN["0>,M&GDF19Y $)VGR7.]0B,6  SMQ(O)Z
MYXS4L?BS0YKJ*VCOU>64J$VHQ4[@I'S8Q_&G?^(>HJFO@JQ6"2$.=D@VMG).
M!LP,DY 'EQX]-M3P>%;6V2)(754B*E!Y?3:4([^L4?\ WS]:+^17(OYE^/\
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MCH<MM%.;MHUDC611)"X.#T&,?>/4+U(YQBG?\(EH@X%EM0%2$$CA5P00 N<
M9 ) ZD FGQ^%M&CD1UM#F/:5!F<@%?NG!.,@< ]<<=.* (=0\7:5IUI%>2RL
MUF\#7#3J.$C#(F2#SU<<=>#Z4I\7Z+$"MS=&WG4*7MW0F1,@$ A<\X(R!G&>
M:GE\.:;*UN&@_=0HT?DYRK*SJ^#GD_,@/Y^M-@\+:-;,3#9[>0<>8Y&0NT'K
MUV\?04 !\5:(&0?VA&2_3:&.!N*Y.!P,@\G@4Y?$^C/93W@OD^SP.$D<JPP2
M<# QDY)XQG-01>$-'CDG<VY8S2B4_.5X"(FS@C*X1<@Y!/)JR_AW27M7MC:#
MRG\O(#MGY#E"#G((- $<7BC29;"ZOUN&^R6KA))O*;;R P(XY&&'(XH7Q#!*
M8%A@EE>>::*-$*Y;RMV6!)Q@X '/\0IT_AG2;FTGM9K4M!/(LDB>:^"RJ%!Z
M\< 9QU[TD_AK39X88?*:.*,R_)&Y&X2*5<$YR,YSP0<@4 4[7QC:7OE^197C
M>8IVDA -X4MLR6QG:"V?NX[TR#QOI]QY#1V]T(IM@$CJ% +>7D'G.1YJ$]NN
M"<5:?PCHDD31O:.R-%Y)!GDY7&/[W7;\N>NWCIQ3I/"VEO*)1'(LFY&9O-9M
MVTH>=Q/7RT!/4A0,T 1W7BRSM;FY@^S74IM23<-&BXB48&\Y(R/F[9/RGCBF
M+XPT^2YLX(XK@FY*+N8*JQNV?D8E@ PVGY1D^F:N7'AO2;JX:>:TS(S%G(D8
M"3)4X8 X8953@\<?6FR>&=*DBFC%NR+-<-=2!)6 >4D'<1G!Y53@C&1TH =J
M'B&QTNZ:WNRZ,%C<,0,%68J2#GHNTEO0>M0/XLTM+:]N0\C06D*RR,$(.2S+
MLVG!#97H<=15FX\/Z;>+:B\MS<O;0O!'),Y+;77:^3GDD#DFHQX9TD121_9G
M(E&)"9G+/R3ECG).6)!/(./04 .T_7K?4;M+:**0,]L+D/E60J6VD!E)R0>O
M:JMYXNL+2_N;)8;FXGMPN1"JX8E79@I) )54)/U Y/%6$\-Z?#-%-;BX@DC4
M(&CN'Y4/O(.3SEN2>IR>>:+KPOHMW<R7,NGQ"XEX>6+,;MUZLI!YW,#Z@X-
M&='X\TJ:=XHXYR$G2!I&V*JE@Q!8EAMX4\'!.5P.:WM/ODU"U,R(R;9)(F5N
MH9'*G]0:S_\ A$]% E5;1E27AT69PK+DML(!QMRS';TYZ5H6%C'I]J8(V9\R
M/*S/C+,[%F/'N30!:HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
&BBB@#__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
